{"text": "Preincubation with 1 microM of the protein kinase C (<< PKC >>) activator [[ phorbol 12-myristate 13-acetate ]] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Preincubation with 1 microM of the << protein kinase C >> (PKC) activator [[ phorbol 12-myristate 13-acetate ]] (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Preincubation with 1 microM of the << protein kinase C >> (PKC) activator phorbol 12-myristate 13-acetate ([[ PMA ]]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Preincubation with 1 microM of the protein kinase C (<< PKC >>) activator phorbol 12-myristate 13-acetate ([[ PMA ]]) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator << phorbol 12-myristate 13-acetate >> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated [[ PKC ]]-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<< PMA >>) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated [[ PKC ]]-mediated heterologous beta(2)-adrenoceptor desensitization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We show that the expression of PIM-1 is induced in response to << estradiol >> in MCF-7 cells and that the induction is mediated by [[ ERÎ± ]]-regulated enhancers located distally upstream from the gene.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSIONS: << CysLTs >> produced after antigen provocation sequentially induced IL-5 production from some immune component cells via [[ CysLT1 ]] receptor activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The dextromethorphan analog << dimemorfan >> attenuates kainate-induced seizures via [[ sigma1 receptor ]] activation: comparison with the effects of dextromethorphan.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The << dextromethorphan >> analog dimemorfan attenuates kainate-induced seizures via [[ sigma1 receptor ]] activation: comparison with the effects of dextromethorphan.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Dimemorfan pre-treatment also attenuated the << KA >>-induced increases in c-fos/c-jun expression, [[ activator protein (AP)-1 ]] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu << PPARalpha1 >> was enhanced 4.5- and 11.5-fold by [[ Wy-14643 ]] and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu << PPARalpha1 >> was enhanced 4.5- and 11.5-fold by Wy-14643 and [[ 5,8,11,14-eicosatetraynoic acid ]] (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu << PPARalpha1 >> was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid ([[ ETYA ]]) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by << Wy-14643 >> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and << 5,8,11,14-eicosatetraynoic acid >> (ETYA) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<< ETYA >>) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, the activities of the two << torafugu PPARalphas >> were enhanced 4.3- and 7.6-fold by [[ arachidonic acid ]], 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, the activities of the two << torafugu PPARalphas >> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by [[ docosahexaenoic acid ]], and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, the activities of the two << torafugu PPARalphas >> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by [[ eicosapentaenoic acid ]] each at 50 microM, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Polymorphisms in << dopamine transporter >> (SLC6A3) are associated with stimulant effects of [[ D-amphetamine ]]: an exploratory pharmacogenetic study using healthy volunteers.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Polymorphisms in dopamine transporter (<< SLC6A3 >>) are associated with stimulant effects of [[ D-amphetamine ]]: an exploratory pharmacogenetic study using healthy volunteers.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< EROD >> activity induction in peripheral blood lymphocytes, liver and brain tissues of rats orally exposed to [[ polycyclic aromatic hydrocarbons ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Little is known in terms of multi-matrix << cytochrome P450 >> activity induction under repeated oral exposure to planar [[ halogenated and polycyclic aromatic hydrocarbons ]] (PHH, PAH).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Little is known in terms of multi-matrix << cytochrome P450 >> activity induction under repeated oral exposure to planar halogenated and polycyclic aromatic hydrocarbons (PHH, [[ PAH ]]).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Saturated << palmitic and stearic acids >> increased ceramides, up-regulated PTP1B, and had AKt and [[ PTP1B ]] phosphorylation at Ser 50 impaired.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cells propagated in medium containing N5-methyltetrahydrofolate and << homocysteine >> showed a substantial increase in [[ MS ]] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cells propagated in medium containing << N5-methyltetrahydrofolate >> and homocysteine showed a substantial increase in [[ MS ]] activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-cdc2 via [[ ATM ]]-Chk1/2 activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additional mechanistic studies revealed that << jaceosidin >> treatment resulted in an increase in phosphorylation of [[ Cdc25C ]] and ATM-Chk1/2.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additional mechanistic studies revealed that << jaceosidin >> treatment resulted in an increase in phosphorylation of Cdc25C and [[ ATM ]]-Chk1/2.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "However, chronic treatment of cLH rats with << MPEP >> did not reverse learned helplessness, indicating that the enhanced [[ mGlu5 receptor ]] function is not the only player in the behavioral phenotype of this genetic model of depression.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 [[ quinone ]] derivatives (AA-861, tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-RExâ¢, and chondrocyte cell lines.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 quinone derivatives ([[ AA-861 ]], tBuBHQ, tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-RExâ¢, and chondrocyte cell lines.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 quinone derivatives (AA-861, [[ tBuBHQ ]], tBuBQ, and duroquinone) observed in 3 different cellular models, HEK293E, T-RExâ¢, and chondrocyte cell lines.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 quinone derivatives (AA-861, tBuBHQ, [[ tBuBQ ]], and duroquinone) observed in 3 different cellular models, HEK293E, T-RExâ¢, and chondrocyte cell lines.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In fact, we demonstrated a significant stimulation of << Nox4 >> activity by 4 quinone derivatives (AA-861, tBuBHQ, tBuBQ, and [[ duroquinone ]]) observed in 3 different cellular models, HEK293E, T-RExâ¢, and chondrocyte cell lines.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Such model of << Nox4 >> activity regulation could provide new insight into the understanding of the molecular mechanism of the electron transfer through the enzyme, i.e., its potential redox regulation, and could also define new therapeutic targets in diseases in which [[ quinones ]] and Nox4 are implicated.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Nox4 >> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Nox4 << oxidase >> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Porcine << TLR8 >> and TLR7 are both activated by a selective TLR7 ligand, [[ imiquimod ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Porcine TLR8 and << TLR7 >> are both activated by a selective TLR7 ligand, [[ imiquimod ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported << NRF2 >> target genes in response to NRF2 inducers ([[ sulforaphane ]], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to << NRF2 >> inducers ([[ sulforaphane ]], tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported << NRF2 >> target genes in response to NRF2 inducers (sulforaphane, [[ tert-butylhydroquinone ]], cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to << NRF2 >> inducers (sulforaphane, [[ tert-butylhydroquinone ]], cinnamic aldehyde, and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported << NRF2 >> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, [[ cinnamic aldehyde ]], and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to << NRF2 >> inducers (sulforaphane, tert-butylhydroquinone, [[ cinnamic aldehyde ]], and hydrogen peroxide) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported << NRF2 >> target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and [[ hydrogen peroxide ]]) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to << NRF2 >> inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and [[ hydrogen peroxide ]]) showed that the aldo-keto reductase (AKR) 1C1 is highly inducible by all treatments.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment of U937 cells with << NRF2 >> inducers including [[ sulforaphane ]] effectively elevated the expression of AKR1B1, 1B10, 1C1, 1C2, and 1C3.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Given the treatment with three doses of << Captopril >> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of [[ PON1 ]] and SOD in serum by single intragastric gavaged L-methionine.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Given the treatment with three doses of << Captopril >> (15 approximately 45 mg/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and [[ SOD ]] in serum by single intragastric gavaged L-methionine.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of << Captopril >> may be related to attenuating the decrease in [[ PON1 ]] activity and NO levels.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of [[ Ras homologous protein A ]], the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBÎ± (IÎºBÎ±) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of [[ apoptosis signal-regulating kinase 1 ]], c-jun-N-terminal kinase, p38, inhibitor of kappaBÎ± (IÎºBÎ±) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, [[ c-jun-N-terminal kinase ]], p38, inhibitor of kappaBÎ± (IÎºBÎ±) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, [[ p38 ]], inhibitor of kappaBÎ± (IÎºBÎ±) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, [[ inhibitor of kappaBÎ± ]] (IÎºBÎ±) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBÎ± ([[ IÎºBÎ± ]]) kinase, and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBÎ± (IÎºBÎ±) [[ kinase ]], and inositol requiring enzyme 1Î±.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, << vinblastine >> enhances the phosphorylation of Ras homologous protein A, the accumulation of reactive oxygen species, the release of intracellular Ca(2+), as well as the activation of apoptosis signal-regulating kinase 1, c-jun-N-terminal kinase, p38, inhibitor of kappaBÎ± (IÎºBÎ±) kinase, and [[ inositol requiring enzyme 1Î± ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor [[ NF-ÎºB ]], HSF1, AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor NF-ÎºB, [[ HSF1 ]], AP-1, and ATF-2, together with the expression of HSP70 and Bax proteins.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor NF-ÎºB, HSF1, [[ AP-1 ]], and ATF-2, together with the expression of HSP70 and Bax proteins.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor NF-ÎºB, HSF1, AP-1, and [[ ATF-2 ]], together with the expression of HSP70 and Bax proteins.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Telmisartan >> downregulates angiotensin II type 1 receptor through activation of [[ peroxisome proliferator-activated receptor gamma ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: Our data provides a novel insight into an effect of telmisartan: << telmisartan >> inhibits AT1R gene expression through [[ PPARgamma ]] activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< n-3 and n-6 polyunsaturated fatty acids >> induce the expression of COX-2 via [[ PPARgamma ]] activation in human keratinocyte HaCaT cells.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover stimulation of << COX-2 promoter >> activity was increased by those [[ PUFAs ]] or rosiglitazone.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover stimulation of << COX-2 promoter >> activity was increased by those PUFAs or [[ rosiglitazone ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of << AA >> metabolites in [[ PPAR ]] activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These findings demonstrate that << n-3 and n-6 PUFA >> increased [[ PPARgamma ]] activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These findings demonstrate that << n-3 and n-6 PUFA >> increased PPARgamma activity is necessary for the [[ COX-2 ]] induction in HaCaT human keratinocyte cells.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Given the anti-inflammatory properties of EPA, we suggest that induction of << COX-2 >> in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of [[ PUFAs n-3 ]] or n-6.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<< MMC >> rats showed higher [[ quinone reductase ]] and depleted xanthine oxidase activities.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In general, rifampicin can act on a pattern: << rifampicin >> activates the [[ nuclear pregnane X receptor ]] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Acetylcholinesterase (<< AChE >>) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [[ oximes ]] due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Acetylcholinesterase >> (AChE) inhibited by the organophosphate soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by [[ oximes ]] due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Therefore, the present results show that the earlier cerebellar responses to << (PhTe)(2) >> include disruption of cytoskeletal homeostasis that could be related with [[ MAPK ]] and PKA activation and reactive astrogliosis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Therefore, the present results show that the earlier cerebellar responses to << (PhTe)(2) >> include disruption of cytoskeletal homeostasis that could be related with MAPK and [[ PKA ]] activation and reactive astrogliosis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "A molecular mechanism of action of << theophylline >>: Induction of [[ histone deacetylase ]] activity to decrease inflammatory gene expression.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We show both in vitro and in vivo that low-dose << theophylline >> enhances [[ HDAC ]] activity in epithelial cells and macrophages.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Thus we have shown that low-dose << theophylline >> exerts an anti-asthma effect through increasing activation of [[ HDAC ]] which is subsequently recruited by corticosteroids to suppress inflammatory genes.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of << PKC >> by [[ phorbol 12-myristate,13-acetate ]] potentiated GluK2/GluK5.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by << phorbol 12-myristate,13-acetate >> potentiated [[ GluK2 ]]/GluK5.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Protein kinase C (PKC) inhibition reduced the potentiation by mGlu1 of GluK2/GluK5, and conversely, direct activation of PKC by << phorbol 12-myristate,13-acetate >> potentiated GluK2/[[ GluK5 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Functional and biochemical studies indicated that << TES >> signaling involved activity of the phosphoinositide 3 (PI3) kinase-protein kinase B (Akt) cascade initiated by activation of the [[ androgen receptor ]] and culminated in enhanced production of cGMP and microvascular vasodilation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as << adenylate cyclase >> activator, [[ forskolin ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by << PP2 >>, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent [[ EGFR ]] autophosphorylation, but not by ERK inhibitor, PD98059.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased << NADPH oxidase >> activity and immunoreactivity for the protein nitration marker [[ 3-nitrotyrosine ]] in the cerebral cortex.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under << NaCl >> and sorbitol stresses, [[ catalase ]] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under << NaCl >> and sorbitol stresses, catalase ([[ CAT ]]) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under NaCl and << sorbitol >> stresses, [[ catalase ]] (CAT) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under NaCl and << sorbitol >> stresses, catalase ([[ CAT ]]) activity in wnk8 mutant was 1.92- and 3.7-times of that in Col-0, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Progestin >> activation of [[ Src ]]/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Progestin >> activation of Src/[[ MAPK ]] occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Progestin >> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on [[ PR ]] activation of the Src/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Progestin >> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src/[[ MAPK ]] pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Progestin >> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the [[ Src ]]/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results highlight the importance of << PR >> activation of the Src/MAPK signaling pathway for [[ progesterone ]]-induced transcription of select target genes and cell cycle progression.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results highlight the importance of PR activation of the Src/<< MAPK >> signaling pathway for [[ progesterone ]]-induced transcription of select target genes and cell cycle progression.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results highlight the importance of PR activation of the << Src >>/MAPK signaling pathway for [[ progesterone ]]-induced transcription of select target genes and cell cycle progression.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Effect of << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity on contractile receptor function in airway smooth muscle.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In the present study, we investigated the effect of << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity on muscarinic receptor agonist- and histamine-induced bovine tracheal smooth muscle contractions.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In conclusion, << fenoterol >>-induced constitutive [[ beta(2)-adrenoceptor ]] activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist timolol.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The << CYP3A4 >> activity could be induced 2-fold by [[ rifampicin ]], whereas CYP2C9 activity remained equally high.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The CYP3A4 activity could be induced 2-fold by << rifampicin >>, whereas [[ CYP2C9 ]] activity remained equally high.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Anabolic effects of << clenbuterol >> on skeletal muscle are mediated by [[ beta 2-adrenoceptor ]] activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under isotonic conditions, << N-ethylmaleimide >> (NEM) produced [[ KCC ]] activation and transient cell shrinkage.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Under isotonic conditions, N-ethylmaleimide (<< NEM >>) produced [[ KCC ]] activation and transient cell shrinkage.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as << buserelin >>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's [[ gonadotrophin-releasing hormone (GnRH) receptor ]], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, << goserelin >>, leuprorelin and triptorelin, stimulate the pituitary's [[ gonadotrophin-releasing hormone (GnRH) receptor ]], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, << leuprorelin >> and triptorelin, stimulate the pituitary's [[ gonadotrophin-releasing hormone (GnRH) receptor ]], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and << triptorelin >>, stimulate the pituitary's [[ gonadotrophin-releasing hormone (GnRH) receptor ]], ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, we provide evidence that << apomorphine >> also acts on endogenous TRPA1 in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP-1, from which serotonin is released upon activation of [[ TRPA1 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our study shows that human TRPA1 is a target for << apomorphine >>, suggesting that an activation of [[ TRPA1 ]] might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with apomorphine.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our study shows that human TRPA1 is a target for apomorphine, suggesting that an activation of << TRPA1 >> might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with [[ apomorphine ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULTS: Rolipram unmasked the inhibitory effect of << beta(2)-adrenoceptor >> stimulation with [[ salmeterol ]] and significantly attenuated the stimulated release of AA and subsequent LTC(4).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The mechanism revealed that wogonin inhibited << H2O2 >>-induced phosphorylation of [[ caveolin-1 ]] (cav-1) associating with the suppression of stabilization of VE-cadherin and Î²-catenin.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The mechanism revealed that wogonin inhibited << H2O2 >>-induced phosphorylation of caveolin-1 ([[ cav-1 ]]) associating with the suppression of stabilization of VE-cadherin and Î²-catenin.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, wogonin repressed << anisomycin >>-induced phosphorylation of [[ p38 ]], cav-1 and vascular permeability.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, wogonin repressed << anisomycin >>-induced phosphorylation of p38, [[ cav-1 ]] and vascular permeability.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggested that wogonin could inhibit << H2O2 >>-induced vascular permeability by downregulating the phosphorylation of [[ cav-1 ]], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Wogonin inhibits << H2O2 >>-induced vascular permeability through suppressing the phosphorylation of [[ caveolin-1 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of << aspartate aminotransferase >>, alanine aminotransferase, levels of tumor necrosis factor-alpha (TNF-Î±) and interleukin-6 (IL-6) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, << alanine aminotransferase >>, levels of tumor necrosis factor-alpha (TNF-Î±) and interleukin-6 (IL-6) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "A prerequisite for this hypothesis was the unproved assumption that rabbit and human << alpha(2A)-adrenoceptors >> are equally activated by [[ rilmenidine ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by << Î±-tocopherol >> in the rat dentate gyrus, increasing [[ cyclic adenosine monophosphate response element binding protein ]] phosphorylation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The TXM peptides were effective in inhibiting << AuF >>-induced [[ MAPK ]], JNK and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The TXM peptides were effective in inhibiting << AuF >>-induced MAPK, [[ JNK ]] and p38(MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The TXM peptides were effective in inhibiting << AuF >>-induced MAPK, JNK and [[ p38 ]](MAPK) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The TXM peptides were effective in inhibiting << AuF >>-induced MAPK, JNK and p38([[ MAPK ]]) phosphorylation, in correlation with preventing caspase-3 cleavage and thereby PARP-1 dissociation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Bile acids >> are signaling molecules that activate [[ nuclear receptors ]], such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Bile acids >> are signaling molecules that activate nuclear receptors, such as [[ farnesoid X receptor ]], pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Bile acids >> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, [[ pregnane X receptor ]], constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Bile acids >> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, [[ constitutive androstane receptor ]], and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Bile acids >> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and [[ vitamin D receptor ]], and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "ABCG5 and ABCG8 themselves are regulated by cholesterol via liver X receptors (<< LXRs >>), which are also activated by oxysterols and some derivatives of plant [[ sterols ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "MeHg significantly increased DA precursor accumulation in cells treated with 3-hydroxybenzylhydrazine (10ÂµM), revealing that << MeHg >> increases [[ tyrosine hydroxylase ]] activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Histamine >> enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via [[ H1-receptor ]] activation.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In summary, these results show that the excitatory effect of << histamine >> on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the [[ H1-receptor ]]-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Activation of cytoprotective << prostaglandin synthase-1 >> by [[ minoxidil ]] as a possible explanation for its hair growth-stimulating effect.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We thus speculated that activation of << PGHS-1 >> might be a mechanism by which [[ minoxidil ]] (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We thus speculated that activation of << PGHS-1 >> might be a mechanism by which minoxidil ([[ 2,4-diamino-6-piperidinopyrimidine-3-oxyde ]]) stimulates hair growth in vivo.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We demonstrate here that << minoxidil >> is a potent activator of purified [[ PGHS-1 ]] (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Since << gemfibrozil >> is known to activate [[ peroxisome proliferator-activated receptor-alpha ]] (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Since << gemfibrozil >> is known to activate peroxisome proliferator-activated receptor-alpha ([[ PPAR-alpha ]]), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of << PPAR-alpha >> in [[ gemfibrozil ]]-mediated inhibition of iNOS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Gemfibrozil >> induced [[ peroxisome proliferator-responsive element ]] (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Gemfibrozil >> induced peroxisome proliferator-responsive element ([[ PPRE ]])-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Peginesatide >>, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [[ erythropoietin receptor ]] dimer that governs erythropoiesis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Peginesatide, a << polyethylene glycol >> (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [[ erythropoietin receptor ]] dimer that governs erythropoiesis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Peginesatide, a polyethylene glycol (<< PEG >>)ylated peptide-based erythropoiesis-stimulating agent, stimulates the [[ erythropoietin receptor ]] dimer that governs erythropoiesis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Galanin attenuates << cyclic AMP regulatory element-binding protein >> (CREB) phosphorylation induced by chronic [[ morphine ]] and naloxone challenge in Cath.a cells and primary striatal cultures.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Galanin attenuates << cyclic AMP regulatory element-binding protein >> (CREB) phosphorylation induced by chronic morphine and [[ naloxone ]] challenge in Cath.a cells and primary striatal cultures.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Galanin attenuates cyclic AMP regulatory element-binding protein (<< CREB >>) phosphorylation induced by chronic [[ morphine ]] and naloxone challenge in Cath.a cells and primary striatal cultures.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Galanin attenuates cyclic AMP regulatory element-binding protein (<< CREB >>) phosphorylation induced by chronic morphine and [[ naloxone ]] challenge in Cath.a cells and primary striatal cultures.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> also caused the phosphorylation of [[ JNK ]] and p38(MAPK).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> also caused the phosphorylation of JNK and [[ p38 ]](MAPK).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> also caused the phosphorylation of JNK and p38([[ MAPK ]]).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at << TFP >> concentrations that promote [[ S100A4 ]] oligomerization.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< ALD >> increased calpain expression and [[ caspase-3 ]] activity and promoted Bid cleavage.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The upregulation of calpain, tBid and << caspase-3 >> activity were further inhibited by treatment with EGTA in the presence of [[ ALD ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Allicin >> treatment showed reduced production of pro-inflammatory cytokines and NO and increased [[ HO-1 ]] activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Creatine phosphokinase >> activity in plasma increased slightly (compared to control, [[ pyridostigmine ]] or exercise group) in mice treated with pyridostigmine plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Creatine phosphokinase >> activity in plasma increased slightly (compared to control, pyridostigmine or exercise group) in mice treated with [[ pyridostigmine ]] plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In a recent study using protein-specific anti-acetyl lysine antibodies and immunological methods, we demonstrated the ability of << aspirin >> to acetylate the [[ tumor suppressor protein p53 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of << caspase 3 >> and release of cytochrome c to the cytosol induced by [[ DZN ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Metformin >> increases [[ AMP-activated protein kinase ]] activity in skeletal muscle of subjects with type 2 diabetes.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We recently reported that << AMPK >> is activated by [[ metformin ]] in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In the present study, we evaluated whether therapeutic doses of << metformin >> increase [[ AMPK ]] activity in vivo in subjects with type 2 diabetes.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Metformin >> treatment for 10 weeks significantly increased [[ AMPK alpha2 ]] activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Metformin >> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of [[ AMPK ]] on Thr172 and decreased acetyl-CoA carboxylase-2 activity.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The increase in << AMPK alpha2 >> activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after [[ metformin ]] treatment.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Metformin >>-induced increases in [[ AMPK ]] activity were associated with higher rates of glucose disposal and muscle glycogen concentrations.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment of mice with << Fe-NTA >> alone enhances [[ ornithine decarboxylase ]] activity to 4.6 folds, protein carbonyl formation increased up to 2.9 folds and DNA synthesis expressed in terms of [(3)H] thymidine incorporation increased to 3.2 folds, and antioxidants and antioxidant enzymes decreased to 1.8-2.5 folds, compared with the corresponding saline-treated controls.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Quinpirole and << 7-OH-DPAT >> also increased the phosphorylation of [[ extracellular signal-regulated kinase ]] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Quinpirole and << 7-OH-DPAT >> also increased the phosphorylation of extracellular signal-regulated kinase ([[ ERK ]]) within minutes, an effect blocked by pretreatment with SB-277011-A.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Quinpirole >> and 7-OH-DPAT also increased the phosphorylation of [[ extracellular signal-regulated kinase ]] (ERK) within minutes, an effect blocked by pretreatment with SB-277011-A.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Quinpirole >> and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase ([[ ERK ]]) within minutes, an effect blocked by pretreatment with SB-277011-A.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Activating << glucocorticoid receptor >>-ERK signaling pathway contributes to [[ ginsenoside Rg1 ]] protection against Î²-amyloid peptide-induced human endothelial cells apoptosis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Activating glucocorticoid receptor-<< ERK >> signaling pathway contributes to [[ ginsenoside Rg1 ]] protection against Î²-amyloid peptide-induced human endothelial cells apoptosis.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against AÎ²25-35-induced apoptosis at least in part by two complementary GR-dependent [[ ERK ]] phosphorylation pathways: (1) down-regulating HIF-1Î± initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of [[ Histone 3 ]] at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with EVn-50 or << VB1 >> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of [[ Histone 3 ]] at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of [[ Cdk1 ]] at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with EVn-50 or << VB1 >> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of [[ Cdk1 ]] at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Epi >> increased the activity of the [[ human WNT6 promoter ]] through Cav1-dependent binding of Î²-catenin to the proximal WNT6 promoter.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Epi >> increased the activity of the human WNT6 promoter through Cav1-dependent binding of Î²-catenin to the proximal [[ WNT6 promoter ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Indomethacin >> treatment led to an increase in lipid peroxidation, [[ glutathione peroxidase ]] and glucose-6-phosphate dehydrogenase activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Indomethacin >> treatment led to an increase in lipid peroxidation, glutathione peroxidase and [[ glucose-6-phosphate dehydrogenase ]] activities and to a decrease in catalase activity and glutathione levels in gastric mucosa.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The discovery that << METH >> and AMPH activate the [[ rTAAR1 ]] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The discovery that METH and << AMPH >> activate the [[ rTAAR1 ]] motivated us to study the effect of these drugs on the mouse TAAR1 (mTAAR1) and a human-rat chimera (hrChTAAR1).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, because S-(+)-isomers of << METH >> and AMPH are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of [[ TAAR1 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, because S-(+)-isomers of METH and << AMPH >> are reported to be more potent and efficacious in vivo than R-(-), we determined the enantiomeric selectivity of all three species of [[ TAAR1 ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "EC50 values for << S-(+)-METH >> were 0.89, 0.92, and 4.44 microM for [[ rTAAR1 ]], mTAAR1, and h-rChTAAR1, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "EC50 values for << S-(+)-METH >> were 0.89, 0.92, and 4.44 microM for rTAAR1, [[ mTAAR1 ]], and h-rChTAAR1, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "EC50 values for << S-(+)-METH >> were 0.89, 0.92, and 4.44 microM for rTAAR1, mTAAR1, and [[ h-rChTAAR1 ]], respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Similar to the << plasma membrane PS transporter >>, Atp8a1 is activated only by the naturally occurring [[ sn-1,2-glycerol ]] isomer of PS and not the sn-2,3-glycerol stereoisomer.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Similar to the plasma membrane PS transporter, << Atp8a1 >> is activated only by the naturally occurring [[ sn-1,2-glycerol ]] isomer of PS and not the sn-2,3-glycerol stereoisomer.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Weakly translocated lipids (<< PE >>, phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak [[ Atp8a1 ]] activators.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Weakly translocated lipids (PE, << phosphatidylhydroxypropionate >>, and phosphatidylhomoserine) are also weak [[ Atp8a1 ]] activators.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and << phosphatidylhomoserine >>) are also weak [[ Atp8a1 ]] activators.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The purified << Atp8a1 >> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by [[ phosphatidylglycerol ]] or phosphatidylethanolamine (PE), and is maximally activated by PS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The purified << Atp8a1 >> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or [[ phosphatidylethanolamine ]] (PE), and is maximally activated by PS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The purified << Atp8a1 >> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine ([[ PE ]]), and is maximally activated by PS.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The purified << Atp8a1 >> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by [[ PS ]].", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results indicate that the ATPase activity of the secretory granule << Atp8a1 >> is activated by phospholipids binding to a specific site whose properties ([[ PS ]] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results indicate that the << ATPase >> activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties ([[ PS ]] selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective << acetylcholinesterase >> reactivator, 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate ([[ MMB-4 ]]).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The current U.S. military and civilian oxime countermeasure, 2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium chloride (2-PAM), is under consideration for replacement with a more effective << acetylcholinesterase >> reactivator, [[ 1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium dimethanesulfonate ]] (MMB-4).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Quercetin >> and rutin also increased [[ alkaline phosphatase ]] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Quercetin and << rutin >> also increased [[ alkaline phosphatase ]] activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Induction of << HO-1 >> through p38 MAPK/Nrf2 signaling pathway by [[ ethanol ]] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Induction of HO-1 through << p38 >> MAPK/Nrf2 signaling pathway by [[ ethanol ]] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Induction of HO-1 through p38 << MAPK >>/Nrf2 signaling pathway by [[ ethanol ]] extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "It has been known for decades that << lithium chloride >> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on [[ GPCR ]] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "It has been known for decades that lithium chloride (<< LiCl >>) leads to D-myo-inositol 1-phosphate accumulation on [[ GPCR ]] activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< CGP 12177A >> mediates cardiostimulation by activation of the 'putative' [[ beta(4)-adrenoceptor ]]; however, it has recently been reported that disruption of the beta(1)-adrenoceptor gene abolishes this effect.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The << BH(4) >> treatment was associated with a 2-fold increase in [[ eNOS ]] activity as well as a 70% reduction in endothelial O(2)(-) production compared with those in fructose-fed rats.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, GCs have a synergistic effect on << GW4064 >>-induced [[ FXR ]] activation, whereas chenodeoxycholate and GW4064 have an additive effect.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Maqui berry (Aristotelia chilensis) and the constituent << delphinidin glycoside >> inhibit [[ photoreceptor ]] cell death induced by visible light.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< LY294002 >>, a specific PI3K/AKT inhibitor, selectively activated the [[ p38 ]] MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< LY294002 >>, a specific PI3K/AKT inhibitor, selectively activated the p38 [[ MAPK ]] kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< LY294002 >>, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK [[ kinase ]] pathway and enhanced c-Jun phosphorylation, but did not activate JNK.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< LY294002 >>, a specific PI3K/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced [[ c-Jun ]] phosphorylation, but did not activate JNK.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Exposure of cells to 4mM << NaF >> for 24h induced [[ caspase-3 ]] activation, ultrastructural alterations, and resulted in the translocation of Bax to the mitochondria and the release of cytochrome c from the mitochondrial inter-membrane space into the cytosol, indicating that fluoride-mediated apoptosis is mitochondria-dependent.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Fluoride >> treatment also increased phosphorylation of [[ JNK ]] and ERK, but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Fluoride >> treatment also increased phosphorylation of JNK and [[ ERK ]], but not p38, and apoptosis induced by fluoride was notably or partly suppressed by treatment with JNK or ERK inhibitors, respectively.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "BACKGROUND: This study examines the effects of << nicorandil >>, a [[ K(+) channel ]] opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long-QT syndrome (LQTS).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The protein exhibited modest << H(2)O(2) >>-dependent [[ peroxidase ]] activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here, translocation studies using the human androgen receptor (hAR) and the human glucocorticoid receptor (hGR) were performed to aid in identifying the mechanism by which anabolic-androgenic << steroids >> (AAS) were activating [[ hAR ]] and potentially interacting with hGR and how glucocorticoid ligands were interacting with the hGR and hAR.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Accordingly, in transfection experiments performed in TPC1 cells, treatment with << PJ34 >> increased [[ NIS promoter ]] activity without affecting PARP-1 binding to the promoter sequence.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Liver << BHMT >> activity was 1.3-fold higher in rats fed the Met deficient diet containing [[ choline ]], which was reflected in corresponding increases in mRNA content and immunodetectable protein.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Independent of dietary choline, supplemental << Met >> increased hepatic [[ BHMT ]] activity approximately 30%.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Independent of dietary << choline >>, supplemental Met increased hepatic [[ BHMT ]] activity approximately 30%.", "metadata": [], "label": "ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our results dissect the roles of HMGB1-associated proteins in DNA damage response: HMGB1 and HMGB2 facilitate << p53 >> phosphorylation after exposure to genotoxic stress, and PDIA3 has been found essential for H2AX phosphorylation (no gamma-H2AX accumulated after 24-72 hours of incubation with 1 micromol/L of [[ cytarabine ]] in PDIA3 knockdown cells).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We show that the expression of << PIM-1 >> is induced in response to [[ estradiol ]] in MCF-7 cells and that the induction is mediated by ERÎ±-regulated enhancers located distally upstream from the gene.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Dimemorfan pre-treatment also attenuated the << KA >>-induced increases in [[ c-fos ]]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Dimemorfan pre-treatment also attenuated the << KA >>-induced increases in c-fos/[[ c-jun ]] expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum << TSH >> level with high dose of [[ levothyroxine ]] might be optimum for normal growth.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Saturated << palmitic and stearic acids >> increased ceramides, up-regulated PTP1B, and had [[ AKt ]] and PTP1B phosphorylation at Ser 50 impaired.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in << plasma prolactin >> and ACTH levels after i.v.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additional neuroendocrine experiments in a parallel group of rats revealed a dose-related increase in plasma prolactin and << ACTH >> levels after i.v.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including [[ X-inactive-specific transcript ]], anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including X-inactive-specific transcript, [[ anterior gradient-2 ]], trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including X-inactive-specific transcript, anterior gradient-2, [[ trefoil factor-1 ]], CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, [[ CRP-ductin ]], ghrelin, and small proline-rich protein-2A, were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, [[ ghrelin ]], and small proline-rich protein-2A, were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Various genes controlled by << estrogen >>, including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and [[ small proline-rich protein-2A ]], were dramatically over-expressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Estrogen >>-regulated genes including [[ cytokeratin 1-19 ]] and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Estrogen >>-regulated genes including cytokeratin 1-19 and [[ Cyp2a4 ]] were over-expressed, although Cyp3a25 was suppressed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition the production of << BrBK1-8 >> was enhanced in the presence of these inhibitors with a greater accumulation being observed with [[ omapatrilat ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< GW660511X >> and omapatrilat increased the production of both [[ BrBK1-8 ]] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "GW660511X and << omapatrilat >> increased the production of both [[ BrBK1-8 ]] and Br-Phe5 but not that of BrBK4-8 and BrBK2-8.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< GW660511X >> and omapatrilat increased the production of both BrBK1-8 and [[ Br-Phe5 ]] but not that of BrBK4-8 and BrBK2-8.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "GW660511X and << omapatrilat >> increased the production of both BrBK1-8 and [[ Br-Phe5 ]] but not that of BrBK4-8 and BrBK2-8.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of << glucose >>-induced [[ insulin ]] secretion.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Nox4 >> oxidase activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Nox4 << oxidase >> activity is thought to be constitutive and regulated at the transcriptional level; however, we challenge this point of view and suggest that specific [[ quinone ]] derivatives could modulate this activity.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here we show that << fisetin >> rapidly increases the levels of both [[ Nrf2 ]] and ATF4 as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here we show that << fisetin >> rapidly increases the levels of both Nrf2 and [[ ATF4 ]] as well as Nrf2- and ATF4-dependent gene transcription via distinct mechanisms.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here we show that << fisetin >> rapidly increases the levels of both Nrf2 and ATF4 as well as [[ Nrf2 ]]- and ATF4-dependent gene transcription via distinct mechanisms.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here we show that << fisetin >> rapidly increases the levels of both Nrf2 and ATF4 as well as Nrf2- and [[ ATF4 ]]-dependent gene transcription via distinct mechanisms.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Although << fisetin >> greatly increases the stability of both [[ Nrf2 ]] and ATF4, only the effect on ATF4 is dependent on protein kinase activity.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Although << fisetin >> greatly increases the stability of both Nrf2 and [[ ATF4 ]], only the effect on ATF4 is dependent on protein kinase activity.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (<< sulforaphane >>, tert-butylhydroquinone, cinnamic aldehyde, and hydrogen peroxide) showed that the [[ aldo-keto reductase (AKR) 1C1 ]] is highly inducible by all treatments.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, << tert-butylhydroquinone >>, cinnamic aldehyde, and hydrogen peroxide) showed that the [[ aldo-keto reductase (AKR) 1C1 ]] is highly inducible by all treatments.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, << cinnamic aldehyde >>, and hydrogen peroxide) showed that the [[ aldo-keto reductase (AKR) 1C1 ]] is highly inducible by all treatments.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Firstly, in the normal human renal epithelial HK-2 cells, the measurement of the expression of 30 previously reported NRF2 target genes in response to NRF2 inducers (sulforaphane, tert-butylhydroquinone, cinnamic aldehyde, and << hydrogen peroxide >>) showed that the [[ aldo-keto reductase (AKR) 1C1 ]] is highly inducible by all treatments.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment of U937 cells with NRF2 inducers including << sulforaphane >> effectively elevated the expression of [[ AKR1B1, 1B10, 1C1, 1C2, and 1C3 ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Whereas, the levels of both the basal and << sulforaphane >>-inducible expression of [[ AKR1C1 ]] were significantly reduced in NRF2-silenced stable U937 cells compared to the control cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Intravenous << arginine >> significantly increased the acute [[ glucagon ]] response (129 +/- 12 vs 36 +/- 6 ng/l in controls; p < 0.01), notably without affecting plasma glucose.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Isolated islets displayed improved << glucose >>-stimulated [[ insulin ]] secretion after GRA treatment (0.061 +/- 0.007 vs 0.030 +/- 0.004 pmol islet(-1) h(-1) at 16.7 mmol/l glucose; p < 0.001), without affecting islet glucose oxidation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor NF-ÎºB, HSF1, AP-1, and ATF-2, together with the expression of [[ HSP70 ]] and Bax proteins.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << vinblastine >> induces the DNA-binding activities of the transcription factor NF-ÎºB, HSF1, AP-1, and ATF-2, together with the expression of HSP70 and [[ Bax ]] proteins.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Since the suppression of << AT1R >> expression was prevented by pretreatment with [[ GW9662 ]], a PPARgamma antagonist, PPARgamma should have participated in the process.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< n-3 and n-6 polyunsaturated fatty acids >> induce the expression of [[ COX-2 ]] via PPARgamma activation in human keratinocyte HaCaT cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We demonstrate that only treatment of HaCaT with << GLA >> and EPA or a PPARgamma ligand (roziglitazone), induced [[ COX-2 ]] expression (protein and mRNA).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We demonstrate that only treatment of HaCaT with GLA and << EPA >> or a PPARgamma ligand (roziglitazone), induced [[ COX-2 ]] expression (protein and mRNA).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (<< roziglitazone >>), induced [[ COX-2 ]] expression (protein and mRNA).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Both << 5 alpha-NET >> and 3 beta,5 alpha-NET blocked the [[ PR ]] down-regulation induced by P4 as assessed by Western and Northern blot methods.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Both 5 alpha-NET and << 3 beta,5 alpha-NET >> blocked the [[ PR ]] down-regulation induced by P4 as assessed by Western and Northern blot methods.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The inhibition of UG synthesis and << PR >> down-regulation by [[ 5 alpha-NET ]] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and << IMG >> or hyperoside inhibited production of [[ thrombin ]] and FXa in HUVECs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Also, reactive astrogliosis takes part of the early responses to the insult with << (PhTe)(2) >>, evidenced by upregulated [[ GFAP ]] in Western blot, PCR and immunofluorescence analysis.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<< CDCA >>)-induced expression of [[ Cdx2 ]] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the << chenodeoxycholic acid >> (CDCA)-induced expression of [[ Cdx2 ]] and MUC2 in normal rat gastric epithelial cells (RGM-1 cells).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the << chenodeoxycholic acid >> (CDCA)-induced expression of Cdx2 and [[ MUC2 ]] in normal rat gastric epithelial cells (RGM-1 cells).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We investigated the involvement of the farnesoid X receptor (FXR), a nuclear receptor for bile acids, in the chenodeoxycholic acid (<< CDCA >>)-induced expression of Cdx2 and [[ MUC2 ]] in normal rat gastric epithelial cells (RGM-1 cells).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< CDCA >> induced dose-dependent expression of [[ Cdx2 ]] and MUC2 at both the mRNA and protein levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< CDCA >> induced dose-dependent expression of Cdx2 and [[ MUC2 ]] at both the mRNA and protein levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The maximum stimulation of << Cdx2 >> and MUC2 mRNA induced by [[ CDCA ]] was observed at 3 h and by 6 h, respectively.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The maximum stimulation of Cdx2 and << MUC2 >> mRNA induced by [[ CDCA ]] was observed at 3 h and by 6 h, respectively.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< GHRP-6 >> is a [[ growth hormone ]] secretagogue that also enhances tissue viability in different organs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Anti-diabetic Activity of Swertiamarin is due to an Active Metabolite, << Gentianine >>, that Upregulates [[ PPAR-Î³ ]] Gene Expression in 3T3-L1 cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Swertiamarin >> treatment had no significant effect on adipogenesis, or the mRNA expression of PPAR-Î³ and GLUT-4; however, there was a significant increase in the mRNA expression of [[ adiponectin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "On the other hand, treatment with << gentianine >> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of [[ PPAR-Î³ ]], GLUT-4 and adiponectin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "On the other hand, treatment with << gentianine >> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-Î³, [[ GLUT-4 ]] and adiponectin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "On the other hand, treatment with << gentianine >> significantly increased adipogenesis, which was associated with a significant increase in the mRNA expression of PPAR-Î³, GLUT-4 and [[ adiponectin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cotreatments of 5, 10 and 20 Âµg/mL concentrations of MEP with << aflatoxin B(1) >> decreased the frequencies of SCE and the malondialdehyde level and increased amount of [[ superoxide dismutase ]], glutathione and glutathione peroxidase which were decreased by aflatoxin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, << bexarotene >>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the [[ p55 ]] and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, << bexarotene >>, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and [[ p75 ]] subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of << bexarotene >> are capable of in vivo upregulation of [[ CD25 ]] expression on circulating leukemia cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In the liver of rats given << flutamide >> as initiating agent at the dose of 500 mg/kg/week for 6 successive weeks, [[ gamma-glutamyltraspeptidase ]]-positive foci were detected only in 3 of 10 rats.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The lysosomal inhibitor << chloroquine >> significantly increased [[ RCAN1 ]] accumulation in +/+ cells, consistent with the hypothesis that higher lysosomal pH impairs RCAN1 degradation, leading to a higher RCAN1/NFATc1 ratio and consequently NFATc1 inhibition.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "High-<< glucose >> environment enhanced oxidative stress and increased [[ interleukin-8 ]] secretion from keratinocytes: New insights on impaired diabetic wound healing.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Using cultured human keratinocytes and diabetic rat model, the current study showed that high-<< glucose >> environment enhanced [[ IL-8 ]] production via epidermal growth factor receptor (EGFR) -extracelluar signal-regulated kinase (ERK) pathway in a reactive oxygen species (ROS)-dependent manner in keratinocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In conclusion, << IL-8 >> production and neutrophil infiltration are increased in high-[[ glucose ]] environment due to elevated ROS level and contributed to impaired wound healing in diabetic skin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Among these differentially expressed lncRNAs, the greatest change was noted for << uc002mbe.2 >>, which had more than 300 folds induction upon [[ TSA ]] treatment.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< TSA >> selectively induced [[ uc002mbe.2 ]] in four studied HCC cell lines.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The << TSA >>-induced [[ uc002mbe.2 ]] expression was positively correlated with the apoptotic effect of TSA in HCC cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The beneficial role of << 17beta-estradiol >> on blood pressure, cardiac hypertrophy, vascular [[ osteopontin ]] expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of medroxyprogesterone acetate.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists [[ carbachol ]] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or [[ muscarine ]], with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of [[ carbachol ]] blocked by the mAChR antagonist atropine.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Exposure to << PAHs >>, their metabolites, and ROS further increase [[ AKRs ]] isoform expression that may amplify oxidative damage.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additionally, << MPTP >> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in [[ Bax ]] expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Additionally, << MPTP >> significantly down-regulated Bcl-2 expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-[[ caspase-3 ]] expression, whereas these were inhibited by CRE or EB treatment.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The mRNA level for << nestin >> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-[[ EDS ]], but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The mRNA level for nestin (<< Nes >>, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-[[ EDS ]], but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We found that wogonin can suppress the << H2O2 >>-stimulated [[ actin ]] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We found that wogonin can suppress the << H2O2 >>-stimulated actin remodeling and [[ albumin ]] uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, alanine aminotransferase, levels of << tumor necrosis factor-alpha >> (TNF-Î±) and interleukin-6 (IL-6) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, alanine aminotransferase, levels of tumor necrosis factor-alpha (<< TNF-Î± >>) and interleukin-6 (IL-6) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, alanine aminotransferase, levels of tumor necrosis factor-alpha (TNF-Î±) and << interleukin-6 >> (IL-6) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, alanine aminotransferase, levels of tumor necrosis factor-alpha (TNF-Î±) and interleukin-6 (<< IL-6 >>) and 8-iso-prostane, and decreases in the activity of superoxide dismutase and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In conclusion, agomelatine administration protects liver cells from << paracetamol >>-induced hepatotoxicity via antioxidant activity and reduced proinflammatory [[ cytokines ]], such as TNF-Î± and IL-6.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In conclusion, agomelatine administration protects liver cells from << paracetamol >>-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as [[ TNF-Î± ]] and IL-6.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In conclusion, agomelatine administration protects liver cells from << paracetamol >>-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as TNF-Î± and [[ IL-6 ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << miR-21 >> expression positively correlated with urine albumin [[ creatine ]] ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the << PGE1 >> mediated stimulation of [[ Na,K-ATPase beta ]] subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of SC-51089.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of << Na,K-ATPase beta >> subunit gene transcription includes the stimulatory effect of [[ 17-phenyl trinor PGE2 ]], as well as the inhibitory effects of SC-51089.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our results showed that low dose << BPA >> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of [[ Oct4 ]] and Nanog proteins, while only BPA could downregulate the expression of E-cadherin protein.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our results showed that low dose << BPA >> and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and [[ Nanog ]] proteins, while only BPA could downregulate the expression of E-cadherin protein.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "However, as a novel finding, << isoflavone >> treatment increased a subclass of [[ high-density lipoprotein ]], the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "However, as a novel finding, << isoflavone >> treatment increased a subclass of high-density lipoprotein, the [[ pre-beta high-density lipoprotein ]] levels by 18% without affecting any other serum lipid concentrations.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: In postmenopausal women, isolated << isoflavone >> treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating [[ pre-beta high-density lipoprotein ]] level, which could provide beneficial vascular effects.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> up-regulated the expression of [[ Bax ]], down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/Bcl-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of [[ Bax ]]/Bcl-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of Bcl-2, and significantly increased the ratio of Bax/[[ Bcl-2 ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with << carvedilol >> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and [[ NGF-beta ]] to the baseline values.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Lintitript >> markedly increased postprandial plasma [[ CCK ]] release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Diet, physical exercise and << Orlistat >> administration increase serum [[ Anti-MÃ¼llerian Hormone ]] (AMH) levels in women with polycystic ovary syndrome (PCOS).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Diet, physical exercise and << Orlistat >> administration increase serum Anti-MÃ¼llerian Hormone ([[ AMH ]]) levels in women with polycystic ovary syndrome (PCOS).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We concluded that in overweight and obese women with PCOS << Orlistat >> administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and insulin sensitivity, and increased serum [[ AMH ]] levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Caerulein >> increased the levels of H(2)S and [[ CSE ]] mRNA expression while CBS mRNA expression was decreased.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, << substance P >> (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (<< SP >>) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (SP) concentration in the acini and expression of << SP >> gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (<< preprotachykinin-A >>, PPT-A) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, << PPT-A >>) and neurokinin-1 receptor (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and << neurokinin-1 receptor >> (NK-1R), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, substance P (SP) concentration in the acini and expression of SP gene (preprotachykinin-A, PPT-A) and neurokinin-1 receptor (<< NK-1R >>), the primary receptor for SP, are increased in secretagogue [[ caerulein ]]-treated acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, << sodium hydrosulphide >> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in [[ SP ]] concentration and expression of PPT-A and NK1-R in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<< NaHS >>), (10, 50 and 100 muM), that resulted in a significant increase in [[ SP ]] concentration and expression of PPT-A and NK1-R in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, << sodium hydrosulphide >> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of [[ PPT-A ]] and NK1-R in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<< NaHS >>), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of [[ PPT-A ]] and NK1-R in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, << sodium hydrosulphide >> (NaHS), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and [[ NK1-R ]] in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "To determine whether H(2)S itself provoked inflammation in acinar cells, the cells were treated with H(2)S donor drug, sodium hydrosulphide (<< NaHS >>), (10, 50 and 100 muM), that resulted in a significant increase in SP concentration and expression of PPT-A and [[ NK1-R ]] in acinar cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of << calpain >> and apoptosis-inducing factor in [[ aldosterone ]]-induced primary cultured cardiomyocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< ALD >> increased [[ calpain ]] expression and caspase-3 activity and promoted Bid cleavage.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and << apoptosis-inducing factor >> in [[ aldosterone ]]-induced primary cultured cardiomyocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the << ALD >>-induced increase of [[ calpain ]] and AIF levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Furthermore, treatment with spironoclactone not only attenuated the pro-apoptotic effect of ALD but reversed the << ALD >>-induced increase of calpain and [[ AIF ]] levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In this study, << aldosterone >> (ALD)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [[ calpain ]] signaling were clarified.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In this study, aldosterone (<< ALD >>)-induced apoptosis of cardiomyocyte was evaluated based on the previous studies, and the roles of [[ calpain ]] signaling were clarified.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The upregulation of calpain, << tBid >> and caspase-3 activity were further inhibited by treatment with EGTA in the presence of [[ ALD ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The upregulation of << calpain >>, tBid and caspase-3 activity were further inhibited by treatment with EGTA in the presence of [[ ALD ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << curcumin >> alleviated [[ Sim2 ]] expression, and reversely raised Drebrin expression in neurons treated with hyperglycaemia.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "It was found that expression of << Sim2 >> protein in cortical neurons was increased in [[ streptozotocin ]]-induced diabetes mellitus rat model.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << curcumin >> alleviated Sim2 expression, and reversely raised [[ Drebrin ]] expression in neurons treated with hyperglycaemia.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Processing of polysialylated NCAM was reproduced in a mouse model by << bleomycin >> administration leading to an activation of the inflammasome and secretion of [[ interleukin (IL)-1Î² ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of [[ amyloid precursor protein ]] (APP), Î²-secretase (BACE-1) and the amyloid Î²-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), [[ Î²-secretase ]] (BACE-1) and the amyloid Î²-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), Î²-secretase ([[ BACE-1 ]]) and the amyloid Î²-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), Î²-secretase (BACE-1) and the [[ amyloid Î²-peptide transporter ]] receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), Î²-secretase (BACE-1) and the amyloid Î²-peptide transporter [[ receptor for advanced glycation end products ]], and decreased A-disintegrin and metalloprotease (ADAM) 10 levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << Acrolein >> resulted in activation of astrocytes, up-regulation of [[ BACE-1 ]] in cortex and down-regulation of ADAM-10 in hippocampus and cortex.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Dietary << carbohydrates >> increase [[ SCD-1 ]] gene expression in liver by sterol response element binding protein (SREBP)-1c-dependent and SREBP-1c -independent pathways.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Finally, we showed that << chlorate >> activated endocrine cell development by inducing [[ neurogenin 3 ]] (Neurog3) expression in early endocrine progenitor cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Finally, we showed that << chlorate >> activated endocrine cell development by inducing neurogenin 3 ([[ Neurog3 ]]) expression in early endocrine progenitor cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [[ caspase 3 ]] and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULTS: << DZN >> induced histophatological damages and elevated the level of cardiac marker [[ CK-MB ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Crocin (25 and 50mg/kg) or << vitamin E >> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of [[ caspase 3 ]] and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Crocin (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of << cytochrome c >> to the cytosol induced by [[ DZN ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Results: The administration of << prallethrin >> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, [[ hemoglobin ]], packed cell volume, platelets, mean corpuscular volume, and mean corpuscular hemoglobin in rats after 24, 48, and 72âh of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48âh to return to normal after 72âh. Significant increases in the levels of CK, Î³-GT, SOD, NO, MDA, AFP, IL-2, and TNFÎ± were recorded.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Results: The administration of << prallethrin >> 1.6% w/w created significant increased changes in the levels of total WBC, lymphocytes, RBC, hemoglobin, packed cell volume, platelets, mean corpuscular volume, and mean corpuscular [[ hemoglobin ]] in rats after 24, 48, and 72âh of continuous inhalation; however, there was a significant reduction in neutrophils at transient reduction in the monocytes after 24 and 48âh to return to normal after 72âh. Significant increases in the levels of CK, Î³-GT, SOD, NO, MDA, AFP, IL-2, and TNFÎ± were recorded.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas << GPx1b1 >> and GPx1b2 were highly induced by exposure to [[ selenium ]] levels that had some toxic effects on the cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and << GPx1b2 >> were highly induced by exposure to [[ selenium ]] levels that had some toxic effects on the cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In macrophages, levels of << TNF-Î± >>, IFN-Î³, NO, IL-6 and IL-10 were increased by [[ CDM ]] used alone or in combination with HSV-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In macrophages, levels of TNF-Î±, << IFN-Î³ >>, NO, IL-6 and IL-10 were increased by [[ CDM ]] used alone or in combination with HSV-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In macrophages, levels of TNF-Î±, IFN-Î³, NO, << IL-6 >> and IL-10 were increased by [[ CDM ]] used alone or in combination with HSV-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In macrophages, levels of TNF-Î±, IFN-Î³, NO, IL-6 and << IL-10 >> were increased by [[ CDM ]] used alone or in combination with HSV-2.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Besides, << CDM >> not only synergized [[ TNF-Î± ]] production combined with IFN-Î³, but also prolonged its expression in time.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Besides, << CDM >> not only synergized TNF-Î± production combined with [[ IFN-Î³ ]], but also prolonged its expression in time.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Results indicate that << CDM >> inhibits HSV-2 multiplication in epithelial cells and also increases [[ cytokine ]] production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Neither ryanodine nor << EGTA >> inhibited down-regulation of [[ alpha-AR ]] mRNA by NE.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Neither << ryanodine >> nor EGTA inhibited down-regulation of [[ alpha-AR ]] mRNA by NE.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor << manumycin A >> caused elevation of [[ ApoA-I ]] secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Repression of farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor << manumycin A >> caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing [[ hApoA-I ]] and cholesterol ester transfer protein transgenes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The above results indicate that polyamine depletion delays the onset of apoptosis in IEC-6 cells and confers protection against DNA damaging agents, suggesting that << polyamines >> might be involved in the [[ caspase ]] activating signal cascade.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Apoptosis studies (DAPI staining and << caspase 3 >> activity) showed a marked increase in the presence of [[ MXF ]] and VP-16 compared to VP-16 alone.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Apoptosis studies (DAPI staining and << caspase 3 >> activity) showed a marked increase in the presence of MXF and [[ VP-16 ]] compared to VP-16 alone.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Apoptosis studies (DAPI staining and << caspase 3 >> activity) showed a marked increase in the presence of MXF and VP-16 compared to [[ VP-16 ]] alone.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Importantly, expression of the acute-phase reactant << serum amyloid A >> (SAA) significantly increased after [[ ritodrine ]] injection, with values indicating the largest fold-change.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Importantly, expression of the acute-phase reactant serum amyloid A (<< SAA >>) significantly increased after [[ ritodrine ]] injection, with values indicating the largest fold-change.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Serum amyloid A >> upsurge precedes standard biomarkers of hepatotoxicity in [[ ritodrine ]]-injected mice.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The increase in << SAA >> expression is specific to [[ ritodrine ]]-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the << ritodrine >>-induced [[ SAA ]] increase.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Reductions in striatal dopamine and << tyrosine hydroxylase >> content were also less pronounced with [[ EHT ]] treatment.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< c-fos >> expression was induced in urethane-anaesthetized rats by intracisternal [[ capsaicin ]] administration.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Sumatriptan and LY 344864 decreased the number of << capsaicin >>-induced [[ c-fos ]]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of [[ cyclin B1 ]], and decreased expression of Cdc25c.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment with EVn-50 or << VB1 >> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of [[ cyclin B1 ]], and decreased expression of Cdc25c.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Epi >> increased both [[ WNT6 ]]/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Epi >> increased both WNT6/[[ Wnt6 ]] and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Epi >> increased both WNT6/Wnt6 and [[ Cav1 ]] expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results showed that WNT6 and << Cav1 >> are upregulated by chemotherapeutics and enhance the resistance of GC cells to [[ anthracycline ]] drugs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results showed that << WNT6 >> and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to [[ anthracycline ]] drugs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of << LPA >> by driving MRTF-dependent [[ CTGF ]] expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J. S., Wada, T., Luster, A. D., Tager, A. M. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of << ABCA1 >> and ABCG1 was induced by [[ 24-OHC ]], as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of ABCA1 and << ABCG1 >> was induced by [[ 24-OHC ]], as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of << ABCA1 >> and ABCG1 was induced by 24-OHC, as well as [[ TO901317 ]] and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of ABCA1 and << ABCG1 >> was induced by 24-OHC, as well as [[ TO901317 ]] and retinoic acid, which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of << ABCA1 >> and ABCG1 was induced by 24-OHC, as well as TO901317 and [[ retinoic acid ]], which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The expression of ABCA1 and << ABCG1 >> was induced by 24-OHC, as well as TO901317 and [[ retinoic acid ]], which are ligands of the nuclear receptors LXR/RXR.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here, we have now found that activation of << p38 >> MAPK by [[ anisomycin ]] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here, we have now found that activation of p38 << MAPK >> by [[ anisomycin ]] potentiated induction of CYP2B6 mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Here, we have now found that activation of p38 MAPK by << anisomycin >> potentiated induction of [[ CYP2B6 ]] mRNA by CAR ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "siRNA knockdown of p38 MAPK abrogated the ability of << anisomycin >> to synergistically induce [[ CYP2B6 ]] mRNA.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition to CYP2B6, << anisomycin >> co-treatment potentiated an increase in [[ CYP2A7 ]] and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition to CYP2B6, << anisomycin >> co-treatment potentiated an increase in CYP2A7 and [[ CYP2C9 ]] mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition to << CYP2B6 >>, [[ anisomycin ]] co-treatment potentiated an increase in CYP2A7 and CYP2C9 mRNAs but not CYP3A4 or UDP-glucuronosyltransferase 1A1 mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Exposure to << Cu >> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of [[ lactate dehydrogenase ]], intracellular reactive oxygen species and interleukin-8 that mirrored our findings from subacute in vivo inhalation studies in mice.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Exposure to << Cu >> NPs decreased cell viability to 73% (p<0.01) and significantly (p<0.05) elevated levels of lactate dehydrogenase, intracellular reactive oxygen species and [[ interleukin-8 ]] that mirrored our findings from subacute in vivo inhalation studies in mice.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Altogether, our findings support a model in which Top2Î² deficiency promotes << CPT >>-induced apoptosis in quiescent non-S-phase cells, possibly due to RNAP LS depletion and [[ p53 ]] accumulation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like [[ osteopontin ]], osterix, RunX2, osteoprotegerin and osteocalcin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, [[ osterix ]], RunX2, osteoprotegerin and osteocalcin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, [[ RunX2 ]], osteoprotegerin and osteocalcin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, [[ osteoprotegerin ]] and osteocalcin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further, both the << flavonoids >> were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like osteopontin, osterix, RunX2, osteoprotegerin and [[ osteocalcin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Human and rat renin >> and angiotensinogen genes were downregulated in dTGR and were increased by [[ losartan ]] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Human and rat renin and << angiotensinogen >> genes were downregulated in dTGR and were increased by losartan and [[ cilazapril ]] treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Endothelial NO synthase >> expression was increased by [[ cilazapril ]] but not by losartan.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Human and rat renin and << angiotensinogen >> genes were downregulated in dTGR and were increased by [[ losartan ]] and cilazapril treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Human and rat renin >> and angiotensinogen genes were downregulated in dTGR and were increased by losartan and [[ cilazapril ]] treatments, whereas no changes in the expression of rat ACE and AT1A receptor genes were observed.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Expression of << L-type pyruvate kinase >> (L-PK) is upregulated in the liver by dietary [[ carbohydrate ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Expression of L-type pyruvate kinase (<< L-PK >>) is upregulated in the liver by dietary [[ carbohydrate ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< TAA >> increased the number and area of [[ glutathione S-transferase placental form ]] (GST-P)(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< TAA >> increased the number and area of glutathione S-transferase placental form ([[ GST-P ]])(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters ([[ alanine aminotransferase ]], aspartate aminotransferase, alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, [[ aspartate aminotransferase ]], alkaline phosphatase, total protein, albumin, bilirubin, cholesterol, urea and creatinine).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, [[ alkaline phosphatase ]], total protein, albumin, bilirubin, cholesterol, urea and creatinine).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The treatment with << arsenic >> exhibited a significant increase in some serum hepatic and renal biochemical parameters (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total protein, [[ albumin ]], bilirubin, cholesterol, urea and creatinine).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "High << p53 >> protein levels, but not genetic or functional p53 status, were associated with increased [[ topotecan ]]-induced DNA/topoisomerase I complex formation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Glucosamine >> at 50Â mM was demonstrated to elevate both the mRNA and protein expression of [[ p53 ]] and heme oxygenase-1 (HO-1), but also caused a reduction in p21 protein expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Glucosamine >> at 50Â mM was demonstrated to elevate both the mRNA and protein expression of p53 and [[ heme oxygenase-1 ]] (HO-1), but also caused a reduction in p21 protein expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In addition, << glucosamine >> attenuated p21 protein stability via the proteasomal proteolytic pathway, as well as inducing [[ p21 ]] nuclear accumulation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Altogether, our results suggest that a high dose of << glucosamine >> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in Rb phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear [[ p21 ]] accumulation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << IGFBP-rP2 >> noticeably increased in response to TGF-beta1 and [[ all-trans retinoic acid ]] (atRA) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << IGFBP-rP2 >> noticeably increased in response to TGF-beta1 and all-trans retinoic acid ([[ atRA ]]) in HPEC and PC-3 cells, and it decreased in response to IGF-I in HPEC.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or << ADP >>-induced [[ CD62P ]] expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In no other subject any activation of platelets by GP IIb/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb/IIIa inhibitors on basal or << ADP >>-stimulated [[ CD62P ]] expression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< CGP 12177A >> but not isoprenaline initiated arrhythmias at lower concentrations following [[ beta(1)-adrenoceptor ]] overexpression.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< (125)I-Cyanopindolol >> saturation binding in Adv.beta(1) myocytes demonstrated approximately 18-fold increase in [[ beta(1)-adrenoceptors ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< (3)H-CGP 12177A >> saturation binding, in the presence of propranolol, increased approximately 5-fold following overexpression of [[ beta(1)-adrenoceptors ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "(3)H-CGP 12177A saturation binding, in the presence of << propranolol >>, increased approximately 5-fold following overexpression of [[ beta(1)-adrenoceptors ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The << BH(4) >> treatment also partially improved the [[ insulin ]] sensitivity and blood pressure, as well as the serum triglyceride concentration, in the fructose-fed rats.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of [[ SHP ]] and OSTÎ², and a down-regulation of CYP27A1.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of SHP and [[ OSTÎ² ]], and a down-regulation of CYP27A1.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Fenofibrate >> and GW2331 induced expression of [[ acyl-coenzyme A (CoA) oxidase ]] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Fenofibrate and << GW2331 >> induced expression of [[ acyl-coenzyme A (CoA) oxidase ]] and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Fenofibrate >> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and [[ enoyl-CoA hydratase ]] and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Fenofibrate and << GW2331 >> induced expression of acyl-coenzyme A (CoA) oxidase and [[ enoyl-CoA hydratase ]] and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Rosiglitazone >> modestly increased [[ apolipoprotein C-III ]] mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Rosiglitazone >> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of [[ glucose transporter 4 ]] and phosphoenolpyruvate carboxykinase in adipose tissue.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Rosiglitazone >> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and [[ phosphoenolpyruvate carboxykinase ]] in adipose tissue.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the << apoA-I >> induction [[ pitavastatin ]] (3 microM)>simvastatin (10 microM)>atorvastatin (30 microM).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the << apoA-I >> induction pitavastatin (3 microM)>[[ simvastatin ]] (10 microM)>atorvastatin (30 microM).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Each statin induced apoA-I expression (mRNA and protein) dose-dependently: the rank order of the << apoA-I >> induction pitavastatin (3 microM)>simvastatin (10 microM)>[[ atorvastatin ]] (30 microM).", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Based on HMG-CoA reductase inhibition, << pitavastatin >>-induced [[ apoA-I ]] more efficiently than simvastatin and atorvastatin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced << apoA-I >> more efficiently than [[ simvastatin ]] and atorvastatin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Based on HMG-CoA reductase inhibition, pitavastatin-induced << apoA-I >> more efficiently than simvastatin and [[ atorvastatin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further study revealed that << pitavastatin >> increased [[ ABCA1 ]] mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and Y27632) increased apoA-I production in the HepG2 cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and Rho kinase inhibitor (C3T and << Y27632 >>) increased [[ apoA-I ]] production in the HepG2 cells.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases [[ apoA-I ]] in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting [[ apoA-I ]] production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through [[ ABCA1 ]] induction and lipidation of apoA-I.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of [[ apoA-I ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The reduction of << P2X3 >> expression levels was reversed by the proteasomal inhibitor [[ MG-132 ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The results demonstrated that Î²-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with Î²-ionone (25, 50, 100 and 200Â Î¼mol/L) for 24Â h. << Î²-ionone >> was also shown to induce the expression of cleaved-[[ caspase-3 ]] and inhibit bcl-2 expression in SGC-7901 cells in a dose-dependent manner.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Ozone >> plus PM(2.5) exposure, however, induced [[ CRP ]], IL-6, CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Ozone >> plus PM(2.5) exposure, however, induced CRP, [[ IL-6 ]], CK, LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Ozone >> plus PM(2.5) exposure, however, induced CRP, IL-6, [[ CK ]], LDH and MDA increase, SOD and HRV decrease significantly in a dose-response way.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Ozone >> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, [[ LDH ]] and MDA increase, SOD and HRV decrease significantly in a dose-response way.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "An angiotensin II AT1 receptor antagonist, << telmisartan >> augments glucose uptake and [[ GLUT4 ]] protein expression in 3T3-L1 adipocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with << telmisartan >> caused a dose-dependent increase in mRNA levels for [[ PPARgamma ]] target genes such as aP2 and adiponectin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with << telmisartan >> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as [[ aP2 ]] and adiponectin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Treatment of both differentiating adipocytes and fully differentiated adipocytes with << telmisartan >> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and [[ adiponectin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "By contrast, << telmisartan >> attenuated [[ 11beta-hydroxysteroid dehydrogenase type 1 ]] mRNA level in differentiated adipocytes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Of note, we demonstrated for the first time that << telmisartan >> augmented [[ GLUT4 ]] protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: Intake of high SFAs and << MUFAs >> appears to increase expression of PBMC [[ D6D ]] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: Intake of high << SFAs >> and MUFAs appears to increase expression of PBMC [[ D6D ]] and D5D genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: Intake of high << SFAs >> and MUFAs appears to increase expression of PBMC D6D and [[ D5D ]] genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION: Intake of high SFAs and << MUFAs >> appears to increase expression of PBMC D6D and [[ D5D ]] genes, whilst high EFAs intake appears to decrease expression of PBMC D6D and D5D genes.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, << all-trans retinoic acid >> (atRA), which regulates the expression of a battery of target genes through several families of [[ nuclear receptors ]] (RARs, RXRs and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, << all-trans retinoic acid >> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors ([[ RARs ]], RXRs and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, << all-trans retinoic acid >> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, [[ RXRs ]] and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, << all-trans retinoic acid >> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARÎ²/Î´), [[ polymorphic retinoic acid (RA) response elements ]] and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<< atRA >>), which regulates the expression of a battery of target genes through several families of [[ nuclear receptors ]] (RARs, RXRs and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<< atRA >>), which regulates the expression of a battery of target genes through several families of nuclear receptors ([[ RARs ]], RXRs and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<< atRA >>), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, [[ RXRs ]] and PPARÎ²/Î´), polymorphic retinoic acid (RA) response elements and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<< atRA >>), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPARÎ²/Î´), [[ polymorphic retinoic acid (RA) response elements ]] and multiple coregulators.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Propranolol >> treatment (4 X 40 mg/day) increased the density of [[ beta 2-adrenoceptors ]] by 25% after 2 days; concomitantly PRA and heart rate were reduced.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of [[ dCK ]] in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the [[ human nucleoside equilibrative transporter 1 ]] (hENT1) in all cell lines.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 ([[ hENT1 ]]) in all cell lines.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) << pemetrexed >> enhances [[ dCK ]] and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) << pemetrexed >> enhances dCK and [[ hENT1 ]] expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULT(S): The expression of endometrial << ERalpha >>, PRAB, PRB, and SRC-1 was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULT(S): The expression of endometrial ERalpha, << PRAB >>, PRB, and SRC-1 was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULT(S): The expression of endometrial ERalpha, PRAB, << PRB >>, and SRC-1 was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and << SRC-1 >> was increased significantly after 1 week of [[ mifepristone ]], but the increase was no longer seen after 10 weeks.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION(S): Short-term exposure of << mifepristone >> in new starters of DMPA increases the expression of endometrial [[ ERalpha ]], PRAB, PRB, and SRC-1 and promotes cell proliferation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION(S): Short-term exposure of << mifepristone >> in new starters of DMPA increases the expression of endometrial ERalpha, [[ PRAB ]], PRB, and SRC-1 and promotes cell proliferation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION(S): Short-term exposure of << mifepristone >> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, [[ PRB ]], and SRC-1 and promotes cell proliferation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "CONCLUSION(S): Short-term exposure of << mifepristone >> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and [[ SRC-1 ]] and promotes cell proliferation.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << 5-ASA >> treatment restored membranous expression of adhesion molecules [[ E-cadherin ]] and Î²-catenin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, << 5-ASA >> treatment restored membranous expression of adhesion molecules E-cadherin and [[ Î²-catenin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In TPC1, BCPAP, FRO, WRO cell lines << PJ34 >> induced a strong increase in [[ NIS ]] mRNA levels.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We also investigated the epigenetic status of NIS promoter after << PJ34 >> treatment in TPC1 cell line: in addition to an increase of [[ histone modification activation marks ]] (H3K9K14ac, H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We also investigated the epigenetic status of NIS promoter after << PJ34 >> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks ([[ H3K9K14ac ]], H3K4me3), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "We also investigated the epigenetic status of NIS promoter after << PJ34 >> treatment in TPC1 cell line: in addition to an increase of histone modification activation marks (H3K9K14ac, [[ H3K4me3 ]]), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Like conventional ACE inhibitors, << omapatrilat >> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of [[ atrial and brain natriuretic peptides ]] and bradykinin.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Like conventional ACE inhibitors, << omapatrilat >> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and [[ bradykinin ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Administration of low, but not high, doses of oral << nicotine >> in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of [[ tumor necrosis factor-Î± ]].", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Liver << BHMT >> activity was 1.3-fold higher in rats fed the Met deficient diet containing [[ choline ]], which was reflected in corresponding increases in mRNA content and immunodetectable protein.", "metadata": [], "label": "INDIRECT-UPREGULATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "In general, << rifampicin >> can act on a pattern: rifampicin activates the [[ nuclear pregnane X receptor ]] that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< Phenylephrine >> elicited a concentration-dependent positive inotropic effect via [[ alpha 1-adrenoceptors ]] in the presence of either (+/-)-bupranolol or S(-)-timolol.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Full agonists to the << peroxisome proliferator-activated receptor (PPAR)Î³ >>, such as [[ Rosiglitazone ]], have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The results suggested that both the << EtOAc >> extract and berberine were able to activate [[ PPARÎ±/Î²/Î³ ]], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The results suggested that both the EtOAc extract and << berberine >> were able to activate [[ PPARÎ±/Î²/Î³ ]], and Rhizoma Coptis contains potential natural agonists of PPARs besides berberine.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "The results suggested that both the EtOAc extract and berberine were able to activate << PPARÎ±/Î²/Î³ >>, and Rhizoma Coptis contains potential natural agonists of PPARs besides [[ berberine ]].", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "<< PEA >> was a potent and full agonist at each species of [[ TAAR1 ]], whereas TYR was a full agonist for the rodent TAAR1s but was a partial agonist at h-rChTAAR1.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "PEA was a potent and full agonist at each species of TAAR1, whereas << TYR >> was a full agonist for the [[ rodent TAAR1s ]] but was a partial agonist at h-rChTAAR1.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, both isomers of << METH >> were full agonists at [[ mTAAR1 ]] and h-rChTAAR1, whereas both were partial agonists at rTAAR1.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Interestingly, both isomers of << METH >> were full agonists at mTAAR1 and [[ h-rChTAAR1 ]], whereas both were partial agonists at rTAAR1.", "metadata": [], "label": "AGONIST-ACTIVATOR", "cid": "3", "custom_label": "REGULATOR-POSITIVE"}
{"text": "Moreover, the specific << PKC >>-inhibitor [[ 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ]] (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, the specific << PKC >>-inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide ([[ GF 109203X ]]) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a << cyclooxygenase-2 >> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [[ salsalate ]], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<< COX-2 >>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, [[ salsalate ]], or acetaminophen) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a << cyclooxygenase-2 >> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or [[ acetaminophen ]]) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<< COX-2 >>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or [[ acetaminophen ]]) randomly received celecoxib 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a << cyclooxygenase-2 >> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received [[ celecoxib ]] 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<< COX-2 >>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received [[ celecoxib ]] 200 mg/day or rofecoxib 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a << cyclooxygenase-2 >> (COX-2) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or [[ rofecoxib ]] 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Patients stable on warfarin therapy and concurrently taking a cyclooxygenase-2 (<< COX-2 >>) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, salsalate, or acetaminophen) randomly received celecoxib 200 mg/day or [[ rofecoxib ]] 25 mg/day for three weeks.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pharmacokinetic and pharmacodynamic modeling of << hedgehog >> inhibitor [[ TAK-441 ]] for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<< TAK-441 >>) is a potent, selective [[ hedgehog ]] signaling pathway inhibitor that binds to Smo and is being developed for the treatment of cancer.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Esmolol >>, a unique cardioselective [[ beta 1-adrenergic receptor ]] blocker with a half-life of 9 minutes, can enable some patients with relative contraindications to beta blockers to nevertheless benefit from early beta-blocking therapy.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of the actions of << ET-1 >> by [[ salicylates ]] is apparently competitive.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical << monocarboxylate transporter >> (MCT) inhibitor, [[ alpha-cyano-4-hydroxycinnamic acid ]], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (<< MCT >>) inhibitor, [[ alpha-cyano-4-hydroxycinnamic acid ]], suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and << imidazo[1,2-c]pyrimidine >>-based [[ kinase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between CHK1 and MK2: Discovery of << imidazo[1,2-a]pyrazine >>- and imidazo[1,2-c]pyrimidine-based [[ kinase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between << CHK1 >> and MK2: Discovery of [[ imidazo[1,2-a]pyrazine ]]- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between CHK1 and << MK2 >>: Discovery of imidazo[1,2-a]pyrazine- and [[ imidazo[1,2-c]pyrimidine ]]-based kinase inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between << CHK1 >> and MK2: Discovery of imidazo[1,2-a]pyrazine- and [[ imidazo[1,2-c]pyrimidine ]]-based kinase inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Potency switch between CHK1 and << MK2 >>: Discovery of [[ imidazo[1,2-a]pyrazine ]]- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: Testosterone-to-estradiol ratio levels in infertile men improve during treatment with the << aromatase >> inhibitor, [[ testolactone ]], and resulting changes in semen parameters.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We evaluated the effect of << anastrozole >>, a more selective [[ aromatase ]] inhibitor, on the hormonal and semen profiles of infertile men with abnormal baseline testosterone-to-estradiol ratios.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Increased << IL-5 >> activity in the serum was inhibited by both [[ pranlukast ]] and MCI-826 by over 90%.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Increased << IL-5 >> activity in the serum was inhibited by both pranlukast and [[ MCI-826 ]] by over 90%.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We investigated the effect of << AT1 receptor >> blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent [[ pancuronium bromide ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dimemorfan >> pre-treatment also attenuated the KA-induced increases in c-fos/c-jun expression, [[ activator protein (AP)-1 ]] DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Fragment-based design, synthesis, and biological evaluation of << N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide >> derivatives as novel [[ Mcl-1 ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We have previously reported a nanomolar inhibitor of antiapoptotic << Mcl-1 >> protein, [[ 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile ]] (S1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A novel potent compound, << N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide >> (12c), which binds [[ Mcl-1 ]] with an IC(50) value of 54 nM was obtained.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A novel << benzo[d]imidazole >> derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of [[ NLRP3 ]] inflammasome.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, the disease activity index, histopathologic scores and << myeloperoxidase >> activity were also significantly reduced by [[ Fc11a-2 ]] treatment.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, a decreased CD11c(+) macrophage infiltration in colons and inactivation of << caspase-1 >> in peritoneal macrophages were detected in [[ Fc11a ]]-2-treated mice.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Taken together, our results demonstrate the ability of << Fc11a-2 >> to inhibit [[ NLRP3 ]] inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism of action of << Fc11a-2 >> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1Î² and pro-IL-18 which in turn suppressed the activation of [[ NLRP3 ]] inflammasome.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These findings demonstrate that cinnamon << polyphenols >> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of [[ iNOS ]], NF-ÎºB activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These findings demonstrate that cinnamon << polyphenols >> can exert the hypoglycemic and hypolipidemic effects through the mechanisms that may be associated with repairing pancreatic beta cells in diabetic mice and improving its anti-oxidative capacity, as well as attenuating cytotoxicity via inhibition of iNOS, [[ NF-ÎºB ]] activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by << indomethacin >>, a preferential [[ COX-1 ]] inhibitor, but not by NS-398, a selective COX-2 inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, PS liposome-induced PGE2 production was significantly suppressed by indomethacin, a preferential COX-1 inhibitor, but not by << NS-398 >>, a selective [[ COX-2 ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenserine >>, a derivative of physostigmine, was first described as an inhibitor of [[ acetylcholinesterase ]] (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenserine, a derivative of << physostigmine >>, was first described as an inhibitor of [[ acetylcholinesterase ]] (AChE) and was shown to improve cognition in various experimental paradigms in rodents and dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenserine >>, a derivative of physostigmine, was first described as an inhibitor of acetylcholinesterase ([[ AChE ]]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenserine, a derivative of << physostigmine >>, was first described as an inhibitor of acetylcholinesterase ([[ AChE ]]) and was shown to improve cognition in various experimental paradigms in rodents and dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenserine >> deserves attention for an additional quality of action: in addition to inhibiting [[ AChE ]], it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing APP translation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenserine is also unique because of differing actions of its enantiomers: << (-)-phenserine >> is the active enantiomer for inhibition of [[ AChE ]], whereas (+)-phenserine ('posiphen') has weak activity as an AChE inhibitor and can be dosed much higher.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas << (+)-phenserine >> ('posiphen') has weak activity as an [[ AChE ]] inhibitor and can be dosed much higher.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenserine is also unique because of differing actions of its enantiomers: (-)-phenserine is the active enantiomer for inhibition of AChE, whereas (+)-phenserine ('<< posiphen >>') has weak activity as an [[ AChE ]] inhibitor and can be dosed much higher.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Selective inhibition of << PDE5 >> is a rational therapeutic approach in ED, as proved by the clinical success of [[ sildenafil ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As free << sildenafil >> plasma concentrations approach concentrations sufficient to inhibit retinal [[ PDE6 ]], usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of << cGMP >>-specific [[ PDE5 ]] is a means of improving erectile function at minimal risk of adverse events.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> exhibits inhibitory potency against [[ PDE5 ]] and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment [[ PDE6 ]], the predominant PDE in the phototransduction cascade in rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant [[ PDE ]] in the phototransduction cascade in rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This approach is validated by the clinical efficacy and safety of << sildenafil >>, the pioneering drug for selective [[ PDE5 ]] inhibitor therapy for ED.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cells were also evaluated in the presence of << wortmannin >>, an inhibitor of [[ phosphatidylinositol 3-kinases ]] and thus AKt (0-100 nM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Only FFAs that increased << ceramides >> caused impairment of AKt and [[ PTP1B ]] phosphorylation at Ser 50.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Mechanism of the irreversible inactivation of << mouse ornithine decarboxylase >> by [[ alpha-difluoromethylornithine ]]. Characterization of sequences at the inhibitor and coenzyme binding sites.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Mouse ornithine decarboxylase >> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [[ alpha-difluoromethylornithine ]] (DFMO).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Mouse ornithine decarboxylase >> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ([[ DFMO ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Mouse ornithine decarboxylase (<< ODC >>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, [[ alpha-difluoromethylornithine ]] (DFMO).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Mouse ornithine decarboxylase (<< ODC >>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine ([[ DFMO ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These compounds resulted from our efforts to merge the pharmacophores of selective << factor Xa >> inhibitor [[ rivaroxaban ]] with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Resulting from this study, a structurally novel class of submicromolar fibrinogen << GPIIb/IIIa >> binding inhibitor bearing [[ 1,2,4-oxadiazol-5(4H)-one ]] moiety is also described.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nicotinic-receptor potentiator drugs, huprine X and << galantamine >>, increase ACh release by blocking [[ AChE ]] activity but not acting on nicotinic receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This effect was reverted in the presence of << atropine >> (ATR; 0.1 microM), which blocks the pre-synaptic [[ muscarinic M2 receptor ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This effect was reverted in the presence of atropine (<< ATR >>; 0.1 microM), which blocks the pre-synaptic [[ muscarinic M2 receptor ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To test the role of << nicotinic receptors >> in the drugs' effects on [3H]-ACh release, [[ mecamylamine ]] (MEC) 100 microM was used to block such receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To test the role of << nicotinic receptors >> in the drugs' effects on [3H]-ACh release, mecamylamine ([[ MEC ]]) 100 microM was used to block such receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<< NEP >> inhibitors [[ GW660511X ]] and omapatrilat.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual << ACE >>/NEP inhibitors [[ GW660511X ]] and omapatrilat.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual << ACE >>/NEP inhibitors GW660511X and [[ omapatrilat ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/<< NEP >> inhibitors GW660511X and [[ omapatrilat ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual << ACE >>/NEP inhibitors ([[ GW660511X ]] and omapatrilat) currently under clinical trial.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/<< NEP >> inhibitors ([[ GW660511X ]] and omapatrilat) currently under clinical trial.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual << ACE >>/NEP inhibitors (GW660511X and [[ omapatrilat ]]) currently under clinical trial.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79/81 Br-Phe5) BrBK in the presence of two new dual ACE/<< NEP >> inhibitors (GW660511X and [[ omapatrilat ]]) currently under clinical trial.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Unlike GW660511X, << omapatrilat >> abolished the production of BrBK1-5 and BrBK1-7, suggesting a better [[ ACE ]] inhibition effect over GW660511X as no NEP activity was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better << ACE >> inhibition effect over [[ GW660511X ]] as no NEP activity was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study shows that the potency of << GW660511X >> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of [[ ACE ]]/NEP inhibition in relation to effects in humans.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study shows that the potency of << GW660511X >> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/[[ NEP ]] inhibition in relation to effects in humans.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study shows that the potency of GW660511X in comparison with << omapatrilat >> is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE/[[ NEP ]] inhibition in relation to effects in humans.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, << MDZ >> caused mechanism-based inactivation of [[ cytochrome P450 3A ]]-dependent TRZ 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited << human Hsp60 >> chaperone activity (IC(50): 6.80 Â± 0.25 Î¼M) and this inhibition activity was higher than that of [[ ETB ]] (IC(50): 10.9 Â± 0.63 Î¼M).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The exception was << bupropion >>, a dual [[ norepinephrine transporter ]]/dopamine transporter blocker, which tended to increase spontaneous locomotor activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The exception was << bupropion >>, a dual norepinephrine transporter/[[ dopamine transporter ]] blocker, which tended to increase spontaneous locomotor activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Coadministration of reboxetine and the << dopamine transporter >> blocker [[ GBR 12909 ]] also increased spontaneous locomotor activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating [[ cdc25C ]]-cdc2 via ATM-Chk1/2 activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Jaceosidin >>, isolated from dietary mugwort (Artemisia princeps), induces G2/M cell cycle arrest by inactivating cdc25C-[[ cdc2 ]] via ATM-Chk1/2 activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the << ERK >> inhibitor, [[ PD98059 ]], attenuated cell growth inhibition by jaceosidin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data suggest that << jaceosidin >>, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the [[ Cdc2 ]]-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data suggest that << jaceosidin >>, isolated from Japanese mugwort, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-[[ cyclin B1 ]] complex, followed by G2/M cell cycle arrest in endometrial cancer cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Activity of << XL184 >> (Cabozantinib), an oral [[ tyrosine kinase ]] inhibitor, in patients with medullary thyroid cancer.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Activity of XL184 (<< Cabozantinib >>), an oral [[ tyrosine kinase ]] inhibitor, in patients with medullary thyroid cancer.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: << XL184 >> (cabozantinib) is a potent inhibitor of [[ MET ]], vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of [[ MET ]], vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: << XL184 >> (cabozantinib) is a potent inhibitor of MET, [[ vascular endothelial growth factor receptor 2 ]] (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: << XL184 >> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([[ VEGFR2 ]]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: << XL184 >> (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and [[ RET ]], with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of MET, [[ vascular endothelial growth factor receptor 2 ]] (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 ([[ VEGFR2 ]]), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PURPOSE: XL184 (<< cabozantinib >>) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and [[ RET ]], with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This effect was potentiated by << isobutylmethylxanthine >>, an inhibitor of [[ phosphodiesterase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of iloprost on << tissue factor >> expression were also potentiated by [[ isobutylmethylxanthine ]] and mimicked by forskolin and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of iloprost on << tissue factor >> expression were also potentiated by isobutylmethylxanthine and mimicked by [[ forskolin ]] and dibutyryl cyclic AMP but not dibutyryl cyclic GMP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of iloprost on << tissue factor >> expression were also potentiated by isobutylmethylxanthine and mimicked by forskolin and d[[ ibutyryl cyclic AMP ]] but not dibutyryl cyclic GMP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis and in-silico studies of some << diaryltriazole >> derivatives as potential [[ cyclooxygenase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ZD1839 >> (\"Iressa\"), a quinazoline [[ tyrosine kinase ]] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ZD1839 >> (\"Iressa\"), a quinazoline tyrosine kinase inhibitor selective for the [[ EGFR ]], has shown good activity in preclinical studies and in the early phase of clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "ZD1839 (\"<< Iressa >>\"), a quinazoline [[ tyrosine kinase ]] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "ZD1839 (\"<< Iressa >>\"), a quinazoline tyrosine kinase inhibitor selective for the [[ EGFR ]], has shown good activity in preclinical studies and in the early phase of clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << tyrosine kinase >> inhibitor [[ ZD1839 ]] (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The tyrosine kinase inhibitor << ZD1839 >> (\"Iressa\") inhibits [[ HER2 ]]-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The tyrosine kinase inhibitor ZD1839 (\"<< Iressa >>\") inhibits HER2-driven signaling and suppresses the growth of [[ HER2 ]]-overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << tyrosine kinase >> inhibitor ZD1839 (\"[[ Iressa ]]\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The tyrosine kinase inhibitor ZD1839 (\"<< Iressa >>\") inhibits [[ HER2 ]]-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, activation of transfected cells and porcine PBMC by << TLR7 >> ligands was inhibited by [[ bafilomycin A(1) ]] indicating the requirement of endosomal/lysosomal acidification for activation of the receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "HeLa cells transfected with the MR77 gene exhibited inhibition of << adenylate cyclase >> in response to [[ serotonin ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Stereospecific inhibition of << monoamine uptake transporters >> by [[ meta-hydroxyephedrine ]] isomers.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We hypothesized that the << HED >> compounds would be most potent at the [[ norepinephrine transporter ]] (NET) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We hypothesized that the << HED >> compounds would be most potent at the norepinephrine transporter ([[ NET ]]) compared to the serotonin or dopamine transporters and that the 1R diastereomers would be more effective than 1S diastereomers.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To extend structure-activity analyses of binding sites within << monoamine transporters >> and to determine which stereoisomer displayed the best selectivity for PET imaging applications, we tested the [[ HED ]] compounds for their abilities to inhibit [(3)H]neurotransmitter uptake into platelets, transfected cells, and chromaffin vesicles.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of << CB1 receptors >> by [[ SR 141716A ]] increases the density of these receptors in the PVN.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We compared the effects of << Captopril >> (an [[ ACE ]] inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We compared the effects of Captopril (an ACE inhibitor with -SH group), << enalapril >> (an [[ ACE ]]-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of << captopril >> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [[ ACE ]] inhibitors in high dieted methionine mice.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of captopril and << enalapril >> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with [[ ACE ]] inhibitors in high dieted methionine mice.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of captopril and enalapril to study the role of the << sulfhydryl >>-group in improvement of endothelial dysfunction with [[ ACE ]] inhibitors in high dieted methionine mice.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We compared the effects of Captopril (an << ACE >> inhibitor with -[[ SH ]] group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "It was found that a single intragastric gavage by << L-methionine >> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of [[ PON1 ]] and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "It was found that a single intragastric gavage by << L-methionine >> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and [[ SOD ]], similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggested that Captopril can protect the vascular endothelium against the damages induced by << L-methionine >> in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in [[ PON1 ]] activity and NO levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< (2R)-IKM-159 >> locks the [[ GluA2 ]] in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Finally, << PLA2 >> inhibitor methyl [[ arachidonyl fluorophosphonate ]] blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Finally, PLA2 inhibitor methyl << arachidonyl fluorophosphonate >> blocked the PUFA effects on [[ COX-2 ]] induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with normally-fed counterparts, PM-CP rats exhibited higher glutathione S-transferase, aminopeptidase N and cysteine S-conjugate beta-lyase (CCBL) and lower gamma-glutamyltransferase activities, PM-FU rats exhibited decreased dihydropyrimidine dehydrogenase and cytochrome P450 1A1/2 activities and PM-<< MMC >> rats showed higher quinone reductase and depleted [[ xanthine oxidase ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Curcumin >> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the [[ TLR4 ]]/NF-ÎºB signaling pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Curcumin >> improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/[[ NF-ÎºB ]] signaling pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study explored whether << curcumin >> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/[[ NF-ÎºB ]] signaling pathway and IL-27 expression.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study explored whether << curcumin >> improves colonic inflammation in a rat colitis model through inhibition of the [[ TLR4 ]]/NF-ÎºB signaling pathway and IL-27 expression.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, [[ myeloperoxidase ]] activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, TLR4 protein, NF-ÎºB p65 protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The anti-inflammatory actions of << curcumin >> on colitis may involve inhibition of the [[ TLR4 ]]/NF-ÎºB signaling pathway and of IL-27 expression.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The anti-inflammatory actions of << curcumin >> on colitis may involve inhibition of the TLR4/[[ NF-ÎºB ]] signaling pathway and of IL-27 expression.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We examined the anti-inflammatory effect of licofelone on atherosclerotic lesions as well as in isolated neutrophils from whole blood of rabbits compared with a selective inhibitor of << COX-2 >>, [[ rofecoxib ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a balanced inhibitor of [[ cyclooxygenase ]] and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a balanced inhibitor of cyclooxygenase and [[ 5-lipoxygenase ]], reduces inflammation in a rabbit model of atherosclerosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to [[ cycloxygenase-1 ]] blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a dual anti-inflammatory drug that inhibits [[ 5-lipoxygenase ]] (LOX) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase ([[ LOX ]]) and cyclooxygenase (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and [[ cyclooxygenase ]] (COX) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >>, a dual anti-inflammatory drug that inhibits 5-lipoxygenase (LOX) and cyclooxygenase ([[ COX ]]) enzymes, may have a better cardiovascular profile that cycloxygenase-2 inhibitors due to cycloxygenase-1 blockade-mediated antithrombotic effect and a better gastrointestinal tolerability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >> almost abolished [[ 5-LOX ]] activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, in the presence of 100 mM << Na+ >>, which is required for opiate inhibition of [[ adenylate cyclase ]] activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +/- 110 nM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Jaspamide >> also inhibited other channels including [[ Cav1.2 ]], Cav3.2, and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Jaspamide >> also inhibited other channels including Cav1.2, [[ Cav3.2 ]], and HCN2; however, the Kv11.1 (hERG) channel was minimally affected.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Jaspamide >> also inhibited other channels including Cav1.2, Cav3.2, and [[ HCN2 ]]; however, the Kv11.1 (hERG) channel was minimally affected.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of << zileuton >>, a specific inhibitor of [[ 5-lipoxygenase ]] (5-LOX) and a clinically used anti-asthmatic drug.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Troglitazone inhibited the antigen-induced production of LTB(4), C(4) and E(4) and the potency of the inhibition was comparable to that of << zileuton >>, a specific inhibitor of 5-lipoxygenase ([[ 5-LOX ]]) and a clinically used anti-asthmatic drug.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to << zileuton >>, suggesting that troglitazone inhibits LT production by direct inhibition of [[ 5-LOX ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Troglitazone inhibited LTB(4) production by the supernatant fraction of RBL-2H3 cell lysate with similar potency to zileuton, suggesting that << troglitazone >> inhibits LT production by direct inhibition of [[ 5-LOX ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These findings suggest that << troglitazone >> inhibits antigen-induced LT production in the IgE-sensitized RBL-2H3 cells and A23187-stimulated rat peritoneal neutrophils by direct inhibition of [[ 5-LOX ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Orlistat >> has been the most used anti-obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal [[ lipases ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to test the hypothesis that << orlistat >> inhibits [[ CESs ]] with higher potency toward CES1 than CES2, a carboxylesterase with little lipase activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to test the hypothesis that << orlistat >> inhibits CESs with higher potency toward [[ CES1 ]] than CES2, a carboxylesterase with little lipase activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to test the hypothesis that << orlistat >> inhibits CESs with higher potency toward CES1 than [[ CES2 ]], a carboxylesterase with little lipase activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to test the hypothesis that << orlistat >> inhibits CESs with higher potency toward CES1 than CES2, a [[ carboxylesterase ]] with little lipase activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to test the hypothesis that << orlistat >> inhibits CESs with higher potency toward CES1 than CES2, a carboxylesterase with little [[ lipase ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Contrary to the hypothesis, orlistat at 1 nM inhibited << CES2 >> activity by 75% but no inhibition on CES1, placing CES2 one of the most sensitive targets of [[ orlistat ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Contrary to the hypothesis, orlistat at 1 nM inhibited CES2 activity by 75% but no inhibition on CES1, placing << CES2 >> one of the most sensitive targets of [[ orlistat ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of this << carboxylesterase >> probably presents a major source for altered therapeutic activity of these medicines if co-administered with [[ orlistat ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We show that << sorafenib >> (BAY 43-9006, Nexavar) potently inhibits [[ FLT3 ]] enzymatic and signaling activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We show that sorafenib (<< BAY 43-9006 >>, Nexavar) potently inhibits [[ FLT3 ]] enzymatic and signaling activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We show that sorafenib (BAY 43-9006, << Nexavar >>) potently inhibits [[ FLT3 ]] enzymatic and signaling activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, << sorafenib >> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as [[ extracellular signal-regulated kinase1/2 ]] and Stat5 phosphorylation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, << sorafenib >> blocked basal and ligand dependent FLT3-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and [[ Stat5 ]] phosphorylation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HEK293 cells stably transfected with FLT3-WT or FLT3-ITD, << sorafenib >> blocked basal and ligand dependent [[ FLT3 ]]-mediated tyrosine autophosphorylation as well as extracellular signal-regulated kinase1/2 and Stat5 phosphorylation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The growth of the << FLT3 >>-independent RS4-11 cell line was only weakly inhibited by [[ sorafenib ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In leukemia cell lines MV4-11 and EOL-1, << sorafenib >> treatment resulted in decreased cell proliferation and inhibition of [[ FLT3 ]] signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The demonstration that << sorafenib >> exhibits potent target inhibition and efficacy in [[ FLT3 ]]-driven models suggests that this compound may have a therapeutic benefit for patients with FLT3-driven leukemias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antitumor activity of << sorafenib >> in [[ FLT3 ]]-driven leukemic cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The demonstration that << sorafenib >> exhibits potent target inhibition and efficacy in FLT3-driven models suggests that this compound may have a therapeutic benefit for patients with [[ FLT3 ]]-driven leukemias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas << NS398 >>, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas << NS398 >>, carprofen, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [[ COX-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, << carprofen >>, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, << carprofen >>, tolfenamic acid, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [[ COX-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, << tolfenamic acid >>, nimesulide, and etodolac had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, << tolfenamic acid >>, nimesulide, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [[ COX-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, << nimesulide >>, and etodolac had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, << nimesulide >>, and etodolac had more than 5 times greater preference for inhibiting COX-2 than [[ COX-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and << etodolac >> had more than 5 times greater preference for inhibiting [[ COX-2 ]] than COX-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Aspirin, diclofenac, indomethacin, ketoprofen, meclofenamic acid, and piroxicam had little selectivity toward COX isozymes, whereas NS398, carprofen, tolfenamic acid, nimesulide, and << etodolac >> had more than 5 times greater preference for inhibiting COX-2 than [[ COX-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS AND CLINICAL RELEVANCE: << Canine COX-2 >> was selectively inhibited by [[ etodolac ]], nimesulide, and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS AND CLINICAL RELEVANCE: << Canine COX-2 >> was selectively inhibited by etodolac, [[ nimesulide ]], and NS398; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS AND CLINICAL RELEVANCE: << Canine COX-2 >> was selectively inhibited by etodolac, nimesulide, and [[ NS398 ]]; tolfenamic acid and carprofen also appeared to be preferential COX-2 inhibitors in dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; << tolfenamic acid >> and carprofen also appeared to be preferential [[ COX-2 ]] inhibitors in dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Canine COX-2 was selectively inhibited by etodolac, nimesulide, and NS398; tolfenamic acid and << carprofen >> also appeared to be preferential [[ COX-2 ]] inhibitors in dogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<< proteasome >> inhibitor I, [[ MG-132 ]], or lactacystin) decreased the extent of U50,488H-induced down-regulation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pretreatment with lysosomal enzyme inhibitors [(2S, 3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester or chloroquine] or proteasome inhibitors (<< proteasome >> inhibitor I, MG-132, or [[ lactacystin ]]) decreased the extent of U50,488H-induced down-regulation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of << soman >>-inhibited [[ human acetylcholinesterase ]] in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Acetylcholinesterase (<< AChE >>) inhibited by the [[ organophosphate ]] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Acetylcholinesterase >> (AChE) inhibited by the [[ organophosphate ]] soman (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Acetylcholinesterase (<< AChE >>) inhibited by the organophosphate [[ soman ]] (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Acetylcholinesterase >> (AChE) inhibited by the organophosphate [[ soman ]] (1,2,2-trimethyl-propylmethylphosphonofluoridate) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Acetylcholinesterase (<< AChE >>) inhibited by the organophosphate soman ([[ 1,2,2-trimethyl-propylmethylphosphonofluoridate ]]) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Acetylcholinesterase >> (AChE) inhibited by the organophosphate soman ([[ 1,2,2-trimethyl-propylmethylphosphonofluoridate ]]) rapidly becomes resistant to reactivation by oximes due to dealkylation of the soman-enzyme complex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effect of the four mono- and bisquaternary ammonium compounds tetramethylammonium (TMA), hexamethonium, decamethonium and suxamethonium on the reactivatability of << soman >>-inhibited, solubilized [[ AChE ]] from human erythrocytes was investigated in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "If the effectors were added after 5 min of aging they increased the activity of << soman >>-inhibited [[ AChE ]], but to a considerably smaller extent than HI 6.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << IMG >> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of [[ thrombin ]] and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << IMG >> and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and [[ FXa ]], and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with IMG and << hyperoside >> resulted in significantly prolonged aPTT and PT and inhibition of the activities of [[ thrombin ]] and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with IMG and << hyperoside >> resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and [[ FXa ]], and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with << IMG >> and hyperoside resulted in inhibition of [[ TNF-Î± ]]-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with IMG and << hyperoside >> resulted in inhibition of [[ TNF-Î± ]]-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of << kinase >> blockers is [[ Imatinib ]] (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of << kinase >> blockers is Imatinib ([[ Imatinib mesylate ]], Gleevec, STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of << kinase >> blockers is Imatinib (Imatinib mesylate, [[ Gleevec ]], STI571), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of << kinase >> blockers is Imatinib (Imatinib mesylate, Gleevec, [[ STI571 ]]), the inhibitor of Bcr/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is << Imatinib >> (Imatinib mesylate, Gleevec, STI571), the inhibitor of [[ Bcr ]]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (<< Imatinib mesylate >>, Gleevec, STI571), the inhibitor of [[ Bcr ]]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, << Gleevec >>, STI571), the inhibitor of [[ Bcr ]]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, << STI571 >>), the inhibitor of [[ Bcr ]]/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is << Imatinib >> (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr/[[ Abl ]] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (<< Imatinib mesylate >>, Gleevec, STI571), the inhibitor of Bcr/[[ Abl ]] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, << Gleevec >>, STI571), the inhibitor of Bcr/[[ Abl ]] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, << STI571 >>), the inhibitor of Bcr/[[ Abl ]] oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include << Dasatinib >> (BMS-354825) specific for [[ ABL ]] non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (<< BMS-354825 >>) specific for [[ ABL ]] non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include << Dasatinib >> (BMS-354825) specific for ABL [[ non-receptor cytoplasmic kinase ]], Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, << Gefitinib >> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, << Gefitinib >> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<< Iressa >>), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<< Iressa >>), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), << Erlotinib >> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), << Erlotinib >> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<< OSI-774 >>, Tarceva) and Sunitinib (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<< OSI-774 >>, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, << Tarceva >>) and Sunitinib (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, << Tarceva >>) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and << Sunitinib >> (SU 11248, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and << Sunitinib >> (SU 11248, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<< SU 11248 >>, Sutent) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<< SU 11248 >>, Sutent) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, << Sutent >>) specific for [[ VEGF receptor ]] kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, << Sutent >>) specific for VEGF receptor [[ kinase ]], AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, << AMN107 >> (Nilotinib) and INNO-406 (NS-187) specific for [[ c-KIT ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (<< Nilotinib >>) and INNO-406 (NS-187) specific for [[ c-KIT ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and << INNO-406 >> (NS-187) specific for [[ c-KIT ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (<< NS-187 >>) specific for [[ c-KIT ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: [[ Lapatinib ]] (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib ([[ Lapatinib ditosylate ]], Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, [[ Tykerb ]], GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, [[ GW-572016 ]]), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), [[ Canertinib ]] (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib ([[ CI-1033 ]]), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), [[ Zactima ]] (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima ([[ ZD6474 ]]), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), [[ Vatalanib ]] (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib ([[ PTK787 ]]/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/[[ ZK 222584 ]]), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), [[ Sorafenib ]] (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib ([[ Bay 43-9006 ]], Nexavar), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, [[ Nexavar ]]), and Leflunomide (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and [[ Leflunomide ]] (SU101, Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide ([[ SU101 ]], Arava).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The following << TK >> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, [[ Arava ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, kinetic analysis revealed that inhibition by << reserpine >>, a typical [[ VMAT2 ]] inhibitor, was uncompetitive, decreasing maximum velocity and affinity for dopamine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << fluoxetine >> inhibited the activity of [[ VMAT2 ]] by a mechanism different from that of reserpine and did not directly interact with the active site of VMAT2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that fluoxetine inhibited the activity of << VMAT2 >> by a mechanism different from that of [[ reserpine ]] and did not directly interact with the active site of VMAT2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << fluoxetine >> inhibited the activity of VMAT2 by a mechanism different from that of reserpine and did not directly interact with the active site of [[ VMAT2 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "All HIV PIs except nelfinavir are coadministered with a low dose of << ritonavir >>, a potent [[ CYP3A ]] inhibitor to improve their pharmacokinetic properties.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The HCV-PIs << boceprevir >> and telaprevir are both, to different extents, inhibitors of [[ CYP3A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The HCV-PIs boceprevir and << telaprevir >> are both, to different extents, inhibitors of [[ CYP3A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent << CYP3A >> inhibitors such as [[ ritonavir ]]- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent << CYP3A >> inhibitors such as ritonavir- or [[ cobicistat ]]-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent << CYP3A >> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, [[ telaprevir ]] or boceprevir, and therefore their coadministration is contraindicated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent << CYP3A >> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or [[ boceprevir ]], and therefore their coadministration is contraindicated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of inhibition of << urokinase-type plasminogen activator >> (u-PA) by [[ amiloride ]] in the cornea and tear fluid of eyes irradiated with UVB.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of inhibition of urokinase-type plasminogen activator (<< u-PA >>) by [[ amiloride ]] in the cornea and tear fluid of eyes irradiated with UVB.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The purpose of the present study was to test our hypothesis that << amiloride >>, a specific [[ u-PA ]] inhibitor, effectively decreases u-PA activity in cornea as well as in tear fluid and favourably affects corneal healing.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The purpose of the present study was to test our hypothesis that << amiloride >>, a specific u-PA inhibitor, effectively decreases [[ u-PA ]] activity in cornea as well as in tear fluid and favourably affects corneal healing.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When << amiloride >> was dropped on the eye surface on the first day of irradiation and subsequently daily until the end of the experiment, [[ u-PA ]] activity in both cornea and tear fluid was strongly inhibited.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, early application of << amiloride >> inhibited [[ u-PA ]] activity in UVB-irradiated corneas as well as in tear fluid and diminished the development of corneal pathology.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the << phosphatase >> inhibitor [[ okadaic acid ]], but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the << tyrosine kinase >> inhibitor [[ lavendustin A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by << mGlu1 >> activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator [[ 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ]] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric << KARs >> by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator [[ 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ]] (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric << KARs >> by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ([[ BAPTA ]]), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by << mGlu1 >> activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid ([[ BAPTA ]]), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric << KARs >> by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor [[ okadaic acid ]], but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by << mGlu1 >> activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor [[ okadaic acid ]], but unaffected by the tyrosine kinase inhibitor lavendustin A.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric << KARs >> by mGlu1 activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor [[ lavendustin A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of heteromeric KARs by << mGlu1 >> activation was attenuated by GDPÎ²S, blocked by an inhibitor of phospholipase C or the calcium chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), prolonged by the phosphatase inhibitor okadaic acid, but unaffected by the tyrosine kinase inhibitor [[ lavendustin A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Orlistat >> is a new inhibitor of [[ pancreatic lipase ]] enzyme.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both << AChE >> and BuChE, [[ rivastigmine ]], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and << BuChE >>, [[ rivastigmine ]], indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, << rivastigmine >>, indicates potential therapeutic benefits of inhibiting both [[ AChE ]] and BuChE in AD and related dementias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, << rivastigmine >>, indicates potential therapeutic benefits of inhibiting both AChE and [[ BuChE ]] in AD and related dementias.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The development of specific << BuChE >> inhibitors and further experience with the dual enzyme inhibitor [[ rivastigmine ]] will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, << topiramate >> at low concentrations causes slow inhibition of [[ GluR5 ]] kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, << topiramate >> at low concentrations causes slow inhibition of GluR5 [[ kainate receptor ]]-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, << topiramate >> at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of [[ GluR5 ]] kainate receptor responses.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, << topiramate >> at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 [[ kainate receptor ]] responses.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVES: The alkaloid << galantamine >> (GAL), which exhibits a combined [[ anticholinesterase ]] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVES: The alkaloid galantamine (<< GAL >>), which exhibits a combined [[ anticholinesterase ]] and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: Following administration of the highest of the << GAL >> doses used (2.5; 5; 10 mg/kg i.m. ), [[ AChE ]] activity decreased mainly in the frontal cortex, hippocampus and hypophysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the interaction of << GAL >> and CAR, [[ AChE ]] inhibition was stronger but without any statistical significance.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nanobody-albumin nanoparticles (NANAPs) for the delivery of a << multikinase >> inhibitor [[ 17864 ]] to EGFR overexpressing tumor cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the << multikinase >> inhibitor [[ 17864 ]]-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Irbesartan >> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this [[ AT1 ]]-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([[ VEGFR-2 ]], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib and << sunitinib >> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 ([[ VEGFR-2 ]], VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, [[ VEGFR-3 ]]) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib and << sunitinib >> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, [[ VEGFR-3 ]]) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and [[ platelet-derived growth factor receptor beta ]] (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib and << sunitinib >> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and [[ platelet-derived growth factor receptor beta ]] (PDGFR-beta), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ([[ PDGFR-beta ]]), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib and << sunitinib >> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta ([[ PDGFR-beta ]]), while temsirolimus is an mTOR inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while << temsirolimus >> is an [[ mTOR ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The turnover of << SERT >> was determined from the rate of recovery of binding after administration of [[ RTI-76 ]], an irreversible inhibitor of ligand binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In preliminary studies, in vitro incubation of rat cerebral cortex with << RTI-76 >> produced a wash and temperature resistant inhibition of [[ SERT ]] binding densities (Bmax).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Citalopram protected against the << RTI-76 >>-induced inhibition of [[ SERT ]] binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by << EGFR >> kinase inhibitor, [[ PD153035 ]], as well as wortmannin, a specific inhibitor of PI3K.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR << kinase >> inhibitor, [[ PD153035 ]], as well as wortmannin, a specific inhibitor of PI3K.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as << wortmannin >>, a specific inhibitor of [[ PI3K ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by << PP2 >>, a selective inhibitor of [[ tyrosine kinase ]] Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by << PP2 >>, a selective inhibitor of tyrosine kinase [[ Src ]] responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by << ERK >> inhibitor, [[ PD98059 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << ERK >>, moreover, did not cause attenuation in mucin secretion in response to [[ cAMP ]] and forskolin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << ERK >>, moreover, did not cause attenuation in mucin secretion in response to cAMP and [[ forskolin ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These << polyphenols >>, but not GvEx, showed a certain level of inhibition of human-cDNA-expressed [[ CYPs ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Optimization of a << 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione >> series of [[ HIV capsid ]] assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-phenyl moiety.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of << HIV capsid >> assembly inhibitors 2: Structure-activity relationships (SAR) of the C3-[[ phenyl ]] moiety.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of << 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione >> inhibitors of [[ HIV capsid ]] (CA) assembly are described.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Detailed structure-activity relationships of the C3-phenyl moiety that allow for the optimization of antiviral potency of a series of << 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione >> inhibitors of HIV capsid ([[ CA ]]) assembly are described.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Mifepriston'e >> blocks [[ glucocorticoid receptor ]] activation without modifying cortisol synthesis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We have examined the effectiveness of two novel << Chk1 >> selective inhibitors, [[ AR323 ]] and AR678, in a panel of melanoma cell lines and normal cell types.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We have examined the effectiveness of two novel << Chk1 >> selective inhibitors, AR323 and [[ AR678 ]], in a panel of melanoma cell lines and normal cell types.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< [-]-Huperzine A >> ([-]-Hup A), is a naturally occurring potent reversible [[ AChE ]] inhibitor that penetrates the blood-brain barrier.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "[-]-Huperzine A (<< [-]-Hup A >>), is a naturally occurring potent reversible [[ AChE ]] inhibitor that penetrates the blood-brain barrier.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The synthetic stereoisomer, << [+]-Hup A >>, is less toxic due to poor [[ AChE ]] inhibition and is suitable for both pre-/post-exposure treatments of nerve agent toxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of << OTCase >> to [[ ornithine ]] and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis and structure-activity relationship of << pyripyropene A >> derivatives as potent and selective [[ acyl-CoA:cholesterol acyltransferase 2 ]] (ACAT2) inhibitors: Part 2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis and structure-activity relationship of << pyripyropene A >> derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 ([[ ACAT2 ]]) inhibitors: Part 2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cloning, Characterization, and << Sulfonamide >> and Thiol Inhibition Studies of an [[ Î±-Carbonic Anhydrase ]] from Trypanosoma cruzi, the Causative Agent of Chagas Disease.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cloning, Characterization, and Sulfonamide and << Thiol >> Inhibition Studies of an [[ Î±-Carbonic Anhydrase ]] from Trypanosoma cruzi, the Causative Agent of Chagas Disease.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A large number of << aromatic/heterocyclic sulfonamides >> and some 5-mercapto-1,3,4-thiadiazoles were investigated as [[ TcCA ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A large number of aromatic/heterocyclic sulfonamides and some << 5-mercapto-1,3,4-thiadiazoles >> were investigated as [[ TcCA ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Intestinal and hepatic first-pass extraction of the << 11Î²-HSD1 >> inhibitor [[ AMG 221 ]] in rats with chronic vascular catheters.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an << 11Î²-HSD1 >> inhibitor, [[ AMG 221 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Flutamide >>, an effective competitive inhibitor of the [[ androgen receptor ]] used orally for palliative treatment of prostatic carcinoma and regulation of prostatic hyperplasia was evaluated for its genotoxic effects in the intact rat and in primary cultures of human hepatocytes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Auranofin >>, an antirheumatic gold compound, is an inhibitor of [[ selenocysteine enzymes ]], such as thioredoxin reductase and glutathione peroxidase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Auranofin >>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as [[ thioredoxin reductase ]] and glutathione peroxidase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Auranofin >>, an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and [[ glutathione peroxidase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was significantly less << thioredoxin reductase >> activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of [[ auranofin ]] used was able to selectively inhibit one of these enzyme systems.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis of a DOTA (Gd(3+))-conjugate of << proton-pump >> inhibitor [[ pantoprazole ]] for gastric wall imaging studies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis of a << DOTA >> (Gd(3+))-conjugate of [[ proton-pump ]] inhibitor pantoprazole for gastric wall imaging studies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis of a DOTA (<< Gd(3+) >>)-conjugate of [[ proton-pump ]] inhibitor pantoprazole for gastric wall imaging studies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a << Gd >>-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used [[ proton pump ]] inhibitor that binds to proton pumps in the stomach and colon.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<< DOTA >>), with pantoprazole, which is a widely used [[ proton pump ]] inhibitor that binds to proton pumps in the stomach and colon.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with << pantoprazole >>, which is a widely used [[ proton pump ]] inhibitor that binds to proton pumps in the stomach and colon.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Tacrine >>, the first of the [[ cholinesterase ]] inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Other << cholinesterase >> inhibitors, including [[ rivastigmine ]], with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We took advantage of the previous observations that << phosphatidylserine >> inhibits [[ DGK-delta ]] (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of << alpha 1B-adrenoceptors >> by treatment with [[ chlorethylclonidine ]], which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pretreatment of rats with glutathione (GSH) depletors (phorone or BSO) delayed the elimination of DMAs(V) and the accumulation of RBC-bound DMAs, whereas the indirect << methyltransferase >> inhibitor periodate-oxidized [[ adenosine ]] was without effect.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although thioredoxin reductase (<< TRR >>) inhibitors ([[ aurothioglucose ]] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although << thioredoxin reductase >> (TRR) inhibitors ([[ aurothioglucose ]] and Sb(III)) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although thioredoxin reductase (<< TRR >>) inhibitors (aurothioglucose and [[ Sb(III) ]]) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although << thioredoxin reductase >> (TRR) inhibitors (aurothioglucose and [[ Sb(III) ]]) inhibited cytosolic DMAs(V) reduction, recombinant rat TRR plus NADPH, alone or when added to the cytosol, failed to support DMAs(V) reduction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-angiotensin-aldosterone system (RAAS) blockade by << renin >>-inhibitor [[ remikiren ]] could be predicted from pretreatment renal vascular tone.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific renin-<< angiotensin >>-aldosterone system (RAAS) blockade by renin-inhibitor [[ remikiren ]] could be predicted from pretreatment renal vascular tone.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This hypothesis was tested by investigating whether, in subjects with essential hypertension, the natriuretic response to specific << renin >>-angiotensin-aldosterone system (RAAS) blockade by renin-inhibitor [[ remikiren ]] could be predicted from pretreatment renal vascular tone.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Histamine H(1) >> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic [[ clozapine ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A << KCC >> inhibitor-[[ [(dihydroindenyl)oxy] alkanoic acid ]] (DIOA)-blocked RVD more in HCEC than RCEC.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A << KCC >> inhibitor-[(dihydroindenyl)oxy] alkanoic acid ([[ DIOA ]])-blocked RVD more in HCEC than RCEC.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Considerable attention has focused on the antitumor effect of << histone deacetylase >> inhibitor ([[ Trichostatin A ]], TSA) as well as the coding gene expression-induced apoptosis of cancer cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Considerable attention has focused on the antitumor effect of << histone deacetylase >> inhibitor (Trichostatin A, [[ TSA ]]) as well as the coding gene expression-induced apoptosis of cancer cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the << phenylaminopyrimidine >> STI571 (Gleevec, Imatinib), a potent inhibitor of other [[ RTKs ]] in the family, such as the PDGFbeta-receptor or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine << STI571 >> (Gleevec, Imatinib), a potent inhibitor of other [[ RTKs ]] in the family, such as the PDGFbeta-receptor or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<< Gleevec >>, Imatinib), a potent inhibitor of other [[ RTKs ]] in the family, such as the PDGFbeta-receptor or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, << Imatinib >>), a potent inhibitor of other [[ RTKs ]] in the family, such as the PDGFbeta-receptor or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the << phenylaminopyrimidine >> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the [[ PDGFbeta-receptor ]] or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine << STI571 >> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the [[ PDGFbeta-receptor ]] or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<< Gleevec >>, Imatinib), a potent inhibitor of other RTKs in the family, such as the [[ PDGFbeta-receptor ]] or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, << Imatinib >>), a potent inhibitor of other RTKs in the family, such as the [[ PDGFbeta-receptor ]] or c-Kit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the << phenylaminopyrimidine >> STI571 (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [[ c-Kit ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine << STI571 >> (Gleevec, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [[ c-Kit ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (<< Gleevec >>, Imatinib), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [[ c-Kit ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although highly homologous to other class III RTKs, Flt3 is resistant to the phenylaminopyrimidine STI571 (Gleevec, << Imatinib >>), a potent inhibitor of other RTKs in the family, such as the PDGFbeta-receptor or [[ c-Kit ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "STI571 binding to Flt3 is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding << Flt3 >> mutant sensitive to [[ STI571 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the << quinoxaline >> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline << AG1296 >>, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the << quinoxaline >> AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline << AG1296 >>, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the << bis(1H-2-indolyl)-1-methanone >> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the << bis(1H-2-indolyl)-1-methanone >> D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone << D-65476 >>, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone << D-65476 >>, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the << indolinones >> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the << indolinones >> SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones << SU5416 >> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones << SU5416 >> and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and << SU11248 >>, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and << SU11248 >>, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the << indolocarbazoles >> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the << indolocarbazoles >> PKC412 and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles << PKC412 >> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles << PKC412 >> and CEP-701, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and << CEP-701 >>, and the piperazonyl quinazoline CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and << CEP-701 >>, and the piperazonyl quinazoline CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the << piperazonyl quinazoline >> CT53518, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the << piperazonyl quinazoline >> CT53518, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline << CT53518 >>, are potent inhibitors of [[ Flt3 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compounds of several other structural families, including the quinoxaline AG1296, the bis(1H-2-indolyl)-1-methanone D-65476, the indolinones SU5416 and SU11248, the indolocarbazoles PKC412 and CEP-701, and the piperazonyl quinazoline << CT53518 >>, are potent inhibitors of Flt3 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Carbonic anhydrase inhibitors. Inhibition of << mammalian isoforms I-XIV >> with a series of natural product [[ polyphenols ]] and phenolic acids.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Carbonic anhydrase inhibitors. Inhibition of << mammalian isoforms I-XIV >> with a series of natural product polyphenols and [[ phenolic acids ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << phenolic acids >> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and << phenol >> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as << p-hydroxybenzoic acid >>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, << p-coumaric acid >>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, << caffeic acid >>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, << ferulic acid >>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, << gallic acid >>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, << syringic acid >>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, << quercetin >>, and ellagic acid, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and << ellagic acid >>, were investigated for their inhibitory effects against the [[ metalloenzyme ]] carbonic anhydrase (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << phenolic acids >> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << phenolic acids >> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << phenolic acids >> and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and << phenol >> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and << phenol >> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and << phenol >> natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as << p-hydroxybenzoic acid >>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, << p-coumaric acid >>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, << caffeic acid >>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, << ferulic acid >>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, << gallic acid >>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, << syringic acid >>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, << quercetin >>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and << ellagic acid >>, were investigated for their inhibitory effects against the metalloenzyme [[ carbonic anhydrase ]] (CA, EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as << p-hydroxybenzoic acid >>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, << p-coumaric acid >>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, << caffeic acid >>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, << ferulic acid >>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, << gallic acid >>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, << syringic acid >>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, << quercetin >>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and << ellagic acid >>, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase ([[ CA ]], EC 4.2.1.1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as << p-hydroxybenzoic acid >>, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, << p-coumaric acid >>, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, << caffeic acid >>, ferulic acid, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, << ferulic acid >>, gallic acid, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, << gallic acid >>, syringic acid, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, << syringic acid >>, quercetin, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, << quercetin >>, and ellagic acid, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of phenolic acids and phenol natural products, such as p-hydroxybenzoic acid, p-coumaric acid, caffeic acid, ferulic acid, gallic acid, syringic acid, quercetin, and << ellagic acid >>, were investigated for their inhibitory effects against the metalloenzyme carbonic anhydrase (CA, [[ EC 4.2.1.1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenols >> like the ones investigated here possess a [[ CA ]] inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the coumarins.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenols like the ones investigated here possess a << CA >> inhibition mechanism distinct of that of the [[ sulfonamides ]]/sulfamates used clinically or the coumarins.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenols like the ones investigated here possess a << CA >> inhibition mechanism distinct of that of the sulfonamides/[[ sulfamates ]] used clinically or the coumarins.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenols like the ones investigated here possess a << CA >> inhibition mechanism distinct of that of the sulfonamides/sulfamates used clinically or the [[ coumarins ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [[ glutathione peroxidase ]], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, [[ glutathione reductase ]], reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and [[ NADH-dehydrogenases ]], cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, [[ cytochrome-C-oxidase ]] and adenosine triphosphate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Catalpol >> inhibits LPS plus [[ IFN-Î³ ]]-induced inflammatory response in astrocytes primary cultures.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Biochemical analyses showed that NO and ROS production and << iNOS >> activity were significantly reduced by [[ catalpol ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, our exploration further revealed that the suppressive action of << catalpol >> on inflammation was mediated via inhibiting [[ nuclear factor-ÎºB ]] (NF-ÎºB) activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, our exploration further revealed that the suppressive action of << catalpol >> on inflammation was mediated via inhibiting nuclear factor-ÎºB ([[ NF-ÎºB ]]) activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Collectively, these results suggest that << catalpol >> can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of [[ NF-ÎºB ]] could be the major determinant for its anti-inflammatory mechanism.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Whereas the addition of << apomorphine >> in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage-dependent inhibition of heterologously expressed [[ TRPA1 ]] channels, resulting from a reduction of single-channel open times.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << sodium channel >>-blocking action of [[ cocaine ]] per se does not appear to be involved in the rapid pressor response to cocaine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers [[ acetylprocainamide ]], dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, [[ dibucaine ]], dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, dibucaine, [[ dyclonine ]], prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, dibucaine, dyclonine, [[ prilocaine ]], proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, [[ proparacaine ]], quinidine, and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, [[ quinidine ]], and tetracaine produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At nonconvulsant doses, the << sodium channel >> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and [[ tetracaine ]] produced a small pressor response or no increase in BP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities ([[ BTCP ]], indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and [[ zimeldine ]]) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities (BTCP, indatraline, GBR 12935, mazindol, [[ nomifensine ]], and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities (BTCP, indatraline, GBR 12935, [[ mazindol ]], nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities (BTCP, indatraline, [[ GBR 12935 ]], mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse << monoamine transporter >> selectivities (BTCP, [[ indatraline ]], GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Following CdClâ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of ICAM2 to << actin >> during [[ CdClâ ]]-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Regarding << urease >> inhibition, [[ n-butanol ]] was the most potent fraction (IC50: 97 Âµg/mL).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: To determine (a) whether << PDE4 >> inhibition alone with [[ rolipram ]] blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: Inhibition of << PDE4 >> by [[ rolipram ]] unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP/B.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition corresponded to increased cAMP production caused by rolipram alone or << rolipram >> plus salmeterol and blocked proportionately the phosphorylation and activation of [[ gIV-PLA(2) ]] in FMLP/B-activated eosinophils.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus << salmeterol >> and blocked proportionately the phosphorylation and activation of [[ gIV-PLA(2) ]] in FMLP/B-activated eosinophils.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Amiloride >> is a specific inhibitor of [[ uPA ]] but does not inhibit tPA.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Reboxetine >>, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [[ human norepinephrine transporter ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Wogonin >> inhibits H2O2-induced vascular permeability through suppressing the phosphorylation of [[ caveolin-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of [[ caveolin-1 ]] (cav-1) associating with the suppression of stabilization of VE-cadherin and Î²-catenin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of caveolin-1 ([[ cav-1 ]]) associating with the suppression of stabilization of VE-cadherin and Î²-catenin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << wogonin >> repressed anisomycin-induced phosphorylation of [[ p38 ]], cav-1 and vascular permeability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << wogonin >> repressed anisomycin-induced phosphorylation of p38, [[ cav-1 ]] and vascular permeability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggested that << wogonin >> could inhibit H2O2-induced vascular permeability by downregulating the phosphorylation of [[ cav-1 ]], and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Neoechinulin A >> suppresses [[ amyloid-Î² ]] oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, focus was given to evaluate the ability of << neoechinulin A >>, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [[ amyloid-Î² 1-42 ]] (AÎ²42).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of [[ mitogen-activated protein kinase ]] (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase ([[ MAPK ]]) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule [[ p38 ]], apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, [[ apoptosis signal-regulating kinase 1 ]] (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 ([[ ASK-1 ]]) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, focus was given to evaluate the ability of << neoechinulin A >>, an indole alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-Î² 1-42 ([[ AÎ²42 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, focus was given to evaluate the ability of neoechinulin A, an << indole >> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric [[ amyloid-Î² 1-42 ]] (AÎ²42).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, focus was given to evaluate the ability of neoechinulin A, an << indole >> alkaloid isolated from marine-derived Microsporum sp., to attenuate microglial activation by oligomeric amyloid-Î² 1-42 ([[ AÎ²42 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Neoechinulin A >> treatment significantly inhibited the generation of reactive oxygen and nitrogen species in [[ AÎ²42 ]]-activated BV-2 microglia cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There were statistically significant increases in the activities of aspartate aminotransferase, alanine aminotransferase, levels of tumor necrosis factor-alpha (TNF-Î±) and interleukin-6 (IL-6) and 8-iso-prostane, and decreases in the activity of << superoxide dismutase >> and level of glutathione in the group treated with [[ paracetamol ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A highly potent inhibition of the << peroxidase >> catalytic reaction by [[ NO ]]/SNO was seen in assays employing the coupled Prx-Trx system.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A highly potent inhibition of the << peroxidase >> catalytic reaction by NO/[[ SNO ]] was seen in assays employing the coupled Prx-Trx system.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this setting, << S-nitrosocysteine >> (10 Î¼m) effectively blocked the [[ Trx ]]-mediated regeneration of oxidized Prx1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this setting, << S-nitrosocysteine >> (10 Î¼m) effectively blocked the Trx-mediated regeneration of [[ oxidized Prx1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Human atrial appendages and rabbit pulmonary arteries were used to determine the potencies of alpha(2)-adrenoceptor agonists in inhibiting the electrically (2 Hz) evoked [(3)H]norepinephrine release and of antagonists in counteracting the << alpha(2)-adrenoceptor >>-mediated inhibition induced by [[ moxonidine ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Structure activity relationship studies of << tricyclic bispyran sulfone >> [[ Î³-secretase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<< SCH 900229 >>), a potent, PS1-selective [[ Î³-secretase ]] inhibitor and clinical candidate for the treatment of Alzheimer's disease.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "An investigation is detailed of the structure activity relationships (SAR) of two sulfone side chains of compound (-)-1a (<< SCH 900229 >>), a potent, [[ PS1 ]]-selective Î³-secretase inhibitor and clinical candidate for the treatment of Alzheimer's disease.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A comparison of bosutinib with << dasatinib >> across the whole [[ kinase ]] panel revealed overlapping, but distinct, inhibition profiles.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Global target profile of the << kinase >> inhibitor [[ bosutinib ]] in primary chronic myeloid leukemia cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Finally, << bosutinib >> is the first [[ kinase ]] inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Finally, << bosutinib >> is the first kinase inhibitor shown to target [[ CAMK2G ]], recently implicated in myeloid leukemia cell proliferation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Here, we characterized the target profile of the dual << SRC >>/ABL inhibitor [[ bosutinib ]] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Here, we characterized the target profile of the dual SRC/<< ABL >> inhibitor [[ bosutinib ]] employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A comparison of << bosutinib >> with dasatinib across the whole [[ kinase ]] panel revealed overlapping, but distinct, inhibition profiles.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In PC3 cells, << hydroxyurea >> inhibited [[ hRRM2 ]] and resulted in increased sensitivity to UV irradiation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis, molecular modeling and evaluation of novel << N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone >> derivatives as dual inhibitors for [[ cholinesterases ]] and AÎ² aggregation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis, molecular modeling and evaluation of novel << N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone >> derivatives as dual inhibitors for cholinesterases and [[ AÎ² ]] aggregation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To develop new drugs for treatment of Alzheimer's disease, a group of << N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones >> was designed, synthesized and tested for their ability to inhibit [[ acetylcholinesterase ]], butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To develop new drugs for treatment of Alzheimer's disease, a group of << N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones >> was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, [[ butyrylcholinesterase ]] and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Î²-Amyloid aggregation results showed that all compounds exhibited remarkable << AÎ² >> fibril aggregation inhibition activity with a nearly similar potential as the reference compound [[ rifampicin ]], which makes them promising anti-Alzheimer drug candidates.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting << TrxR >> with [[ auranofin ]] (AuF).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Trx mimetics peptides (TXM) protected insulinoma INS 832/13 cells from oxidative stress induced by selectively inhibiting << TrxR >> with auranofin ([[ AuF ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In general, antiproliferative activity is greatly enhanced by low levels of the << glutathione synthase >> inhibitor [[ l-buthionine sulfoxime ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Arsenic trioxide >> depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of [[ Notch ]] pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ATO >> inhibited the phosphorylation and activation of [[ AKT ]] and STAT3 through Notch signaling blockade.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ATO >> inhibited the phosphorylation and activation of AKT and [[ STAT3 ]] through Notch signaling blockade.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data show that the << ATO >> is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of [[ Notch ]] pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< CBDP >> irreversibly inhibits [[ butyrylcholinesterase ]] (BChE) in human plasma by forming adducts on the active site serine (Ser-198).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< CBDP >> irreversibly inhibits butyrylcholinesterase ([[ BChE ]]) in human plasma by forming adducts on the active site serine (Ser-198).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Mass spectral analysis of << CBDP >>-inhibited [[ BChE ]] digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Nitrooxy >> derivatives showed NO-dependent vasorelaxing properties, while most of the compounds proved to be very potent and selective [[ COX-2 ]] inhibitors in in vitro experimental models.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Novel analgesic/anti-inflammatory agents: 1,5-diarylpyrrole nitrooxyalkyl ethers and related compounds as << cyclooxygenase-2 >> inhibiting [[ nitric oxide ]] donors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Novel analgesic/anti-inflammatory agents: << 1,5-diarylpyrrole nitrooxyalkyl ethers >> and related compounds as [[ cyclooxygenase-2 ]] inhibiting nitric oxide donors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "New classes of << pyrrole >>-derived nitrooxyalkyl inverse esters, carbonates, and ethers (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "New classes of pyrrole-derived << nitrooxyalkyl >> inverse esters, carbonates, and ethers (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "New classes of pyrrole-derived nitrooxyalkyl inverse << esters >>, carbonates, and ethers (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters, << carbonates >>, and ethers (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "New classes of pyrrole-derived nitrooxyalkyl inverse esters, carbonates, and << ethers >> (7-10) as [[ COX-2 ]] selective inhibitors and NO donors were synthesized and are herein reported.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In summary, << ketoconazole >> had no clinically significant effect on the pharmacokinetics or safety profile of ambrisentan; therefore, no changes in ambrisentan dose should be necessary when the drug is administered concomitantly with known [[ CYP3A4 ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potential for << ketoconazole >>, the archetypal strong inhibitor of [[ CYP3A4 ]], to alter the pharmacokinetic profile of ambrisentan and its oxidative metabolite, 4-hydroxymethyl ambrisentan, was assessed in an open-label, nonrandomized, 2-period, single-sequence study in 16 healthy men.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the << PKC >> inhibitor Go 6976, [[ thapsigargin ]], as well as the calmodulin antagonists W7 and W13.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the << PKC >> inhibitor [[ Go 6976 ]], thapsigargin, as well as the calmodulin antagonists W7 and W13.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Neither the superoxide radical scavenger, tiron, nor the inhibitor of the << dopamine (DA) transporter >>, [[ GBR 12909 ]], prevented the metabolites' toxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Importantly, pre-treatment with << buthionine sulfoximine >> (BSO), an inhibitor of [[ Î³-GCS ]], prevented Î±-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Importantly, pre-treatment with buthionine sulfoximine (<< BSO >>), an inhibitor of [[ Î³-GCS ]], prevented Î±-MeDA induced increase in GSH levels, but did not augment this metabolite cytotoxicity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << tyrosine hydroxylase >> inhibitor [[ Î±-methyltyrosine ]] (300ÂµM, 24h) completely abolished MeHg-induced DA release.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective << monoamine oxidase-A >> inhibitors [[ moclobemide ]] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of the << monoamine oxidase >> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors [[ moclobemide ]] and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of the monoamine oxidase inhibiting properties of two reversible and selective << monoamine oxidase-A >> inhibitors moclobemide and [[ toloxatone ]], and assessment of their effect on psychometric performance in healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of the << monoamine oxidase >> inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and [[ toloxatone ]], and assessment of their effect on psychometric performance in healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effects of two reversible, predominantly << monoamine oxidase-A >> (MAO-A) inhibitors, [[ moclobemide ]] (150 mg three times daily) and toloxatone (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effects of two reversible, predominantly << monoamine oxidase-A >> (MAO-A) inhibitors, moclobemide (150 mg three times daily) and [[ toloxatone ]] (400-200-400 mg day-1) on monoamine metabolites and psychometric performance were compared in a double-blind placebo controlled crossover study in 12 healthy subjects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Before the next drug intake, << MAO-A >> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with [[ moclobemide ]] but not with toloxatone.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Before the next drug intake, << MAO-A >> inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with [[ toloxatone ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral << protease >> inhibitors [[ lopinavir ]] (LPV) and ritonavir (RTV) are reported BSEP inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral << protease >> inhibitors lopinavir ([[ LPV ]]) and ritonavir (RTV) are reported BSEP inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral << protease >> inhibitors lopinavir (LPV) and [[ ritonavir ]] (RTV) are reported BSEP inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral << protease >> inhibitors lopinavir (LPV) and ritonavir ([[ RTV ]]) are reported BSEP inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral protease inhibitors << lopinavir >> (LPV) and ritonavir (RTV) are reported [[ BSEP ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral protease inhibitors lopinavir (<< LPV >>) and ritonavir (RTV) are reported [[ BSEP ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral protease inhibitors lopinavir (LPV) and << ritonavir >> (RTV) are reported [[ BSEP ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Antiretroviral protease inhibitors lopinavir (LPV) and ritonavir (<< RTV >>) are reported [[ BSEP ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of << human iNOS promoter >>-driven luciferase activity by [[ gemfibrozil ]] in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in << gemfibrozil >>-mediated inhibition of [[ iNOS ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, DeltahPPAR-alpha was unable to abrogate << gemfibrozil >>-mediated inhibition of [[ iNOS ]] suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that << gemfibrozil >> inhibits [[ iNOS ]] independent of PPAR-alpha.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gemfibrozil >>, a lipid-lowering drug, inhibits the induction of [[ nitric-oxide synthase ]] in human astrocytes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gemfibrozil >>, a lipid-lowering drug, inhibited [[ cytokine ]]-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Interestingly, << gemfibrozil >> strongly inhibited the activation of [[ NF-kappaB ]], AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Interestingly, << gemfibrozil >> strongly inhibited the activation of NF-kappaB, [[ AP-1 ]], and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Interestingly, << gemfibrozil >> strongly inhibited the activation of NF-kappaB, AP-1, and [[ C/EBPbeta ]] but not that of GAS in cytokine-stimulated astroglial cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << gemfibrozil >> inhibits the induction of [[ iNOS ]] probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << gemfibrozil >> inhibits the induction of iNOS probably by inhibiting the activation of [[ NF-kappaB ]], AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << gemfibrozil >> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, [[ AP-1 ]], and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << gemfibrozil >> inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and [[ C/EBPbeta ]] and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Indomethacin >>, piroxicam, and sulindac sulfide were found to preferentially inhibit [[ PGHS-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Indomethacin, << piroxicam >>, and sulindac sulfide were found to preferentially inhibit [[ PGHS-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Indomethacin, piroxicam, and << sulindac sulfide >> were found to preferentially inhibit [[ PGHS-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 6-Methoxy-2-naphthylacetic acid >>, the active metabolite of Relafen, inhibits murine [[ PGHS-2 ]] preferentially.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "6-Methoxy-2-naphthylacetic acid, the active metabolite of << Relafen >>, inhibits murine [[ PGHS-2 ]] preferentially.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Aspirin >> irreversibly inhibits [[ PGHS-1 ]], preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of PGHS-2 causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid (15-HETE) instead of PGH2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Ki for << mycophenolic acid >> inhibition of the [[ L263F ]] variant was comparable with the wild-type, and the variant Km for inosine 5'-monophosphate and nicotinamide adenine dinucleotide did not change significantly.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The solubility-driven structural modification of (pyridin-3-yl) benzoxazinyl-oxazolidinones is described, which resulted in the development of a new series of << benzoxazinyl-oxazolidinone >> analogues with high antibacterial activity against Gram-positive pathogens, including that against linezolid-resistant strains and low [[ hERG ]] inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The compounds << 5'-azacytidine >> (AZC) and procainamide (PCA) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The compounds 5'-azacytidine (<< AZC >>) and procainamide (PCA) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The compounds 5'-azacytidine (AZC) and << procainamide >> (PCA) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The compounds 5'-azacytidine (AZC) and procainamide (<< PCA >>) belong to inhibitors of [[ DNMT1 ]], whose low activity correlates with increase in transcription of various genes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using a unique biosensor-based assay, << trifluoperazine >> (TFP) was identified as an inhibitor that disrupts the [[ S100A4 ]]/myosin-IIA interaction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using a unique biosensor-based assay, << trifluoperazine >> (TFP) was identified as an inhibitor that disrupts the S100A4/[[ myosin-IIA ]] interaction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using a unique biosensor-based assay, trifluoperazine (<< TFP >>) was identified as an inhibitor that disrupts the [[ S100A4 ]]/myosin-IIA interaction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using a unique biosensor-based assay, trifluoperazine (<< TFP >>) was identified as an inhibitor that disrupts the S100A4/[[ myosin-IIA ]] interaction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenothiazines >> inhibit [[ S100A4 ]] function by inducing protein oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Assays examining the ability of << TFP >> to block [[ S100A4 ]]-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Assays examining the ability of << TFP >> to block S100A4-mediated disassembly of [[ myosin-IIA ]] filaments demonstrate that significant inhibition of S100A4 function occurs only at TFP concentrations that promote S100A4 oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Assays examining the ability of TFP to block S100A4-mediated disassembly of myosin-IIA filaments demonstrate that significant inhibition of << S100A4 >> function occurs only at [[ TFP ]] concentrations that promote S100A4 oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Together these studies support a unique mode of inhibition in which << phenothiazines >> disrupt the [[ S100A4 ]]/myosin-IIA interaction by sequestering S100A4 via small molecule-induced oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Together these studies support a unique mode of inhibition in which << phenothiazines >> disrupt the S100A4/[[ myosin-IIA ]] interaction by sequestering S100A4 via small molecule-induced oligomerization.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including [[ tacrine ]], donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, [[ donepezil ]], rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, [[ rivastigmine ]], galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, [[ galantamine ]], xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, galantamine, [[ xanthostigmine ]], para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, [[ para-aminobenzoic acid ]], coumarin, flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, [[ coumarin ]], flavonoid, and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, [[ flavonoid ]], and pyrrolo-isoxazole analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This review discusses the different classes of << cholinesterase >> inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and [[ pyrrolo-isoxazole ]] analogues developed for the treatment of AD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Chronic insulin (24 h) activates NHE3 through the classic << phosphatidylinositol 3-kinase >>-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [[ wortmannin ]] or a dominant-negative SGK1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (<< PI3K >>-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the PI3K inhibitor [[ wortmannin ]] or a dominant-negative SGK1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Chronic insulin (24 h) activates NHE3 through the classic phosphatidylinositol 3-kinase-serum- and glucocorticoid-dependent kinase 1 (PI3K-SGK1) pathway as insulin stimulates SGK1 phosphorylation and the insulin effect can be blocked by the << PI3K >> inhibitor [[ wortmannin ]] or a dominant-negative SGK1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, cells pre-treated with << DL-propargylglycine >> (PAG, 3 mM), a [[ CSE ]] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, cells pre-treated with DL-propargylglycine (<< PAG >>, 3 mM), a [[ CSE ]] inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that CSE may be the main enzyme involved in H(2)S formation in mouse acinar cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The upregulation of calpain, tBid and << caspase-3 >> activity were further inhibited by treatment with [[ EGTA ]] in the presence of ALD.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of << cyclooxygenase >> inhibitory activity and ocular anti-inflammatory effects of [[ ketorolac tromethamine ]] and bromfenac sodium.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comparison of << cyclooxygenase >> inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and [[ bromfenac sodium ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The group treated with << pyridostigmine >> alone showed decreased plasma [[ butyrylcholinesterase ]] (BChE) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The group treated with << pyridostigmine >> alone showed decreased plasma butyrylcholinesterase ([[ BChE ]]) activity (87% of control), whereas pyridostigmine plus exercise significantly decreased the BChE activity (79% of control), indicating an interactive effect of the combination.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The group treated with pyridostigmine alone showed decreased plasma butyrylcholinesterase (BChE) activity (87% of control), whereas << pyridostigmine >> plus exercise significantly decreased the [[ BChE ]] activity (79% of control), indicating an interactive effect of the combination.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, << AChE >> activity in triceps muscle decreased significantly (78% of control) in the group treated with [[ pyridostigmine ]] plus exercise.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The affinity labeling << nucleotide >> analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the [[ dehydrogenase ]] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The affinity labeling nucleotide analog, << 5'-[p-(fluorosulfonyl)benzoyl]adenosine >> (FSA), inactivates the [[ dehydrogenase ]] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (<< FSA >>), inactivates the [[ dehydrogenase ]] and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as << dehydrogenase >> from inactivation by [[ FSA ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We previously employed a chemical genomic strategy to identify a novel small molecule, << MAC13243 >>, as a likely inhibitor of the [[ bacterial lipoprotein ]] targeting chaperone, LolA.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We previously employed a chemical genomic strategy to identify a novel small molecule, << MAC13243 >>, as a likely inhibitor of the bacterial lipoprotein targeting [[ chaperone ]], LolA.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We previously employed a chemical genomic strategy to identify a novel small molecule, << MAC13243 >>, as a likely inhibitor of the bacterial lipoprotein targeting chaperone, [[ LolA ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When further examined for its anticancer mechanism, << SB365 >> effectively suppressed the [[ AKT ]]/mTOR pathway both in vitro and in vivo.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When further examined for its anticancer mechanism, << SB365 >> effectively suppressed the AKT/[[ mTOR ]] pathway both in vitro and in vivo.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Taken together, our study demonstrated that << SB365 >> inhibits the [[ AKT ]]/mTOR pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Taken together, our study demonstrated that << SB365 >> inhibits the AKT/[[ mTOR ]] pathway, leading to the suppression of tumor growth and angiogenesis together with induction of apoptosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The ability of << sorafenib >> to inhibit oncogenic [[ PDGFRbeta ]] and FLT3 mutants and overcome resistance to other small molecule inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The ability of << sorafenib >> to inhibit oncogenic PDGFRbeta and [[ FLT3 ]] mutants and overcome resistance to other small molecule inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> (BAY43-9006, Nexavar) is a small molecule [[ B-RAF ]] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib (<< BAY43-9006 >>, Nexavar) is a small molecule [[ B-RAF ]] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sorafenib (BAY43-9006, << Nexavar >>) is a small molecule [[ B-RAF ]] inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We investigated the efficacy of << sorafenib >> at inhibiting mutants of the [[ receptor tyrosine kinases ]] PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We investigated the efficacy of << sorafenib >> at inhibiting mutants of the receptor tyrosine kinases [[ PDGFRbeta ]], KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We investigated the efficacy of << sorafenib >> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, [[ KIT ]], and FLT3, which are implicated in the pathogenesis of myeloid malignancies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We investigated the efficacy of << sorafenib >> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and [[ FLT3 ]], which are implicated in the pathogenesis of myeloid malignancies.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: We show that << sorafenib >> is a potent inhibitor of [[ ETV6 ]]-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: We show that << sorafenib >> is a potent inhibitor of ETV6-[[ PDGFRbeta ]] and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: We show that << sorafenib >> is a potent inhibitor of ETV6-PDGFRbeta and [[ FLT3 ]] mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: We show that << sorafenib >> is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other [[ FLT3 ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sorafenib >> induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing [[ FLT3 ]] with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of << sorafenib >> for the treatment of myeloid malignancies expressing activated forms of [[ PDGFRbeta ]] and FLT3.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of << sorafenib >> for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and [[ FLT3 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The contractions to 5-HT were inhibited by << ketanserin >> and alosetron indicating involvement of [[ 5-HT(2A) ]] and 5-HT(3) receptors, respectively.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The contractions to 5-HT were inhibited by ketanserin and << alosetron >> indicating involvement of 5-HT(2A) and [[ 5-HT(3) ]] receptors, respectively.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Î±-Amino-Î±Â´-Halomethylketones >>: Synthetic Methodologies and Pharmaceutical Applications as [[ Serine and Cysteine Protease ]] Inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of the << EGFR >>/HER2 kinase inhibitor [[ GW572016 ]] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of the EGFR/<< HER2 >> kinase inhibitor [[ GW572016 ]] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of the EGFR/HER2 << kinase >> inhibitor [[ GW572016 ]] on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual << EGFR >>/HER2 inhibitor, [[ GW572016 ]], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/<< HER2 >> inhibitor, [[ GW572016 ]], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: << GW572016 >> inhibited constitutive and/or ligand-induced [[ EGFR ]] or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: << GW572016 >> inhibited constitutive and/or ligand-induced EGFR or [[ HER2 ]] tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of << GW572016 >> to inhibit downstream ERK and Akt activation, despite inhibition of [[ HER2 ]] phosphorylation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSION: << GW572016 >> potently inhibits receptor phosphorylation in either [[ EGFR ]]- or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSION: << GW572016 >> potently inhibits receptor phosphorylation in either EGFR- or [[ HER2 ]]-overexpressing cell lines and has both antiproliferative and radiosensitizing effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of << dipeptidyl peptidase-IV >> (DPP-IV) by [[ atorvastatin ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of dipeptidyl peptidase-IV (<< DPP-IV >>) by [[ atorvastatin ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this report, we show that the hypolipidemic agent << atorvastatin >> is a competitive inhibitor of [[ porcine DPP-IV ]] in vitro, with K(i)=57.8+/-2.3 microM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results may have implications in the development of novel << DPP-IV >> inhibitors based on the use of [[ atorvastatin ]] as a lead compound for the treatment of type 2 diabetes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "With exposure to << rofecoxib >>, a selective [[ COX-2 ]] inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "With exposure to << rofecoxib >>, a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective [[ COX-2 ]] inhibitors in breast cancer prophylaxis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS: We conducted a case-control study to measure the association between selective << cox-2 >> inhibitors, particularly [[ celecoxib ]], rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS: We conducted a case-control study to measure the association between selective << cox-2 >> inhibitors, particularly celecoxib, [[ rofecoxib ]], valdecoxib and non-specific NSAID subgroups, and breast cancer risk.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS: We conducted a case-control study to measure the association between selective << cox-2 >> inhibitors, particularly celecoxib, rofecoxib, [[ valdecoxib ]] and non-specific NSAID subgroups, and breast cancer risk.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<< steroidal >> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of [[ cyclooxygenase-2 ]] (COX-2).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<< steroidal >> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 ([[ COX-2 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in << SGLT1 >> activity induced by [[ gentamicin C ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, using a model of << gentamicin C >> (GMC)-induced reduction in [[ SGLT1 ]] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, using a model of gentamicin C (<< GMC >>)-induced reduction in [[ SGLT1 ]] activity, we examined whether ligands for megalin protect LLC-PK1 cells from the GMC-induced reduction in SGLT1 activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, using a model of gentamicin C (GMC)-induced reduction in SGLT1 activity, we examined whether ligands for megalin protect LLC-PK1 cells from the << GMC >>-induced reduction in [[ SGLT1 ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis and in vitro evaluation of << N-Aryl pyrido-quinazolines >> derivatives as potent [[ EGFR ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << pyrido-quinazolines >> have been synthesised, characterised and tested for their in vitro [[ EGFR ]] tyrosine kinase inhibitory activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of << pyrido-quinazolines >> have been synthesised, characterised and tested for their in vitro EGFR [[ tyrosine kinase ]] inhibitory activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pemetrexed disodium >> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [[ thymidylate synthase ]], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pemetrexed disodium >> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, [[ dihydrofolate reductase ]], and glycinamide ribonucleotide formyltransferase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pemetrexed disodium >> (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and [[ glycinamide ribonucleotide formyltransferase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pemetrexed disodium (<< ALIMTA >>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, [[ thymidylate synthase ]], dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pemetrexed disodium (<< ALIMTA >>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, [[ dihydrofolate reductase ]], and glycinamide ribonucleotide formyltransferase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pemetrexed disodium (<< ALIMTA >>) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and [[ glycinamide ribonucleotide formyltransferase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although the inhibition of << cyclooxygenases >> by [[ aspirin ]], which leads to its anti-inflammatory/analgesic properties, has been well studied, the mechanisms involved in its chemopreventive effects as well as some of its adverse effects are as yet ill-defined.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Consequently, << PDE4 >> inhibitors including [[ cilomilast ]] and AWD 12-281 have been tested in several models of allergic and irritant skin inflammation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Consequently, << PDE4 >> inhibitors including cilomilast and [[ AWD 12-281 ]] have been tested in several models of allergic and irritant skin inflammation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Results of early clinical trials with both topically (<< cipamfylline >>, CP80,633) and systemically (CC-10004) active [[ PDE4 ]] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Results of early clinical trials with both topically (cipamfylline, << CP80,633 >>) and systemically (CC-10004) active [[ PDE4 ]] inhibitors demonstrated efficacy in atopic dermatitis and in the case of CC-10004, also in psoriasis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pranlukast >> is a new, orally active, selective inhibitor of [[ CysLt1 ]] leukotriene receptor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pranlukast >> is a new, orally active, selective inhibitor of CysLt1 [[ leukotriene receptor ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, we demonstrate significant inhibitory activity of << dasatinib >> against both wild-type [[ KIT ]] and the KITD816V mutation in the nanomolar range in in vitro and cell-based kinase assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, we demonstrate significant inhibitory activity of << dasatinib >> against both wild-type KIT and the [[ KIT ]]D816V mutation in the nanomolar range in in vitro and cell-based kinase assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, we demonstrate significant inhibitory activity of << dasatinib >> against both wild-type KIT and the KIT[[ D816V ]] mutation in the nanomolar range in in vitro and cell-based kinase assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, << dasatinib >> leads to growth inhibition of a [[ KIT ]]D816V-harboring human masto-cytosis cell line.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, << dasatinib >> leads to growth inhibition of a KIT[[ D816V ]]-harboring human masto-cytosis cell line.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dasatinib >> (BMS-354825) inhibits [[ KIT ]]D816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dasatinib >> (BMS-354825) inhibits KIT[[ D816V ]], an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Dasatinib (<< BMS-354825 >>) inhibits KIT[[ D816V ]], an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dasatinib >> (BMS-354825) is a novel orally bioavailable [[ SRC ]]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dasatinib >> (BMS-354825) is a novel orally bioavailable SRC/[[ ABL ]] inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Dasatinib (<< BMS-354825 >>) is a novel orally bioavailable [[ SRC ]]/ABL inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Dasatinib (<< BMS-354825 >>) is a novel orally bioavailable SRC/[[ ABL ]] inhibitor that has activity against multiple imatinib-resistant BCR-ABL isoforms in vitro that is presently showing considerable promise in early-phase clinical trials of chronic myeloid leukemia (CML).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As opposed to the rat and flounder orthologs, << hNaDC-3 >> was hardly inhibited by [[ lithium ]] concentrations up to 5 mM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Blockade of << JAK >> and ERK pathways with [[ AG490 ]] and U0126, respectively, abrogated the myocardial infarct size reduction by NDP-Î±-MSH.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Blockade of JAK and << ERK >> pathways with AG490 and [[ U0126 ]], respectively, abrogated the myocardial infarct size reduction by NDP-Î±-MSH.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Long-chain alkanols >> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral [[ nicotinic acetylcholine receptor ]] (AChR) by binding to one or more specific sites on the AChR.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cembranoids >> are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal [[ AChRs ]], which have no demonstrable general anesthetic activity in vivo.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: [[ carbenoxolone ]] > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > [[ disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate ]] (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate ([[ DIDS ]]) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately [[ disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate ]] approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately [[ 5-nitro-2-(3-phenylpropylamino)benzoic acid ]] > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > [[ indanyloxyacetic acid 94 ]] >> probenecid >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> [[ probenecid ]] >> flufenamic acid = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> [[ flufenamic acid ]] = niflumic acid.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found compounds that inhibited << Panx1 >> currents with a rank order of potency: carbenoxolone > disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate (DIDS) approximately disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate approximately 5-nitro-2-(3-phenylpropylamino)benzoic acid > indanyloxyacetic acid 94 >> probenecid >> flufenamic acid = [[ niflumic acid ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Triphosphate nucleotides >> (ATP, GTP, and UTP) rapidly and reversibly inhibited [[ Panx1 ]] currents via mechanism(s) independent of purine receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Triphosphate nucleotides (<< ATP >>, GTP, and UTP) rapidly and reversibly inhibited [[ Panx1 ]] currents via mechanism(s) independent of purine receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Triphosphate nucleotides (ATP, << GTP >>, and UTP) rapidly and reversibly inhibited [[ Panx1 ]] currents via mechanism(s) independent of purine receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Triphosphate nucleotides (ATP, GTP, and << UTP >>) rapidly and reversibly inhibited [[ Panx1 ]] currents via mechanism(s) independent of purine receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Enhancement of radiosensitivity by << topoisomerase II >> inhibitor, [[ amrubicin ]] and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Enhancement of radiosensitivity by << topoisomerase II >> inhibitor, amrubicin and [[ amrubicinol ]], in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to << AMR >> and AMROH, adriamycin and etoposide (VP-16) are [[ DNA topoisomerase II ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to AMR and << AMROH >>, adriamycin and etoposide (VP-16) are [[ DNA topoisomerase II ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to AMR and AMROH, << adriamycin >> and etoposide (VP-16) are [[ DNA topoisomerase II ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to AMR and AMROH, adriamycin and << etoposide >> (VP-16) are [[ DNA topoisomerase II ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to AMR and AMROH, adriamycin and etoposide (<< VP-16 >>) are [[ DNA topoisomerase II ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates << ZD1694 >> (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent [[ TS ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (<< raltitrexed >>, Tomudex) and AG337 (Thymitag) are more specific and potent [[ TS ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, << Tomudex >>) and AG337 (Thymitag) are more specific and potent [[ TS ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and << AG337 >> (Thymitag) are more specific and potent [[ TS ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (<< Thymitag >>) are more specific and potent [[ TS ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by [[ 4-methylpyrazole ]] or 1,10-phenanthroline.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or [[ 1,10-phenanthroline ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the << VEGFR >> tyrosine kinase inhibitors sunitinib and/or [[ sorafenib ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR << tyrosine kinase >> inhibitors sunitinib and/or [[ sorafenib ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Everolimus >> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of [[ mTOR ]] (mammalian target of rapamycin) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Everolimus >> (RAD001, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ([[ mammalian target of rapamycin ]]) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Everolimus (<< RAD001 >>, Afinitor((R)) Novartis) is the first oral inhibitor of [[ mTOR ]] (mammalian target of rapamycin) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Everolimus (<< RAD001 >>, Afinitor((R)) Novartis) is the first oral inhibitor of mTOR ([[ mammalian target of rapamycin ]]) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Everolimus (RAD001, << Afinitor((R)) Novartis >>) is the first oral inhibitor of [[ mTOR ]] (mammalian target of rapamycin) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Everolimus (RAD001, << Afinitor((R)) Novartis >>) is the first oral inhibitor of mTOR ([[ mammalian target of rapamycin ]]) to reach the oncology clinic.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the << VEGFR >> tyrosine kinase inhibitors [[ sunitinib ]] and/or sorafenib.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A phase III randomized placebo-controlled trial has examined the impact of everolimus in patients with clear cell renal cancers and progressive disease on or within 6 months of the VEGFR << tyrosine kinase >> inhibitors [[ sunitinib ]] and/or sorafenib.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "State-dependent << cocaine >> block of [[ sodium channel ]] isoforms, chimeras, and channels coexpressed with the beta1 subunit.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cocaine >> block of [[ human cardiac (hH1) ]] and rat skeletal (mu1) muscle sodium channels was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cocaine >> block of human cardiac (hH1) and [[ rat skeletal (mu1) muscle sodium channels ]] was examined under whole-cell voltage clamp in transiently transfected HEK293t cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cocaine >> block of [[ hH1 channels ]] was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cocaine >> block of hH1 channels was greater than block of [[ mu1 channels ]] at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of hH1 channels in this voltage range makes them more susceptible to cocaine block.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Cocaine >> block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of [[ hH1 channels ]] in this voltage range makes them more susceptible to cocaine block.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cocaine block of hH1 channels was greater than block of mu1 channels at voltages between -120 mV and -90 mV, suggesting that greater steady-state inactivation of << hH1 channels >> in this voltage range makes them more susceptible to [[ cocaine ]] block.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of the << human ether-a-go-go-related gene (HERG) potassium channel >> by [[ cisapride ]]: affinity for open and inactivated states.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "2 In a chronic transfection model using CHO-K1 cells, << cisapride >> inhibited [[ HERG ]] tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "6 In conclusion, << HERG >> channel inhibition by [[ cisapride ]] exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "TREK-1 currents are insensitive to pharmacological agents that block << TWIK-1 >> activity such as [[ quinine ]] and quinidine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "TREK-1 currents are insensitive to pharmacological agents that block << TWIK-1 >> activity such as quinine and [[ quinidine ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: << Fondaparinux sodium >> is the first in a new class of synthetic [[ factor Xa ]] inhibitors that binds reversibly with high affinity to antithrombin III.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the << COX-2 >> inhibitor [[ NS-398 ]]; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed << COX-1 >>/COX-2 inhibitor [[ ibuprofen ]]; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/<< COX-2 >> inhibitor [[ ibuprofen ]]; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (FLAP) inhibitor MK-886.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the << 5-LOX >> inhibitor [[ REV 5901 ]]; and the 5-LOX activating protein (FLAP) inhibitor MK-886.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the << 5-LOX activating protein >> (FLAP) inhibitor [[ MK-886 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "They included the COX-1 inhibitor indomethacin; the COX-2 inhibitor NS-398; the mixed COX-1/COX-2 inhibitor ibuprofen; the nitric oxide (NO) derivatives of indomethacin, ibuprofen and flurbiprofen; the 5-LOX inhibitor REV 5901; and the 5-LOX activating protein (<< FLAP >>) inhibitor [[ MK-886 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Metformin >> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased [[ acetyl-CoA carboxylase-2 ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Acute and chronic << PLZ >> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, [[ GABA transaminase ]] (GABA-T).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Acute and chronic << PLZ >> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase ([[ GABA-T ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of << PLZ >> on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of << PLZ >> on alanine transaminase ([[ ALA-T ]]), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we also showed that the elevation in alanine levels and the inhibition of << alanine transaminase >> in the brain are retained after 14 days of [[ PLZ ]] treatment, and that PLZ produces a marked increase in extracellular levels of alanine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Of these, the << thrombin >> inhibitor [[ dabigatran ]] and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Of these, the thrombin inhibitor dabigatran and << factor Xa >> inhibitor [[ rivaroxaban ]] have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, the << factor Xa >> inhibitor [[ apixaban ]] is in late-stage clinical development.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << protein kinase C >> inhibitor [[ (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride ]] (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << protein kinase C >> inhibitor (+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride ([[ H-7 ]]) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << protein phosphatase >> inhibitor [[ okadaic acid ]] prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Repression of << farnesyltransferase >> (FNTA) by siRNA and the enzyme inhibitor [[ manumycin A ]] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Repression of farnesyltransferase (<< FNTA >>) by siRNA and the enzyme inhibitor [[ manumycin A ]] caused elevation of ApoA-I secretion from hepatocytes and from transgenic mice expressing hApoA-I and cholesterol ester transfer protein transgenes.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Repeated Low Dose Administration of the << Monoacylglycerol Lipase >> Inhibitor [[ JZL184 ]] Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << monoacylglycerol lipase >> (MAGL) inhibitor [[ JZL184 ]] produces antinociceptive and anti-inflammatory effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The monoacylglycerol lipase (<< MAGL >>) inhibitor [[ JZL184 ]] produces antinociceptive and anti-inflammatory effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Triclosan >> inhibited both [[ cyclooxygenase 1 ]] and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Triclosan >> inhibited both cyclooxygenase 1 and [[ cyclo-oxygenase 2 ]] with IC-50 values of 43 microM and 227 microM, respectively.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Triclosan >> also inhibited [[ 5-lipoxygenase ]] with an IC-50 of 43 microM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << 15-lipoxygenase >> was similarly inhibited by [[ triclosan ]] with an IC-50 of 61 microM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Hence, << triclosan >> has the ability to inhibit both the [[ cyclo-oxygenase ]] and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Hence, << triclosan >> has the ability to inhibit both the cyclo-oxygenase and [[ lipoxygenase ]] pathways of arachidonic acid metabolism with similar efficacy.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In cell culture experiments, it was found that << triclosan >> inhibited [[ IL-1 beta ]] induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<< DFMO >>), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Depletion of putrescine, spermidine, and spermine by << DL-alpha-difluoromethylornithine >> (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Depletion of putrescine, spermidine, and spermine by << DL-alpha-difluoromethylornithine >> (DFMO), a specific inhibitor of ornithine decarboxylase ([[ ODC ]]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Depletion of putrescine, spermidine, and spermine by DL-alpha-difluoromethylornithine (<< DFMO >>), a specific inhibitor of ornithine decarboxylase ([[ ODC ]]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [[[ diethylglyoxal bis-(guanylhydrazone) ]]; DEGBG] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); [[ DEGBG ]]] led to depletion of spermidine and spermine with a significant accumulation of putrescine and induction of ODC.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << clomipramine >> induces hyperglycemia in mice by blocking the [[ 5-HT(2B ) ]]and/or 5-HT(2C) receptors, which results in facilitation of adrenaline release.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << clomipramine >> induces hyperglycemia in mice by blocking the 5-HT(2B )and/or [[ 5-HT(2C) ]] receptors, which results in facilitation of adrenaline release.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenformin >> causes lactic acidosis in clinical situations due to inhibition of [[ mitochondrial respiratory chain complex I ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Role of organic cation/carnitine transporter 1 in uptake of << phenformin >> and inhibitory effect on [[ complex I ]] respiration in mitochondria.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, uptake of phenformin and [(14)C]tetraethylammonium (TEA) and << complex I >> inhibition by [[ phenformin ]] were examined in isolated liver and heart mitochondria.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition by << phenformin >> of oxygen consumption via [[ complex I ]] respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of phenformin on complex I respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition by phenformin of oxygen consumption via complex I respiration in isolated rat liver mitochondria was greater than that in heart mitochondria, whereas inhibitory effect of << phenformin >> on [[ complex I ]] respiration was similar in inside-out structured submitochondrial particles prepared from rat livers and hearts.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These observations suggest that uptake of << phenformin >> into liver mitochondria is at least partly mediated by OCTN1 and functionally relevant to its inhibition potential of [[ complex I ]] respiration.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Valproic acid >> selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by [[ brain microsomal long-chain fatty acyl-CoA synthetases ]]: relevance to bipolar disorder.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: This study shows that << valproic acid >> acts as a non-competitive inhibitor of [[ brain microsomal Acsl ]], and that inhibition is substrate-selective.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "MATERIALS AND METHODS/RESULTS: By isolating rat brain microsomal long-chain fatty acyl-CoA synthetases (Acsl), we show in vitro that << valproic acid >> is a non-competitive inhibitor of [[ Acsl ]], as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RATIONALE: Several drugs used to treat bipolar disorder (<< lithium >> and carbamazepine), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [[ phospholipase A(2) ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RATIONALE: Several drugs used to treat bipolar disorder (lithium and << carbamazepine >>), when administered chronically to rats, reduce the turnover of arachidonic acid, but not docosahexaenoic acid, in brain phospholipids by decreasing the activity of an arachidonic acid-selective [[ phospholipase A(2) ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Experimental as well as clinical reports support the hypothesis that << calcium channel >> blockers such as [[ verapamil ]] may be an appropriate therapeutic approach in LQTS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS AND RESULTS: In 8 Langendorff-perfused rabbit hearts, << veratridine >> (0.1 microM), an inhibitor of [[ sodium channel ]] inactivation, led to a marked increase in QT-interval and simultaneously recorded monophasic ventricular action potentials (MAPs) (p < 0.05) thereby mimicking LQT3.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by << minocycline >> may involve a mitochondrial apoptotic pathway, probably through preventing cytochrome c release and thereby blocking downstream [[ caspase ]] activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ThioTEPA >> ([[ CYP2B6 ]] inhibitor, 25 Î¼M) and the monoclonal antibody against CYP2B6 but not troleandomycin (CYP3A4 inhibitor, 25 Î¼M) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "ThioTEPA (CYP2B6 inhibitor, 25 Î¼M) and the monoclonal antibody against CYP2B6 but not << troleandomycin >> ([[ CYP3A4 ]] inhibitor, 25 Î¼M) or the monoclonal antibody against CYP3A4 inhibited ketamine N-demethylation at clinically relevant concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Efficacy and safety of the << dipeptidyl peptidase-4 >> inhibitor, [[ sitagliptin ]], in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "AIM: To assess the efficacy and safety of a 24-week treatment with << sitagliptin >>, a highly selective once-daily oral [[ dipeptidyl peptidase-4 ]] (DPP-4) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "AIM: To assess the efficacy and safety of a 24-week treatment with << sitagliptin >>, a highly selective once-daily oral dipeptidyl peptidase-4 ([[ DPP-4 ]]) inhibitor, in patients with type 2 diabetes who had inadequate glycaemic control [glycosylated haemoglobin (HbA(1c)) >or=7.5% and <or=10.5%] while on glimepiride alone or in combination with metformin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of extracellular signal-regulated kinase (<< ERK >>) within minutes, an effect blocked by pretreatment with [[ SB-277011-A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Quinpirole and 7-OH-DPAT also increased the phosphorylation of << extracellular signal-regulated kinase >> (ERK) within minutes, an effect blocked by pretreatment with [[ SB-277011-A ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [[ KIT ]], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [[ KIT ]], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [[ KIT ]], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of [[ KIT ]], ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [[ ABL ]], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [[ ABL ]], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [[ ABL ]], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, [[ ABL ]], BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [[ BCR ]]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [[ BCR ]]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [[ BCR ]]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, [[ BCR ]]-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[[ ABL ]], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[[ ABL ]], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[[ ABL ]], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-[[ ABL ]], PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [[ PDGFRA ]], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [[ PDGFRA ]], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [[ PDGFRA ]], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, [[ PDGFRA ]], and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Imatinib >> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [[ PDGFRB, ]] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (<< STI571 >>, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [[ PDGFRB, ]] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, << Gleevec >>, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [[ PDGFRB, ]] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Imatinib (STI571, Gleevec, << Glivec >>; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and [[ PDGFRB, ]] represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual << COX-1 >>/COX-2 inhibitor ([[ ketorolac ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1/<< COX-2 >> inhibitor ([[ ketorolac ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective << cyclooxygenase (COX)-2 >> inhibitor ([[ celecoxib ]]) in comparison to a dual COX-1/COX-2 inhibitor (ketorolac).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Celecoxib >> selectively suppressed PGE2 but not TxB2 at time points consistent with [[ COX-2 ]] activity, while producing analgesia.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Etoposide >> (VP-16) is a [[ topoisomerase-II ]] (topo II) inhibitor chemotherapeutic agent.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Etoposide >> (VP-16) is a topoisomerase-II ([[ topo II ]]) inhibitor chemotherapeutic agent.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Etoposide (<< VP-16 >>) is a [[ topoisomerase-II ]] (topo II) inhibitor chemotherapeutic agent.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Etoposide (<< VP-16 >>) is a topoisomerase-II ([[ topo II ]]) inhibitor chemotherapeutic agent.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< MXF >> or VP-16 slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [[ topo II ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "MXF or << VP-16 >> slightly affected cellular topo II activity in nuclear extracts derived from drug-treated cells while the combination enhanced inhibitory activity and the reduction in band depletion of [[ topo II ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, the results suggest that the enhancement in the reduction of << topo II >> activity by the combined MXF/[[ VP-16 ]] treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, the results suggest that the enhancement in the reduction of << topo II >> activity by the combined [[ MXF ]]/VP-16 treatments was probably due to the increase in the level of the DNA-enzyme cleavable complexes formed by both drugs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our previous work, built on the early pioneering multikinase inhibitor << LY294002 >>, resulted in the only [[ PI3K ]] vascular-targeted PI3K inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our previous work, built on the early pioneering multikinase inhibitor << LY294002 >>, resulted in the only PI3K vascular-targeted [[ PI3K ]] inhibitor prodrug, SF1126, which has now completed Phase I clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only << PI3K >> vascular-targeted PI3K inhibitor prodrug, [[ SF1126 ]], which has now completed Phase I clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our previous work, built on the early pioneering multikinase inhibitor LY294002, resulted in the only PI3K vascular-targeted << PI3K >> inhibitor prodrug, [[ SF1126 ]], which has now completed Phase I clinical trials.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This work resulted in the discovery of the << 5-morpholino-7H-thieno[3,2-b]pyran-7-one >> system as the foundation of a new compound class of potential [[ PI3K ]] inhibitors having improved potency toward PI3K.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This work resulted in the discovery of the << 5-morpholino-7H-thieno[3,2-b]pyran-7-one >> system as the foundation of a new compound class of potential PI3K inhibitors having improved potency toward [[ PI3K ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis and cancer stem cell-based activity of substituted << 5-morpholino-7H-thieno[3,2-b]pyran-7-ones >> designed as next generation [[ PI3K ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Discovery of a series of novel << 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers >>, as potent [[ JAK3 ]] kinase inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Discovery of a series of novel << 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers >>, as potent JAK3 [[ kinase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report the discovery of a novel series of ATP-competitive << Janus kinase 3 >> (JAK3) inhibitors based on the [[ 5H-pyrrolo[2,3-b]pyrazine ]] scaffold.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report the discovery of a novel series of ATP-competitive Janus kinase 3 (<< JAK3 >>) inhibitors based on the [[ 5H-pyrrolo[2,3-b]pyrazine ]] scaffold.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and << JNK >> activation were significantly prevented with [[ EHT ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In cultured primary microglia and astrocytes, << EHT >> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced [[ NFÎºB ]] activation, iNOS induction, and nitric oxide production.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In cultured primary microglia and astrocytes, << EHT >> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFÎºB activation, [[ iNOS ]] induction, and nitric oxide production.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << Hsp90 >>-specific inhibitor [[ geldanamycin ]] selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Hsp90-specific inhibitor << geldanamycin >> selectively disrupts [[ kinase ]]-mediated signaling events of T-lymphocyte activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Improper function of these proteins can be induced by selective disruption of their complexes with << Hsp90 >> using the [[ benzoquinonoid ansamycin ]] geldanamycin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Improper function of these proteins can be induced by selective disruption of their complexes with << Hsp90 >> using the benzoquinonoid ansamycin [[ geldanamycin ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of [[ Lck ]] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and [[ Raf-1 ]] kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and Raf-1 [[ kinases ]] and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the [[ extracellular signal regulated kinase (ERK)-2 ]] kinase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 [[ kinase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Geldanamycin >> also disrupts the [[ T-cell receptor ]]-mediated activation of nuclear factor of activated T-cells (NF-AT).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Geldanamycin >> also disrupts the T-cell receptor-mediated activation of [[ nuclear factor of activated T-cells ]] (NF-AT).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Geldanamycin >> also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells ([[ NF-AT ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Through demonstrating the selective inhibition of << kinase >>-related T-lymphocyte responses by [[ geldanamycin ]], our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Activating glucocorticoid receptor-ERK signaling pathway contributes to << ginsenoside Rg1 >> protection against [[ Î²-amyloid peptide ]]-induced human endothelial cells apoptosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Rg1 >> attenuated the [[ AÎ²25-35 ]]-associated mitochondrial apoptotic events, accompanied by inhibiting HIF-1Î± expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or << p-ERK >> inhibitor [[ U0126 ]] rather than estrogen receptor Î± antagonist ICI 82,780.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against [[ AÎ²25-35 ]]-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating HIF-1Î± initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data provided a novel insight to the mechanisms of << Rg1 >>protective effects on [[ AÎ²25-35 ]]-induced endothelial cells apoptosis, suggesting that GR-ERK signaling pathway might play an important role in it.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Rasagiline [<< N-propargyl-l(R)-aminoindan >>] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [[ MAO-B ]] and is specifically designed for the treatment of Parkinson's disease (PD).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation << propargylamine >> pharmacophore that selectively and irreversibly inhibits brain [[ MAO-B ]] and is specifically designed for the treatment of Parkinson's disease (PD).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Comprehensive review of << rasagiline >>, a second-generation [[ monoamine oxidase ]] inhibitor, for the treatment of Parkinson's disease.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Based on the results from those studies, we concluded that << rasagiline >> PO QD, at the therapeutic dosage range of 0.5 to 1 rag/d, is effective and well tolerated and completely, selectively, and specifically inhibited [[ MAO-B ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Rasagiline >> [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain [[ MAO-B ]] and is specifically designed for the treatment of Parkinson's disease (PD).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenelzine >> causes an increase in brain ornithine that is prevented by prior [[ monoamine oxidase ]] inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenelzine >> (PLZ), a nonselective irreversible inhibitor of [[ monoamine oxidase ]] (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenelzine (<< PLZ >>), a nonselective irreversible inhibitor of [[ monoamine oxidase ]] (MAO), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenelzine >> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase ([[ MAO ]]), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenelzine (<< PLZ >>), a nonselective irreversible inhibitor of monoamine oxidase ([[ MAO ]]), also inhibits GABA-transaminase (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenelzine >> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits [[ GABA-transaminase ]] (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenelzine >> (PLZ), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([[ GABA-T ]]), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenelzine (<< PLZ >>), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits [[ GABA-transaminase ]] (GABA-T), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phenelzine (<< PLZ >>), a nonselective irreversible inhibitor of monoamine oxidase (MAO), also inhibits GABA-transaminase ([[ GABA-T ]]), markedly increasing brain GABA levels.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the << MAO >> inhibitor [[ tranylcypromine ]] (TCP) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine whether a metabolite formed by the action of MAO on PLZ may be responsible for the elevation in brain ORN observed, animals were pretreated with vehicle or the << MAO >> inhibitor tranylcypromine ([[ TCP ]]) before vehicle or PLZ (15 mg/kg), and brains collected 3 h later.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Optimization of << 5-hydroxytryptamines >> as dual function inhibitors targeting [[ phospholipase A2 ]] and leukotriene A4 hydrolase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Optimization of << 5-hydroxytryptamines >> as dual function inhibitors targeting phospholipase A2 and [[ leukotriene A4 hydrolase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<< JMC08-4 >>) for [[ human nonpancreatic secretory phospholipase A(2) ]] (hnps-PLA(2)) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<< JMC08-4 >>) for human nonpancreatic secretory phospholipase A(2) ([[ hnps-PLA(2) ]]) and human leukotriene A(4) hydrolase (LTA(4)H-h) was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<< JMC08-4 >>) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and [[ human leukotriene A(4) hydrolase ]] (LTA(4)H-h) was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In previous study, we discovered multi-target drugs towards the AA metabolic network, among which a dual-target inhibitor (<< JMC08-4 >>) for human nonpancreatic secretory phospholipase A(2) (hnps-PLA(2)) and human leukotriene A(4) hydrolase ([[ LTA(4)H-h ]]) was found.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 5-(N,N-dimethyl)-amiloride >> (50 microM; DMA), a concentration that selectively inhibits the [[ NHE ]] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "5-(N,N-dimethyl)-amiloride (50 microM; << DMA >>), a concentration that selectively inhibits the [[ NHE ]] isoforms NHE1 and NHE2, but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 5-(N,N-dimethyl)-amiloride >> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms [[ NHE1 ]] and NHE2, but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 5-(N,N-dimethyl)-amiloride >> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and [[ NHE2 ]], but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 5-(N,N-dimethyl)-amiloride >> (50 microM; DMA), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not [[ NHE3 ]], did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "5-(N,N-dimethyl)-amiloride (50 microM; << DMA >>), a concentration that selectively inhibits the NHE isoforms [[ NHE1 ]] and NHE2, but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "5-(N,N-dimethyl)-amiloride (50 microM; << DMA >>), a concentration that selectively inhibits the NHE isoforms NHE1 and [[ NHE2 ]], but not NHE3, did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "5-(N,N-dimethyl)-amiloride (50 microM; << DMA >>), a concentration that selectively inhibits the NHE isoforms NHE1 and NHE2, but not [[ NHE3 ]], did not affect DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nevertheless, 3 mM << DMA >>, a higher concentration that inhibits [[ NHE1 ]], NHE2, and NHE3, significantly increased DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nevertheless, 3 mM << DMA >>, a higher concentration that inhibits NHE1, [[ NHE2 ]], and NHE3, significantly increased DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nevertheless, 3 mM << DMA >>, a higher concentration that inhibits NHE1, NHE2, and [[ NHE3 ]], significantly increased DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << S1611 >> and S3226, both specific inhibitors of [[ NHE3 ]] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, S1611 and << S3226 >>, both specific inhibitors of [[ NHE3 ]] only, or perfusion with Na+-free solutions, dose dependently increased DBS, as measured by pH-stat and CO2-sensitive electrode, without affecting intracellular pH.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nevertheless, coperfusion with 0.1 and 0.3 mM << 5-nitro-2-(3-phenylpropylamino) benzoic acid >>, which inhibits the [[ cystic fibrosis transmembrane conductor regulator ]] (CFTR), dose dependently inhibited S3226-induced DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Nevertheless, coperfusion with 0.1 and 0.3 mM << 5-nitro-2-(3-phenylpropylamino) benzoic acid >>, which inhibits the cystic fibrosis transmembrane conductor regulator ([[ CFTR ]]), dose dependently inhibited S3226-induced DBS.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Indomethacin >> treatment led to an increase in lipid peroxidation, glutathione peroxidase and glucose-6-phosphate dehydrogenase activities and to a decrease in [[ catalase ]] activity and glutathione levels in gastric mucosa.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The objective of the present study was to compare the anti-inflammatory effects of the preferential COX-2 inhibitor etodolac with the non-selective << COX >> inhibitor [[ phenylbutazone ]] in horses with lipopolysaccharide (LPS)-induced synovitis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The two basic mainstays of gastrointestinal stromal tumours (GIST) treatment are surgery and << imatinib >>, a selective [[ tyrosine kinase ]] inhibitor that allows achieving a stable or responding disease in about 80% of patients with unresectable/metastatic GIST.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Second, << ICRF-187 >>, a [[ Top2 ]] catalytic inhibitor known to deplete Top2Î², specifically sensitized MEFs to CPT.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Second, << ICRF-187 >>, a Top2 catalytic inhibitor known to deplete [[ Top2Î² ]], specifically sensitized MEFs to CPT.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of testicular << LDH-X >> from laboratory animals and man by [[ gossypol ]] and its isomers.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effect of (+)-, (-)-, (+/-)-gossypol and << (+/-)-gossypol acetic acid >> upon testicular cytosolic [[ LDH-X ]] was measured in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effect of << (+)-, (-)-, (+/-)-gossypol >> and (+/-)-gossypol acetic acid upon testicular cytosolic [[ LDH-X ]] was measured in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gossypol acetic acid >> (0-100 mumol/l) inhibited [[ LDH-X ]] prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gossypol >> and its isomers were non-competitive inhibitors of [[ human and hamster LDH-X ]] with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme << NADH >>, competitive inhibitors of [[ human LDH-X ]] and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The channel activators << avermectin >> and moxidectin usually retain their inhibitory potency in the [[ Rdl ]] subunit mutants.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The channel activators avermectin and << moxidectin >> usually retain their inhibitory potency in the [[ Rdl ]] subunit mutants.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The induction of << HO-1 >> by EIH was inhibited by [[ SB203580 ]] but not by SP600125, PD98059, nor LY294002.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Design, Synthesis, Biological Evaluation, and Docking Studies of << (S)-Phenylalanine >> Derivatives with a 2-Cyanopyrrolidine Moiety as Potent [[ Dipeptidyl Peptidase 4 ]] Inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a << 2-Cyanopyrrolidine >> Moiety as Potent [[ Dipeptidyl Peptidase 4 ]] Inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the << cyclopropyl-substituted phenylalanine >> derivative 11h displayed the most potent [[ DPP-4 ]] inhibitory activity with an IC50 value of 0.247 Î¼M.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "It has been known for decades that << lithium chloride >> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "It has been known for decades that lithium chloride (<< LiCl >>) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Lung inflammation, << IL-4 >> production, and airway mast cell activity were also prevented under this early short-term treatment with [[ PGE2 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Local << PGE2 >> administration prevented the increase of airway [[ IL-13 ]] and osteopontin and kept lung plasmacytoid dendritic cell counts close to baseline.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Local << PGE2 >> administration prevented the increase of airway IL-13 and [[ osteopontin ]] and kept lung plasmacytoid dendritic cell counts close to baseline.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In support of this observation, elongation can be reversed by the << tyrosine kinase >> inhibitor [[ SU5402 ]], mRNA for the FGFR antagonist sprouty4, or FGF8 morpholino.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Topotecan >> is a [[ topoisomerase I ]] inhibitor which is currently evaluated as an adjuvant agent for malignant glioma.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Examination of phosphorylation in << retinoblastoma (Rb) protein >>, we found an inhibitory effect by [[ glucosamine ]] at 20 and 50Â mM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Altogether, our results suggest that a high dose of << glucosamine >> may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0)/G(1) phase, and that this occurs, at least in part, by a reduction in [[ Rb ]] phosphorylation together with modulation of p21, p53 and HO-1 expression, and nuclear p21 accumulation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Suppression of << TÎ²R1 >> by the pharmacological inhibitor ([[ SB431542 ]]) markedly reduced VEGF release by HFL-1 in response to CSE and this effect was confirmed by TÎ²R1 siRNA.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A review of the structural and functional features of << olmesartan medoxomil >>, an [[ angiotensin receptor ]] blocker.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The marked antihypertensive efficacy of << olmesartan medoxomil >> may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of [[ A-II ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Upamostat >> (MesupronÂ®) is a new small molecule [[ serine protease ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Upamostat (<< Mesupron >>Â®) is a new small molecule [[ serine protease ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Galantamine >> is a reversible, competitive [[ acetylcholinesterase ]] (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Galantamine >> is a reversible, competitive acetylcholinesterase ([[ AChE ]]) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibitory effects of the << monoamine oxidase >> inhibitor [[ tranylcypromine ]] on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of << tranylcypromine >>, a nonselective irreversible inhibitor of [[ monoamine oxidase ]] (MAO), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of << tranylcypromine >>, a nonselective irreversible inhibitor of monoamine oxidase ([[ MAO ]]), on three cytochrome P450 (CYP) enzymes, namely CYP2C9, CYP2C19, and CYP2D6, have been evaluated in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The results demonstrated that << tranylcypromine >> is a competitive inhibitor of [[ CYP2C19 ]] (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The results demonstrated that << tranylcypromine >> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and [[ CYP2D6 ]] (Ki = 367 microM) and a noncompetitive inhibitor of CYP2C9 (Ki = 56 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The results demonstrated that << tranylcypromine >> is a competitive inhibitor of CYP2C19 (Ki = 32 microM) and CYP2D6 (Ki = 367 microM) and a noncompetitive inhibitor of [[ CYP2C9 ]] (Ki = 56 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study identified four clinically approved antihypertensive drugs (<< efonidipine >>, felodipine, isradipine, and nitrendipine) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study identified four clinically approved antihypertensive drugs (efonidipine, << felodipine >>, isradipine, and nitrendipine) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, << isradipine >>, and nitrendipine) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study identified four clinically approved antihypertensive drugs (efonidipine, felodipine, isradipine, and << nitrendipine >>) as potent [[ T-channel ]] blockers (IC(50) < 3 microM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These findings suggest that the anti-allodynia effect of << CP-101,606 >> is ascribable to blockade of [[ NR2B ]] receptors at the brain, but not at the spinal cord.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that << Rho >> and Rho kinase inhibitor (C3T and [[ Y27632 ]]) increased apoA-I production in the HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Further study revealed that pitavastatin increased ABCA1 mRNA in HMG-CoA reductase-dependent manner and that Rho and << Rho kinase >> inhibitor (C3T and [[ Y27632 ]]) increased apoA-I production in the HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of [[ HMG-CoA reductase ]] and suppression of Rho activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << pitavastatin >> efficiently increases apoA-I in the culture medium of HepG2 cells by promoting apoA-I production through inhibition of HMG-CoA reductase and suppression of [[ Rho ]] activity and by protecting apoA-I from catabolism through ABCA1 induction and lipidation of apoA-I.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These findings indicate that MBE and its << anthocyanidins >> suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of [[ phosphorylated-p38 ]] may be involved in the underlying mechanism.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When the anti-corticosterone drug << aminoglutethimide >> ([[ CYP11A1 ]] inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the << OCT3 >> inhibitors cyanine 863, [[ oestradiol ]] and corticosterone.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the << OCT3 >> inhibitors cyanine 863, oestradiol and [[ corticosterone ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "No influence of moderate hepatic impairment on the pharmacokinetics of << lumiracoxib >>, an oral [[ COX-2 ]] selective inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel << cyclooxygenase-2 >> (COX-2) selective inhibitor [[ lumiracoxib ]] (Prexige), so that dose recommendations for clinical use can be provided.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<< COX-2 >>) selective inhibitor [[ lumiracoxib ]] (Prexige), so that dose recommendations for clinical use can be provided.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel << cyclooxygenase-2 >> (COX-2) selective inhibitor lumiracoxib ([[ Prexige ]]), so that dose recommendations for clinical use can be provided.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The aim of this study was to evaluate the influence of hepatic impairment on the pharmacokinetics (PK) of the novel cyclooxygenase-2 (<< COX-2 >>) selective inhibitor lumiracoxib ([[ Prexige ]]), so that dose recommendations for clinical use can be provided.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< LY294002 >>, a specific [[ PI3K ]]/AKT inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< LY294002 >>, a specific PI3K/[[ AKT ]] inhibitor, selectively activated the p38 MAPK kinase pathway and enhanced c-Jun phosphorylation, but did not activate JNK.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The pharmacological inhibitors << SB203580 >> ([[ p38 ]] inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The pharmacological inhibitors SB203580 (p38 inhibitor) and << SP600125 >> (a [[ JNK ]] inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Terbinafine >>: mode of action and properties of the [[ squalene epoxidase ]] inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Terbinafine >> (Lamisil) has primarily fungicidal action against many fungi as a result of its specific mechanism of [[ squalene epoxidase ]] inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Terbinafine (<< Lamisil >>) has primarily fungicidal action against many fungi as a result of its specific mechanism of [[ squalene epoxidase ]] inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Terbinafine >> is a potent non-competitive inhibitor of [[ squalene epoxidase ]] from Candida (Ki = 30 nM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, inhibition of << rat liver squalene epoxidase >> only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with [[ squalene ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Torasemide >> inhibits [[ angiotensin II ]]-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Isometric contraction induced by a submaximal concentration of << Ang II >> (10(-7) mol/L) was reduced in a dose-dependent way by [[ torasemide ]] (IC(50)=0.5+/-0.04 micromol/L).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The stimulatory effect of [Ca(2+)](i) induced by a submaximal concentration of << Ang II >> (10(-7) mol/L) was blocked by [[ torasemide ]] (IC(50)=0.5+/-0.3 nmol/L).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our findings suggest that << torasemide >> blocks the vasoconstrictor action of [[ Ang II ]] in vitro.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This action can be related to the ability of << torasemide >> to block the increase of [Ca(2+)](i) induced by [[ Ang II ]] in VSMCs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The cardiovascular effects of three different << acetylcholinesterase >> inhibitors: [[ physostigmine ]], tacrine and rivastigmine injected by intravenous (i.v.)", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The cardiovascular effects of three different << acetylcholinesterase >> inhibitors: physostigmine, [[ tacrine ]] and rivastigmine injected by intravenous (i.v.)", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The cardiovascular effects of three different << acetylcholinesterase >> inhibitors: physostigmine, tacrine and [[ rivastigmine ]] injected by intravenous (i.v.)", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Tacrine >> was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. [[ cholinesterase ]] inhibitors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Alendronate >> inhibition of [[ protein-tyrosine-phosphatase-meg1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Here we report that << alendronate >> is a potent inhibitor of the [[ protein-tyrosine-phosphatase-meg1 ]] (PTPmeg1).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Here we report that << alendronate >> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 ([[ PTPmeg1 ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "With either substrate, << alendronate >> was a slow binding inhibitor of [[ PTPmeg1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Among the other bisphosphonates studied, << alendronate >> was more potent and selective for [[ PTPmeg1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Among the other << bisphosphonates >> studied, alendronate was more potent and selective for [[ PTPmeg1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; << PTPsigma >>, however, under the same conditions, was inhibited by only 50% with 141 microM [[ alendronate ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Alendronate >> inhibited [[ PTPmeg1 ]] with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Alendronate >> inhibited PTPmeg1 with an IC50 value of 23 microM, [[ PTPsigma ]] with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << alendronate >> inhibition of these three [[ PTPs ]] and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< PTP >> inhibition by [[ hisphosphonates ]] or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< PTP >> inhibition by hisphosphonates or [[ vanadate ]] was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These observations show substrate- and enzyme-specific << PTP >> inhibition by [[ alendronate ]] and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the << P-gp >> inhibitor [[ zosuquidar ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of << ketoconazole >> on [[ P-gp ]] as the main mechanism for the increased transport of darunavir across the small intestine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various << progestogens >> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including << dydrogesterone >> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, << medrogestone >>, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, << promegestone >>, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, << nomegestrol acetate >> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and << norelgestromin >> can reduce intratissular levels of estradiol in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various << progestogens >> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including << dydrogesterone >> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, << medrogestone >>, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, << promegestone >>, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, << nomegestrol acetate >> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and << norelgestromin >> can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "After 7 days of << DMI >> administration the number of [[ beta-adrenoceptors ]] was lower in frontal and occipital cortex and hippocampus.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << DMI >> induced reduction in [[ beta-adrenoceptors ]] did not differ in OB and sham-operated control rats.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< DMI >> administration for up to 21 days produced a progressive reduction in the number of [[ 5-HT2A ]] receptors in frontal cortex, without significant alterations in occipital cortex.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The time course of the reduction in the number of << 5-HT2A >> receptors was similar to that of the [[ DMI ]]-induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The time course of the reduction in the number of 5-HT2A receptors was similar to that of the << DMI >>-induced behavioural changes whereas that for the reduction in [[ beta-adrenoceptors ]] was clearly different.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present results suggest that the action of << DMI >> in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical [[ 5-HT2A ]] receptors.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Among the isolated compounds, << trans-dihydromorin >> (8), oxyresveratrol (9), and steppogenin (12) were found to exhibit significant [[ tyrosinase ]] inhibition activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Among the isolated compounds, trans-dihydromorin (8), << oxyresveratrol >> (9), and steppogenin (12) were found to exhibit significant [[ tyrosinase ]] inhibition activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Among the isolated compounds, trans-dihydromorin (8), oxyresveratrol (9), and << steppogenin >> (12) were found to exhibit significant [[ tyrosinase ]] inhibition activities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Tyrosine kinase >> inhibitors are [[ quinazoline ]]-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular [[ tyrosine kinase domain ]] of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including [[ EGFR ]], Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, [[ Erb2 ]], and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and [[ vascular endothelial growth factor receptor ]], and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "3D-QSAR-assisted drug design: identification of a potent << quinazoline >>-based [[ Aurora kinase ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Based on these suggestions, the rational redesign of << furanopyrimidine >> 24 (clogâP=7.41; [[ AuroraâA ]] IC(50) =43ânM; HCT-116 IC(50) =400ânM) led to the identification of quinazoline 67 (clogâP=5.28; AuroraâA IC(50) =25ânM; HCT-116 IC(50) =23ânM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Based on these suggestions, the rational redesign of furanopyrimidine 24 (clogâP=7.41; AuroraâA IC(50) =43ânM; HCT-116 IC(50) =400ânM) led to the identification of << quinazoline >> 67 (clogâP=5.28; [[ AuroraâA ]] IC(50) =25ânM; HCT-116 IC(50) =23ânM).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Three different 3D-QSAR models were built and validated by using a set of 66 << pyrazole >> (ModelâI) and furanopyrimidine (ModelâII) compounds with IC(50) values toward [[ Aurora kinaseâA ]] ranging from 33ânM to 10.5âÎ¼M.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Three different 3D-QSAR models were built and validated by using a set of 66 pyrazole (ModelâI) and << furanopyrimidine >> (ModelâII) compounds with IC(50) values toward [[ Aurora kinaseâA ]] ranging from 33ânM to 10.5âÎ¼M.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << aminopeptidase >> activity in the presence of [[ bestatin ]] and puromycin inhibitors was also investigated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << aminopeptidase >> activity in the presence of bestatin and [[ puromycin ]] inhibitors was also investigated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Telmisartan >> is an [[ angiotensin II receptor ]] blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Xanthines >> are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of [[ adenosine receptors ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The reaction was inhibited by the specific << CYP2D >> inhibitors [[ quinine ]] and fluoxetine.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The reaction was inhibited by the specific << CYP2D >> inhibitors quinine and [[ fluoxetine ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: << Celecoxib >> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [[ cyclo-oxygenase-2 ]] (COX-2) isoenzyme at therapeutic concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: << Celecoxib >> and rofecoxib are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ([[ COX-2 ]]) isoenzyme at therapeutic concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: Celecoxib and << rofecoxib >> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the [[ cyclo-oxygenase-2 ]] (COX-2) isoenzyme at therapeutic concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: Celecoxib and << rofecoxib >> are two relatively new nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclo-oxygenase-2 ([[ COX-2 ]]) isoenzyme at therapeutic concentrations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was conducted in order to understand the association between acute renal failure and the two << COX-2 >> inhibitors [[ celecoxib ]] and rofecoxib.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was conducted in order to understand the association between acute renal failure and the two << COX-2 >> inhibitors celecoxib and [[ rofecoxib ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Fulvestrant >> is a novel ER antagonist that destroys the [[ ER ]] and its signaling pathway and is not associated with tamoxifen-like agonist effects.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Structural basis for << LFA-1 >> inhibition upon [[ lovastatin ]] binding to the CD11a I-domain.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report here that << lovastatin >>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor [[ intercellular adhesion molecule-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report here that << lovastatin >>, a drug clinically used for lowering cholesterol levels, inhibits the interaction of [[ human LFA-1 ]] with its counter-receptor intercellular adhesion molecule-1.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Miglustat >>, an imino sugar that reversibly inhibits [[ glucosylceramide synthase ]] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Miglustat, an << imino sugar >> that reversibly inhibits [[ glucosylceramide synthase ]] and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As a prodrug << leflunomide >> is completely converted to its active metabolite A 77 1726 (M1) which blocks the [[ dihydroorotate dehydrogenase ]], a key enzyme of the pyrimidine de novo synthesis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As a prodrug leflunomide is completely converted to its active metabolite << A 77 1726 >> (M1) which blocks the [[ dihydroorotate dehydrogenase ]], a key enzyme of the pyrimidine de novo synthesis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Losartan >> is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [[ AT(1) receptor ]] (non-competitive inhibition).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus << captopril >>, a drug from the [[ angiotensin-converting-enzyme ]] inhibitor class with proven benefit in this population.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Clinical experience in heart failure is growing, and recent data suggest an improved survival with << losartan >> versus captopril, a drug from the [[ angiotensin-converting-enzyme ]] inhibitor class with proven benefit in this population.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The current comprehensive losartan clinical end-point programme (4 large scale morbidity/mortality trials) should provide evidence regarding the efficacy of direct blockade of the << AT(1) receptor >> with [[ losartan ]] compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "With the use of << sildenafil >>, it has been clearly, clinically demonstrated that the selective inhibition of [[ PDE5 ]] is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of << sildenafil >> (Viagra, Pfizer) - the first approved selective [[ PDE ]] inhibitor for the treatment of ED.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Many clinical studies, both pre- and post-marketing, have demonstrated the clinical efficacy and safety of sildenafil (<< Viagra >>, Pfizer) - the first approved selective [[ PDE ]] inhibitor for the treatment of ED.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> is inhibitory of [[ PDE5 ]] at a rate tenfold higher than for the next PDE (PDE6), which produces visual changes through the retinal rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> is inhibitory of PDE5 at a rate tenfold higher than for the next [[ PDE ]] (PDE6), which produces visual changes through the retinal rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sildenafil >> is inhibitory of PDE5 at a rate tenfold higher than for the next PDE ([[ PDE6 ]]), which produces visual changes through the retinal rods.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synthesis, << dihydrofolate reductase >> inhibition, antitumor testing, and molecular modeling study of some new [[ 4(3H)-quinazolinone ]] analogs.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In order to produce potent new leads for anticancer drugs, a new series of << quinazoline >> analogs was designed to resemble methotrexate (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [[ mammalian DHFR ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble << methotrexate >> (MTX, 1) structure features and fitted with functional groups believed to enhance inhibition of [[ mammalian DHFR ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In order to produce potent new leads for anticancer drugs, a new series of quinazoline analogs was designed to resemble methotrexate (<< MTX >>, 1) structure features and fitted with functional groups believed to enhance inhibition of [[ mammalian DHFR ]] activity.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Synergistic cytotoxicity was demonstrated, and << pemetrexed >> significantly decreased the amount of [[ phosphorylated Akt ]], enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data demonstrated that 1) << gemcitabine >> and pemetrexed synergistically interact against NSCLC cells through the suppression of [[ Akt ]] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data demonstrated that 1) gemcitabine and << pemetrexed >> synergistically interact against NSCLC cells through the suppression of [[ Akt ]] phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block [[ I(Kr) ]] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, << d-sotalol >> (100 micromol/L) to block [[ I(Kr) ]] (LQT2 model), and ATX-II (20 nmol/L) to augment late I(Na) (LQT3 model).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, d-sotalol (100 micromol/L) to block I(Kr) (LQT2 model), and [[ ATX-II ]] (20 nmol/L) to augment late I(Na) (LQT3 model).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Isoproterenol (50 to 100 nmol/L) was used to mimic an increase in beta-adrenergic tone, << d-sotalol >> (100 micromol/L) to block I(Kr) (LQT2 model), and [[ ATX-II ]] (20 nmol/L) to augment late I(Na) (LQT3 model).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< COX-1 >> and COX-2 inhibition in horse blood by [[ phenylbutazone ]], flunixin, carprofen and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "COX-1 and << COX-2 >> inhibition in horse blood by [[ phenylbutazone ]], flunixin, carprofen and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< COX-1 >> and COX-2 inhibition in horse blood by phenylbutazone, [[ flunixin ]], carprofen and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "COX-1 and << COX-2 >> inhibition in horse blood by phenylbutazone, [[ flunixin ]], carprofen and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< COX-1 >> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, [[ carprofen ]] and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "COX-1 and << COX-2 >> inhibition in horse blood by phenylbutazone, flunixin, [[ carprofen ]] and meloxicam: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< COX-1 >> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and [[ meloxicam ]]: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "COX-1 and << COX-2 >> inhibition in horse blood by phenylbutazone, flunixin, carprofen and [[ meloxicam ]]: an in vitro analysis.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report on the inhibitory activity of the NSAIDs << meloxicam >>, carprofen, phenylbutazone and flunixin, on blood [[ cyclooxygenases ]] in the horse using in vitro enzyme-linked assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report on the inhibitory activity of the NSAIDs meloxicam, << carprofen >>, phenylbutazone and flunixin, on blood [[ cyclooxygenases ]] in the horse using in vitro enzyme-linked assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, << phenylbutazone >> and flunixin, on blood [[ cyclooxygenases ]] in the horse using in vitro enzyme-linked assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and << flunixin >>, on blood [[ cyclooxygenases ]] in the horse using in vitro enzyme-linked assays.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As expected, comparison of IC50 indicated that meloxicam and << carprofen >> are more selective inhibitors of [[ COX-2 ]] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As expected, comparison of IC50 indicated that << meloxicam >> and carprofen are more selective inhibitors of [[ COX-2 ]] than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of << COX-2 >> than [[ phenylbutazone ]] and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of << COX-2 >> than phenylbutazone and [[ flunixin ]]; meloxicam was the most advantageous for horses of four NSAIDs examined.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However at IC80, phenylbutazone (+134.4%) and << flunixin >> (+29.7%) had greater [[ COX-2 ]] selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However at IC80, << phenylbutazone >> (+134.4%) and flunixin (+29.7%) had greater [[ COX-2 ]] selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and << carprofen >> (-12.9%) had lower [[ COX-2 ]] selectivity than at IC50.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and << meloxicam >> (-41.2%) and carprofen (-12.9%) had lower [[ COX-2 ]] selectivity than at IC50.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Mesalamine >> modulates intercellular adhesion through inhibition of [[ p-21 activated kinase-1 ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism of << PAK1 >> inhibition and induction of membranous translocation of adhesion proteins by [[ 5-ASA ]] might be independent of its known anti-inflammatory action.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the << VMAT >> inhibitor [[ reserpine ]] and a proton ionophore, but not by tetrabenazine, which has a high affinity for VMAT-2.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Western blot analysis indicated that << TSN >> inhibits the [[ CDC42 ]]/MEKK1/JNK pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Western blot analysis indicated that << TSN >> inhibits the CDC42/[[ MEKK1 ]]/JNK pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Western blot analysis indicated that << TSN >> inhibits the CDC42/MEKK1/[[ JNK ]] pathway.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between << phenoxybenzamine >> and calmodulin may be useful for inhibiting certain [[ calmodulin ]]-dependent reactions and for studying the various biological functions of calmodulin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << PARP >> inhibitor [[ PJ34 ]] modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Since PARP-1 is supposed to be part of a multimeric repressor of sodium iodide symporter (NIS) expression, in this study the effect of the << PARP >> inhibitor [[ PJ34 ]] on several properties of thyroid cancer cell lines was investigated.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The folding rate for wild-type << RNase A >> is faster in the presence of the inhibitor [[ 2'CMP ]] than in its absence, indicating that the transition-state structure in the rate-determining step is stabilized by 2'CMP.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact << bovine pancreatic ribonuclease A >> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [[ 2'-cytidine monophosphate ]] (2'CMP) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<< RNase A >>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [[ 2'-cytidine monophosphate ]] (2'CMP) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<< Pro42Ala >>) have been studied by monitoring tyrosine burial and [[ 2'-cytidine monophosphate ]] (2'CMP) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact << bovine pancreatic ribonuclease A >> (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([[ 2'CMP ]]) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<< RNase A >>) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([[ 2'CMP ]]) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its proline-42-to-alanine mutant (<< Pro42Ala >>) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([[ 2'CMP ]]) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its << proline-42-to-alanine >> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and [[ 2'-cytidine monophosphate ]] (2'CMP) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (RNase A) and its << proline-42-to-alanine >> mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate ([[ 2'CMP ]]) inhibitor binding.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with << omapatrilat >>, a [[ vasopeptidase ]] inhibitor.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Omapatrilat >>, the prototypical [[ vasopeptidase ]] inhibitor, inhibits not only ACE but also neutral endopeptidase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Omapatrilat >>, the prototypical vasopeptidase inhibitor, inhibits not only [[ ACE ]] but also neutral endopeptidase.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Omapatrilat >>, the prototypical vasopeptidase inhibitor, inhibits not only ACE but also [[ neutral endopeptidase ]].", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Like conventional << ACE >> inhibitors, [[ omapatrilat ]] causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major [[ human cytochrome P450 ]] enzymes, inhibition of the biliary efflux transporters BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary [[ efflux transporters ]] BSEP and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters [[ BSEP ]] and MRP2 or mitochondrial toxicity to THLE or HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "No effects were observed when << fenclozic acid >> was assessed for P450-dependent and P450-independent cytotoxicity to THLE cell lines, time-dependent inhibition of five major human cytochrome P450 enzymes, inhibition of the biliary efflux transporters BSEP and [[ MRP2 ]] or mitochondrial toxicity to THLE or HepG2 cells.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: The active metabolite of the anti-inflammatory drug << nabumetone >> has been characterized as a selective inhibitor of the inducible [[ prostaglandin H synthase ]] (PGHS).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: The active metabolite of the anti-inflammatory drug << nabumetone >> has been characterized as a selective inhibitor of the inducible prostaglandin H synthase ([[ PGHS ]]).", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The daily administration of low-dose << aspirin >> (40 mg), a selective inhibitor of platelet [[ PGHS-1 ]], caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: << Nabumetone >> does dose-dependently inhibit the [[ cyclooxygenase ]] activity of platelet PGHS-1 of healthy subjects both in vivo and ex vivo.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: << Nabumetone >> does dose-dependently inhibit the cyclooxygenase activity of platelet [[ PGHS-1 ]] of healthy subjects both in vivo and ex vivo.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "One group of experimental animals was treated with << 5-lipoxygenase >> (5-LO) inhibitor, [[ diethylcarbamazine ]] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "One group of experimental animals was treated with 5-lipoxygenase (<< 5-LO >>) inhibitor, [[ diethylcarbamazine ]] (DEC, Sigma, St. Louis, Missouri) (50 mg/kg, i.v.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "One group of experimental animals was treated with << 5-lipoxygenase >> (5-LO) inhibitor, diethylcarbamazine ([[ DEC ]], Sigma, St. Louis, Missouri) (50 mg/kg, i.v.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "One group of experimental animals was treated with 5-lipoxygenase (<< 5-LO >>) inhibitor, diethylcarbamazine ([[ DEC ]], Sigma, St. Louis, Missouri) (50 mg/kg, i.v.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although << DEC >> exerts local antioxidant activity with beneficial effects on lung tissue, this [[ 5-LO ]] inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.", "metadata": [], "label": "INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This effect has been attributed to the antagonist effects of << pindolol >> at the [[ 5-HT(1A) ]] receptor.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the present study, we compared the pharmacology of << (+/-)pindolol >>, WAY-100635 (a [[ 5-HT(1A) ]] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the present study, we compared the pharmacology of (+/-)pindolol, << WAY-100635 >> (a [[ 5-HT(1A) ]] antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and isamoltane (a 5-HT(1B) antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the present study, we compared the pharmacology of (+/-)pindolol, WAY-100635 (a 5-HT(1A) antagonist), GR127935 (a 5-HT(1B/1D) antagonist), and << isamoltane >> (a [[ 5-HT(1B) ]] antagonist), when given acutely in combination with fluoxetine, using in vivo microdialysis in the frontal cortex of the freely moving rat.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, by comparing the combined administration of (+/-)pindolol with either WAY100635, GR127935 or isamoltane, we have determined that << (+/-)pindolol >> produces much of its acute potentiation of fluoxetine-induced increases in extracellular 5-HT via its action at the 5-HT(1B/D) receptor in addition to any activity it has at the presynaptic [[ 5-HT(1A) ]] receptor.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Angiotensin AT1 receptor >> antagonist [[ losartan ]] and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective << sigma1 receptor >> antagonist [[ BD 1047 ]], suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Complementary experiments using the 5-HT3-dependent Bezold-Jarisch reflex confirmed that << amoxapine >> really acts in vivo as a [[ 5-HT3 ]] antagonist (IC50 = 50 micrograms/kg i.v.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The nonselective << opioid receptor >> antagonist, [[ naloxone ]] (3 mg/kg, i.m.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << delta-receptor >> antagonist, [[ SB 244525 ]] (10 mg/kg, i.p.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, combined pretreatment with << beta-funaltrexamine >> ([[ mu-receptor ]] antagonist; 20 mg/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg/kg, s.c.) and << norbinaltorphimine >> ([[ kappa-receptor ]] antagonist; 20 mg/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg/kg, i.p.).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << sigma-receptor >> antagonist [[ rimcazole ]] (3 mg/kg, i.p.)", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective << 5-HT2A >>/5-HT2C antagonist [[ ritanserin ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed 5-HT1/5-HT2 receptor antagonists such as pizotifen and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/<< 5-HT2C >> antagonist [[ ritanserin ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed 5-HT1/<< 5-HT2 >> receptor antagonists such as [[ pizotifen ]] and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed << 5-HT1 >>/5-HT2 receptor antagonists such as [[ pizotifen ]] and methysergide, and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed << 5-HT1 >>/5-HT2 receptor antagonists such as pizotifen and [[ methysergide ]], and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These data indicate that mixed 5-HT1/<< 5-HT2 >> receptor antagonists such as pizotifen and [[ methysergide ]], and mixed 5-HT and catecholamine antagonists such as mianserin and mirtazapine are more potent antagonists of mCPP-induced behavioural inhibition in rats than the more selective 5-HT2A/5-HT2C antagonist ritanserin.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of << haloperidol >> (HAL; 0.01 microM), a [[ dopamine D2 ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (<< HAL >>; 0.01 microM), a [[ dopamine D2 ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Combination chemotherapy with a << substance P receptor >> antagonist ([[ aprepitant ]]) and melarsoprol in a mouse model of human African trypanosomiasis.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Combination chemotherapy with a << substance P receptor >> antagonist (aprepitant) and [[ melarsoprol ]] in a mouse model of human African trypanosomiasis.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a << humanised SP receptor >> antagonist [[ aprepitant ]] (EMEND) in this mouse model.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study we investigated the effects of combination chemotherapy with melarsoprol and a << humanised SP receptor >> antagonist aprepitant ([[ EMEND ]]) in this mouse model.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, other << alpha(1)-adrenoceptor >> antagonists ([[ tamsulosin ]], WB4101 and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, other << alpha(1)-adrenoceptor >> antagonists (tamsulosin, [[ WB4101 ]] and corynanthine) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, other << alpha(1)-adrenoceptor >> antagonists (tamsulosin, WB4101 and [[ corynanthine ]]) did not inhibit the binding at a range of concentrations that generally exhibit alpha(1)-adrenoceptor antagonism, and noradrenaline, rauwolscine and propranolol were without effect on the [(3)H]prazosin binding.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of [[ duloxetine ]] [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of duloxetine [[[ (+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine ]]], which blocks the NE reuptake process.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "[<< N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide >>] (SR 141716A), a selective [[ cannabinoid CB1 receptor ]] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<< SR 141716A >>), a selective [[ cannabinoid CB1 receptor ]] antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid << (AMPA) receptor >> antagonist [[ IKM-159 ]]: asymmetric synthesis, neuroactivity, and structural characterization.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< IKM-159 >> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as [[ AMPA receptor ]]-selective antagonists.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "IKM-159 was developed and identified as a member of a new class of heterotricyclic << glutamate >> analogues that act as [[ AMPA receptor ]]-selective antagonists.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< (2R)-IKM-159 >> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of [[ AMPA receptors ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: << Telmisartan >>, an [[ angiotensin II type 1 receptor ]] (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "OBJECTIVE: << Telmisartan >>, an angiotensin II type 1 receptor ([[ AT1R ]]) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma (PPARgamma).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, the expression of AT1R was not suppressed by other << AT1R >> antagonists such as [[ candesartan ]] or olmesartan.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, the expression of AT1R was not suppressed by other << AT1R >> antagonists such as candesartan or [[ olmesartan ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Since the suppression of AT1R expression was prevented by pretreatment with << GW9662 >>, a [[ PPARgamma ]] antagonist, PPARgamma should have participated in the process.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Yohimbine >> is a potent and selective [[ alpha2- versus alpha1-adrenoceptor ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of << GW9662 >> and T0070907 ([[ PPARgamma ]] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effects of GW9662 and << T0070907 >> ([[ PPARgamma ]] antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both << 5'-AMN >> and 5'-MABN had high affinity for Îº-receptors (K (i) 1.36 Â± 0.98 and 0.27 Â± 0.08, respectively) and were revealed as potent Îº-antagonists (pA(2) 7.43 and 8.18, respectively) and [[ Î¼-receptor ]] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both 5'-AMN and << 5'-MABN >> had high affinity for Îº-receptors (K (i) 1.36 Â± 0.98 and 0.27 Â± 0.08, respectively) and were revealed as potent Îº-antagonists (pA(2) 7.43 and 8.18, respectively) and [[ Î¼-receptor ]] antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RGM-1 cells were treated with CDCA or GW4064, an FXR agonist, in the presence or absence of << guggulsterone >>, an [[ FXR ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, these findings indicate that << [3H]SR 142948A >> is a new potent antagonist radioligand which recognizes with high affinity both [[ neurotensin NT1 ]] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, these findings indicate that << [3H]SR 142948A >> is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and [[ NT2 receptors ]] and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of << neurotensin receptors >>, [[ [3H]SR 142948A ]] (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of << neurotensin receptors >>, [3H]SR 142948A ([[ 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride ]]), in the rat brain.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Characterization of binding sites of a new << neurotensin receptor >> antagonist, [[ [3H]SR 142948A ]], in the rat brain.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Saturation and competition studies in the presence or absence of the << histamine H1 receptor >> antagonist, [[ levocabastine ]], revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the GluR5 << kainate receptor >> antagonist [[ LY293558 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The selective GluR5 kainate receptor agonist ATPA induces spontaneous epileptiform bursting that is sensitive to the << GluR5 >> kainate receptor antagonist [[ LY293558 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A novel membrane sensor for << histamine H1-receptor >> antagonist \"[[ fexofenadine ]]\".", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Irbesartan >> is a long-acting [[ angiotensin II ]] antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Preclinical efficacy of << emedastine >>, a potent, selective [[ histamine H1 ]] antagonist for topical ocular use.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< 5-HT3 receptor >> antagonism with [[ alosetron ]] reduced responses to 5-HT in controls but not during inflammation.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The selective << beta1AR >> antagonists [[ atenolol ]] and metoprolol blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The selective << beta1AR >> antagonists atenolol and [[ metoprolol ]] blocked isoproterenol-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, the selective << beta2AR >> antagonists [[ ICI-118,551 ]] and butoxamine inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, the selective << beta2AR >> antagonists ICI-118,551 and [[ butoxamine ]] inhibited isoproterenol-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the present study we tested whether << propranolol >>, a [[ Î²-receptor ]] antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< (+/-)-tamsulosin >>, an [[ alpha 1A-adrenoceptor ]] antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The influence of << (+/-)-tamsulosin >>, a selective [[ alpha 1A-adrenoceptor ]] antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another alpha 1A-adrenoceptor ligand oxymetazoline in the rabbit ventricular myocardium.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< (+/-)-Tamsulosin >> effectively antagonized the positive inotropic effect of phenylephrine even after inactivation of [[ alpha 1B-adrenoceptors ]] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< (+/-)-Tamsulosin >>, over the range of concentrations at which it antagonized the positive inotropic effect mediated by [[ alpha 1-adrenoceptors ]], did not affect the accumulation of [3H]inositol phosphates that was induced by 10 microM phenylephrine.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results indicate that the positive inotropic effect, mediated via << (+/-)-tamsulosin >>- and oxymetazoline-sensitive subtype of [[ alpha 1-adrenoceptors ]], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "It is currently not known how much this << H(1) >> antagonism of [[ clozapine ]] contributes to the therapeutic or adverse side effects of clozapine.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the current project, we found that the selective << H(1) >> antagonist [[ pyrilamine ]] also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the << H(1) >> antagonist [[ pyrilamine ]], while pyrilamine had a mixed effect on cognition.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the << H(1) >> antagonist pyrilamine, while [[ pyrilamine ]] had a mixed effect on cognition.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Thus, << H(1) >> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as [[ clozapine ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Two pure << GnRH >> antagonists have been developed, [[ abarelix ]] and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Two pure << GnRH >> antagonists have been developed, abarelix and [[ degarelix ]], that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Abarelix >> was the first [[ GnRH ]] antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the << mAChR >> antagonist [[ atropine ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In vitro metabolism of the << 5-hydroxytryptamine1B >> receptor antagonist [[ elzasonan ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effect of fenoldopam on insulin-mediated VSMC proliferation was receptor specific, because its effect could be blocked by << SCH23390 >>, a [[ D1-like receptor ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "cocaine (0.03-3 mg/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the << dopamine receptor >> antagonist, [[ SCH 23390 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The non-selective << adenosine receptor >> antagonist ([[ caffeine ]]), and the selective adenosine A1 receptor antagonist (DPCPX), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The non-selective adenosine receptor antagonist (caffeine), and the selective << adenosine A1 receptor >> antagonist ([[ DPCPX ]]), injected 15 min before the application of pentetrazole and flumazenil, were able to intensify BDZ withdrawal signs in mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The concomitant application of subconvulsive dose of pentetrazole (55.0 mg/kg) with low dose of << flumazenil >> (5.0 mg/kg) - a [[ BDZ receptor ]] antagonist, immediately induced BDZ withdrawal signs in these animals.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The antagonistic property of << rilmenidine >> at [[ human alpha(2A)-adrenoceptors ]] indicates that in contrast to the suggestion based on rabbit data, the hypotensive property of the drug in humans is not due to activation of alpha(2A)-adrenoceptors but other, presumably I(1)-imidazoline receptors, are probably involved.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the rabbit pulmonary artery, rilmenidine and << oxymetazoline >> are potent full agonists, whereas in the human atrial appendages they are antagonists at the [[ alpha(2)-autoreceptors ]], sharing this property with rauwolscine, phentolamine, and idazoxan.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the rabbit pulmonary artery, << rilmenidine >> and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the [[ alpha(2)-autoreceptors ]], sharing this property with rauwolscine, phentolamine, and idazoxan.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the << alpha(2)-autoreceptors >>, sharing this property with [[ rauwolscine ]], phentolamine, and idazoxan.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the << alpha(2)-autoreceptors >>, sharing this property with rauwolscine, [[ phentolamine ]], and idazoxan.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the rabbit pulmonary artery, rilmenidine and oxymetazoline are potent full agonists, whereas in the human atrial appendages they are antagonists at the << alpha(2)-autoreceptors >>, sharing this property with rauwolscine, phentolamine, and [[ idazoxan ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with << alpha(2A)-autoreceptors >>, at which, however, both [[ rilmenidine ]] and oxymetazoline exhibit different properties (antagonism and agonism, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Ambrisentan >> is an [[ endothelin type A (ET(A))-selective receptor ]] antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the << calmodulin >> antagonists [[ W7 ]] and W13.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also consistent with the involvement of Gq coupled EP1 receptors, the PGE1 stimulation is inhibited by the PKCI vector (encoding the PKC inhibitory domain), the PKC inhibitor Go 6976, thapsigargin, as well as the << calmodulin >> antagonists W7 and [[ W13 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and << AH 6809 >> ([[ EP1 ]] and EP2 specific).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and << AH 6809 >> (EP1 and [[ EP2 ]] specific).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the << histamine H2-receptor >> antagonist, [[ cimetidine ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the << H1-receptor >> antagonist [[ promethazine ]], but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effects of a << serotonin 5-HT(4) receptor >> antagonist [[ SB-207266 ]] on gastrointestinal motor and sensory function in humans.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS: Part A compared the effects of placebo to four doses of a << 5-HT(4) >> receptor antagonist ([[ SB-207266 ]]) on the cisapride mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "METHODS: Part A compared the effects of placebo to four doses of a 5-HT(4) receptor antagonist (<< SB-207266 >>) on the cisapride mediated increase in plasma aldosterone (a [[ 5-HT(4) ]] mediated response) and orocaecal transit in 18 subjects.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "PNU-282987 on the other hand displayed an increase in anxiety-like behavior at a higher dose (10Â mg/kg) that was significantly reduced by the << serotonin 5-HT1a receptor >> antagonist [[ WAY-100135 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However the << Î±7 receptor >> antagonist [[ methyllycaconitine ]] was unable to reverse these anxiety-like effects seen with PNU-282987.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As a result of this study, << microgrewiapine A >> (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit [[ nicotinic receptor ]] antagonistic activity for both the hÎ±3Î²4 and hÎ±4Î²2 receptor subtypes.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Assessment of the abuse liability of << ABT-288 >>, a novel [[ histamine H3 receptor ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RATIONALE: << Histamine H3 receptor >> antagonists, such as [[ ABT-288 ]], have been shown to possess cognitive-enhancing and wakefulness-promoting effects.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to H3 antagonists, indicates that << ABT-288 >> is unlikely to possess a high potential for abuse in the human population and suggests that [[ H3 ]] antagonists, as a class, are similar in this regard.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "At least 4 h of estrogen pre-treatment was required to elicit protection, an effect that was blocked by the << ER >> antagonist, [[ ICI 182,780 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pentosan polysulfate << sodium >> (PPS) has been shown to exert antitumor activity by antagonizing the binding of [[ bFGF ]] to cell surface receptors.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Effect of << lintitript >>, a new [[ CCK-A receptor ]] antagonist, on gastric emptying of a solid-liquid meal in humans.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We studied the role of endogenous CCK in the emptying of a solid/liquid meal administering the new, highly specific and potent << CCK-A receptor >> antagonist [[ lintitript ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The study demonstrates for the first time the marked gastrokinetic properties of the new << CCK-A receptor >> antagonist [[ lintitript ]] in humans.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sedation and << histamine H1-receptor >> antagonism: studies in man with the enantiomers of [[ chlorpheniramine ]] and dimethindene.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sedation and << histamine H1-receptor >> antagonism: studies in man with the enantiomers of chlorpheniramine and [[ dimethindene ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Differentiating the roles of mGlu2 and mGlu3 receptors using << LY541850 >>, an mGlu2 agonist/[[ mGlu3 ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< LY541850 >> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric mGlu2 agonist and [[ mGlu3 ]] antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results confirm the selective mGlu2 agonist and << mGlu3 >> antagonist actions of [[ LY541850 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Clinical effects of << pranlukast >>, an oral [[ leukotriene receptor ]] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Incubation of rat aortic membranes with the irreversible << alpha 1B-adrenoceptor >> antagonist, [[ chloroethylclonidine ]] (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Incubation of rat aortic membranes with the irreversible << alpha 1B-adrenoceptor >> antagonist, chloroethylclonidine ([[ CEC ]]: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When Panx1 was coexpressed with purinergic P2X(7) receptor (P2X(7)R), << DIDS >> was found to act as a [[ P2X(7)R ]] antagonist to inhibit ATP-evoked currents, but none of the other compounds inhibited P2X(7)R currents.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Only pMPPI [<< 4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide hydrochloride >>], a selective [[ 5-HT(1A) ]] antagonist, was effective in inhibiting all 5-HT syndrome behaviors produced by lisuride, whereas pMPPI was without effect on any behavior induced by LSD.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effect of << histamine-H1 receptor >> antagonism with [[ terfenadine ]] on concentration-related AMP-induced bronchoconstriction in asthma.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Olopatadine hydrochloride >> (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[[ histamine H1-receptor ]] antagonistic drug that was synthesized and evaluated in our laboratories.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Olopatadine hydrochloride (<< olopatadine >>, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic/[[ histamine H1-receptor ]] antagonistic drug that was synthesized and evaluated in our laboratories.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Olopatadine hydrochloride (olopatadine, << 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride >>) is a novel antiallergic/[[ histamine H1-receptor ]] antagonistic drug that was synthesized and evaluated in our laboratories.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Olopatadine >> is a selective [[ histamine H1-receptor ]] antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The memory-improving effect of minaprine on cycloheximide-induced amnesia was potentiated by a selective << 5-HT2 >> antagonist, [[ ritanserin ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the << 5-HT(2A/2B/2C)-receptor >> antagonist [[ LY 53857 ]] enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the << 5-HT(1A/1B)-receptor >> antagonist [[ (-)-propranolol ]] and the 5-HT(3/4)-receptor antagonist tropisetron did not affect it.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The 5-HT(1/2/5/7)-receptor antagonist methysergide and the 5-HT(2A/2B/2C)-receptor antagonist LY 53857 enhanced clomipramine-induced hyperglycemia, while the 5-HT(1A/1B)-receptor antagonist (-)-propranolol and the << 5-HT(3/4)-receptor >> antagonist [[ tropisetron ]] did not affect it.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << 5-HT(2B/2C)-receptor >> antagonist [[ SB 206553 ]] facilitated hyperglycemia induced by clomipramine, although the 5-HT(2A)-receptor antagonist ketanserin was without effect.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The 5-HT(2B/2C)-receptor antagonist SB 206553 facilitated hyperglycemia induced by clomipramine, although the << 5-HT(2A) >>-receptor antagonist [[ ketanserin ]] was without effect.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We examined the effect of << JTH-601 >> (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [[ alpha(1L)-adrenoceptor ]] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We examined the effect of JTH-601 (3- inverted question mark<< N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom >> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [[ alpha(1L)-adrenoceptor ]] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom << ethyl >> inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new [[ alpha(1L)-adrenoceptor ]] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-<< 4-methoxy-2,5,6-trimethylphenol hemifumarate >>), a new [[ alpha(1L)-adrenoceptor ]] antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In these tissues, << JTH-601 >>, prazosin (a non-selective [[ alpha(1)-adrenoceptor ]] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In these tissues, JTH-601, << prazosin >> (a non-selective [[ alpha(1)-adrenoceptor ]] antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and << tamsulosin >> (an [[ alpha(1A)-adrenoceptor ]] antagonist) competitively antagonized contraction in a concentration-dependent manner.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< JTH-601 >> is expected to be an effective [[ alpha(1)-adrenoceptor ]] antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potency of the antipsychotic drug, << risperidone >>, to antagonize [[ alpha 1A-adrenoceptor ]]-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potency of the antipsychotic drug, << risperidone >>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and [[ alpha 1B-adrenoceptor ]]-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of alpha 1-adrenoceptor subtype-discriminating antagonists.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potency of the antipsychotic drug, << risperidone >>, to antagonize alpha 1A-adrenoceptor-mediated contraction in rat vas deferens and vasoconstriction in rat perfused kidney, and alpha 1B-adrenoceptor-mediated contractions in spleen from guinea-pig and mouse was evaluated and compared to that of [[ alpha 1-adrenoceptor ]] subtype-discriminating antagonists.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic << benzamide >> derivative agonist of 5-HT4 and 5-HT1 receptors and [[ 5-HT2 ]] antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to determine the gastroprotective properties of << cinitapride >> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [[ 5-HT2 ]] antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (<< CNT >>), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and [[ 5-HT2 ]] antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using the << alpha 1-adrenoceptor >> subtype-selective antagonists [[ chlorethylclonidine ]] (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using the << alpha 1-adrenoceptor >> subtype-selective antagonists chlorethylclonidine ([[ CEC ]]), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using the << alpha 1-adrenoceptor >> subtype-selective antagonists chlorethylclonidine (CEC), [[ WB4101 ]], and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using the << alpha 1-adrenoceptor >> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and [[ 5-methyl-urapidil ]], we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand [[ 125I-BE2254 ]] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Schild plots for the competitive antagonists << WB4101 >> and 5-methyl-urapidil against [[ alpha 1a-adrenoceptor ]]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Schild plots for the competitive antagonists WB4101 and << 5-methyl-urapidil >> against [[ alpha 1a-adrenoceptor ]]-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for [[ WB4101 ]] and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for [[ 5-methyl-urapidil ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that << alpha 1-adrenoceptor >> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for [[ WB4101 ]] and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that << alpha 1-adrenoceptor >> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for [[ 5-methyl-urapidil ]]) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "All neurotrophic effects were blocked by the unselective D2/D3 receptor antagonist sulpiride (5 microm) and by the selective << D3 receptor >> antagonist [[ SB-277011-A ]] at a low dose (50 nm).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the << alpha 2-adrenoceptor >> antagonist, [[ idazoxan ]], the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent << alpha 2A-adrenoceptor >> antagonist, [[ RX 821002 ]] and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential << alpha 2A-adrenoceptor >> antagonist, [[ BRL 44408 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist [[ SCH 39166 ]] ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the dopamine D1 receptor antagonist SCH 39166 ((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine) and the << dopamine D2 receptor >> antagonist [[ raclopride ]] (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Doses of dimethocaine (1.7 mg/kg) and cocaine (0.3 mg/kg) which produced full (> 80%) substitution for cocaine were administered in combination with the << dopamine D1 receptor >> antagonist SCH 39166 ([[ (-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo [d]naphtho-(2,1-b)azepine ]]) and the dopamine D2 receptor antagonist raclopride (both at 0.003-0.03 mg/kg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effect of sumatriptan, but not of LY 344864, was prevented by pretreatment with the antagonist << SDZ 21-009 >>, which displays high affinity for [[ rat 5-HT1B ]] receptors.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These protective effects were abolished by glucocorticoid receptor (<< GR >>) antagonist [[ RU486 ]] or p-ERK inhibitor U0126 rather than estrogen receptor Î± antagonist ICI 82,780.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These protective effects were abolished by << glucocorticoid receptor >> (GR) antagonist [[ RU486 ]] or p-ERK inhibitor U0126 rather than estrogen receptor Î± antagonist ICI 82,780.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These protective effects were abolished by glucocorticoid receptor (GR) antagonist RU486 or p-ERK inhibitor U0126 rather than << estrogen receptor Î± >> antagonist [[ ICI 82,780 ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Bevantolol >>: a [[ beta-1 adrenoceptor ]] antagonist with unique additional actions.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "UNLABELLED: << Bevantolol >> is a [[ beta-1 adrenoceptor ]] antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "injection of a subthreshold dose of << picrotoxin >>, a use-dependent [[ gamma-aminobutyric acid receptor ]] antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effect of endothelin-1 on the contraction induced by 5-HT is abolished by deendothelialization, by the << endothelin ET(B) receptor >> antagonist [[ RES 701-1 ]], by indomethacin, or by glibenclamide.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the << thromboxane A2 receptor >> antagonists [[ GR32191 ]] and ridogrel.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The potentiation of the contractile effect induced by 5-HT is only somewhat modified by deendothelialization, but abolished by the << thromboxane A2 receptor >> antagonists GR32191 and [[ ridogrel ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "An investigation of the absolute configuration of the potent << histamine H3 receptor >> antagonist [[ GT-2331 ]] using vibrational circular dichroism.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an << NR2B >> subunit-selective antagonist [[ CP-101,606 ]] in a rat chronic constriction injury model.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Brain but not spinal << NR2B >> receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist [[ CP-101,606 ]] in a rat chronic constriction injury model.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In order to examine the site of action of an NR2B subtype-selective << NMDA >> antagonist [[ CP-101,606 ]], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In order to examine the site of action of an << NR2B >> subtype-selective NMDA antagonist [[ CP-101,606 ]], we investigated its analgesic effect in a rat model of neuropathic pain at various routes of administration.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast, intrathecal injection of a non-selective << NMDA >> antagonist, [[ memantine ]], significantly inhibited CCI-induced mechanical allodynia at a dose of 300 nmol, indicating the difference in the site of action between the non-selective NMDA antagonist and the NR2B-specific NMDA antagonist.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Prazosin >> (nonselective [[ alpha(1)-adrenoceptor ]] antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), << silodosin >> (selective [[ alpha(1A)-adrenoceptor ]] antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and << BMY-7378 >> (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective [[ alpha(1D)-adrenoceptor ]] antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (<< 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride >>) (selective [[ alpha(1D)-adrenoceptor ]] antagonist) competitively antagonized the phenylephrine-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A << naloxone-steroid hybrid azine >> with selective and long-acting opioid antagonism at [[ delta receptors ]] in vitro.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << alpha1-adrenoceptor >> antagonist [[ prazosin ]] or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The alpha1-adrenoceptor antagonist prazosin or the << vasopressin V1 receptor >> antagonist, [[ [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin ]] partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "administration of the non-selective << muscarinic receptor >> antagonist [[ atropine ]] (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the << muscarinic M1 receptor >> antagonist [[ pirenzepine ]] (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the << muscarinic M2 receptor >> antagonist [[ methoctramine ]] (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the << muscarinic M3 receptor >> antagonist [[ para-fluoro-hexahydro-sila-difenidol ]] (ID50 = 31.19 microg).", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "An << angiotensin II AT1 receptor >> antagonist, [[ telmisartan ]] augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Xanthines >> are classical antagonists for [[ adenosine receptors ]] for many of their pharmacological actions may be due to blockade of adenosine receptors.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective << beta-adrenoceptor >> antagonists [[ propranolol ]] [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective << beta-adrenoceptor >> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], [[ alprenolol ]] (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To study the mechanism underlying this phenomenon, the effects of the nonselective << beta-adrenoceptor >> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and [[ mepindolol ]] (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Tamoxifen >> blocks the action of estrogen by binding to the ER, and possesses both [[ ER ]]-agonist and antagonist properties.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Fulvestrant >> is a novel [[ ER ]] antagonist that destroys the ER and its signaling pathway and is not associated with tamoxifen-like agonist effects.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using << D1 >>/D5 ([[ SCH23390 ]]), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/<< D5 >> ([[ SCH23390 ]]), D2/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), << D2 >>/D3 ([[ raclopride ]], amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<< D3 >> ([[ raclopride ]], amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), << D2 >>/D3 (raclopride, [[ amisulpride ]]) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/<< D3 >> (raclopride, [[ amisulpride ]]) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The involvement of the various DA receptor subtypes in the motor effects of N/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1/D5 (SCH23390), D2/D3 (raclopride, amisulpride) and << D3 >> ([[ S33084 ]]) receptor antagonists, and by using D2 receptor knockout mice.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Losartan >>: a selective [[ angiotensin II type 1 (AT1) receptor ]] antagonist for the treatment of heart failure.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Losartan >> (COZAAR) is the prototype of a new class of potent and selective [[ angiotensin II (AII) type 1 (AT(1)) receptor ]] antagonists with the largest published preclinical and clinical data base.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Losartan (<< COZAAR >>) is the prototype of a new class of potent and selective [[ angiotensin II (AII) type 1 (AT(1)) receptor ]] antagonists with the largest published preclinical and clinical data base.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Efficacy of the << GluK1 >>/AMPA receptor antagonist [[ LY293558 ]] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Efficacy of the GluK1/<< AMPA receptor >> antagonist [[ LY293558 ]] against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the << GluK1 >> (GluR5)/Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [[ (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ]] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<< GluR5 >>)/Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist [[ (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ]] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/<< Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor >> antagonist [[ (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ]] (LY293558) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the << GluK1 >> (GluR5)/Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([[ LY293558 ]]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (<< GluR5 >>)/Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([[ LY293558 ]]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the GluK1 (GluR5)/<< Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor >> antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid ([[ LY293558 ]]) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent soman.", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific << CB1 >> antagonist [[ SR 141716A ]].", "metadata": [], "label": "ANTAGONIST", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor << TAK-441 >> for the inhibition of [[ Gli1 ]] messenger RNA expression and antitumor efficacy in xenografted tumor model mice.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The IC50 values for << Gli1 >> mRNA inhibition in the tumor and skin by [[ TAK-441 ]] were estimated to be 0.0457 and 0.113 Î¼g/ml, respectively.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dimemorfan >> pre-treatment also attenuated the KA-induced increases in [[ c-fos ]]/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Dimemorfan >> pre-treatment also attenuated the KA-induced increases in c-fos/[[ c-jun ]] expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including << TNF-Î± >>, IL-1Î², IL-18, IL-17A and IFN-Î³, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-Î±, << IL-1Î² >>, IL-18, IL-17A and IFN-Î³, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-Î±, IL-1Î², << IL-18 >>, IL-17A and IFN-Î³, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-Î±, IL-1Î², IL-18, << IL-17A >> and IFN-Î³, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-Î±, IL-1Î², IL-18, IL-17A and << IFN-Î³ >>, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, protein and mRNA levels of DSS-induced proinflammatory << cytokines >> in colon, including TNF-Î±, IL-1Î², IL-18, IL-17A and IFN-Î³, were markedly suppressed by [[ Fc11a-2 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism of action of << Fc11a-2 >> was related to the inhibition of the cleavage of [[ pro-caspase-1 ]], pro-IL-1Î² and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism of action of << Fc11a-2 >> was related to the inhibition of the cleavage of pro-caspase-1, [[ pro-IL-1Î² ]] and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism of action of << Fc11a-2 >> was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1Î² and [[ pro-IL-18 ]] which in turn suppressed the activation of NLRP3 inflammasome.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As revealed by glucose oxidase (GOD) and radioimmunoassay (RIA), both << dimethyldiguanide >> (DC, 0.6gkg(-1)d(-1)) and CPS (0.3, 0.6, 1.2gkg(-1)d(-1)) treatments significantly resulted in down-regulation of blood glucose and [[ insulin ]] levels in serum, while the levels of oxidative stress markers were markedly lowered through ELISA assay.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenserine >> deserves attention for an additional quality of action: in addition to inhibiting AChE, it modulates the amount of beta-amyloid precursor protein (APP) in neuronal cell culture by reducing [[ APP ]] translation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Phenserine >> apparently reduces translational efficiency of [[ APP ]] mRNA into protein, a process that may involve an interaction with iron and/or an iron-responsive element.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As a consequence, << phenserine >> reduces [[ beta-amyloid ]] peptide (Abeta) formation in vitro and in vivo.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As a consequence, << phenserine >> reduces beta-amyloid peptide ([[ Abeta ]]) formation in vitro and in vivo.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cells were also evaluated in the presence of << wortmannin >>, an inhibitor of phosphatidylinositol 3-kinases and thus [[ AKt ]] (0-100 nM).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Only FFAs that increased << ceramides >> caused impairment of [[ AKt ]] and PTP1B phosphorylation at Ser 50.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Estrogen >>-regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although [[ Cyp3a25 ]] was suppressed.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Unlike GW660511X, << omapatrilat >> abolished the production of [[ BrBK1-5 ]] and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Unlike GW660511X, << omapatrilat >> abolished the production of BrBK1-5 and [[ BrBK1-7 ]], suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The production of << Br-Phe5 >> was reduced with [[ GW660511X ]] while no significant change was observed with omapatrilat after 4 h of incubation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< GW660511X >> and omapatrilat reduced the production of [[ BrBK1-5 ]] and BrBK1-7 with more effect being observed with omapatrilat.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< GW660511X >> and omapatrilat reduced the production of BrBK1-5 and [[ BrBK1-7 ]] with more effect being observed with omapatrilat.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "GW660511X and << omapatrilat >> reduced the production of [[ BrBK1-5 ]] and BrBK1-7 with more effect being observed with omapatrilat.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "GW660511X and << omapatrilat >> reduced the production of BrBK1-5 and [[ BrBK1-7 ]] with more effect being observed with omapatrilat.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "GW660511X and omapatrilat reduced the production of << BrBK1-5 >> and BrBK1-7 with more effect being observed with [[ omapatrilat ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "GW660511X and omapatrilat reduced the production of BrBK1-5 and << BrBK1-7 >> with more effect being observed with [[ omapatrilat ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These results suggest that << prostacyclin >> may play a role in downregulating [[ tissue factor ]] expression in monocytes, at least in part via elevation of intracellular levels of cyclic AMP.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present studies were undertaken to determine whether stable analogues of << prostacyclin >>, a potent endothelium-derived platelet inhibitor and vasodilator, could inhibit [[ tissue factor ]] expression by human monocytic cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Preincubation for 30 minutes with << iloprost >>, ciprostene, and carbacyclin led to a dose-dependent inhibition of [[ tissue factor ]] expression induced by all three challenging agents.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Preincubation for 30 minutes with iloprost, << ciprostene >>, and carbacyclin led to a dose-dependent inhibition of [[ tissue factor ]] expression induced by all three challenging agents.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Preincubation for 30 minutes with iloprost, ciprostene, and << carbacyclin >> led to a dose-dependent inhibition of [[ tissue factor ]] expression induced by all three challenging agents.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Prostacyclin >> analogues inhibit [[ tissue factor ]] expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both << apo-lycopenoic acids >> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in [[ NOX-4 ]] and COX-2 expressions caused by CSE.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both << apo-lycopenoic acids >> also decreased CSE-induced ROS production, 8-OHdG formation and reduced the increase in NOX-4 and [[ COX-2 ]] expressions caused by CSE.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: << Telmisartan >> decreased the expression of [[ AT1R ]] at the mRNA and protein levels in a dose- and time-dependent manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Decreased AT1R promoter activity with unchanged mRNA stability suggested that << telmisartan >> suppressed [[ AT1R ]] gene expression at the transcriptional level.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The deletion and mutation analysis of the AT1R gene promoter indicated that a << GC box >> located in the proximal promoter region is responsible for the [[ telmisartan ]]-induced downregulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The deletion and mutation analysis of the << AT1R >> gene promoter indicated that a GC box located in the proximal promoter region is responsible for the [[ telmisartan ]]-induced downregulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSION: Our data provides a novel insight into an effect of telmisartan: << telmisartan >> inhibits [[ AT1R ]] gene expression through PPARgamma activation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Curcumin >> improves TNBS-induced colitis in rats by inhibiting [[ IL-27 ]] expression via the TLR4/NF-ÎºB signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "This study explored whether << curcumin >> improves colonic inflammation in a rat colitis model through inhibition of the TLR4/NF-ÎºB signaling pathway and [[ IL-27 ]] expression.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of [[ NF-ÎºB ]] mRNA, IL-27 mRNA, TLR4 protein, NF-ÎºB p65 protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, [[ IL-27 ]] mRNA, TLR4 protein, NF-ÎºB p65 protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, [[ TLR4 ]] protein, NF-ÎºB p65 protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, TLR4 protein, [[ NF-ÎºB ]] p65 protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, TLR4 protein, NF-ÎºB [[ p65 ]] protein, and IL-27 p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, TLR4 protein, NF-ÎºB p65 protein, and [[ IL-27 ]] p28 protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Compared with the untreated colitis group, the << curcumin >>-treated group showed significant decreases in the disease activity index, colonic mucosa damage index, histological score, myeloperoxidase activity, and expressions of NF-ÎºB mRNA, IL-27 mRNA, TLR4 protein, NF-ÎºB p65 protein, and IL-27 [[ p28 ]] protein (p < 0.05).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in << TLR4 >>, NF-ÎºB, and IL-27 mRNA and proteins between [[ curcumin ]]-treated and sulfasalazine-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in TLR4, << NF-ÎºB >>, and IL-27 mRNA and proteins between [[ curcumin ]]-treated and sulfasalazine-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in TLR4, NF-ÎºB, and << IL-27 >> mRNA and proteins between [[ curcumin ]]-treated and sulfasalazine-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in << TLR4 >>, NF-ÎºB, and IL-27 mRNA and proteins between curcumin-treated and [[ sulfasalazine ]]-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in TLR4, << NF-ÎºB >>, and IL-27 mRNA and proteins between curcumin-treated and [[ sulfasalazine ]]-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "There was no significant difference in TLR4, NF-ÎºB, and << IL-27 >> mRNA and proteins between curcumin-treated and [[ sulfasalazine ]]-treated groups.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The anti-inflammatory actions of << curcumin >> on colitis may involve inhibition of the TLR4/NF-ÎºB signaling pathway and of [[ IL-27 ]] expression.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, [[ monocyte chemoattractant protein-1 ]] (MCP-1) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 ([[ MCP-1 ]]) gene expression, and the activation of nuclear factor-kappaB in rabbit atheroma.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Licofelone >> reduced intima/media ratio in injured arteries, the macrophages infiltration in the neointimal area, monocyte chemoattractant protein-1 (MCP-1) gene expression, and the activation of [[ nuclear factor-kappaB ]] in rabbit atheroma.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << licofelone >> inhibited [[ COX-2 ]] and 5-LOX protein expression in vascular lesions.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << licofelone >> inhibited COX-2 and [[ 5-LOX ]] protein expression in vascular lesions.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Rofecoxib >> only diminished [[ COX-2 ]] protein expression and MCP-1 gene expression in vascular atheroma.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Rofecoxib >> only diminished COX-2 protein expression and [[ MCP-1 ]] gene expression in vascular atheroma.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, experiments showed that treatment with << DEC >> results in a reduction in the amount of [[ COX-1 ]] protein in peritoneal exudate cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "As determined by Western and Northern blot analyses, << 5 alpha-NET >> inhibited the P4-induced [[ UG ]] gene expression in a dose-dependent manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The estrogenic agent << 3 beta,5 alpha-NET >> and estradiol at a dose of 1.0 mg also inhibited the [[ UG ]] gene expression induced by P4.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The estrogenic agent 3 beta,5 alpha-NET and << estradiol >> at a dose of 1.0 mg also inhibited the [[ UG ]] gene expression induced by P4.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of UG synthesis and << PR >> down-regulation by 5 alpha-NET and [[ 3 beta,5 alpha-NET ]] indicates that these NET metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of UG synthesis and << PR >> down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these [[ NET ]] metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << UG >> synthesis and PR down-regulation by [[ 5 alpha-NET ]] and 3 beta,5 alpha-NET indicates that these NET metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << UG >> synthesis and PR down-regulation by 5 alpha-NET and [[ 3 beta,5 alpha-NET ]] indicates that these NET metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibition of << UG >> synthesis and PR down-regulation by 5 alpha-NET and 3 beta,5 alpha-NET indicates that these [[ NET ]] metabolites possess antiprogestational properties.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and << IMG >> or hyperoside inhibited production of thrombin and [[ FXa ]] in HUVECs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or << hyperoside >> inhibited production of [[ thrombin ]] and FXa in HUVECs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or << hyperoside >> inhibited production of thrombin and [[ FXa ]] in HUVECs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with << IMG >> and hyperoside resulted in inhibition of TNF-Î±-induced production of [[ PAI-1 ]], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with IMG and << hyperoside >> resulted in inhibition of TNF-Î±-induced production of [[ PAI-1 ]], and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-Î±-induced production of PAI-1, and treatment with << IMG >> resulted in significant reduction of the [[ PAI-1 ]] to t-PA ratio.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-Î±-induced production of PAI-1, and treatment with << IMG >> resulted in significant reduction of the PAI-1 to [[ t-PA ]] ratio.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased << Akt >> immunoreactivity, however phospho-GSK-3-Î² (Ser9) was not altered in [[ (PhTe)(2) ]] injected rat.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for << NeuN >>, suggesting that the in vivo exposure to [[ (PhTe)(2) ]] progressed to neuronal death.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effects of CDCA and GW4064 on expression of << Cdx2 >> and MUC2 were abolished by [[ guggulsterone ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The effects of CDCA and GW4064 on expression of Cdx2 and << MUC2 >> were abolished by [[ guggulsterone ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In the long term, << orlistat >> has been shown to be more effective than placebo in reducing body weight and serum total and [[ low-density lipoprotein ]] cholesterol levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on << mucin >> secretion was inhibited by EGFR kinase inhibitor, [[ PD153035 ]], as well as wortmannin, a specific inhibitor of PI3K.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on << mucin >> secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as [[ wortmannin ]], a specific inhibitor of PI3K.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The << gastric mucin >> secretory responses to isoproterenol, furthermore, were inhibited by [[ PP2 ]], a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both inhibitors, moreover, blunted the << mucin >> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, [[ forskolin ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cotreatments of 5, 10 and 20 Âµg/mL concentrations of MEP with aflatoxin B(1) decreased the frequencies of SCE and the malondialdehyde level and increased amount of superoxide dismutase, glutathione and << glutathione peroxidase >> which were decreased by [[ aflatoxin ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Desipramine >> treatment decreases 3H-nisoxetine binding and [[ norepinephrine transporter ]] mRNA in SK-N-SHSY5Y cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The antidepressant << desipramine >> has been shown to decrease synaptic membrane concentrations of the [[ norepinephrine re-uptake transporter ]] (NET) in vivo and in vitro, on both an acute and a chronic basis.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The antidepressant << desipramine >> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter ([[ NET ]]) in vivo and in vitro, on both an acute and a chronic basis.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The beneficial role of 17beta-estradiol on blood pressure, cardiac hypertrophy, vascular << osteopontin >> expression, perivascular fibrosis, and impaired NO-dependent relaxation of isolated aortic rings was completely abrogated by coadministration of [[ medroxyprogesterone acetate ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as << buserelin >>, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [[ LH ]] and testosterone levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, << goserelin >>, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [[ LH ]] and testosterone levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, << leuprorelin >> and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [[ LH ]] and testosterone levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and << triptorelin >>, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of [[ LH ]] and testosterone levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cellular release of << AChE >> by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (mAChR) agonists carbachol or muscarine, with the effect of carbachol blocked by the mAChR antagonist [[ atropine ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with << fenoldopam >>, a D1-like receptor agonist, inhibited the stimulatory effect of [[ insulin ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The inhibitory effect of << fenoldopam >> on [[ insulin ]]-mediated VSMC proliferation was receptor specific, because its effect could be blocked by SCH23390, a D1-like receptor antagonist.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Fenoldopam >> also inhibited [[ insulin receptor ]] mRNA and protein expression, which was time dependent and concentration dependent.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A PKC or MAP kinase inhibitor blocked the inhibitory effect of << fenoldopam >> on [[ insulin receptor ]] expression, indicating that PKC and MAP kinase were involved in the signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial [[ glutathione peroxidase ]], glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, [[ glutathione reductase ]], reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and [[ NADH-dehydrogenases ]], cytochrome-C-oxidase and adenosine triphosphate.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Isoproterenol >> induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, calcium, and a significant decrease in the activities/levels of heart mitochondrial glutathione peroxidase, glutathione reductase, reduced glutathione, isocitrate, succinate, malate, Î±-ketoglutarate and NADH-dehydrogenases, [[ cytochrome-C-oxidase ]] and adenosine triphosphate.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Data at transcriptional level also demonstrated that << catalpol >> potently attenuated gene expressions involved in inflammation, such as [[ iNOS ]], COX-2 and TLR4.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Data at transcriptional level also demonstrated that << catalpol >> potently attenuated gene expressions involved in inflammation, such as iNOS, [[ COX-2 ]] and TLR4.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Data at transcriptional level also demonstrated that << catalpol >> potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and [[ TLR4 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, << MPTP >> significantly down-regulated [[ Bcl-2 ]] expression in the mitochondria of dopaminergic cells in the SN, followed by an increase in Bax expression, cytochrome C translocation to the cytosol, andcleaved-caspase-3 expression, whereas these were inhibited by CRE or EB treatment.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ([[ COX-2 ]]), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), [[ inducible nitric oxide synthase ]] (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ([[ iNOS ]]), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and [[ tumor necrosis factor-Î± ]] (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, << buthanol >> and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± ([[ TNF- Î± ]]).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ([[ COX-2 ]]), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), [[ inducible nitric oxide synthase ]] (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ([[ iNOS ]]), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and [[ tumor necrosis factor-Î± ]] (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and << ethylacetate >> fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± ([[ TNF- Î± ]]).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ([[ COX-2 ]]), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), [[ inducible nitric oxide synthase ]] (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ([[ iNOS ]]), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and [[ tumor necrosis factor-Î± ]] (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% << methanol >> C. fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± ([[ TNF- Î± ]]).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ([[ COX-2 ]]), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), [[ inducible nitric oxide synthase ]] (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ([[ iNOS ]]), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and [[ tumor necrosis factor-Î± ]] (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, << clerosterol >> (CLS) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± ([[ TNF- Î± ]]).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including [[ cyclooxygenase-2 ]] (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 ([[ COX-2 ]]), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), [[ inducible nitric oxide synthase ]] (iNOS), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase ([[ iNOS ]]), and tumor necrosis factor-Î± (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and [[ tumor necrosis factor-Î± ]] (TNF- Î±).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In HaCaT cells, buthanol and ethylacetate fractions of 80% methanol C. fragile extract (CFB or CFE) and a single compound, clerosterol (<< CLS >>) isolated from CFE attenuated UVB (60mJ/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-Î± ([[ TNF- Î± ]]).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In another experiment, topical application of CFB, CFE or << CLS >> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of [[ COX-2 ]], iNOS, and TNF-Î±.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In another experiment, topical application of CFB, CFE or << CLS >> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, [[ iNOS ]], and TNF-Î±.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In another experiment, topical application of CFB, CFE or << CLS >> prior to UVB irradiation (200mJ/cm(2)) on BALB/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and [[ TNF-Î± ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found that << wogonin >> can suppress the H2O2-stimulated [[ actin ]] remodeling and albumin uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We found that << wogonin >> can suppress the H2O2-stimulated actin remodeling and [[ albumin ]] uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell MDA-MB-231.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of [[ VE-cadherin ]] and Î²-catenin.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism revealed that << wogonin >> inhibited H2O2-induced phosphorylation of caveolin-1 (cav-1) associating with the suppression of stabilization of VE-cadherin and [[ Î²-catenin ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of [[ nuclear factor-ÎºB ]] (NF-ÎºB) p65 and p50 subunits.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB ([[ NF-ÎºB ]]) p65 and p50 subunits.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) [[ p65 ]] and p50 subunits.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The molecular mechanism studies suggested that << neoechinulin A >> may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) p65 and [[ p50 ]] subunits.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator [[ tumour necrosis factor-Î± ]] (TNF-Î±), interleukin-1Î² (IL-1Î²), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-Î± ([[ TNF-Î± ]]), interleukin-1Î² (IL-1Î²), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-Î± (TNF-Î±), [[ interleukin-1Î² ]] (IL-1Î²), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-Î± (TNF-Î±), interleukin-1Î² ([[ IL-1Î² ]]), interleukin-6 (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-Î± (TNF-Î±), interleukin-1Î² (IL-1Î²), [[ interleukin-6 ]] (IL-6), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, we found that << neoechinulin A >> significantly suppressed the production of neurotoxic inflammatory mediator tumour necrosis factor-Î± (TNF-Î±), interleukin-1Î² (IL-1Î²), interleukin-6 ([[ IL-6 ]]), and prostaglandin E2 (PGE2) in activated BV-2 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, << agomelatine >> administration protects liver cells from paracetamol-induced hepatotoxicity via antioxidant activity and reduced proinflammatory [[ cytokines ]], such as TNF-Î± and IL-6.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, << agomelatine >> administration protects liver cells from paracetamol-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as [[ TNF-Î± ]] and IL-6.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, << agomelatine >> administration protects liver cells from paracetamol-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as TNF-Î± and [[ IL-6 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Selective precipitation of cytosol receptors with 36% << (NH4)2SO4 >> reduced [[ CBG ]] concentrations to negligible levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, << sinapic acid >> reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of [[ type I collagen ]] mRNA and histological analysis of collagen in liver tissue.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, the expression of hepatic fibrosis-related factors such as << Î±-smooth muscle actin >> and transforming growth factor-Î²1 (TGF-Î²1), were reduced in rats treated with [[ sinapic acid ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, the expression of hepatic fibrosis-related factors such as Î±-smooth muscle actin and << transforming growth factor-Î²1 >> (TGF-Î²1), were reduced in rats treated with [[ sinapic acid ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, the expression of hepatic fibrosis-related factors such as Î±-smooth muscle actin and transforming growth factor-Î²1 (<< TGF-Î²1 >>), were reduced in rats treated with [[ sinapic acid ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, we find that << sinapic acid >> exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress [[ TGF-Î²1 ]] and its ability to attenuate activation of hepatic stellate cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "On the other hand, in patients with a mean serum carvedilol level (Cmin) of less than 2.5 nmol/l up to 2 weeks after the start of<< carvedilol >> therapy, the degree of reduction in the [[ BNP ]] value after the 3rd month was significantly larger, relative to the patient group with Cmin over 2.5 nmol/l.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< ATO >> inhibited the phosphorylation and activation of AKT and STAT3 through [[ Notch ]] signaling blockade.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Interestingly, << miR-21 >> expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with [[ creatine ]] clearance ratio (Ccr) and MMP-9 protein.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition to this evidence (for the involvement of EP2 receptors), evidence for the involvement of EP1 receptors in the PGE1 mediated stimulation of << Na,K-ATPase beta >> subunit gene transcription includes the stimulatory effect of 17-phenyl trinor PGE2, as well as the inhibitory effects of [[ SC-51089 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our results showed that low dose BPA and E2 could influence the mammosphere area of iDMECs and upregulate the expression level of Oct4 and Nanog proteins, while only << BPA >> could downregulate the expression of [[ E-cadherin ]] protein.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of human iNOS promoter-driven luciferase activity by << gemfibrozil >> in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of [[ iNOS ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gemfibrozil >>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of [[ inducible nitric-oxide synthase ]] (iNOS) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Gemfibrozil >>, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase ([[ iNOS ]]) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to << gemfibrozil >>, clofibrate, another fibrate drug, also inhibited the expression of [[ iNOS ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to gemfibrozil, << clofibrate >>, another fibrate drug, also inhibited the expression of [[ iNOS ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Similar to gemfibrozil, clofibrate, another << fibrate >> drug, also inhibited the expression of [[ iNOS ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased [[ nuclear factor (NF)-kB ]] translocation, pro-inflammatory cytokine production such as interleukin-1Î² (IL-1Î²), and apoptosis (Bax and caspase 3 expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory [[ cytokine ]] production such as interleukin-1Î² (IL-1Î²), and apoptosis (Bax and caspase 3 expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as [[ interleukin-1Î² ]] (IL-1Î²), and apoptosis (Bax and caspase 3 expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1Î² ([[ IL-1Î² ]]), and apoptosis (Bax and caspase 3 expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1Î² (IL-1Î²), and apoptosis ([[ Bax ]] and caspase 3 expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive << RS -GRA >> significantly decreased nuclear factor (NF)-kB translocation, pro-inflammatory cytokine production such as interleukin-1Î² (IL-1Î²), and apoptosis (Bax and [[ caspase 3 ]] expression).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These actions are consistent with a pre-junctional inhibition of neuropeptide release from perivascular afferents of the trigeminal nerve, as confirmed by independent studies showing that << zolmitriptan >> blocks elevations of [[ calcitonin-gene-related peptide ]] in jugular venous blood during electrical stimulation of the trigeminal ganglion.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, the flowcytometric analysis revealed that << AZC >> and PCA decreased intracellular contents of [[ CD3-zeta chain ]] in these cells in dose dependent manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, the flowcytometric analysis revealed that AZC and << PCA >> decreased intracellular contents of [[ CD3-zeta chain ]] in these cells in dose dependent manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< DBDCT >> up-regulated the expression of Bax, down-regulated the expression of [[ Bcl-2 ]], and significantly increased the ratio of Bax/Bcl-2.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << carvedilol >> reversed both protein and mRNA of [[ HIF-1alpha ]], VEGF, BNP, and NGF-beta to the baseline values.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << carvedilol >> reversed both protein and mRNA of HIF-1alpha, [[ VEGF ]], BNP, and NGF-beta to the baseline values.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << carvedilol >> reversed both protein and mRNA of HIF-1alpha, VEGF, [[ BNP ]], and NGF-beta to the baseline values.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Increased immunohistochemical labeling of << HIF-1alpha >>, VEGF, and BNP in the ventricular myocardium was observed in the shunt group and [[ carvedilol ]] again normalized the labeling.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Increased immunohistochemical labeling of HIF-1alpha, << VEGF >>, and BNP in the ventricular myocardium was observed in the shunt group and [[ carvedilol ]] again normalized the labeling.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Increased immunohistochemical labeling of HIF-1alpha, VEGF, and << BNP >> in the ventricular myocardium was observed in the shunt group and [[ carvedilol ]] again normalized the labeling.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << carvedilol >> is associated with a reversal of abnormal regulation of [[ HIF-1alpha ]] and VEGF in the failing ventricular myocardium.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << carvedilol >> is associated with a reversal of abnormal regulation of HIF-1alpha and [[ VEGF ]] in the failing ventricular myocardium.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Lintitript >> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial [[ PP ]] levels (P<0.01) as compared to placebo.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Caerulein >> increased the levels of H(2)S and CSE mRNA expression while [[ CBS ]] mRNA expression was decreased.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of endogenous production of << H(2)S >> by PAG significantly suppressed [[ SP ]] concentration, PPT-A expression and NK1-R expression in the acini.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of endogenous production of << H(2)S >> by PAG significantly suppressed SP concentration, [[ PPT-A ]] expression and NK1-R expression in the acini.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Inhibition of endogenous production of << H(2)S >> by PAG significantly suppressed SP concentration, PPT-A expression and [[ NK1-R ]] expression in the acini.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "RESULTS: << Ethanol >> given to rats in drinking water decreased the level of [[ p-CREB ]] protein in the nucleus accumbens (-75 %) at the time of exposure to ethanol.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, when naloxone was administered concurrently with << ethanol >> treatment, it antagonized the down-regulation of [[ p-CREB ]] protein in the nucleus accumbens (142 %) of rats exposed to ethanol.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "However, when naloxone was administered concurrently with ethanol treatment, it antagonized the down-regulation of << p-CREB >> protein in the nucleus accumbens (142 %) of rats exposed to [[ ethanol ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The decrement of << p-CREB >> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of [[ ethanol ]] withdrawal, which recovered toward control level after 7 d of ethanol withdrawal.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The decrement of << p-CREB >> protein in the nucleus accumbens remained at 24 h (-35 %) and 72 h (-28 %) of ethanol withdrawal, which recovered toward control level after 7 d of [[ ethanol ]] withdrawal.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The upregulation of << calpain >>, tBid and caspase-3 activity were further inhibited by treatment with [[ EGTA ]] in the presence of ALD.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The upregulation of calpain, << tBid >> and caspase-3 activity were further inhibited by treatment with [[ EGTA ]] in the presence of ALD.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Additionally, << AIF >> levels in the cytosol decreased due to [[ EGTA ]] but not due to calpeptin.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, treatment with << spironoclactone >> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of [[ calpain ]] and AIF levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, treatment with << spironoclactone >> not only attenuated the pro-apoptotic effect of ALD but reversed the ALD-induced increase of calpain and [[ AIF ]] levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Allicin >> treatment showed reduced production of pro-inflammatory [[ cytokines ]] and NO and increased HO-1 activity.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Interestingly, << Acrolein >> increased proteins' levels of amyloid precursor protein (APP), Î²-secretase (BACE-1) and the amyloid Î²-peptide transporter receptor for advanced glycation end products, and decreased [[ A-disintegrin and metalloprotease (ADAM) 10 ]] levels.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << Acrolein >> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of [[ ADAM-10 ]] in hippocampus and cortex.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also, << SB365 >> showed anti-angiogenic activity by decreasing the expression of [[ HIF-1Î± ]] and VEGF.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Also, << SB365 >> showed anti-angiogenic activity by decreasing the expression of HIF-1Î± and [[ VEGF ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Human stearoyl-CoA desaturase 1 >> (SCD-1) gene expression is negatively regulated by [[ thyroid hormone ]] without direct binding of thyroid hormone receptor to the gene promoter.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Human stearoyl-CoA desaturase 1 (<< SCD-1 >>) gene expression is negatively regulated by [[ thyroid hormone ]] without direct binding of thyroid hormone receptor to the gene promoter.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Previous report demonstrated that << thyroid hormone >> (TH) negatively regulates [[ mouse SCD-1 gene promoter ]] before SREBP-1c was revealed.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and [[ CK-MB ]], increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of [[ Bax ]]/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Crocin >> (25 and 50mg/kg) or vitamin E improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/[[ Bcl2 ]] ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Crocin (25 and 50mg/kg) or << vitamin E >> improved histopathological damages, decreased MDA and [[ CK-MB ]], increased GSH content and attenuated the increase of Bax/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Crocin (25 and 50mg/kg) or << vitamin E >> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of [[ Bax ]]/Bcl2 ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Crocin (25 and 50mg/kg) or << vitamin E >> improved histopathological damages, decreased MDA and CK-MB, increased GSH content and attenuated the increase of Bax/[[ Bcl2 ]] ratio, activation of caspase 3 and release of cytochrome c to the cytosol induced by DZN.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Phorbol esters and << norepinephrine >> destabilize [[ alpha 1B-adrenergic receptor ]] mRNA in vascular smooth muscle cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism by which << norepinephrine >> (NE) down-regulates [[ alpha 1B-adrenergic receptor ]] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism by which norepinephrine (<< NE >>) down-regulates [[ alpha 1B-adrenergic receptor ]] (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism by which << norepinephrine >> (NE) down-regulates alpha 1B-adrenergic receptor ([[ alpha-AR ]]) mRNA was studied in rabbit aortic smooth muscle cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The mechanism by which norepinephrine (<< NE >>) down-regulates alpha 1B-adrenergic receptor ([[ alpha-AR ]]) mRNA was studied in rabbit aortic smooth muscle cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< NE >>, phorbol esters, and bradykinin each decreased [[ alpha-AR ]] mRNA levels by 70-80%.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "NE, << phorbol esters >>, and bradykinin each decreased [[ alpha-AR ]] mRNA levels by 70-80%.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Neither ryanodine nor EGTA inhibited down-regulation of << alpha-AR >> mRNA by [[ NE ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Actinomycin D >> caused [[ alpha-AR ]] mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Actinomycin D >> caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal [[ alpha-AR ]] mRNA level.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both NE and << phorbol esters >> increased the rate of [[ alpha-AR ]] mRNA degradation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Both << NE >> and phorbol esters increased the rate of [[ alpha-AR ]] mRNA degradation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In << NE >>-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of [[ alpha-AR ]] mRNA.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In NE-desensitized cells, << phorbol esters >> and bradykinin each caused the expected down-regulation of [[ alpha-AR ]] mRNA.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << minocycline >> efficiently suppressed the release of [[ cytochrome c ]] from mitochondria of the liver tissues from Jo2-challenged mice.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Our results suggest that easing of Fas-triggered fulminant hepatitis by << minocycline >> may involve a mitochondrial apoptotic pathway, probably through preventing [[ cytochrome c ]] release and thereby blocking downstream caspase activation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in f[[ ocal adhesion kinase ]] (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase ([[ FAK ]])/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/[[ c-Src ]]/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/[[ extracellular signal-regulated kinase ]] (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase ([[ ERK ]]) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and [[ phosphoinositide 3-kinase ]] (PI3K)/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase ([[ PI3K ]])/Akt/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/[[ Akt ]]/ glycogen synthase kinase 3Î² (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ [[ glycogen synthase kinase 3Î² ]] (GSK-3Î²) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Pinosylvin >> was also found to attenuate the activation of proteins involved in focal adhesion kinase (FAK)/c-Src/extracellular signal-regulated kinase (ERK) signaling, and phosphoinositide 3-kinase (PI3K)/Akt/ glycogen synthase kinase 3Î² ([[ GSK-3Î² ]]) signaling pathway.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of [[ Î²-catenin ]], one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of [[ PI3K ]]/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/[[ Akt ]]/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/[[ GSK-3Î² ]] signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of [[ Î²-catenin ]]-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including [[ BMP4 ]], ID2, survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, [[ ID2 ]], survivin, cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, [[ survivin ]], cyclin D1, MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, [[ cyclin D1 ]], MMP7, and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, [[ MMP7 ]], and c-Myc.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Subsequently, << pinosylvin >> suppressed the nuclear translocation of Î²-catenin, one of downstream molecules of PI3K/Akt/GSK-3Î² signaling, and these events led to the sequential downregulation of Î²-catenin-mediated transcription of target genes including BMP4, ID2, survivin, cyclin D1, MMP7, and [[ c-Myc ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, we demonstrate that << geldanamycin >> treatment blocks [[ interleukin (IL)-2 ]] secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In this study, we demonstrate that << geldanamycin >> treatment blocks interleukin (IL)-2 secretion, [[ IL-2 receptor ]] expression, and proliferation of stimulated T-lymphocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of [[ Lck ]] and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and [[ Raf-1 ]] kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << geldanamycin >> decreases the amount and phosphorylation of Lck and Raf-1 [[ kinases ]] and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Sumatriptan >> and LY 344864 decreased the number of capsaicin-induced [[ c-fos ]]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Sumatriptan and << LY 344864 >> decreased the number of capsaicin-induced [[ c-fos ]]-like immunoreactive cells within trigeminal nucleus caudalis (ID50 = 0.04 and 0.6 mg kg(-1)).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Rg1 >> attenuated the AÎ²25-35-associated mitochondrial apoptotic events, accompanied by inhibiting [[ HIF-1Î± ]] expression followed by intracellular reactive nitrogen species generation, and protein nitrotyrosination.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Taken together, our results suggested that << Rg1 >> protected against AÎ²25-35-induced apoptosis at least in part by two complementary GR-dependent ERK phosphorylation pathways: (1) down-regulating [[ HIF-1Î± ]] initiated protein nitrotyrosination, and (2) inhibiting mitochondrial apoptotic cascades.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with << EVn-50 >> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [[ Cdc25c ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Treatment with EVn-50 or << VB1 >> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of [[ Cdc25c ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, both drugs significantly reduced PGE2 levels (P<0.05) 6-h following LPS injection, whereas the probable << COX-1 >> prostanoid TXB2 was significantly reduced by [[ phenylbutazone ]] (P<0.05), but not etodolac.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To explore the molecular basis for CPT hypersensitivity in Top2Î²-deficient cells, we found that upon << CPT >> exposure, the [[ RNA polymerase II large subunit ]] (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2Î²-deficient cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To explore the molecular basis for CPT hypersensitivity in Top2Î²-deficient cells, we found that upon << CPT >> exposure, the RNA polymerase II large subunit ([[ RNAP LS ]]) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas RNAP LS remained depleted without recovery in Top2Î²-deficient cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "To explore the molecular basis for CPT hypersensitivity in Top2Î²-deficient cells, we found that upon << CPT >> exposure, the RNA polymerase II large subunit (RNAP LS) became progressively depleted, followed by recovery to nearly the original level in wild-type MEFs, whereas [[ RNAP LS ]] remained depleted without recovery in Top2Î²-deficient cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Altogether, our findings support a model in which Top2Î² deficiency promotes << CPT >>-induced apoptosis in quiescent non-S-phase cells, possibly due to [[ RNAP LS ]] depletion and p53 accumulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< TAA >> also increased the numbers of ED2(+), [[ cyclooxygenase-2 ]](+), and heme oxygenase-1(+) liver cells, as well as the number of CD3(+) lymphocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< TAA >> also increased the numbers of ED2(+), cyclooxygenase-2(+), and [[ heme oxygenase-1 ]](+) liver cells, as well as the number of CD3(+) lymphocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< TAA >> also increased the numbers of ED2(+), cyclooxygenase-2(+), and heme oxygenase-1(+) liver cells, as well as the number of [[ CD3 ]](+) lymphocytes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Glucosamine >> at 50Â mM was demonstrated to elevate both the mRNA and protein expression of p53 and heme oxygenase-1 (HO-1), but also caused a reduction in [[ p21 ]] protein expression.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In addition, << glucosamine >> attenuated [[ p21 ]] protein stability via the proteasomal proteolytic pathway, as well as inducing p21 nuclear accumulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Although the data collected on << IGFBP-rP3 >> in prostate are modest, its role as a growth stimulator and/or protooncogene is supported by its preferential expression in cancerous cells and its down-regulation by [[ atRA ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Suppression of TÎ²R1 by the pharmacological inhibitor (<< SB431542 >>) markedly reduced [[ VEGF ]] release by HFL-1 in response to CSE and this effect was confirmed by TÎ²R1 siRNA.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In Alexander cells, only when they were transfected with FXR+RXR, << GW4064 >> caused up-regulation of SHP and OSTÎ², and a down-regulation of [[ CYP27A1 ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Thalidomide >> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and [[ TNF-alpha ]] production.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Thalidomide >> has been shown to suppress [[ TNF-alpha ]] production from macrophages.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Furthermore, << thalidomide >> abolished the LPS-induced increase in [[ CD14 ]] expression and [Ca2+]i elevation in KCs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << thalidomide >> reduced the LPS-induced [[ TNF-alpha ]] production by KCs by decreasing TNF-alpha messenger RNA.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Moreover, << thalidomide >> reduced the LPS-induced TNF-alpha production by KCs by decreasing [[ TNF-alpha ]] messenger RNA.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSIONS: These results collectively indicate that << thalidomide >> prevents alcoholic liver injury through suppression of [[ TNF-alpha ]] production and abolishment of KC sensitization.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Fenofibrate >> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [[ apolipoprotein C-III ]] and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Fenofibrate and << GW2331 >> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced [[ apolipoprotein C-III ]] and phosphoenolpyruvate carboxykinase mRNAs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Fenofibrate >> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and [[ phosphoenolpyruvate carboxykinase ]] mRNAs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Fenofibrate and << GW2331 >> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and [[ phosphoenolpyruvate carboxykinase ]] mRNAs.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The induction of << apoA-I >> by statins disappeared with addition of [[ mevalonate ]], which indicates that the effect is HMG-CoA reductase inhibition-dependent.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "When the anti-corticosterone drug << aminoglutethimide >> (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and [[ CYP11A1 ]] mRNA expression were decreased at 14 days after tumor inoculation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The results demonstrated that Î²-ionone-induced apoptosis in a dose-dependent manner in SGC-7901 cells treated with Î²-ionone (25, 50, 100 and 200Â Î¼mol/L) for 24Â h. << Î²-ionone >> was also shown to induce the expression of cleaved-caspase-3 and inhibit [[ bcl-2 ]] expression in SGC-7901 cells in a dose-dependent manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The significantly decreased levels of << p-PI3K >> and p-AKT expression were observed in SGC-7901 cells after [[ Î²-ionone ]] treatments in a time- and dose-dependent manner (PÂ <Â 0.01).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The significantly decreased levels of p-PI3K and << p-AKT >> expression were observed in SGC-7901 cells after [[ Î²-ionone ]] treatments in a time- and dose-dependent manner (PÂ <Â 0.01).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Ozone >> plus PM(2.5) exposure, however, induced CRP, IL-6, CK, LDH and MDA increase, [[ SOD ]] and HRV decrease significantly in a dose-response way.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Epididymal tissue from wild-type mice responded in vitro to << noradrenaline >> and isoprenaline with increased glycerol release, reduced [[ IL-6 ]] release, and increased cAMP accumulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Epididymal tissue from wild-type mice responded in vitro to noradrenaline and << isoprenaline >> with increased glycerol release, reduced [[ IL-6 ]] release, and increased cAMP accumulation.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cell culture studies demonstrated that << PKAA >> is capable of delivering anti-TNF (tumor necrosis factor)-Î± siRNA to lipopolysaccharide (LPS)-stimulated macrophages and significantly inhibits the expression of [[ TNF-Î± ]].", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< PKAA >>/anti-TNF-Î± siRNA nanocomplexes significantly reduced the [[ ALT ]] (alanine transaminase) and the hepatic cellular damages in APAP-intoxicated mice.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< PKAA >>/anti-TNF-Î± siRNA nanocomplexes significantly reduced the ALT ([[ alanine transaminase ]]) and the hepatic cellular damages in APAP-intoxicated mice.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "The present results suggest that the action of << DMI >> in this animal model is unlikely to be directly related to a reduction in [[ beta-adrenoceptors ]] but may be related to a reduction in frontal cortical 5-HT2A receptors.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Tyrosine kinase inhibitors are << quinazoline >>-derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of [[ EGFR ]] signaling.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of << linoleic acid >> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC [[ D6D ]] and D5D genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<< LA >>) and alpha-linolenic acid (LNA) and the expression of PBMC [[ D6D ]] and D5D genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and << alpha-linolenic acid >> (LNA) and the expression of PBMC [[ D6D ]] and D5D genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<< LNA >>) and the expression of PBMC [[ D6D ]] and D5D genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of << linoleic acid >> (LA) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and [[ D5D ]] genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (<< LA >>) and alpha-linolenic acid (LNA) and the expression of PBMC D6D and [[ D5D ]] genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and << alpha-linolenic acid >> (LNA) and the expression of PBMC D6D and [[ D5D ]] genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "A significant positive correlation was found between dietary intake of total SFAs and total MUFAs and expression of PBMC D6D and D5D genes, but a significant negative correlation between dietary intake of linoleic acid (LA) and alpha-linolenic acid (<< LNA >>) and the expression of PBMC D6D and [[ D5D ]] genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high << EFAs >> intake appears to decrease expression of PBMC [[ D6D ]] and D5D genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "CONCLUSION: Intake of high SFAs and MUFAs appears to increase expression of PBMC D6D and D5D genes, whilst high << EFAs >> intake appears to decrease expression of PBMC D6D and [[ D5D ]] genes.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Mepindolol >> treatment (2 X 5 mg/day) caused a 30% decrease of [[ beta 2-adrenoceptor ]] density and PRA after 2 days; both parameters remained reduced during treatment.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced << NPC1L1 >> expression only in [[ 7-ketocholesterol ]]-incubated cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Minocycline >> treatment prevents the formation of activated [[ caspase-3 ]], a known effector of apoptosis, as well as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Adrenaline >> inhibits [[ insulin ]] secretion via pertussis toxin-sensitive mechanisms.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Somatostatin >> which also inhibits [[ insulin ]] secretion was less efficient (inhibition by 20%).", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast to << adrenaline >> and somatostatin, galanin, another inhibitor of [[ insulin ]] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In contrast to adrenaline and << somatostatin >>, galanin, another inhibitor of [[ insulin ]] secretion, reduced Ca2+ currents by about 40% in a pertussis toxin-insensitive manner.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "These G-proteins are likely to be involved in the adrenaline-induced inhibition of dihydropyridine-sensitive Ca2+ currents and in other signal transduction pathways contributing to the << adrenaline >>-induced inhibition of [[ insulin ]] secretion.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< PAK1 >> expression was elevated in APC(min) polyps and [[ 5-ASA ]] treatment reduced its expression.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "We propose that inhibition of << PAK1 >> expression by [[ 5-ASA ]] can impede with neoplastic progression in colorectal carcinogenesis.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "<< Toosendanin >> induces apoptosis through suppression of [[ JNK ]] signaling pathway in HL-60 cells.", "metadata": [], "label": "INDIRECT-DOWNREGULATOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "In conclusion, fenoterol-induced constitutive << beta(2)-adrenoceptor >> activity reduces muscarinic receptor agonist- and histamine-induced contractions of bovine tracheal smooth muscle, which can be reversed by the inverse agonist [[ timolol ]].", "metadata": [], "label": "AGONIST-INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Binding of the agonist angiotensin II (AngII) and inverse agonist << losartan >> in wild-type [[ AT1R ]] changed the accessibility of reporter cysteines, and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2.", "metadata": [], "label": "AGONIST-INHIBITOR", "cid": "4", "custom_label": "REGULATOR-NEGATIVE"}
{"text": "Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased << isoprenaline >>-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the [[ beta(2)-adrenoceptor ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in << isoprenaline >>-induced E(max), indicating activated PKC-mediated heterologous [[ beta(2)-adrenoceptor ]] desensitization.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this study, the activity of the << delta-opioid receptor >> subtype-selective agonist, [[ SB 227122 ]], was investigated in a guinea pig model of citric acid-induced cough.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Parenteral administration of selective agonists of the << delta-opioid receptor >> ([[ SB 227122 ]]), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), << mu-opioid receptor >> ([[ codeine ]] and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), << mu-opioid receptor >> (codeine and [[ hydrocodone ]]), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and << kappa-opioid receptor >> ([[ BRL 52974 ]]) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg/kg, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The nonselective << opioid receptor >> antagonist, naloxone (3 mg/kg, i.m. ), attenuated the antitussive effects of [[ codeine ]] or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The nonselective << opioid receptor >> antagonist, naloxone (3 mg/kg, i.m. ), attenuated the antitussive effects of codeine or [[ SB 227122 ]], indicating that the antitussive activity of both compounds is opioid receptor-mediated.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "), attenuated the antitussive effects of << codeine >> or SB 227122, indicating that the antitussive activity of both compounds is [[ opioid receptor ]]-mediated.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "), attenuated the antitussive effects of codeine or << SB 227122 >>, indicating that the antitussive activity of both compounds is [[ opioid receptor ]]-mediated.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << delta-receptor >> antagonist, SB 244525 (10 mg/kg, i.p. ), inhibited the antitussive effect of [[ SB 227122 ]] (20 mg/kg, i.p.).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << sigma-receptor >> antagonist rimcazole (3 mg/kg, i.p.) inhibited the antitussive effect of [[ dextromethorphan ]] (30 mg/kg, i.p.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These studies provide compelling evidence that the antitussive effects of << SB 227122 >> in this guinea pig cough model are mediated by agonist activity at the [[ delta-opioid receptor ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Terbutaline >> (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent [[ beta(2)-adrenoceptor ]] agonists often used in asthma patients.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Terbutaline (<< Bricanyl >>) and its prodrug Bambuterol (Bambec) are highly potent [[ beta(2)-adrenoceptor ]] agonists often used in asthma patients.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Terbutaline (Bricanyl) and its prodrug << Bambuterol >> (Bambec) are highly potent [[ beta(2)-adrenoceptor ]] agonists often used in asthma patients.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Terbutaline (Bricanyl) and its prodrug Bambuterol (<< Bambec >>) are highly potent [[ beta(2)-adrenoceptor ]] agonists often used in asthma patients.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Design, Synthesis, and Pharmacological Characterization of Novel << Endomorphin-1 >> Analogues as Extremely Potent [[ Î¼-Opioid ]] Agonists.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The specific binding is displaced by the selective << 5-HT1D >> agonist [[ sumatriptan ]] but not by the mixed 5-HT1A/1D agonist 5-carboxyamidotryptamine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVE: << Telmisartan >>, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of [[ peroxisome proliferator-activated receptor gamma ]] (PPARgamma).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVE: << Telmisartan >>, an angiotensin II type 1 receptor (AT1R) antagonist, was found to have a unique property: it is a partial agonist of peroxisome proliferator-activated receptor gamma ([[ PPARgamma ]]).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Antiarrhythmic effects of << (-)-epicatechin-3-gallate >>, a novel [[ sodium channel ]] agonist in cultured neonatal rat ventricular myocytes.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "RGM-1 cells were treated with CDCA or << GW4064 >>, an [[ FXR ]] agonist, in the presence or absence of guggulsterone, an FXR antagonist.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "RGM-1 cells were treated with << CDCA >> or GW4064, an [[ FXR ]] agonist, in the presence or absence of guggulsterone, an FXR antagonist.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the << beta(2)-adrenoceptor >> agonist [[ formoterol ]] [eformoterol].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the << beta(2)-adrenoceptor >> agonist formoterol [[[ eformoterol ]]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The selective << betaAR >> agonist [[ isoproterenol ]] caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The selective << beta1AR >> antagonists atenolol and metoprolol blocked [[ isoproterenol ]]-induced enhancement, with apparent K(b) values of 85 +/- 36 and 3.9 +/- 1.7 nM, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In contrast, the selective << beta2AR >> antagonists ICI-118,551 and butoxamine inhibited [[ isoproterenol ]]-mediated enhancement with apparent low affinities (K(b) of 222 +/- 61 and 9268 +/- 512 nM, respectively).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Together, this pharmacological profile of subtype-selective betaAR antagonists indicates that in this model, << beta1AR >> activation is responsible for the enhanced hippocampal CA3 network activity initiated by [[ isoproterenol ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Oral << lorcaserin >> (BELVIQ(Â®)), a selective serotonin [[ 5-HT2C ]] receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Oral lorcaserin (<< BELVIQ >>(Â®)), a selective serotonin [[ 5-HT2C ]] receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full << muscarinic receptor >> agonist [[ methacholine ]], the partial muscarinic receptor agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and histamine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial << muscarinic receptor >> agonist [[ 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium ]] (McN-A-343) and histamine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Bovine tracheal smooth muscle strips were incubated with 10 microM fenoterol or vehicle for various periods of time (5, 30 min, 18 h) at 37 degrees C. After extensive washout (3 h, 37 degrees C), isometric contractions were measured to the full muscarinic receptor agonist methacholine, the partial << muscarinic receptor >> agonist 4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium (McN-A-343) and [[ histamine ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Systemic administration of << beta2-adrenoceptor >> agonists, [[ formoterol ]] and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Systemic administration of << beta2-adrenoceptor >> agonists, formoterol and [[ salmeterol ]], elicit skeletal muscle hypertrophy in rats at micromolar doses.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two beta(2)-agonists, << formoterol >> and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [[ beta(2)-adrenoceptor ]] selectivity.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two beta(2)-agonists, formoterol and << salmeterol >>, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater [[ beta(2)-adrenoceptor ]] selectivity.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "(+/-)-Tamsulosin effectively antagonized the positive inotropic effect of << phenylephrine >> even after inactivation of [[ alpha 1B-adrenoceptors ]] by treatment with chlorethylclonidine, which is an indication that the (+/-)-tamsulosin-sensitive subtype belongs to a class resistant to chlorethylclonidine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results indicate that the positive inotropic effect, mediated via (+/-)-tamsulosin- and << oxymetazoline >>-sensitive subtype of [[ alpha 1-adrenoceptors ]], is exerted by a subcellular mechanism that is independent of the accumulation of inositol phosphates.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The potent anabolic effects of the << beta 2-adrenoceptor >> agonist [[ clenbuterol ]] on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These effects were not mimicked by oral administration of the << beta 2-adrenoceptor >> agonist [[ salbutamol ]] even at high dose (52 mg/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg/kg diet).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These effects were not mimicked by oral administration of the << beta 2-adrenoceptor >> agonist salbutamol even at high dose (52 mg/kg diet), and the effects of [[ clenbuterol ]] were not inhibited by addition of DL-propranolol (200 mg/kg diet).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Luteinizing hormone-releasing hormone >> (LHRH) agonists, such as [[ buserelin ]], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Luteinizing hormone-releasing hormone (<< LHRH >>) agonists, such as [[ buserelin ]], goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Luteinizing hormone-releasing hormone >> (LHRH) agonists, such as buserelin, [[ goserelin ]], leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Luteinizing hormone-releasing hormone (<< LHRH >>) agonists, such as buserelin, [[ goserelin ]], leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Luteinizing hormone-releasing hormone >> (LHRH) agonists, such as buserelin, goserelin, [[ leuprorelin ]] and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Luteinizing hormone-releasing hormone (<< LHRH >>) agonists, such as buserelin, goserelin, [[ leuprorelin ]] and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Luteinizing hormone-releasing hormone >> (LHRH) agonists, such as buserelin, goserelin, leuprorelin and [[ triptorelin ]], stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Luteinizing hormone-releasing hormone (<< LHRH >>) agonists, such as buserelin, goserelin, leuprorelin and [[ triptorelin ]], stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the << muscarinic acetylcholine receptor >> (mAChR) agonists [[ carbachol ]] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the << muscarinic acetylcholine receptor >> (mAChR) agonists carbachol or [[ muscarine ]], with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<< mAChR >>) agonists [[ carbachol ]] or muscarine, with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cellular release of AChE by SH-SY5Y is significantly enhanced by the muscarinic acetylcholine receptor (<< mAChR >>) agonists carbachol or [[ muscarine ]], with the effect of carbachol blocked by the mAChR antagonist atropine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "for 15 days or along with a << peroxisome proliferator-activated receptor alpha >> agonist [[ bezafibrate ]] (Bzf; 30âÎ¼g/100âg BW, oral) and were found to improve in the Bzf co-treated condition.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "for 15 days or along with a << peroxisome proliferator-activated receptor alpha >> agonist bezafibrate ([[ Bzf ]]; 30âÎ¼g/100âg BW, oral) and were found to improve in the Bzf co-treated condition.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although the D1-like receptor, by itself, had no effect on VSMC proliferation, stimulation with << fenoldopam >>, a [[ D1-like receptor ]] agonist, inhibited the stimulatory effect of insulin.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Agomelatine >>, commonly known as [[ melatonin receptor ]] agonist, is a new antidepressant, which resynchronizes circadian rhythms with subjective and objective improvements in sleep quality and architecture, as melatonin does.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The sympathetic nerves of both the human atrial appendages and rabbit pulmonary artery are endowed with << alpha(2A)-autoreceptors >>, at which, however, both rilmenidine and [[ oxymetazoline ]] exhibit different properties (antagonism and agonism, respectively).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In an earlier report, DRD2 E8 A/A genotype was associated with reduced responsiveness to the << dopamine D2 >> agonist [[ apomorphine ]]; however, it is not clear whether both findings share the same biological basis.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of << EP1 >> and EP2 receptors is indicated by studies with the EP1 selective agonist [[ 17-phenyl trinor PGE2 ]], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the << EP1 >> selective agonist [[ 17-phenyl trinor PGE2 ]], and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and << EP2 receptors >> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist [[ butaprost ]] (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the << EP2 >> selective agonist [[ butaprost ]] (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of << EP1 >> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists [[ SC-51089 ]] (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the << EP1 >> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists [[ SC-51089 ]] (EP1 specific) and AH 6809 (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists << SC-51089 >> (EP1 specific) and AH 6809 ([[ EP1 ]] and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of << EP1 >> and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [[ AH 6809 ]] (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and << EP2 receptors >> is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [[ AH 6809 ]] (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the << EP1 >> selective agonist 17-phenyl trinor PGE2, and the EP2 selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [[ AH 6809 ]] (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of EP1 and EP2 receptors is indicated by studies with the EP1 selective agonist 17-phenyl trinor PGE2, and the << EP2 >> selective agonist butaprost (which stimulate), as well as by studies with the antagonists SC-51089 (EP1 specific) and [[ AH 6809 ]] (EP1 and EP2 specific).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The enhancement of the depolarizing afterpotential by histamine was mimicked by the << histamine H1-receptor >> agonist [[ 2-thiazolylethylamine ]] and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "METHODS: Part A compared the effects of placebo to four doses of a << 5-HT(4) >> receptor antagonist (SB-207266) on the [[ cisapride ]] mediated increase in plasma aldosterone (a 5-HT(4) mediated response) and orocaecal transit in 18 subjects.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was [[ A-54741 ]] (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>[[ dexmedetomidine ]] (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>[[ UK-14304 ]] (8.42)>B-HT 920 (7.05)>noradrenaline (6.92).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>[[ B-HT 920 ]] (7.05)>noradrenaline (6.92).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << alpha(2A)-adrenoceptor >> transfected cells the rank order of agonist potency was A-54741 (mean pEC(50)=8.96)>dexmedetomidine (8.88)>UK-14304 (8.42)>B-HT 920 (7.05)>[[ noradrenaline ]] (6.92).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Zolmitriptan (Zomig; formerly << 311C90 >>) is a novel [[ 5-hydroxytryptamine (5HT)1B/1D ]] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pre-clinical pharmacology of << zolmitriptan >> (Zomig; formerly 311C90), a centrally and peripherally acting [[ 5HT1B/1D ]] agonist for migraine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Zolmitriptan >> (Zomig; formerly 311C90) is a novel [[ 5-hydroxytryptamine (5HT)1B/1D ]] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pre-clinical pharmacology of zolmitriptan (<< Zomig >>; formerly 311C90), a centrally and peripherally acting [[ 5HT1B/1D ]] agonist for migraine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly << 311C90 >>), a centrally and peripherally acting [[ 5HT1B/1D ]] agonist for migraine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Zolmitriptan (<< Zomig >>; formerly 311C90) is a novel [[ 5-hydroxytryptamine (5HT)1B/1D ]] receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< D-Serine >> was previously identified in mammalian brain and was shown to be a co-agonist at the 'glycine' site of the [[ N-methyl-D-aspartate (NMDA)-type receptors ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, ERalpha mediated the protection afforded by estrogen since only the ERalpha agonist, HPTE, but not the << ERbeta >> agonist, [[ DPN ]], protected against dopamine cell loss.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Differentiating the roles of mGlu2 and mGlu3 receptors using << LY541850 >>, an [[ mGlu2 ]] agonist/mGlu3 antagonist.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< LY541850 >> was claimed from human mGlu receptors expressed in non-neuronal cells to be a selective orthosteric [[ mGlu2 ]] agonist and mGlu3 antagonist.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results confirm the selective << mGlu2 >> agonist and mGlu3 antagonist actions of [[ LY541850 ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "RESULTS: In drug discrimination studies, << lisuride >> fully mimicked the [[ 5-HT(1A) ]] agonist LY 293284, only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "RESULTS: In drug discrimination studies, lisuride fully mimicked the << 5-HT(1A) >> agonist [[ LY 293284 ]], only partially substituted for LSD and DOI, and failed to substitute for (+)-amphetamine.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Lisuride dose dependently decreased body temperature in rats with a potency similar to that of the selective << 5-HT(1A) >> agonist [[ LY 293284 ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a << 5-HT1A >>-selective agonist, [[ 8-hydroxy-2-(di-n-propylamino)tetralin ]], was inactive.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic << benzamide >> derivative agonist of [[ 5-HT4 ]] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic << benzamide >> derivative agonist of 5-HT4 and [[ 5-HT1 ]] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of << cinitapride >> (CNT), a novel prokinetic benzamide derivative agonist of [[ 5-HT4 ]] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of << cinitapride >> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and [[ 5-HT1 ]] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (<< CNT >>), a novel prokinetic benzamide derivative agonist of [[ 5-HT4 ]] and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study was designed to determine the gastroprotective properties of cinitapride (<< CNT >>), a novel prokinetic benzamide derivative agonist of 5-HT4 and [[ 5-HT1 ]] receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v/v) ethanol.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting << alpha2 adrenergic receptor >> (AR) agonist ([[ dexmedetomidine ]]).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVES: The aim of this study was to determine whether cocaine's sympathomimetic actions can be reversed by a potent centrally acting alpha2 adrenergic receptor (<< AR >>) agonist ([[ dexmedetomidine ]]).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against << alpha 1a-adrenoceptor >>-selective agonist [[ methoxamine ]]-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the hot-plate test in mice, the antinociceptive action of the << alpha 2-adrenoceptor >> agonist, [[ UK 14,304 ]], was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The preferential << alpha 2A-adrenoceptor >> partial agonist, [[ guanfacine ]], partially inhibited UK 14,304-induced antinociception.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The preferential << alpha 2A-adrenoceptor >> partial agonist, guanfacine, partially inhibited [[ UK 14,304 ]]-induced antinociception.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Discovery of a novel series of << quinolone >> [[ Î±7 nicotinic acetylcholine receptor ]] agonists.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High throughput screening led to the identification of a novel series of << quinolone >> [[ Î±7 nicotinic acetylcholine receptor ]] (nAChR) agonists.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High throughput screening led to the identification of a novel series of << quinolone >> Î±7 nicotinic acetylcholine receptor ([[ nAChR ]]) agonists.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To establish the relative importance of these subtypes, we compared the effects of sumatriptan with those of a selective << 5-HT1F >> receptor agonist ([[ LY 344864 ]]) on c-fos protein expression in the trigeminal nucleus caudalis.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It is suggested that all the additional actions of << bevantolol >> can be attributed to a partial agonist action on [[ alpha-adrenoceptors ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The results suggested that both the EtOAc extract and berberine were able to activate PPARÎ±/Î²/Î³, and Rhizoma Coptis contains potential natural agonists of << PPARs >> besides [[ berberine ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PEA was a potent and full agonist at each species of TAAR1, whereas << TYR >> was a full agonist for the rodent TAAR1s but was a partial agonist at [[ h-rChTAAR1 ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Interestingly, both isomers of << METH >> were full agonists at mTAAR1 and h-rChTAAR1, whereas both were partial agonists at [[ rTAAR1 ]].", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Safety and tolerability of << denufosol tetrasodium >> inhalation solution, a novel [[ P2Y2 receptor ]] agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Denufosol tetrasodium >> (INS37217) is a selective [[ P2Y(2) ]] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Denufosol tetrasodium (<< INS37217 >>) is a selective [[ P2Y(2) ]] agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Denufosol >> is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated [[ P2Y(2) ]] agonists.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "alpha(1)-Adrenoceptor antagonists were tested against the << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist)-induced contraction in isolated hamster ureteral preparations using a functional experimental approach.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Noradrenaline >> and phenylephrine ([[ alpha(1)-adrenoceptor ]] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Noradrenaline and << phenylephrine >> ([[ alpha(1)-adrenoceptor ]] agonist) each produced a concentration-dependent tonic contraction, their pD(2) values being 6.87+/-0.08 and 6.10+/-0.05, respectively.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Prazosin (nonselective << alpha(1)-adrenoceptor >> antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [[ phenylephrine ]]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective << alpha(1A)-adrenoceptor >> antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective alpha(1D)-adrenoceptor antagonist) competitively antagonized the [[ phenylephrine ]]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Prazosin (nonselective alpha(1)-adrenoceptor antagonist), silodosin (selective alpha(1A)-adrenoceptor antagonist) and BMY-7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride) (selective << alpha(1D)-adrenoceptor >> antagonist) competitively antagonized the [[ phenylephrine ]]-induced contraction (pA(2) values, 8.60+/-0.07, 9.44+/-0.06 and 5.75+/-0.07, respectively).", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Tamoxifen >> blocks the action of estrogen by binding to the ER, and possesses both [[ ER ]]-agonist and antagonist properties.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the effects of the << DRD3 >> agonist [[ 7-hydroxy-N,N-dipropyl-2-aminotetralin ]] (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the effects of the << DRD3 >> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin ([[ 7-OH-DPAT ]])-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the effects of the DRD3 agonist << 7-hydroxy-N,N-dipropyl-2-aminotetralin >> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when [[ DRD3 ]] proteins were abundant.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<< 7-OH-DPAT >>)-induced locomotor hypoactivity were significantly increased when [[ DRD3 ]] proteins were abundant.", "metadata": [], "label": "AGONIST", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Previously, we reported that a primary heparin or heparan << sulfate >> binding site resides in a distinct sequence in [[ immunoglobulin (Ig)-like module II ]] of the three modules of FGFR.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Previously, we reported that a primary heparin or heparan << sulfate >> binding site resides in a distinct sequence in immunoglobulin (Ig)-like module II of the three modules of [[ FGFR ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that a complex of << Ig module II >> and heparan [[ sulfate ]] is the base common active core of the FGFR ectodomain and that flanking structural domains modify FGF affinity and determine specificity.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide (<< TAK-441 >>) is a potent, selective hedgehog signaling pathway inhibitor that binds to [[ Smo ]] and is being developed for the treatment of cancer.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Salicylates >> inhibit (125)I-[[ ET-1 ]] binding to recombinant rat ETA receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Salicylates inhibit << (125)I >>-[[ ET-1 ]] binding to recombinant rat ETA receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Salicylates >> inhibit (125)I-ET-1 binding to recombinant [[ rat ETA receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Salicylic acid promotes dissociation of << (125)I >>-[[ ET-1 ]] ETA receptor complexes both in the absence and the presence of unlabeled ET-1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Salicylic acid promotes dissociation of << (125)I >>-ET-1 [[ ETA receptor ]] complexes both in the absence and the presence of unlabeled ET-1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Salicylic acid >> promotes dissociation of (125)I-[[ ET-1 ]] ETA receptor complexes both in the absence and the presence of unlabeled ET-1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Salicylic acid >> promotes dissociation of (125)I-ET-1 [[ ETA receptor ]] complexes both in the absence and the presence of unlabeled ET-1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Salicylates do not promote dissociation of << (125)I >>-[[ ET-1 ]] ETB receptor complexes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Salicylates do not promote dissociation of << (125)I >>-ET-1 [[ ETB receptor ]] complexes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has no influence on the rate of association of << (125)I >>-[[ ET-1 ]] to ETA receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has no influence on the rate of association of << (125)I >>-ET-1 to [[ ETA receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Dextromethorphan >> and dimemorfan are high-affinity ligands at [[ sigma1 receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Dextromethorphan and << dimemorfan >> are high-affinity ligands at [[ sigma1 receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A novel potent compound, << N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide >> (12c), which binds [[ Mcl-1 ]] with an IC(50) value of 54 nM was obtained.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding studies showed that both << amoxapine >> and amitriptyline interact in the nanomolar range with [[ 5-HT2 ]] receptors labelled by [3H]ketanserin in cortical membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding studies showed that both amoxapine and << amitriptyline >> interact in the nanomolar range with [[ 5-HT2 ]] receptors labelled by [3H]ketanserin in cortical membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding studies showed that both amoxapine and amitriptyline interact in the nanomolar range with << 5-HT2 >> receptors labelled by [[ [3H]ketanserin ]] in cortical membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Interestingly, << amoxapine >> binds with a good affinity (IC50 = 0.30 microM) to [[ 5-HT3 ]] receptors labelled by [3H]zacopride in cortical membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Interestingly, amoxapine binds with a good affinity (IC50 = 0.30 microM) to << 5-HT3 >> receptors labelled by [[ [3H]zacopride ]] in cortical membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Consistent with the results of a computer analysis, the binding of << R316C >> to [[ triiodothyronine ]] (T3) was significantly decreased to 38% that of the wild type.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Consistent with the results of a computer analysis, the binding of << R316C >> to triiodothyronine ([[ T3 ]]) was significantly decreased to 38% that of the wild type.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This effect probably involves interaction of << phenserine >> with a regulatory element in the 5'-untranslated region of the [[ APP ]] gene that controls APP expression.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by << Wy-14643 >> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and << 5,8,11,14-eicosatetraynoic acid >> (ETYA) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<< ETYA >>) each at 10 microM, respectively, whereas that of [[ PPARalpha2 ]], 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of << [(125)I]RTI-55 >> from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the << DAT >>, and partially inhibited [[ [(3)H]dopamine ]] uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (<< RTI-55 >>) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited << [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester >> (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine >> (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (<< SoRI-9804 >>), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), << N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine >> (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (<< SoRI-20040 >>), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and << N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine >> (SoRI-20041) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine (SoRI-9804), N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine (SoRI-20040), and N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine (<< SoRI-20041 >>) partially inhibited [(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic acid methyl ester (RTI-55) binding, slowed the dissociation rate of [(125)I]RTI-55 from the [[ DAT ]], and partially inhibited [(3)H]dopamine uptake.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied accumulation of lipid metabolites [<< triglycerides >> (TAGs), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of [[ PTP1B ]] by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 Î¼M).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied accumulation of lipid metabolites [triglycerides (<< TAGs >>), diglycerides (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of [[ PTP1B ]] by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 Î¼M).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied accumulation of lipid metabolites [triglycerides (TAGs), << diglycerides >> (DAGs)] and ceramides in relation to insulin signaling and expression and phosphorylation of [[ PTP1B ]] by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 Î¼M).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (<< DAGs >>)] and ceramides in relation to insulin signaling and expression and phosphorylation of [[ PTP1B ]] by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 Î¼M).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied accumulation of lipid metabolites [triglycerides (TAGs), diglycerides (DAGs)] and << ceramides >> in relation to insulin signaling and expression and phosphorylation of [[ PTP1B ]] by preincubating rat skeletal muscle cells (L6 myotubes) with three saturated and three unsaturated free fatty acids (FFAs) (200 Î¼M).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the new compounds, << Dmt >>(1)-(R)-Î²Pro(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [[ MOR ]], in the picomolar range (Ki(Î¼) = 3.72 pM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the new compounds, Dmt(1)-<< (R)-Î²Pro >>(2)-Trp(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [[ MOR ]], in the picomolar range (Ki(Î¼) = 3.72 pM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the new compounds, Dmt(1)-(R)-Î²Pro(2)-<< Trp >>(3)-(2-furyl)Map(4) (analogue 12) displayed the highest affinity toward [[ MOR ]], in the picomolar range (Ki(Î¼) = 3.72 pM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the new compounds, Dmt(1)-(R)-Î²Pro(2)-Trp(3)-<< (2-furyl)Map >>(4) (analogue 12) displayed the highest affinity toward [[ MOR ]], in the picomolar range (Ki(Î¼) = 3.72 pM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Mouse ornithine decarboxylase >> (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for [[ pyridoxal 5'-phosphate ]] and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mouse ornithine decarboxylase (<< ODC >>) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for [[ pyridoxal 5'-phosphate ]] and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << pyridoxal 5'-phosphate >> binding lysine in [[ mouse ODC ]] was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Using a similar procedure to analyze << ODC >> labeled by reaction with [[ [5-14C]DFMO ]], it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of << [57Co]cyanocobalamin >> (CN-Cbl) bound to [[ transcobalamin II ]] (transcobalamin, TC).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<< CN-Cbl >>) bound to [[ transcobalamin II ]] (transcobalamin, TC).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of << [57Co]cyanocobalamin >> (CN-Cbl) bound to transcobalamin II ([[ transcobalamin ]], TC).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<< CN-Cbl >>) bound to transcobalamin II ([[ transcobalamin ]], TC).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of << [57Co]cyanocobalamin >> (CN-Cbl) bound to transcobalamin II (transcobalamin, [[ TC ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Extracellular Cbl (protein bound and free) and intracellular Cbl (protein bound and free) were determined after culturing L-1210 cells in the presence of [57Co]cyanocobalamin (<< CN-Cbl >>) bound to transcobalamin II (transcobalamin, [[ TC ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Intracellular protein-bound << [57Co]Cbl >> fractionated with [[ methionine synthase ]] (MS) and methylmalonyl-CoA mutase (MU) activity.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Intracellular protein-bound << [57Co]Cbl >> fractionated with methionine synthase ([[ MS ]]) and methylmalonyl-CoA mutase (MU) activity.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Intracellular protein-bound << [57Co]Cbl >> fractionated with methionine synthase (MS) and [[ methylmalonyl-CoA mutase ]] (MU) activity.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Intracellular protein-bound << [57Co]Cbl >> fractionated with methionine synthase (MS) and methylmalonyl-CoA mutase ([[ MU ]]) activity.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of << adapalene >> and tretinoin for the [[ nuclear transcription factors ]], retinoic acid receptors (RARs).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of << adapalene >> and tretinoin for the nuclear transcription factors, [[ retinoic acid receptors ]] (RARs).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of << adapalene >> and tretinoin for the nuclear transcription factors, retinoic acid receptors ([[ RARs ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and << tretinoin >> for the [[ nuclear transcription factors ]], retinoic acid receptors (RARs).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and << tretinoin >> for the nuclear transcription factors, [[ retinoic acid receptors ]] (RARs).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding and transactivation assays were used to compare affinities and transcriptional activities of adapalene and << tretinoin >> for the nuclear transcription factors, retinoic acid receptors ([[ RARs ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the << ATP >>-binding-cassette superfamily with two [[ nucleotide-binding folds ]] (NBF1 and NBF2) and the pore-forming Kir6.2 subunits.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the << ATP >>-binding-cassette superfamily with two nucleotide-binding folds ([[ NBF1 ]] and NBF2) and the pore-forming Kir6.2 subunits.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The KATP channel is a heterooligomeric complex of SUR1 subunits of the << ATP >>-binding-cassette superfamily with two nucleotide-binding folds (NBF1 and [[ NBF2 ]]) and the pore-forming Kir6.2 subunits.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we report that MgATP and MgADP, but not the Mg salt of gamma-thio-ATP, stabilize the binding of prebound << 8-azido-[alpha-32P]ATP >> to [[ SUR1 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << SUR1 >> binds [[ 8-azido-ATP ]] strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that SUR1 binds << 8-azido-ATP >> strongly at [[ NBF1 ]] and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that << MgADP >>, either by direct binding to [[ NBF2 ]] or by hydrolysis of bound MgATP at NBF2, stabilizes prebound 8-azido-ATP binding at NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2, stabilizes prebound << 8-azido-ATP >> binding at [[ NBF1 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << sulfonylurea glibenclamide >> caused release of prebound 8-azido-[alpha-32P]ATP from [[ SUR1 ]] in the presence of MgADP or MgATP in a concentration-dependent manner.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cooperative binding of << ATP >> and MgADP in the [[ sulfonylurea receptor ]] is modulated by glibenclamide.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cooperative binding of ATP and << MgADP >> in the [[ sulfonylurea receptor ]] is modulated by glibenclamide.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The sulfonylurea glibenclamide caused release of prebound << 8-azido-[alpha-32P]ATP >> from [[ SUR1 ]] in the presence of MgADP or MgATP in a concentration-dependent manner.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in << nucleotide >> binding of the two [[ NBFs ]] of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in << nucleotide >> binding of the two NBFs of [[ SUR1 ]] suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that << glibenclamide >> both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at [[ NBF2 ]], causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that << glibenclamide >> both blocks this cooperative binding of ATP and MgADP and, in cooperation with the MgADP bound at NBF2, causes ATP to be released from [[ NBF1 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of << ATP >> and MgADP and, in cooperation with the MgADP bound at [[ NBF2 ]], causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and << MgADP >> and, in cooperation with the MgADP bound at [[ NBF2 ]], causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This direct biochemical evidence of cooperative interaction in nucleotide binding of the two NBFs of SUR1 suggests that glibenclamide both blocks this cooperative binding of ATP and MgADP and, in cooperation with the << MgADP >> bound at [[ NBF2 ]], causes ATP to be released from NBF1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the other hand, ligands for the renal << Na(+)-transporter >> ([[ amiloride ]] and triamterene) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the other hand, ligands for the renal << Na(+)-transporter >> (amiloride and [[ triamterene ]]) and for imidazoline recognition sites (guanabenz, guanfacine and agmatine) displaced the binding of [(3)H]prazosin to phentolamine-insensitive sites at micromolar concentrations.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for << iloprost >> binding to the platelet [[ prostacyclin receptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Iloprost was the most potent: 50% inhibition occurred at 5 nM, a concentration close to the reported dissociation constant for iloprost binding to the platelet << prostacyclin >> [[ prostacyclin receptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phenoxybenzamine >>, an alpha-adrenergic antagonist containing a (chloroethyl)amine group, labels [[ calmodulin ]] in the presence of calcium.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Drug-protein interactions: isolation and characterization of covalent adducts of << phenoxybenzamine >> and [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Phenoxybenzamine, an alpha-adrenergic antagonist containing a << (chloroethyl)amine >> group, labels [[ calmodulin ]] in the presence of calcium.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Adducts of << calmodulin >> and [[ phenoxybenzamine ]] were separated by high-performance liquid chromatography into four major fractions: two containing 0.6 and 1.2 mol of drug per mol of protein and two different fractions each containing 2.0 mol/mol.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the chlorpromazine binding capacities of the << phenoxybenzamine >>-[[ calmodulin ]] adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Each adduct had a reduced ability to activate cyclic nucleotide phosphodiesterase and myosin light chain kinase, and the << chlorpromazine >> binding capacities of the phenoxybenzamine-[[ calmodulin ]] adducts were diminished to the extent of phenoxybenzamine incorporation into each adduct.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Isolation and characterization of labeled peptides from << phenoxybenzamine >>-modified [[ calmodulins ]] indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained phenoxybenzamine label.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Isolation and characterization of labeled peptides from phenoxybenzamine-modified << calmodulins >> indicated that peptides encompassing residues 38-75, 107-126, and 127-148 contained [[ phenoxybenzamine ]] label.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Porcine TLR8 and TLR7 are both activated by a selective << TLR7 >> ligand, [[ imiquimod ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both [[ porcine TLR7 ]] and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both porcine TLR7 and [[ TLR8 ]] whereas only human TLR7, but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both porcine TLR7 and TLR8 whereas only [[ human TLR7 ]], but not TLR8, was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two << imidazoquinoline >> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [[ TLR8 ]], was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, << imiquimod >> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [[ TLR8 ]], was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two imidazoquinoline molecules, imiquimod and << gardiquimod >>, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not [[ TLR8 ]], was activated by the ligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, << p-aminobenzamidine >> (p-ABZ) and proflavin binding to the catalytic site of two proteolyzed forms of [[ alpha-thrombin ]], i.e.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (<< p-ABZ >>) and proflavin binding to the catalytic site of two proteolyzed forms of [[ alpha-thrombin ]], i.e.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An experimental strategy based on solution viscosity perturbation allowed us to study the energetics of amide-substrates, p-aminobenzamidine (p-ABZ) and << proflavin >> binding to the catalytic site of two proteolyzed forms of [[ alpha-thrombin ]], i.e.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A phenomenological analysis of thermodynamic data showed that the amide substrates and << p-ABZ >> interactions with [[ zeta-thrombin ]] were respectively, associated with a chemical compensation (i.e.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, these data demonstrate that: (1) the Leu144-Gly150 loop and the FRS are both involved in the conformational transition linked to the binding of << p-aminobenzamidine >> to the [[ thrombin ]] active site; (2) the extent of thrombin's capacity to undergo conformational transitions in alpha-, zeta- and gamma T forms is positively correlated to the free energy of activation for hydrolysis of macromolecular substrates interacting with both the catalytic domain and the FRS.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Plasma from << duloxetine >>-treated subjects (ex vivo effect) dose-dependently decreased radioligand binding to [[ human NET ]] (maximum inhibition was 60%) (P=0.02).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We report herein the location of the binding site for the inhaled anesthetic << halothane >> at the amino acid residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, [[ bovine rhodopsin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Radiosequence analysis of << [(14)C]halothane >>-labeled [[ rhodopsin ]] revealed that halothane contacts an amino acid residue (Trp265) lining the ligand binding cavity in the transmembrane core of the receptor.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Autoradiography studies with << [(3)H](-)-CP 55,940 >> show that chronic treatment with SR 141716A for 15 days twice daily (1 mg/kg i.p.) significantly increases the density of [[ CB1 receptors ]] in the PVN.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Racemic IKM-159 >> was crystallized with the ligand-binding domain of [[ GluA2 ]], and the structure revealed a complex containing (2R)-IKM-159 at the glutamate binding site.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Racemic IKM-159 was crystallized with the ligand-binding domain of << GluA2 >>, and the structure revealed a complex containing [[ (2R)-IKM-159 ]] at the glutamate binding site.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Each dimeric analog showed higher affinities for alpha2A- and alpha2C-adrenoceptor versus the alpha2B-adrenoceptor; and << yohimbine >> dimers with spacers of n = 2, 3, 4, 18, and 24 exhibited selectivity for the [[ alpha2C-adrenoceptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << yohimbine >> dimers n = 3 and n = 24 showed the highest potency and selectivity (32- and 82-fold. respectively) for the [[ alpha2C-adrenoceptor ]] in receptor binding and in functional studies (42- and 29-fold, respectively) measuring cAMP changes using a cell-based luciferase reporter gene assay.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We demonstrate that only treatment of HaCaT with GLA and EPA or a << PPARgamma >> ligand ([[ roziglitazone ]]), induced COX-2 expression (protein and mRNA).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Multiple affinity states of << opiate receptor >> can be demonstrated further by Scatchard analysis of saturation binding studies with [[ [3H]DADLE ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Opioid receptor >> binding affinity and activity were assessed using [[ [(3)H]-diprenorphine ]] binding, guanosine-5'-O-(3-[35S]-thio) triphosphate ([(35)S]-GTPÎ³S) binding and isolated guinea-pig ileum.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vivo and in vitro characterization of << naltrindole >>-derived ligands at the [[ Îº-opioid receptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Opioid receptor >> binding affinity and activity were assessed using [(3)H]-diprenorphine binding, [[ guanosine-5'-O-(3-[35S]-thio) triphosphate ]] ([(35)S]-GTPÎ³S) binding and isolated guinea-pig ileum.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Opioid receptor >> binding affinity and activity were assessed using [(3)H]-diprenorphine binding, guanosine-5'-O-(3-[35S]-thio) triphosphate ([[ [(35)S]-GTPÎ³S ]]) binding and isolated guinea-pig ileum.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Both << 5'-AMN >> and 5'-MABN had high affinity for [[ Îº-receptors ]] (K (i) 1.36 Â± 0.98 and 0.27 Â± 0.08, respectively) and were revealed as potent Îº-antagonists (pA(2) 7.43 and 8.18, respectively) and Î¼-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Both 5'-AMN and << 5'-MABN >> had high affinity for [[ Îº-receptors ]] (K (i) 1.36 Â± 0.98 and 0.27 Â± 0.08, respectively) and were revealed as potent Îº-antagonists (pA(2) 7.43 and 8.18, respectively) and Î¼-receptor antagonists (pA(2) 7.62 and 7.85, respectively) in the ileum.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the << DAT >> ligand [[ WIN35428 ]], and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal DA transport.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, these findings indicate that << [3H]SR 142948A >> is a new potent antagonist radioligand which recognizes with high affinity both [[ neurotensin NT1 ]] and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, these findings indicate that << [3H]SR 142948A >> is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and [[ NT2 receptors ]] and represents thus an excellent tool to study neurotensin receptors in the rat brain.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that << [3H]SR 142948A >> bound with similar affinities to both the levocabastine-insensitive [[ neurotensin NT1 receptors ]] (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that << [3H]SR 142948A >> bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive [[ neurotensin NT2 receptors ]] (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The affinities of << dfbp >> and dfbp-o for the regulatory domain of [[ cTnC ]] were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The affinities of dfbp and << dfbp-o >> for the regulatory domain of [[ cTnC ]] were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than dfbp.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The affinities of dfbp and dfbp-o for the regulatory domain of << cTnC >> were measured in the absence and presence of cTnI by NMR spectroscopy, and [[ dfbp-o ]] was found to bind more strongly than dfbp.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The affinities of dfbp and dfbp-o for the regulatory domain of << cTnC >> were measured in the absence and presence of cTnI by NMR spectroscopy, and dfbp-o was found to bind more strongly than [[ dfbp ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Dfbp-o >> also increased the affinity of [[ cTnI ]] for cTnC.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Dfbp-o >> also increased the affinity of cTnI for [[ cTnC ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structural and functional data reveal that the << levosimendan >> class of Ca(2+)-sensitizers work by binding to the regulatory domain of [[ cTnC ]] and stabilizing the pivotal cTnC-cTnI regulatory unit via a network of hydrophobic and electrostatic interactions, in contrast to the destabilizing effects of antagonists such as W7 at the same interface.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The high resolution NMR solution structure of the cTnC-<< cTnI >>-[[ dfbp-o ]] ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The high resolution NMR solution structure of the << cTnC >>-cTnI-[[ dfbp-o ]] ternary complex showed that dfbp-o bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of cTnI.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that << dfbp-o >> bound at the hydrophobic interface formed by [[ cTnC ]] and cTnI making critical interactions with residues such as Arg147 of cTnI.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that << dfbp-o >> bound at the hydrophobic interface formed by cTnC and [[ cTnI ]] making critical interactions with residues such as Arg147 of cTnI.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The high resolution NMR solution structure of the cTnC-cTnI-dfbp-o ternary complex showed that << dfbp-o >> bound at the hydrophobic interface formed by cTnC and cTnI making critical interactions with residues such as Arg147 of [[ cTnI ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the absence of cTnI, docking localized << dfbp-o >> to the same position in the hydrophobic groove of [[ cTnC ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Citalopram >> protected against the RTI-76-induced inhibition of [[ SERT ]] binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Following 6 h of in vivo intracerebroventricular injections of 100 nmol of << RTI-76 >>, there was a dose- and time-dependent reduction (- 60%) of [[ SERT ]] binding in hippocampus and striatum, without a change in the Kd.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << OTCase >>, mutations of putative [[ ornithine ]] binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for [[ ornithine ]] and impaired the interaction with arginase.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << keto >> and phenolic -OH are major factors that are prominently involved in interaction with [[ COX-2 ]] active site.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The keto and << phenolic >> -OH are major factors that are prominently involved in interaction with [[ COX-2 ]] active site.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The keto and phenolic -<< OH >> are major factors that are prominently involved in interaction with [[ COX-2 ]] active site.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We begin by capturing << RISC >> using a complementary [[ 2'-O-methyl ]] oligonucleotide tethered to beads.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "For example, << clozapine >> revealed a radioligand-independent value of 1.6 nM at the [[ dopamine D4 receptor ]], agreeing with the value directly measured with [3H]-clozapine at D4.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "For example, clozapine revealed a radioligand-independent value of 1.6 nM at the dopamine D4 receptor, agreeing with the value directly measured with << [3H]-clozapine >> at [[ D4 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, because << clozapine >> competes with endogenous dopamine, the in vivo concentration of clozapine (to occupy [[ dopamine D4 receptors ]]) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, because clozapine competes with endogenous << dopamine >>, the in vivo concentration of clozapine (to occupy [[ dopamine D4 receptors ]]) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, because clozapine competes with endogenous dopamine, the in vivo concentration of << clozapine >> (to occupy [[ dopamine D4 receptors ]]) can be derived to be about 13 nM, agreeing with the value of 12 to 20 nM in the plasma water or spinal fluid observed in treated patients.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The atypical neuroleptics << remoxipride >>, clozapine, perlapine, seroquel, and melperone had low affinity for the dopamine [[ D2 receptor ]] (radioligand-independent dissociation constants of 30 to 90 nM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The atypical neuroleptics remoxipride, << clozapine >>, perlapine, seroquel, and melperone had low affinity for the dopamine [[ D2 receptor ]] (radioligand-independent dissociation constants of 30 to 90 nM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The atypical neuroleptics remoxipride, clozapine, << perlapine >>, seroquel, and melperone had low affinity for the dopamine [[ D2 receptor ]] (radioligand-independent dissociation constants of 30 to 90 nM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The atypical neuroleptics remoxipride, clozapine, perlapine, << seroquel >>, and melperone had low affinity for the dopamine [[ D2 receptor ]] (radioligand-independent dissociation constants of 30 to 90 nM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The atypical neuroleptics remoxipride, clozapine, perlapine, seroquel, and << melperone >> had low affinity for the dopamine [[ D2 receptor ]] (radioligand-independent dissociation constants of 30 to 90 nM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most typical neuroleptics have radioligand-independent values of 0.3 to 5 nM at << dopamine D2 receptors >>, making them more resistant to displacement by endogenous [[ dopamine ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Muscarinic cholinergic and << histamine H1 receptor >> binding of [[ phenothiazine ]] drug metabolites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding affinities of << chlorpromazine >>, fluphenazine, levomepromazine, perphenazine and some of their metabolites for [[ dopamine D2 receptors ]], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding affinities of chlorpromazine, << fluphenazine >>, levomepromazine, perphenazine and some of their metabolites for [[ dopamine D2 receptors ]], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding affinities of chlorpromazine, fluphenazine, << levomepromazine >>, perphenazine and some of their metabolites for [[ dopamine D2 receptors ]], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro binding affinities of chlorpromazine, fluphenazine, levomepromazine, << perphenazine >> and some of their metabolites for [[ dopamine D2 receptors ]], alpha 1- and alpha 2 adrenoceptors in rat brain were previously reported from our laboratories.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The present study reports the in vitro binding affinities of the same compounds for << muscarinic cholinergic receptors >> and for histamine H1 receptors in rat brain, using [[ 3H-quinuclidinyl benzilate ]] and 3H-mepyramine as radioligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The present study reports the in vitro binding affinities of the same compounds for << muscarinic cholinergic receptors >> and for histamine H1 receptors in rat brain, using 3H-quinuclidinyl benzilate and [[ 3H-mepyramine ]] as radioligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for << histamine H1 receptors >> in rat brain, using [[ 3H-quinuclidinyl benzilate ]] and 3H-mepyramine as radioligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The present study reports the in vitro binding affinities of the same compounds for muscarinic cholinergic receptors and for << histamine H1 receptors >> in rat brain, using 3H-quinuclidinyl benzilate and [[ 3H-mepyramine ]] as radioligands.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Chlorpromazine >>, levomepromazine, and their metabolites had 5-30 times higher binding affinities for [[ muscarinic cholinergic receptors ]] than fluphenazine, perphenazine and their metabolites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Chlorpromazine, << levomepromazine >>, and their metabolites had 5-30 times higher binding affinities for [[ muscarinic cholinergic receptors ]] than fluphenazine, perphenazine and their metabolites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for << muscarinic cholinergic receptors >> than [[ fluphenazine ]], perphenazine and their metabolites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Chlorpromazine, levomepromazine, and their metabolites had 5-30 times higher binding affinities for << muscarinic cholinergic receptors >> than fluphenazine, [[ perphenazine ]] and their metabolites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Levomepromazine >> was the most potent and fluphenazine the least potent of the four drugs in [[ histamine H1 receptor ]] binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Levomepromazine was the most potent and << fluphenazine >> the least potent of the four drugs in [[ histamine H1 receptor ]] binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 7-Hydroxy levomepromazine >>, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [[ histamine H1 receptor ]] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "7-Hydroxy levomepromazine, << 3-hydroxy levomepromazine >> and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in [[ histamine H1 receptor ]] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and << 7-hydroxy fluphenazine >> had only 10% of the potency of the parent drug in [[ histamine H1 receptor ]] binding, while the 7-hydroxy-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in << histamine H1 receptor >> binding, while the [[ 7-hydroxy ]]-metabolites of chlorpromazine and perphenazine had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in << histamine H1 receptor >> binding, while the 7-hydroxy-metabolites of [[ chlorpromazine ]] and perphenazine had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "7-Hydroxy levomepromazine, 3-hydroxy levomepromazine and 7-hydroxy fluphenazine had only 10% of the potency of the parent drug in << histamine H1 receptor >> binding, while the 7-hydroxy-metabolites of chlorpromazine and [[ perphenazine ]] had about 75% of the potency of the parent drug in this binding system.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Their << histamine H1 receptor >> binding affinities indicate that metabolites may contribute to the sedative effects of [[ chlorpromazine ]] and levomepromazine.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Their << histamine H1 receptor >> binding affinities indicate that metabolites may contribute to the sedative effects of chlorpromazine and [[ levomepromazine ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a << Gd >>-based MRI contrast agent, encaged with a chelating agent (DOTA), with pantoprazole, which is a widely used proton pump inhibitor that binds to [[ proton pumps ]] in the stomach and colon.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (<< DOTA >>), with pantoprazole, which is a widely used proton pump inhibitor that binds to [[ proton pumps ]] in the stomach and colon.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To overcome this limitation, we de novo synthesized a conjugate that covalently combines a Gd-based MRI contrast agent, encaged with a chelating agent (DOTA), with << pantoprazole >>, which is a widely used proton pump inhibitor that binds to [[ proton pumps ]] in the stomach and colon.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The influence of (+/-)-tamsulosin, a selective alpha 1A-adrenoceptor antagonist, on the positive inotropic effect and the accumulation of inositol phosphates that are induced via alpha 1-adrenoceptors was studied in comparison with that of another << alpha 1A-adrenoceptor >> ligand [[ oxymetazoline ]] in the rabbit ventricular myocardium.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Occupancy of dopamine D(1), D (2) and << serotonin (2A) receptors >> in schizophrenic patients treated with [[ flupentixol ]] in comparison with risperidone and haloperidol.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Occupancy of dopamine D(1), D (2) and << serotonin (2A) receptors >> in schizophrenic patients treated with flupentixol in comparison with [[ risperidone ]] and haloperidol.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Occupancy of dopamine D(1), D (2) and << serotonin (2A) receptors >> in schizophrenic patients treated with flupentixol in comparison with risperidone and [[ haloperidol ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: We were able to demonstrate a moderate << 5-HT(2A) >> and D(1) occupancy under clinically relevant doses of [[ flupentixol ]], albeit lower than expected from in vitro data and clearly below saturation.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: We were able to demonstrate a moderate 5-HT(2A) and << D(1) >> occupancy under clinically relevant doses of [[ flupentixol ]], albeit lower than expected from in vitro data and clearly below saturation.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to << dopamine D(2) >>, D(1) and 5-HT(2A) receptors and recently, [[ FLX ]] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), << D(1) >> and 5-HT(2A) receptors and recently, [[ FLX ]] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and << 5-HT(2A) receptors >> and recently, [[ FLX ]] showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, << FLX >> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with [[ 5-HT(2A) ]] and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, << FLX >> showed to be not inferior to risperidone in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or [[ D(1) receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to << dopamine D(2) >>, D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [[ risperidone ]] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), << D(1) >> and 5-HT(2A) receptors and recently, FLX showed to be not inferior to [[ risperidone ]] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and << 5-HT(2A) receptors >> and recently, FLX showed to be not inferior to [[ risperidone ]] in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to << risperidone >> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with [[ 5-HT(2A) ]] and/or D(1) receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In vitro data show comparable affinity to dopamine D(2), D(1) and 5-HT(2A) receptors and recently, FLX showed to be not inferior to << risperidone >> in schizophrenic patients with predominant negative symptomatology, which was implicated with flupentixol's interaction with 5-HT(2A) and/or [[ D(1) receptors ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Desipramine treatment decreases << 3H-nisoxetine >> binding and [[ norepinephrine transporter ]] mRNA in SK-N-SHSY5Y cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< STI571 >> binding to [[ Flt3 ]] is prevented by the phenylalanine 691 side-chain in the ATP binding center and mutating this site to threonine renders the corresponding Flt3 mutant sensitive to STI571.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, a lid conformation was induced by [<< Sar >>(1),Gln(2),Ile(8)] AngII, a specific analog that binds to the [[ D281A ]] mutant with better affinity than AngII.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, a lid conformation was induced by [Sar(1),<< Gln >>(2),Ile(8)] AngII, a specific analog that binds to the [[ D281A ]] mutant with better affinity than AngII.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, a lid conformation was induced by [Sar(1),Gln(2),<< Ile >>(8)] AngII, a specific analog that binds to the [[ D281A ]] mutant with better affinity than AngII.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Following CdClâ treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h. Interestingly, there was a loss in the binding of << ICAM2 >> to actin during [[ CdClâ ]]-induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding site of << amiloride >> to [[ urokinase plasminogen activator ]] depends on species.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of << amiloride >> to the [[ tissue plasminogen activator ]] (tPA).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Significant differences were observed in a different region (loop B93-B101), that we identified as binding site of << amiloride >> to the tissue plasminogen activator ([[ tPA ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By theoretical calculations we have determined most probable structure of << amiloride >>/[[ uPAs ]] complexes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Reboxetine >>, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the [[ human norepinephrine transporter ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Characterization of << rat brain aldosterone receptors >> reveals high affinity for [[ corticosterone ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, due to the very high affinity of << CBG >> for [[ corticosterone ]] at 4 C, this slight contamination resulted in significant alterations in the apparent affinity of steroids competing for aldosterone-binding sites.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of << steroid >> binding similar to that of the kidney [[ mineralocorticoid receptor ]] (aldosterone greater than desoxycorticosterone greater than corticosterone).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney << mineralocorticoid receptor >> ([[ aldosterone ]] greater than desoxycorticosterone greater than corticosterone).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Readdition of a small quantity of dialyzed serum to cytosol preparations yielded a profile of steroid binding similar to that of the kidney << mineralocorticoid receptor >> (aldosterone greater than [[ desoxycorticosterone ]] greater than corticosterone).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the basis of data obtained in rabbits, the << imidazoline receptor >> ligand [[ rilmenidine ]] has been suggested to decrease blood pressure in humans by activating central alpha(2A)-adrenoceptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Binding of << dimemorfan >> to [[ sigma-1 receptor ]] and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of << DF >> to the [[ sigma receptors ]] and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that << DF >>, DM, and DR were relative high-affinity ligands at [[ sigma-1 receptors ]] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, << DM >>, and DR were relative high-affinity ligands at [[ sigma-1 receptors ]] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and << DR >> were relative high-affinity ligands at [[ sigma-1 receptors ]] (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at sigma-2 receptors (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that << DF >>, DM, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [[ sigma-2 receptors ]] (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, << DM >>, and DR were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [[ sigma-2 receptors ]] (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This study therefore characterized the binding of DF to the sigma receptors and NMDA-linked PCP sites and examined the anticonvulsant as well as locomotor effects of DF in mice in comparison with those of DM and DR. We found that DF, DM, and << DR >> were relative high-affinity ligands at sigma-1 receptors (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at [[ sigma-2 receptors ]] (Ki=4-11 microM).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to << sigma-1 receptors >>, the very low affinity of [[ DF ]] at PCP sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to << sigma-1 receptors >>, the very low affinity of DF at [[ PCP ]] sites may suggest that acting on the PCP sites may not be the requisite for mediating the anticonvulsant activity of these DM analogs.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Glycylsarcosine >> coadministration could inhibit the uptake of cefadroxil in [[ PEPT2 ]](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mass spectral analysis of CBDP-inhibited << BChE >> digested with Glu-C showed an [[ o-hydroxybenzyl ]] adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Finally, molecular modeling and (1)H- and (13)C-NMR studies performed on compounds 6c,d, 9c, and 10b allowed the right conformation of << nitrooxyalkyl ester and ether >> side chain of these molecules within the [[ COX-2 ]] active site to be assessed.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In competition experiments with << human lung glucocorticoid receptors >> we have determined the relative receptor affinities (RRA) of these substances with reference to [[ dexamethasone ]] (RRA = 100).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Effects of a << serotonin >> [[ serotonin 5-HT(4) receptor ]] antagonist SB-207266 on gastrointestinal motor and sensory function in humans.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "BACKGROUND: << Serotonin >> [[ Serotonin 5-HT(4) receptors ]] are located on enteric cholinergic neurones and may regulate peristalsis.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The selective << alpha(2)-adrenoceptor >> ligand [[ rauwolscine ]] antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against noradrenaline was 8.43.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The selective << alpha(1)-adrenoceptor >> ligands [[ prazosin ]] and doxazosin (each 3 microM) had no effect on noradrenaline responses.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The selective << alpha(1)-adrenoceptor >> ligands prazosin and [[ doxazosin ]] (each 3 microM) had no effect on noradrenaline responses.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The NMR solution structure of the << copper(I) >>-loaded form of [[ hCCSD1 ]] reported here contributes further to characterization of the copper-transfer mechanism to hSOD1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that the first domain of << human CCS >> (hCCSD1) is responsible for [[ copper ]] transfer to its protein partner, human SOD1 (hSOD1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that the first domain of human CCS (<< hCCSD1 >>) is responsible for [[ copper ]] transfer to its protein partner, human SOD1 (hSOD1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that the first domain of human CCS (hCCSD1) is responsible for << copper >> transfer to its protein partner, [[ human SOD1 ]] (hSOD1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that the first domain of human CCS (hCCSD1) is responsible for << copper >> transfer to its protein partner, human SOD1 ([[ hSOD1 ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the << copper >>-transfer process from [[ hCCS ]] to hSOD1.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Together, the information on both hCCS and hSOD1, along with a sequence analysis of eukaryotic CCSD1, allows us to propose important mechanistic aspects regarding the << copper >>-transfer process from hCCS to [[ hSOD1 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mechanistic Aspects of << hSOD1 >> Maturation from the Solution Structure of [[ Cu(I) ]] -Loaded hCCS Domain 1 and Analysis of Disulfide-Free hSOD1 Mutants.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mechanistic Aspects of hSOD1 Maturation from the Solution Structure of << Cu(I) >> -Loaded [[ hCCS Domain 1 ]] and Analysis of Disulfide-Free hSOD1 Mutants.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Consistent with its selectivity for << 5HT1B/1D >> receptors, [[ zolmitriptan ]] produces constriction of various isolated blood vessels, most notably cranial arteries.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To examine the interaction of S100A4 with TFP, we determined the 2.3 A crystal structure of human Ca(2+)-<< S100A4 >> bound to [[ TFP ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two << TFP >> molecules bind within the hydrophobic target binding pocket of Ca(2+)-[[ S100A4 ]] with no significant conformational changes observed in the protein upon complex formation.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "NMR chemical shift perturbations are consistent with the crystal structure and demonstrate that << TFP >> binds to the target binding cleft of [[ S100A4 ]] in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Remarkably, << TFP >> binding results in the assembly of five Ca(2+)-[[ S100A4 ]]/TFP dimers into a tightly packed pentameric ring.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Within each pentamer most of the contacts between << S100A4 >> dimers occurs through the [[ TFP ]] moieties.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The Ca(2+)-<< S100A4 >>/[[ prochlorperazine ]] (PCP) complex exhibits a similar pentameric assembly.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The Ca(2+)-<< S100A4 >>/prochlorperazine ([[ PCP ]]) complex exhibits a similar pentameric assembly.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Equilibrium sedimentation and cross-linking studies demonstrate the cooperative formation of a similarly sized << S100A4 >>/[[ TFP ]] oligomer in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pentosan polysulfate << sodium >> (PPS) has been shown to exert antitumor activity by antagonizing the binding of [[ bFGF ]] to cell surface receptors.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cerebral << histamine H1 receptor >> (H(1)R) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [[ [(11)C]-doxepin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cerebral histamine H1 receptor (<< H(1)R >>) binding was measured in 10 patients with major depression and in 10 normal age-matched subjects using PET and [[ [(11)C]-doxepin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Analysis of coenzyme binding by << human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase >> and steroid 5----4-ene-isomerase using [[ 5'-[p-(fluorosulfonyl)benzoyl]adenosine ]], an affinity labeling cofactor analog.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Analysis of coenzyme binding by human placental 3 beta-hydroxy-5-ene-steroid dehydrogenase and << steroid 5----4-ene-isomerase >> using [[ 5'-[p-(fluorosulfonyl)benzoyl]adenosine ]], an affinity labeling cofactor analog.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In mature lung tissue of healthy donors, << polySia >> was exclusively attached to the transmembrane isoform [[ NCAM-140 ]] and located to intracellular compartments of epithelial cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As shown in a cell culture model, << polySia >>-[[ NCAM-140 ]] was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1Î² or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Interestingly, << polySia >> chains of secreted [[ NCAM ]] neutralized the cytotoxic activity of extracellular histones as well as DNA/histone-network-containing \"neutrophil extracellular traps\", which are formed during invasion of microorganisms.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We provide STD NMR data which confirms a physical interaction between << LolA >> and the thiourea degradation product of [[ MAC13243 ]], with a Kd of ~150 Î¼M.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We provide STD NMR data which confirms a physical interaction between << LolA >> and the [[ thiourea ]] degradation product of MAC13243, with a Kd of ~150 Î¼M.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Taken together, we conclude that the << thiourea >> series of compounds share a similar cellular mechanism that includes interaction with [[ LolA ]] in addition to the well-characterized target MreB.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Taken together, we conclude that the << thiourea >> series of compounds share a similar cellular mechanism that includes interaction with LolA in addition to the well-characterized target [[ MreB ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Studies over the past decades suggest that, besides << cyclooxygenases >>, [[ aspirin ]] acetylates other cellular proteins.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Dopamine D2-receptor >> imaging with [[ 123I-iodobenzamide ]] SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two migraine patients were studied by in vivo SPECT using the << dopamine D2-receptor >> specific radioligand [[ 123I-3-iodo-6-methoxybenzamide ]] (123I-IBZM) during ergotamine abuse and after withdrawal.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Two migraine patients were studied by in vivo SPECT using the << dopamine D2-receptor >> specific radioligand 123I-3-iodo-6-methoxybenzamide ([[ 123I-IBZM ]]) during ergotamine abuse and after withdrawal.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Clinical effects of pranlukast, an oral << leukotriene >> [[ leukotriene receptor ]] antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pranlukast is a new, orally active, selective inhibitor of << CysLt1 >> [[ leukotriene ]] receptor.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pranlukast is a new, orally active, selective inhibitor of CysLt1 << leukotriene >> [[ leukotriene receptor ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer modeling suggests that the << KIT >>D816V mutation destabilizes the inactive conformation of the KIT activation loop to which [[ imatinib ]] binds, but it is not predicted to impair binding of KIT by dasatinib.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the << KIT activation loop >> to which [[ imatinib ]] binds, but it is not predicted to impair binding of KIT by dasatinib.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which << imatinib >> binds, but it is not predicted to impair binding of [[ KIT ]] by dasatinib.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer modeling suggests that the << KIT >>D816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of KIT by [[ dasatinib ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer modeling suggests that the KITD816V mutation destabilizes the inactive conformation of the KIT activation loop to which imatinib binds, but it is not predicted to impair binding of << KIT >> by [[ dasatinib ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Incubation of rat aortic membranes with the irreversible << alpha 1B-adrenoceptor >> antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [[ [3H]-prazosin ]] binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cembranoid and << long-chain alkanol >> sites on the [[ nicotinic acetylcholine receptor ]] and their allosteric interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cembranoid >> and long-chain alkanol sites on the [[ nicotinic acetylcholine receptor ]] and their allosteric interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Long-chain alkanols >> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the [[ AChR ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Synthesis, radiosynthesis, and biological evaluation of << carbon-11 labeled 2beta-carbomethoxy-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes >>: candidate radioligands for in vivo imaging of the [[ serotonin transporter ]] with positron emission tomography.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Chase studies with << citalopram >> and methylphenidate demonstrated that this uptake is the result of preferential binding to the [[ SERT ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Chase studies with citalopram and << methylphenidate >> demonstrated that this uptake is the result of preferential binding to the [[ SERT ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane >> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([[ SERT ]], DAT, and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<< mZIENT >>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([[ SERT ]], DAT, and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and << 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane >> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([[ SERT ]], DAT, and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<< mZBrENT >>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters ([[ SERT ]], DAT, and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane >> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [[ DAT ]], and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<< mZIENT >>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [[ DAT ]], and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and << 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane >> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [[ DAT ]], and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<< mZBrENT >>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, [[ DAT ]], and NET, respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane >> (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [[ NET ]], respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (<< mZIENT >>, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [[ NET ]], respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and << 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane >> (mZBrENT, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [[ NET ]], respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "2beta-carbomethoxy-3beta-(3'-((Z)-2-iodoethenyl)phenyl)nortropane (mZIENT, 1) and 2beta-carbomethoxy-3beta-(3'-((Z)-2-bromoethenyl)phenyl)nortropane (<< mZBrENT >>, 2) were synthesized and evaluated for binding to the human serotonin, dopamine, and norepinephrine transporters (SERT, DAT, and [[ NET ]], respectively) using transfected cells.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Characterization of << 5-hydroxytryptamine1B >> receptors in rat spinal cord via [[ [125I]iodocyanopindolol ]] binding and inhibition of [3H]-5-hydroxytryptamine release.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Structure of << acetylcholinesterase >> complexed with [[ (-)-galanthamine ]] at 2.3 A resolution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVE: << Fondaparinux sodium >> is the first in a new class of synthetic factor Xa inhibitors that binds reversibly with high affinity to [[ antithrombin III ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "RATIONALE: There is substantial evidence that << lisuride >> can produce effects linked to [[ 5-HT(1A) ]] receptor occupancy.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These conclusions are surprising when one considers that the potent interaction of << lisuride >> with [[ 5-HT(1A) ]] receptors has been demonstrated in several different laboratories and that activation of 5-HT(1A) and 5-HT(1B) receptors can modulate dopaminergically mediated responses.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << tetra-aspartate motif >> in the trypsinogen activation peptide binds [[ calcium ]] (KD ~1.6 mM), which stimulates autoactivation.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In untrained and trained treated animals with the amnesic dose (1.0mg/kg) of << METH >> [[ SERT ]] binding in several areas including hippocampus and cortex decreased, more remarkably in the trained animals.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< beta2AR >> density measured with [[ [3H]dihydroalprenolol ]] ([3H]DHA) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< beta2AR >> density measured with [3H]dihydroalprenolol ([[ [3H]DHA ]]) increased either 13- or 77-fold in infected cells compared to mock infected controls depending on the culture conditions used.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << [3H]DHA >> binding was to a single receptor population with a dissociation constant of 0.42 nM, as would be expected for wild-type [[ beta2AR ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: << isoproterenol >>>epinephrine> norepinephrine, consistent with [[ beta2AR ]] interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol><< epinephrine >>> norepinephrine, consistent with [[ beta2AR ]] interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Agonist competition assays with [3H]DHA showed the following rank order of potency: isoproterenol>epinephrine> << norepinephrine >>, consistent with [[ beta2AR ]] interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Agonist competition assays with << [3H]DHA >> showed the following rank order of potency: isoproterenol>epinephrine> norepinephrine, consistent with [[ beta2AR ]] interaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mice given daily injections of high dose JZL184 (â¥16 mg/kg) for six days displayed decreased << CB(1) >> receptor density and function in brain, as assessed in [[ [(3)H]SR141716A ]] binding and CP55,940-stimulated [(35)S]GTPÎ³S binding assays, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mice given daily injections of high dose JZL184 (â¥16 mg/kg) for six days displayed decreased << CB(1) >> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and [[ CP55,940 ]]-stimulated [(35)S]GTPÎ³S binding assays, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mice given daily injections of high dose JZL184 (â¥16 mg/kg) for six days displayed decreased << CB(1) >> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [[[ (35)S ]]]GTPÎ³S binding assays, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to << hNET >> occurs at a site that is distinct from but overlaps with the binding sites for [[ tricyclic ]] antidepressants and cocaine.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A comparison of the results with previous data for desipramine and cocaine inhibition of norepinephrine uptake by the mutant hNETs reveals that MrIA binding to << hNET >> occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and [[ cocaine ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Crystal structures of << protein phosphatase-1 >> bound to [[ motuporin ]] and dihydromicrocystin-LA: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Crystal structures of << protein phosphatase-1 >> bound to motuporin and [[ dihydromicrocystin-LA ]]: elucidation of the mechanism of enzyme inhibition by cyanobacterial toxins.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A previous crystal structure of a << microcystin >> bound to the catalytic subunit of [[ protein phosphatase-1 ]] (PP-1c) showed distinct changes in the active site region when compared with protein phosphatase-1 structures bound to other toxins.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A previous crystal structure of a << microcystin >> bound to the catalytic subunit of protein phosphatase-1 ([[ PP-1c ]]) showed distinct changes in the active site region when compared with protein phosphatase-1 structures bound to other toxins.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We have elucidated the crystal structures of the cyanotoxins, << motuporin >> (nodularin-V) and dihydromicrocystin-LA bound to [[ human protein phosphatase-1c (gamma isoform) ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We have elucidated the crystal structures of the cyanotoxins, motuporin (<< nodularin-V >>) and dihydromicrocystin-LA bound to [[ human protein phosphatase-1c (gamma isoform) ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We have elucidated the crystal structures of the cyanotoxins, motuporin (nodularin-V) and << dihydromicrocystin-LA >> bound to [[ human protein phosphatase-1c (gamma isoform) ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which << microcystins >> but not nodularins permanently modify their [[ protein phosphatase ]] targets by covalent addition to an active site cysteine residue.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, at << guinea-pig and mouse splenic alpha 1B-adrenoceptors >>, the affinity values of [[ risperidone ]] were 10-fold lower than those of prazosin.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, at << guinea-pig and mouse splenic alpha 1B-adrenoceptors >>, the affinity values of risperidone were 10-fold lower than those of [[ prazosin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand [[ 125I-BE2254 ]] showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are [[ CEC ]] sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for [[ WB4101 ]] (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Radioligand binding studies with the nonselective << alpha 1-adrenoceptor >> antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for [[ 5-methylurapidil ]] (pKd = 7.1).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that << alpha 1-adrenoceptor >> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both [[ WB4101 ]] and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that << alpha 1-adrenoceptor >> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and [[ 5-methyl-urapidil ]]), which was in good agreement with radioligand binding studies.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Similar to << cocaine >>, other local anesthetics bind to the [[ dopamine transporter ]] (DAT) and inhibit DA uptake in rodent and monkey brain.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< DAT >> occupancy was determined by displacement of [[ 8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane ]] (FECNT).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< DAT >> occupancy was determined by displacement of 8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane ([[ FECNT ]]).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Similar to << cocaine >>, other local anesthetics bind to the dopamine transporter ([[ DAT ]]) and inhibit DA uptake in rodent and monkey brain.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< DAT >> occupancy was between 66 and 82% and <10-41% for doses of [[ dimethocaine ]] and procaine that maintained maximum response rates, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< DAT >> occupancy was between 66 and 82% and <10-41% for doses of dimethocaine and [[ procaine ]] that maintained maximum response rates, respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "There was close correspondence between peak increases in << DA >> and [[ DAT ]] occupancy.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as << TO901317 >> and retinoic acid, which are ligands of the [[ nuclear receptors ]] LXR/RXR.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as << TO901317 >> and retinoic acid, which are ligands of the nuclear receptors [[ LXR ]]/RXR.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as << TO901317 >> and retinoic acid, which are ligands of the nuclear receptors LXR/[[ RXR ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and << retinoic acid >>, which are ligands of the [[ nuclear receptors ]] LXR/RXR.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and << retinoic acid >>, which are ligands of the nuclear receptors [[ LXR ]]/RXR.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and << retinoic acid >>, which are ligands of the nuclear receptors LXR/[[ RXR ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we have now found that activation of p38 MAPK by << anisomycin >> potentiated induction of CYP2B6 mRNA by [[ CAR ]] ligand in HepG2 cells to levels observed in ligand-treated human primary hepatocytes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Interaction of << human alpha-lactalbumin >> with [[ fatty acids ]]: determination of binding parameters.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The interaction of holo- and apo-forms of << human alpha-lactalbumin >> with [[ fatty acids ]] was studied by a partition equilibrium method.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Apo-alpha-lactalbumin >>, obtained by treatment with EDTA, displays one binding site for [[ fatty acids ]], the association constants for oleic and palmitic acids being 1.9.10(6) and 4.2.10(5) M(-1), respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Apo-alpha-lactalbumin >>, obtained by treatment with EDTA, displays one binding site for fatty acids, the association constants for [[ oleic and palmitic acids ]] being 1.9.10(6) and 4.2.10(5) M(-1), respectively.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We propose that << Cu(I) >> binds the [[ type-1 copper ion-binding site ]] in the A1 domain and provides the essential requirement for a stable interaction between the heavy and light chains.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We propose that << Cu(I) >> binds the type-1 copper ion-binding site in the [[ A1 domain ]] and provides the essential requirement for a stable interaction between the heavy and light chains.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Both << myosin-18A >> isoforms bound [[ N-methylanthraniloyl-nucleotides ]], but the rate of ATP hydrolysis was very slow (<0.002 s(-1)) and not significantly enhanced by actin.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The non-competitive blocker site of the << GABA-gated chloride ion channel >> in normal susceptible strains of Drosophila melanogaster and simulans binds [[ 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate ]] ([3H]EBOB) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The non-competitive blocker site of the << GABA-gated chloride ion channel >> in normal susceptible strains of Drosophila melanogaster and simulans binds 4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate ([[ [3H]EBOB ]]) at specific sites with KdS of 1.6-1.9 nM and BmaxS of 171-181 fmol/mg protein.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Drosophila GABA-gated chloride channel >>: modified [[ [3H]EBOB ]] binding site associated with Ala-->Ser or Gly mutants of Rdl subunit.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << ganglioside >>-bound [[ AÎ² ]] (GAÎ²), which acts as an endogenous seed for AÎ² fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << ganglioside >>-bound AÎ² (G[[ AÎ² ]]), which acts as an endogenous seed for AÎ² fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Galantamine >> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of [[ nicotinic acetylcholine receptors ]] (nAChR-APL) that shares many common structural elements with morphinan-based opioids.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Galantamine >> is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors ([[ nAChR ]]-APL) that shares many common structural elements with morphinan-based opioids.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids << codeine >> and eseroline, like galantamine, are also [[ nAChR ]]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids codeine and << eseroline >>, like galantamine, are also [[ nAChR ]]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids codeine and eseroline, like << galantamine >>, are also [[ nAChR ]]-APL that have greatly diminished affinity for AChE, representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids << codeine >> and eseroline, like galantamine, are also nAChR-APL that have greatly diminished affinity for [[ AChE ]], representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids codeine and << eseroline >>, like galantamine, are also nAChR-APL that have greatly diminished affinity for [[ AChE ]], representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The structurally diverse opioids codeine and eseroline, like << galantamine >>, are also nAChR-APL that have greatly diminished affinity for [[ AChE ]], representing potential lead compounds for selective nAChR-APL development.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Discovery and optimization of << anthranilic acid sulfonamides >> as inhibitors of [[ methionine aminopeptidase-2 ]]: a structural basis for the reduction of albumin binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As part of an effort to discover orally active reversible inhibitors of << MetAP2 >>, a series of [[ anthranilic acid sulfonamides ]] with micromolar affinities for human MetAP2 were identified using affinity selection by mass spectrometry (ASMS) screening.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As part of an effort to discover orally active reversible inhibitors of MetAP2, a series of << anthranilic acid sulfonamides >> with micromolar affinities for [[ human MetAP2 ]] were identified using affinity selection by mass spectrometry (ASMS) screening.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Fibrates >> bind to the [[ peroxisome proliferator-activated receptor (PPAR)-alpha ]], and thiazolidinediones are ligands of PPAR-gamma.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)-alpha, and << thiazolidinediones >> are ligands of [[ PPAR-gamma ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To elucidate the target genes regulated by these compounds, we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR-alpha-specific compound, fenofibrate, a << PPAR-gamma >>-specific ligand, [[ rosiglitazone ]], and a PPAR-alpha/-gamma coagonist, GW2331, and measured the levels of several messenger RNAs (mRNAs) in liver by real-time polymerase chain reaction.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A receptor binding assay using rat forebrain and spinal cord membrane preparations demonstrated that << [3H]CP-101,606 >> bound to the brain [[ NR2B ]] receptor with a greater extent compared to the spinal cord one.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the active << MalP >> enzyme, the residue Arg569 stabilizes the negative-charged [[ Glc1P ]], whereas in the inactive form of GP this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The comparison between << MalP >> structures shows that His377, through a hydrogen bond with the 6-hydroxyl group of [[ Glc1P ]] substrate, triggers a conformational change of the 380s loop.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The comparison between << MalP >> structures shows that His377, through a hydrogen bond with the [[ 6-hydroxyl ]] group of Glc1P substrate, triggers a conformational change of the 380s loop.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The interaction of << naloxone estrone azine >> (N-EH) with various [[ opioid receptor ]] types was studied in vitro.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The interaction of naloxone estrone azine (<< N-EH >>) with various [[ opioid receptor ]] types was studied in vitro.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and << GTX2,3-aldehyde >>- [[ keyhole limpet hemocyanin ]] (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens GTX2,3-aldehyde-bovine serum albumin (BSA) and << GTX2,3-aldehyde >>- keyhole limpet hemocyanin ([[ KLH ]]) were then prepared by cross-linking the intermediate with BSA or KLH.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens << GTX2,3-aldehyde >>-[[ bovine serum albumin ]] (BSA) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An intermediate GTX2,3-aldehyde was first synthesized by activating the NH2 group of the 2nd and 8th amino acid residues with three different aldehydes and two artificial complete antigens << GTX2,3-aldehyde >>-bovine serum albumin ([[ BSA ]]) and GTX2,3-aldehyde- keyhole limpet hemocyanin (KLH) were then prepared by cross-linking the intermediate with BSA or KLH.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (<< prostaglandin H2 >>) mimic (U46619) to the engineered [[ prostacyclin (PGI2) synthase ]] (PGIS) in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<< U46619 >>) to the engineered [[ prostacyclin (PGI2) synthase ]] (PGIS) in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (<< prostaglandin H2 >>) mimic (U46619) to the engineered prostacyclin (PGI2) synthase ([[ PGIS ]]) in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High-resolution NMR spectroscopy was used to determine the docking of a substrate (prostaglandin H2) mimic (<< U46619 >>) to the engineered prostacyclin (PGI2) synthase ([[ PGIS ]]) in solution.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The binding of << U46619 >> to the [[ PGIS ]] protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The binding of U46619 to the PGIS protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of U46619 were observed upon << U46619 >> binding to the engineered [[ PGIS ]] in a concentration-dependent manner.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The detailed conformational change and 3D structure of the << PGIS >>-bound [[ U46619 ]] were further demonstrated by 2D 1H NMR experiments using the transferred NOE technique.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The bound conformation of << U46619 >> fits the crystal structure of the [[ PGIS ]] substrate binding pocket considerably better than that of the unbound U46619.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the << PGIS >>-bound form of [[ U46619 ]] and the PGIS crystal structure.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "For example, Trp282 could be one of the most important residues and is suspected to play a role in the determination of specific catalytic function, which has been established by the docking studies using the NMR structure of the PGIS-bound form of << U46619 >> and the [[ PGIS ]] crystal structure.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The noted conformational changes where the C-6 position is closer to the C-9 position of << U46619 >> provided the first experimental data for understanding the molecular mechanism of the catalytic function of [[ PGIS ]] in the isomerization of PGH2 to prostacyclin.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Beta 2-Adrenoceptor density, however, declined slowly being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h. The affinity of << ICYP >> to [[ beta 2-adrenoceptors ]] was not changed during or after treatment.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Tamoxifen >> blocks the action of estrogen by binding to the [[ ER ]], and possesses both ER-agonist and antagonist properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Tamoxifen blocks the action of << estrogen >> by binding to the [[ ER ]], and possesses both ER-agonist and antagonist properties.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Structural basis for LFA-1 inhibition upon << lovastatin >> binding to the [[ CD11a I-domain ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Losartan >> (parent compound), has moderate affinity for the [[ AT(1) receptor ]] (competitive inhibition).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Losartan >> is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the [[ AT(1) receptor ]] (non-competitive inhibition).", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Transfection of the brain cDNA into COS-1 cells resulted in transporter activity that was blocked by the VMAT inhibitor reserpine and a proton ionophore, but not by << tetrabenazine >>, which has a high affinity for [[ VMAT-2 ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "METHOD: The authors conducted a PET study to evaluate << D(2) >> occupancy (using [[ [(11)C]raclopride ]]) and 5-HT(2) occupancy (using [(18)F]setoperone) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVE: << Ziprasidone >> is an atypical antipsychotic drug that shows a higher affinity for serotonin [[ 5-HT(2) receptors ]] compared with dopamine D(2) receptors in vitro.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVE: << Ziprasidone >> is an atypical antipsychotic drug that shows a higher affinity for serotonin 5-HT(2) receptors compared with [[ dopamine D(2) receptors ]] in vitro.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "METHOD: The authors conducted a PET study to evaluate D(2) occupancy (using [(11)C]raclopride) and << 5-HT(2) >> occupancy (using [[ [(18)F]setoperone ]]) in brain regions of interest in 16 patients with schizophrenia or schizoaffective disorder randomly assigned to receive 40, 80, 120, or 160 mg/day of ziprasidone, which reflected the recommended dose range.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The estimated plasma << ziprasidone >> concentration associated with 50% maximal [[ 5-HT(2) ]] receptor occupancy was almost four times lower than that for D(2) receptor occupancy.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The estimated plasma << ziprasidone >> concentration associated with 50% maximal 5-HT(2) receptor occupancy was almost four times lower than that for [[ D(2) receptor ]] occupancy.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: These data affirm that << ziprasidone >> is similar to other novel antipsychotics in having greater [[ 5-HT(2) ]] than D(2) receptor occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasidone is closer to 120 mg/day than to the lower doses suggested by previous PET studies.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: These data affirm that << ziprasidone >> is similar to other novel antipsychotics in having greater 5-HT(2) than [[ D(2) receptor ]] occupancy at therapeutic doses and suggest that the optimal effective dose of ziprasidone is closer to 120 mg/day than to the lower doses suggested by previous PET studies.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The relatively high << D(2) receptor >> occupancy, even at trough plasma levels, suggests that [[ ziprasidone ]] is more similar to risperidone and olanzapine in receptor occupancy profile than to clozapine and quetiapine.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The relatively high << D(2) receptor >> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to [[ risperidone ]] and olanzapine in receptor occupancy profile than to clozapine and quetiapine.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The relatively high << D(2) receptor >> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to risperidone and olanzapine in receptor occupancy profile than to [[ clozapine ]] and quetiapine.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The relatively high << D(2) receptor >> occupancy, even at trough plasma levels, suggests that ziprasidone is more similar to risperidone and olanzapine in receptor occupancy profile than to clozapine and [[ quetiapine ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Characteristics of the binding of << phenoxybenzamine >> to [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To determine the factors that influence the interaction between << phenoxybenzamine >> and [[ calmodulin ]], the binding of phenoxybenzamine to calmodulin was determined by equilibrium dialysis under a variety of experimental conditions.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To determine the factors that influence the interaction between phenoxybenzamine and calmodulin, the binding of << phenoxybenzamine >> to [[ calmodulin ]] was determined by equilibrium dialysis under a variety of experimental conditions.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This interaction was found to be similar in some respects to the interaction between << phenothiazines >> and [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The site at which << phenoxybenzamine >> bound to [[ calmodulin ]] appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to calmodulin.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and spiroperidol, prevented the binding of << phenoxybenzamine >> to [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including << penfluridol >>, pimozide and spiroperidol, prevented the binding of phenoxybenzamine to [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, << pimozide >> and spiroperidol, prevented the binding of phenoxybenzamine to [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The site at which phenoxybenzamine bound to calmodulin appears to be similar to that at which certain antipsychotic agents bind, since several of them, including penfluridol, pimozide and << spiroperidol >>, prevented the binding of phenoxybenzamine to [[ calmodulin ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, in contrast to the reversible binding of most << phenothiazines >> to [[ calmodulin ]], phenoxybenzamine bound to calmodulin irreversibly.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, in contrast to the reversible binding of most phenothiazines to calmodulin, << phenoxybenzamine >> bound to [[ calmodulin ]] irreversibly.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The binding of << phenoxybenzamine >> to [[ calmodulin ]] was fairly selective in that other alpha-adrenergic agents such as prazosin, yohimbine and clonidine failed to bind to calmodulin when examined under the same experimental conditions.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In addition, phenoxybenzamine showed little or no << calcium >>-dependent binding to the S-100 protein, bovine serum albumin or [[ cytochrome c ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In addition, phenoxybenzamine showed little or no calcium-dependent binding to the S-100 protein, bovine serum albumin or cytochrome c. The irreversible complex between << phenoxybenzamine >> and [[ calmodulin ]] may be useful for inhibiting certain calmodulin-dependent reactions and for studying the various biological functions of calmodulin.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Accordingly, in transfection experiments performed in TPC1 cells, treatment with << PJ34 >> increased NIS promoter activity without affecting [[ PARP-1 ]] binding to the promoter sequence.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The folding rate monitored by << 2'CMP >> binding to the major slow-folding species of [[ Pro42Ala ]] RNase A is faster than the folding rate monitored by tyrosine burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The folding rate monitored by << 2'CMP >> binding to the major slow-folding species of Pro42Ala [[ RNase A ]] is faster than the folding rate monitored by tyrosine burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The folding rate monitored by 2'CMP binding to the major slow-folding species of << Pro42Ala >> RNase A is faster than the folding rate monitored by [[ tyrosine ]] burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The folding rate monitored by 2'CMP binding to the major slow-folding species of Pro42Ala << RNase A >> is faster than the folding rate monitored by [[ tyrosine ]] burial; however, the folding rate monitored by inhibitor binding to the minor slow-folding species is decreased significantly over the folding rate monitored by tyrosine burial, indicating that the major and minor slow-folding species of Pro42Ala fold to the native state with different transition-state conformations in the rate-determining step.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Folding pathway of guanidine-denatured << disulfide >>-intact wild-type and mutant [[ bovine pancreatic ribonuclease A ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The refolding kinetics of guanidine-denatured << disulfide >>-intact [[ bovine pancreatic ribonuclease A ]] (RNase A) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The refolding kinetics of guanidine-denatured << disulfide >>-intact bovine pancreatic ribonuclease A ([[ RNase A ]]) and its proline-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ka values in nM for << rauwolscine >> (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [[ alpha-2D adrenoceptor ]] subtype.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ka values in nM for rauwolscine (19), << WB-4101 >> (265), SKF-104078 (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [[ alpha-2D adrenoceptor ]] subtype.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ka values in nM for rauwolscine (19), WB-4101 (265), << SKF-104078 >> (197), spiroxatrine (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [[ alpha-2D adrenoceptor ]] subtype.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), << spiroxatrine >> (128), and prazosin (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [[ alpha-2D adrenoceptor ]] subtype.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ka values in nM for rauwolscine (19), WB-4101 (265), SKF-104078 (197), spiroxatrine (128), and << prazosin >> (1531) for blocking relaxation in rat arteries were consistent with their affinities for binding at the [[ alpha-2D adrenoceptor ]] subtype.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Structural features of the central cannabinoid << CB1 >> receptor involved in the binding of the specific CB1 antagonist [[ SR 141716A ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The antagonist << SR 141716A >> has a high specificity for the central [[ CB1 ]] cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The antagonist << SR 141716A >> has a high specificity for the central CB1 [[ cannabinoid receptor ]] and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The region delineated by the fourth and fifth transmembrane helices of << CB1 >> proved to be crucial for high affinity binding of [[ SR 141716A ]].", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on << SR 141716A >> binding in the [[ CB1 ]] variant but that eliminated CP 55,940 binding in both mutants.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << e2 domain >> thus plays some role in [[ CP 55,940 ]] binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << e2 domain >> thus plays some role in CP 55,940 binding but none in [[ SR 141716A ]] recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.", "metadata": [], "label": "DIRECT-REGULATOR", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that << nicotinate >> uptake by rat astrocytes is mediated by H(+)-coupled [[ monocarboxylate transport system ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that << nicotinate >> uptake in rat astrocytes is mediated by [[ MCT1 ]] and/or MCT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that << nicotinate >> uptake in rat astrocytes is mediated by MCT1 and/or [[ MCT2 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown << H(+)-coupled monocarboxylate transport system >>, for [[ nicotinate ]] in rat cerebrocortical astrocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a << low-affinity monocarboxylate transporter >> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for [[ nicotinate ]] in rat cerebrocortical astrocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter << MCT4 >> or other unknown H(+)-coupled monocarboxylate transport system, for [[ nicotinate ]] in rat cerebrocortical astrocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< PDE5 >> is the predominant PDE in the corpus cavernosum, and [[ cGMP ]] is its primary substrate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PDE5 is the predominant << PDE >> in the corpus cavernosum, and [[ cGMP ]] is its primary substrate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Furthermore, MDZ caused mechanism-based inactivation of << cytochrome P450 3A >>-dependent [[ TRZ ]] 1'-hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated << cysteine S-conjugates >> are metabolized by cysteine S-conjugate [[ beta-lyases ]] to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound << MgATP >> at [[ NBF2 ]], stabilizes prebound 8-azido-ATP binding at NBF1.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of << arylhydroxylamine >> carcinogens was catalyzed by [[ NADH cytochrome b5 reductase ]] (b5R) and cytochrome b5 (cyt b5).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of << arylhydroxylamine >> carcinogens was catalyzed by NADH cytochrome b5 reductase ([[ b5R ]]) and cytochrome b5 (cyt b5).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of << arylhydroxylamine >> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and [[ cytochrome b5 ]] (cyt b5).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "On the basis of our findings with structurally similar arylhydroxylamine metabolites of therapeutic drugs, we hypothesized that the reductive detoxification of << arylhydroxylamine >> carcinogens was catalyzed by NADH cytochrome b5 reductase (b5R) and cytochrome b5 ([[ cyt b5 ]]).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic << hydroxylamines >> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic << hydroxylamines >> of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the << aromatic amine >> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the << aromatic amine >> 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine << 4-aminobiphenyl >> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine << 4-aminobiphenyl >> (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<< 4-ABP >>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (<< 4-ABP >>; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the << heterocyclic amine >> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the << heterocyclic amine >> 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine << 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine >> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine << 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine >> (PhIP; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reductive detoxification of << arylhydroxylamine >> carcinogens by human NADH cytochrome b5 reductase and [[ cytochrome b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reductive detoxification of << arylhydroxylamine >> carcinogens by [[ human NADH cytochrome b5 reductase ]] and cytochrome b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<< PhIP >>; found in grilled meats) was indeed catalyzed by a purified system containing only [[ human b5R ]] and cyt b5.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We found that reduction of the carcinogenic hydroxylamines of the aromatic amine 4-aminobiphenyl (4-ABP; found in cigarette smoke) and the heterocyclic amine 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (<< PhIP >>; found in grilled meats) was indeed catalyzed by a purified system containing only human b5R and [[ cyt b5 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Polyclonal antisera to either << b5R >> or cyt b5 significantly inhibited [[ N-hydroxy-4-aminobiphenyl ]] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Polyclonal antisera to either b5R or << cyt b5 >> significantly inhibited [[ N-hydroxy-4-aminobiphenyl ]] (NHOH-4-ABP) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Polyclonal antisera to either << b5R >> or cyt b5 significantly inhibited N-hydroxy-4-aminobiphenyl ([[ NHOH-4-ABP ]]) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Polyclonal antisera to either b5R or << cyt b5 >> significantly inhibited N-hydroxy-4-aminobiphenyl ([[ NHOH-4-ABP ]]) reduction by 95 and 89%, respectively, and immunoreactive cyt b5 protein content in individual HLM was significantly correlated with individual reduction of both NHOH-4-ABP and N-hydroxy-PhIP (NHOH-PhIP).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << tyrosine >> [[ tyrosine kinase ]] inhibitor ZD1839 (\"Iressa\") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These studies suggest that HER2-overexpressing tumors are particularly susceptible to the inhibition of HER family << tyrosine >> [[ tyrosine kinase ]] signaling and suggest novel strategies to treat these particularly aggressive tumors.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "ZD1839 (\"Iressa\"), a << quinazoline tyrosine >> [[ tyrosine kinase ]] inhibitor selective for the EGFR, has shown good activity in preclinical studies and in the early phase of clinical trials.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Growth inhibition of these tumor cell lines was associated with the dephosphorylation of EGFR, HER2, and HER3, accompanied by the loss of association of HER3 with << phosphatidylinositol >> [[ phosphatidylinositol 3-kinase ]], and down-regulation of Akt activity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the [[ neutral amino acid transporters ]] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the [[ neutral amino acid transporters ]] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the [[ neutral amino acid transporters ]] of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the [[ solute carrier 1 ]] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the [[ solute carrier 1 ]] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the [[ solute carrier 1 ]] [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[[ SLC1 ]], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[[ SLC1 ]], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [[[ SLC1 ]], alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [[ alanine serine cysteine transporter 1 ]] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([[ ASCT1 ]]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [[ ASCT2 ]]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and [[ SLC38 ]] families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[[ sodium-coupled neutral amino acid transporter 1 ]] (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([[ SNAT1 ]]), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [[ SNAT2 ]], and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral << amino acids >>, such as glutamine and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [[ SNAT4 ]]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [[ alanine serine cysteine transporter 1 ]] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([[ ASCT1 ]]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [[ ASCT2 ]]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and [[ SLC38 ]] families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[[ sodium-coupled neutral amino acid transporter 1 ]] (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([[ SNAT1 ]]), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [[ SNAT2 ]], and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as << glutamine >> and alanine, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [[ SNAT4 ]]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, [[ alanine serine cysteine transporter 1 ]] (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 ([[ ASCT1 ]]), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and [[ ASCT2 ]]] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [[[ sodium-coupled neutral amino acid transporter 1 ]] (SNAT1), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 ([[ SNAT1 ]]), SNAT2, and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), [[ SNAT2 ]], and SNAT4].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Na+-Dependent transmembrane transport of small neutral amino acids, such as glutamine and << alanine >>, is mediated, among others, by the neutral amino acid transporters of the solute carrier 1 [SLC1, alanine serine cysteine transporter 1 (ASCT1), and ASCT2] and SLC38 families [sodium-coupled neutral amino acid transporter 1 (SNAT1), SNAT2, and [[ SNAT4 ]]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile << alanine >> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [[ ASCT2 ]], SNAT1, and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile << alanine >> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [[ SNAT1 ]], and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile << alanine >> derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [[ SNAT2 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of << alanine >> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [[ ASCT2 ]], SNAT1, and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of << alanine >> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [[ SNAT2 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of << alanine >> with the 4-methoxy-7-nitroindolinyl (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [[ SNAT1 ]], and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the << 4-methoxy-7-nitroindolinyl >> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [[ ASCT2 ]], SNAT1, and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<< MNI >>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by [[ ASCT2 ]], SNAT1, and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the << 4-methoxy-7-nitroindolinyl >> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [[ SNAT2 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<< MNI >>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, SNAT1, and [[ SNAT2 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the << 4-methoxy-7-nitroindolinyl >> (MNI) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [[ SNAT1 ]], and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we describe a new photolabile alanine derivative based on protection of alanine with the 4-methoxy-7-nitroindolinyl (<< MNI >>) caging group, which we use for pre-steady-state kinetic analysis of alanine transport by ASCT2, [[ SNAT1 ]], and SNAT2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVES: The hypothesis of the present study was that differences among << dopamine transporter >> (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [[ DA ]] uptake inhibitors.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<< DAT >>) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as [[ DA ]] uptake inhibitors.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Accordingly, self-administration of a group of local anesthetics that are << DAT >> ligands was compared to their effects as [[ DA ]] uptake blockers in vitro in brain tissue.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized << NET >> by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the [[ NE ]] reuptake process.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Conclusively, protein malnutrition alters CP, FU and << MMC >> metabolism in rat stomach by enhancing [[ CCBL ]] pathway for CP activation, delaying FU elimination and activating two-electron reduction of MMC, potentiating their gastrotoxicity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The concomitantly administered effects of << rifampicin >> on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by [[ p-glycoprotein ]] in the gastrointestinal tract and liver.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The concomitantly administered effects of << rifampicin >> on other drugs can result in their altered metabolism or transportation that are metabolised by [[ cytochromes P450 ]] or transported by p-glycoprotein in the gastrointestinal tract and liver.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "KIEs were measured on the arsenolysis of << 5'-methylthioadenosine >> (MTA) catalyzed by [[ MTAP ]] and were corrected for the forward commitment to catalysis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "KIEs were measured on the arsenolysis of 5'-methylthioadenosine (<< MTA >>) catalyzed by [[ MTAP ]] and were corrected for the forward commitment to catalysis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In eukaryotes, the most prominent Mo-enzymes are (1) << sulfite oxidase >>, which catalyzes the final step in the degradation of [[ sulfur ]]-containing amino acids and is involved in detoxifying excess sulfite, (2) xanthine dehydrogenase, which is involved in purine catabolism and reactive oxygen production, (3) aldehyde oxidase, which oxidizes a variety of aldehydes and is essential for the biosynthesis of the phytohormone abscisic acid, and in autotrophic organisms also (4) nitrate reductase, which catalyzes the key step in inorganic nitrogen assimilation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, kinetic analysis revealed that inhibition by reserpine, a typical << VMAT2 >> inhibitor, was uncompetitive, decreasing maximum velocity and affinity for [[ dopamine ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The present study examined the effect of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), on << VMAT2 >> activity by measuring adenosine triphosphate-dependent [[ [(3)H]dopamine ]] uptake into synaptic vesicles prepared from rat striatum.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has been claimed that hCTR1, the << human high affinity copper transporter >>, is the major entry pathway for [[ cDDP ]] and related drugs via a mechanism that mimics copper.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has been claimed that << hCTR1 >>, the human high affinity copper transporter, is the major entry pathway for [[ cDDP ]] and related drugs via a mechanism that mimics copper.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We confirm the correlation between higher << hCTR1 >> levels and higher [[ Pt ]]-drug uptake in tumor cells sensitive to the drug.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: << simvastatin >>, lovastatin and atorvastatin are metabolized through [[ cytochrome P450 (CYP) 3A ]], while the metabolism of the other statins is independent of this CYP.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, << lovastatin >> and atorvastatin are metabolized through [[ cytochrome P450 (CYP) 3A ]], while the metabolism of the other statins is independent of this CYP.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and << atorvastatin >> are metabolized through [[ cytochrome P450 (CYP) 3A ]], while the metabolism of the other statins is independent of this CYP.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Simvastatin >> and lovastatin metabolized through [[ CYP3A ]] have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Simvastatin and << lovastatin >> metabolized through [[ CYP3A ]] have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Atorvastatin >> is also a [[ CYP3A ]] substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Therefore, comparative histochemical and biochemical studies of << u-PA >> and the effects of amiloride were performed on rabbit corneas and tear fluid using the sensitive fluorogenic substrate [[ Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the << DAT >> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of DA prevented the MDMA-induced reduction in plasmalemmal [[ DA ]] transport.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Also in contrast to effects of multiple METH injections, 1) MDMA caused little or no decrease in binding of the << DAT >> ligand WIN35428, and 2) neither prevention of hyperthermia nor prior depletion of [[ DA ]] prevented the MDMA-induced reduction in plasmalemmal DA transport.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In addition to affecting << DAT >> function, MDMA rapidly decreased vesicular [[ DA ]] transport as assessed in striatal vesicles prepared from treated rats.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Acetylcholinesterase >> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain [[ acetylcholine ]] (ACh) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (<< AChE >>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain [[ acetylcholine ]] (ACh) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with << butyrylcholinesterase >> (BuChE) considered to play a minor role in regulating brain [[ acetylcholine ]] (ACh) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<< BuChE >>) considered to play a minor role in regulating brain [[ acetylcholine ]] (ACh) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Acetylcholinesterase >> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ([[ ACh ]]) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (<< AChE >>) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine ([[ ACh ]]) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with << butyrylcholinesterase >> (BuChE) considered to play a minor role in regulating brain acetylcholine ([[ ACh ]]) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<< BuChE >>) considered to play a minor role in regulating brain acetylcholine ([[ ACh ]]) levels.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Human serum butyrylcholinesterase (<< HuBChE >>) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [[ organophosphate ]] (OP) nerve agents.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Human serum butyrylcholinesterase >> (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic [[ organophosphate ]] (OP) nerve agents.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The decrease and recovery of << [3H]-5-HT >> uptake correlated highly (r = 0.93) with the recovery of [[ SERT ]] binding.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, << cAMP >> as well as [[ adenylate cyclase ]] activator, forskolin.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The progress of the enzymatic reaction of the hydrolysis of << acetylthiocholine >> at pH 8 in the presence of [[ AChE ]] and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product thiocholine (TCh).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired << pyridoxal kinase >> for the conversion of [[ pyridoxine ]] and pyridoxal to PLP.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired << pyridoxal kinase >> for the conversion of pyridoxine and [[ pyridoxal ]] to PLP.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The enzyme (<< TcCA >>) has a very high catalytic activity for the [[ CO(2) ]] hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The enzyme (TcCA) has a very high catalytic activity for the << CO(2) >> hydration reaction, being similar kinetically to the human (h) isoform [[ hCA II ]], although it is devoid of the His64 proton shuttle.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cat-1 >>, the transporter for the essential [[ amino acids ]], arginine and lysine, is one of the up-regulated genes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cat-1 >>, the transporter for the essential amino acids, [[ arginine ]] and lysine, is one of the up-regulated genes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cat-1 >>, the transporter for the essential amino acids, arginine and [[ lysine ]], is one of the up-regulated genes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Diacylglycerol kinase >> (DGK) catalyzes the conversion of [[ diacylglycerol ]] to phosphatidic acid, making it an attractive candidate for a signal transduction component.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Diacylglycerol kinase (<< DGK >>) catalyzes the conversion of [[ diacylglycerol ]] to phosphatidic acid, making it an attractive candidate for a signal transduction component.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although glutathione S-transferase omega 1 (GSTO1) and << arsenic methyltransferase >> have been shown or thought to catalyze [[ DMAs(V) ]] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although << glutathione S-transferase omega 1 >> (GSTO1) and arsenic methyltransferase have been shown or thought to catalyze [[ DMAs(V) ]] reduction, their role in DMAs(V) reduction in vivo, or in cell extracts is uncertain.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the in vitro model we observed high permeability of << imperatorin >> and isoimperatorin with the [[ P-gp ]]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the in vitro model we observed high permeability of imperatorin and << isoimperatorin >> with the [[ P-gp ]]-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the << P-gp >>-mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of [[ cnidilin ]] with 0.82.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The specific activity of only << ornithine aminotransferase >> (OAT), the rate-limiting enzyme in the conversion of [[ ornithine ]] to proline, increased in 2 weeks of hypertrophy.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The specific activity of only ornithine aminotransferase (<< OAT >>), the rate-limiting enzyme in the conversion of [[ ornithine ]] to proline, increased in 2 weeks of hypertrophy.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phenytoin >> is principally metabolized by [[ CYP2C9 ]], and both are probable substrates of the drug transporter P-glycoprotein.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phenytoin >> is principally metabolized by CYP2C9, and both are probable substrates of the [[ drug transporter ]] P-glycoprotein.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phenytoin >> is principally metabolized by CYP2C9, and both are probable substrates of the drug transporter [[ P-glycoprotein ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We have identified << adenosine deaminase >>, an enzyme involved in [[ purine ]] metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although << acetylcholinesterase >> (AChE) is primarily a hydrolytic enzyme, metabolising the neurotransmitter [[ acetylcholine ]] in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although acetylcholinesterase (<< AChE >>) is primarily a hydrolytic enzyme, metabolising the neurotransmitter [[ acetylcholine ]] in cholinergic synapses, it also has some non-catalytic functions in the brain which are far less well characterised.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including [[ polycyclic aromatic hydrocarbons ]] (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aldo-keto reductases (<< AKRs >>) metabolize a wide range of substrates, including [[ polycyclic aromatic hydrocarbons ]] (PAHs), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ([[ PAHs ]]), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aldo-keto reductases (<< AKRs >>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons ([[ PAHs ]]), generating metabolites (o-quinones) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ([[ o-quinones ]]) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aldo-keto reductases (<< AKRs >>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites ([[ o-quinones ]]) and reactive oxygen species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Despite the importance of << AKRs >> in [[ PAHs ]] metabolism, there are no studies that evaluate, in general human populations, the effect of PAHs on AKRs expression in peripheral blood lymphocytes (PBLs).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each << rCYP >> in the metabolism of [[ elzasonan ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PSMA acts as a glutamate carboxypeptidase (<< GCPII >>) on small molecule substrates, including [[ folate ]], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PSMA acts as a << glutamate carboxypeptidase >> (GCPII) on small molecule substrates, including [[ folate ]], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< PSMA >> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including [[ folate ]], the anticancer drug methotrexate, and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< PSMA >> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug [[ methotrexate ]], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PSMA acts as a << glutamate carboxypeptidase >> (GCPII) on small molecule substrates, including folate, the anticancer drug [[ methotrexate ]], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PSMA acts as a glutamate carboxypeptidase (<< GCPII >>) on small molecule substrates, including folate, the anticancer drug [[ methotrexate ]], and the neuropeptide N-acetyl-l-aspartyl-l-glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< PSMA >> acts as a glutamate carboxypeptidase (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide [[ N-acetyl-l-aspartyl-l-glutamate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "PSMA acts as a << glutamate carboxypeptidase >> (GCPII) on small molecule substrates, including folate, the anticancer drug methotrexate, and the neuropeptide [[ N-acetyl-l-aspartyl-l-glutamate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Elucidation of the << PSMA >> structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate [[ N-acetyl-l-aspartyl-l-glutamate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Using a transient heterologous cell expression system, we find that the transport activities of the << short OATP2B1 >> variant towards substrates [[ estrone sulfate ]] and rosuvastatin are similar to the well-characterized full length variant.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Using a transient heterologous cell expression system, we find that the transport activities of the << short OATP2B1 >> variant towards substrates estrone sulfate and [[ rosuvastatin ]] are similar to the well-characterized full length variant.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface << glucose transporter isoform 4 >> (GLUT4) and [[ glucose ]] uptake.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (<< GLUT4 >>) and [[ glucose ]] uptake.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Bile acid coenzyme A:amino acid N-acyltransferase >> (BAT) is responsible for the amidation of [[ bile acids ]] with the amino acids glycine and taurine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Bile acid coenzyme A:amino acid N-acyltransferase (<< BAT >>) is responsible for the amidation of [[ bile acids ]] with the amino acids glycine and taurine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Ribonucleotide reductase >> (RR) is responsible for the de novo conversion of the [[ ribonucleoside diphosphates ]] to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ribonucleotide reductase (<< RR >>) is responsible for the de novo conversion of the [[ ribonucleoside diphosphates ]] to deoxyribonucleoside diphosphates, which are essential for DNA synthesis and repair.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mechanisms of << cefadroxil >> uptake in the choroid plexus: studies in wild-type and [[ PEPT2 ]] knockout mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The choroid plexus uptake of << [(3)H]cefadroxil >> was studied in [[ peptide transporter 2 ]] (PEPT2) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The choroid plexus uptake of << [(3)H]cefadroxil >> was studied in peptide transporter 2 ([[ PEPT2 ]]) wild-type and null mice as a function of temperature, transport inhibitors, pH, and saturability.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM << cefadroxil >> was reduced by 83% in [[ PEPT2 ]](-/-) mice as compared with PEPT2(+/+) mice (p < 0.001).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "At normal pH (7.4) and temperature (37 degrees C), the uptake of 1 microM << cefadroxil >> was reduced by 83% in PEPT2(-/-) mice as compared with [[ PEPT2 ]](+/+) mice (p < 0.001).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Glycylsarcosine coadministration could inhibit the uptake of << cefadroxil >> in [[ PEPT2 ]](+/+) mice (p < 0.01) but not PEPT2(-/-) mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Glycylsarcosine coadministration could inhibit the uptake of << cefadroxil >> in PEPT2(+/+) mice (p < 0.01) but not [[ PEPT2 ]](-/-) mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although a proton-stimulated uptake of << cefadroxil >> was demonstrated in [[ PEPT2 ]](+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in PEPT2(-/-) mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Although a proton-stimulated uptake of << cefadroxil >> was demonstrated in PEPT2(+/+) mice (pH 6.5 versus pH 7.4; p < 0.01), no pH dependence was observed in [[ PEPT2 ]](-/-) mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings demonstrate that << PEPT2 >> is the primary transporter responsible for [[ cefadroxil ]] uptake in the choroid plexus.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "NPC1L1 could recently be identified as a major << sterol transporter >> for the intestinal uptake of [[ cholesterol ]] as well as plant sterols.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "NPC1L1 could recently be identified as a major << sterol transporter >> for the intestinal uptake of cholesterol as well as plant [[ sterols ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< NPC1L1 >> could recently be identified as a major sterol transporter for the intestinal uptake of [[ cholesterol ]] as well as plant sterols.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< NPC1L1 >> could recently be identified as a major sterol transporter for the intestinal uptake of cholesterol as well as plant [[ sterols ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Ambrisentan >> is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by [[ CYP3A4 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Gemcitabine >> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by [[ cytidine deaminase ]] (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (<< dFdC >>, 2',2'-difluorodeoxycytidine) is metabolized by [[ cytidine deaminase ]] (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (dFdC, << 2',2'-difluorodeoxycytidine >>) is metabolized by [[ cytidine deaminase ]] (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Gemcitabine >> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ([[ CDA ]]) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (<< dFdC >>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase ([[ CDA ]]) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (dFdC, << 2',2'-difluorodeoxycytidine >>) is metabolized by cytidine deaminase ([[ CDA ]]) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Gemcitabine >> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and [[ deoxycytidine kinase ]] (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (<< dFdC >>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and [[ deoxycytidine kinase ]] (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (dFdC, << 2',2'-difluorodeoxycytidine >>) is metabolized by cytidine deaminase (CDA) and [[ deoxycytidine kinase ]] (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Gemcitabine >> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([[ DCK ]]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (<< dFdC >>, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([[ DCK ]]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemcitabine (dFdC, << 2',2'-difluorodeoxycytidine >>) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase ([[ DCK ]]), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (<< Lys27Gln >> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and << Ala70Thr >>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and << DCK >> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<< Ile24Val >>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, << Ala119Gly >>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and << Pro122Ser >>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for [[ cytarabine ]] (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (<< Lys27Gln >> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and << Ala70Thr >>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and << DCK >> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<< Ile24Val >>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, << Ala119Gly >>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and << Pro122Ser >>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine ([[ Ara-C ]]), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (<< Lys27Gln >> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and << Ala70Thr >>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and << DCK >> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<< Ile24Val >>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, << Ala119Gly >>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and << Pro122Ser >>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), [[ dFdC ]], and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (<< Lys27Gln >> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and << Ala70Thr >>) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and << DCK >> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<< Ile24Val >>, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, << Ala119Gly >>, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and << Pro122Ser >>) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite [[ 2',2'-difluorodeoxyuridine ]] (dFdU) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Wild-type enzymes and variants of << CDA >> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine ([[ dFdU ]]) as substrates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All three << CDA >> proteins showed similar K(m) and V(max) for [[ Ara-C ]] and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All three << CDA >> proteins showed similar K(m) and V(max) for Ara-C and [[ dFdC ]] deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for << CDA >>70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for [[ Ara-C ]] deamination.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All four << DCK >> proteins yielded comparable metabolic activity for [[ Ara-C ]] and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All four << DCK >> proteins yielded comparable metabolic activity for Ara-C and [[ dFdC ]] monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for << DCK >>24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of [[ dFdC ]] monophosphorylation due to a 40% decrease in K(m) (P < 0.05).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, the Lys27Gln substitution does not significantly modulate << CDA >> activity toward [[ dFdC ]], and therefore would not contribute to interindividual variability in response to gemcitabine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, the << Lys27Gln >> substitution does not significantly modulate CDA activity toward [[ dFdC ]], and therefore would not contribute to interindividual variability in response to gemcitabine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The higher in vitro catalytic efficiency of << DCK >>24Val toward [[ dFdC ]] monophosphorylation may be relevant to dFdC clinical response.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The higher in vitro catalytic efficiency of << DCK >>24Val toward dFdC monophosphorylation may be relevant to [[ dFdC ]] clinical response.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Adenine phosphoribosyltransferase >> plays a role in purine salvage by catalyzing the direct conversion of [[ adenine ]] to adenosine monophosphate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by << adenosine triphosphate-binding cassette A1 >>- (ABCA1), dependent [[ cholesterol ]] efflux from macrophages.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (<< ABCA1 >>), dependent [[ cholesterol ]] efflux from macrophages.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and << ABCA1 >>-dependent [[ cholesterol ]] efflux and serum lipid and lipoprotein levels were assessed.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Thus, isoflavone supplementation did not affect << ABCA1 >>-dependent [[ cholesterol ]] efflux to serum.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< ABCA1 >>-facilitated [[ cholesterol ]] efflux and lipid parameters did not differ between equol-producing and non-equol-producing women.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect << ABCA1 >>-dependent [[ cholesterol ]] efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in << glucosinolates >>, which upon [[ myrosinase ]] hydrolysis release the corresponding isothiocyanates.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<< Pin1 >>), an enzyme that catalyzes the conversion of the peptide bond of [[ pSer ]]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<< Pin1 >>), an enzyme that catalyzes the conversion of the peptide bond of pSer/[[ pThr ]]-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that peptidyl-prolyl cis/trans-isomerase A1 (<< Pin1 >>), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-[[ Pro ]] moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that << peptidyl-prolyl cis/trans-isomerase A1 >> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of [[ pSer ]]/pThr-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that << peptidyl-prolyl cis/trans-isomerase A1 >> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/[[ pThr ]]-Pro moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we demonstrate that << peptidyl-prolyl cis/trans-isomerase A1 >> (Pin1), an enzyme that catalyzes the conversion of the peptide bond of pSer/pThr-[[ Pro ]] moieties in signaling proteins from cis to trans, is highly susceptible to HNE modification.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Racemization of << serine >> is catalyzed by [[ serine racemase ]], a pyridoxal 5'-phosphate-dependent enzyme expressed mainly in brain and liver.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Mouse brain serine racemase >> catalyzes specific elimination of [[ L-serine ]] to pyruvate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through << Cl- >> uptake across the basolateral membrane mediated by [[ NKCC1 ]] in series with Cl- efflux across the apical membrane.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of << NKCC1 >>-mediated [[ Cl- ]] transport.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through << NKCC1 >>-mediated [[ Cl- ]] uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The physiological role of << NKCC1 >>-mediated [[ Cl- ]] uptake remains to be determined.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Contribution of the Na+-K+-2Cl- cotransporter << NKCC1 >> to [[ Cl- ]] secretion in rat OMCD.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Contribution of the << Na+-K+-2Cl- cotransporter >> NKCC1 to [[ Cl- ]] secretion in rat OMCD.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by << NKCC1 >> in series with [[ Cl- ]] efflux across the apical membrane.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through << NKCC1 >>-mediated Cl- uptake across the basolateral membrane in series with [[ Cl- ]] efflux across the apical membrane.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete << Cl- >> into the luminal fluid through [[ NKCC1 ]]-mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cholinesterase inhibitors enhance cholinergic transmission directly by inhibiting the enzyme << acetylcholinesterase >> (AChE) which hydrolyses [[ acetylcholine ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cholinesterase inhibitors enhance cholinergic transmission directly by inhibiting the enzyme acetylcholinesterase (<< AChE >>) which hydrolyses [[ acetylcholine ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (H(2)S) is synthesized from << L-cysteine >> via the action of [[ cystathionine-gamma-lyase ]] (CSE) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (H(2)S) is synthesized from << L-cysteine >> via the action of cystathionine-gamma-lyase ([[ CSE ]]) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (H(2)S) is synthesized from << L-cysteine >> via the action of cystathionine-gamma-lyase (CSE) and [[ cystathionine-beta-synthase ]] (CBS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (H(2)S) is synthesized from << L-cysteine >> via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ([[ CBS ]]).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the << dehydrogenase >> and isomerase substrate [[ steroids ]] bind at different sites on the same protein.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Megalin, a family of << endocytic receptors >> related to the low-density lipoprotein (LDL) receptor, is a major pathway for proximal tubular [[ aminoglycoside ]] accumulation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Megalin, a family of endocytic receptors related to the << low-density lipoprotein (LDL) receptor >>, is a major pathway for proximal tubular [[ aminoglycoside ]] accumulation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the << SGLT1 >>-dependent [[ methyl alpha-D-glucopyranoside ]] (AMG) uptake and levels of SGLT1 expression were determined.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Then the cells were treated with various concentrations of apoE3, lactoferrin and bovine serum albumin with or without 100 microg/ml of GMC, and the << SGLT1 >>-dependent methyl alpha-D-glucopyranoside ([[ AMG ]]) uptake and levels of SGLT1 expression were determined.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << phosphodiesterase (PDE) 4 >> is the predominant [[ cyclic AMP ]] degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "MicroPET imaging in nonhuman primates with [<< 11C >>]1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [[ SERT ]]-rich brain regions and peak uptake being achieved in about 55 min postinjection.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "MicroPET imaging in nonhuman primates with [11C]1 and [<< 11C >>]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the [[ SERT ]]-rich brain regions and peak uptake being achieved in about 55 min postinjection.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that << thymidine phosphorylase >>, the activating enzyme for [[ 5-FU ]], is expressed at a higher level in tumor tissue compared with normal tissue counterparts.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for [[ ethanol ]] oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The identity of the lung << beta-ADHs >> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and [[ ethanol ]], and inhibition by 4-methylpyrazole or 1,10-phenanthroline.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings indicate that human pulmonary << ethanol >>-metabolizing activities differ significantly with respect to genetic polymorphism at both the [[ ADH2 ]] and the ALDH2 loci.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings indicate that human pulmonary << ethanol >>-metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the [[ ALDH2 ]] loci.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The results suggest that individuals with high Vmax << beta 2-ADH >> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during [[ alcohol ]] consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial << ALDH2 >>, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during [[ alcohol ]] consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 6-DHSG >> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of [[ glutathione-S-transferase ]] (GST).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 6-DHSG >> was metabolised by GSH to form a GSH conjugate (GS-6-DHSG) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ([[ GST ]]).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< AMP-activated protein kinase >> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [[ glucose ]] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "AMP-activated protein kinase (<< AMPK >>) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of [[ glucose ]] uptake into skeletal muscle and the inhibition of liver gluconeogenesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the << GABA >> metabolizing enzyme, [[ GABA transaminase ]] (GABA-T).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the << GABA >> metabolizing enzyme, GABA transaminase ([[ GABA-T ]]).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As with GABA, the metabolism of << alanine >> involves a [[ pyridoxal phosphate-dependent transaminase ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In the study reported here, the effects of acute PLZ treatment on the levels of various << amino acids >>, some of which are also metabolized by [[ pyridoxal phosphate-dependent transaminases ]] were compared in rat whole brain.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The elevation in brain << alanine >> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on [[ alanine transaminase ]] (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The elevation in brain << alanine >> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase ([[ ALA-T ]]), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In addition, we also showed that the elevation in << alanine >> levels and the inhibition of [[ alanine transaminase ]] in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In terms of the mechanisms, we found that << fatty acid amide hydrolase >> (FAAH) which degrades [[ anandamide ]], was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In terms of the mechanisms, we found that fatty acid amide hydrolase (<< FAAH >>) which degrades [[ anandamide ]], was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, enzymes contributing to oxidative metabolism of << anandamide >>, namely [[ cyclooxygenase-1 ]] and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, enzymes contributing to oxidative metabolism of << anandamide >>, namely cyclooxygenase-1 and [[ Cyp2D6 ]], were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, enzymes contributing to oxidative metabolism of anandamide, namely << cyclooxygenase-1 >> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of [[ anandamide ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and << Cyp2D6 >>, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of [[ anandamide ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hence, triclosan has the ability to inhibit both the << cyclo-oxygenase >> and lipoxygenase pathways of [[ arachidonic acid ]] metabolism with similar efficacy.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and << lipoxygenase >> pathways of [[ arachidonic acid ]] metabolism with similar efficacy.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The potency of MrIA was greater for inhibition of uptake by << hNET >> of [[ [3H]norepinephrine ]] (Ki 1.89 microM) than [3H]dopamine (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The potency of MrIA was greater for inhibition of uptake by << hNET >> of [3H]norepinephrine (Ki 1.89 microM) than [[ [3H]dopamine ]] (Ki 4.33 microM), and the human dopamine transporter and serotonin transporter were not inhibited by MrIA (to 7 microM).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "A comparison of the results with previous data for desipramine and cocaine inhibition of << norepinephrine >> uptake by the mutant [[ hNETs ]] reveals that MrIA binding to hNET occurs at a site that is distinct from but overlaps with the binding sites for tricyclic antidepressants and cocaine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Pharmacogenetic analysis of two genes, the << warfarin >> metabolic enzyme [[ CYP2C9 ]] and warfarin target enzyme, vitamin K epoxide reductase complex 1 VKORC1, confirmed their influence on warfarin maintenance dose.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Possession of << CYP2C9 >>*2 or CYP2C9*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [[ warfarin ]] dose.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Possession of CYP2C9*2 or << CYP2C9 >>*3 variant alleles, which result in decreased enzyme activity, is associated with a significant decrease in the mean [[ warfarin ]] dose.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The discovery of an inducible << oxidase >> whose apparent substrate preference is [[ spermine ]] indicates that polyamine catabolism is more complex than that originally proposed.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Purified << PAOh1 >>/SMO oxidizes both [[ spermine ]] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Purified PAOh1/<< SMO >> oxidizes both [[ spermine ]] (K(m)=1.6 microM) and N(1)-acetylspermine (K(m)=51 microM), but does not oxidize spermidine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Purified PAOh1/<< SMO >> oxidizes both spermine (K(m)=1.6 microM) and [[ N(1)-acetylspermine ]] (K(m)=51 microM), but does not oxidize spermidine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Purified << PAOh1 >>/SMO oxidizes both spermine (K(m)=1.6 microM) and [[ N(1)-acetylspermine ]] (K(m)=51 microM), but does not oxidize spermidine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of << spermine >> by [[ PAOh1 ]]/SMO.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The purified human enzyme also does not oxidize eight representative antitumor polyamine analogues; however, specific oligamine analogues were found to be potent inhibitors of the oxidation of << spermine >> by PAOh1/[[ SMO ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Role of << organic cation/carnitine transporter 1 >> in uptake of [[ phenformin ]] and inhibitory effect on complex I respiration in mitochondria.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These observations suggest that uptake of << phenformin >> into liver mitochondria is at least partly mediated by [[ OCTN1 ]] and functionally relevant to its inhibition potential of complex I respiration.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Valproic acid selectively inhibits conversion of << arachidonic acid >> to arachidonoyl-CoA by [[ brain microsomal long-chain fatty acyl-CoA synthetases ]]: relevance to bipolar disorder.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cynomolgus FMO1 >>, FMO2, FMO3, and FMO5 metabolized [[ benzydamine ]], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, << FMO2 >>, FMO3, and FMO5 metabolized [[ benzydamine ]], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, << FMO3 >>, and FMO5 metabolized [[ benzydamine ]], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and << FMO5 >> metabolized [[ benzydamine ]], and FMO1/FMO3 and FMO3 also metabolized methimazole and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and << FMO1 >>/FMO3 and FMO3 also metabolized [[ methimazole ]] and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/<< FMO3 >> and FMO3 also metabolized [[ methimazole ]] and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and << FMO3 >> also metabolized [[ methimazole ]] and trimethylamine, respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and << FMO1 >>/FMO3 and FMO3 also metabolized methimazole and [[ trimethylamine ]], respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/<< FMO3 >> and FMO3 also metabolized methimazole and [[ trimethylamine ]], respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO1, FMO2, FMO3, and FMO5 metabolized benzydamine, and FMO1/FMO3 and << FMO3 >> also metabolized methimazole and [[ trimethylamine ]], respectively.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Rates of << benzydamine >> N-oxygenation (catalyzed by [[ FMO3 ]]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Rates of benzydamine << N >>-oxygenation (catalyzed by [[ FMO3 ]]) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine N-oxygenation might be partly accounted for by the variable FMO3 expression.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cynomolgus FMO6 >> metabolized [[ benzydamine ]] only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and FMO5 which were all functional.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO6 metabolized << benzydamine >> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus [[ FMO1 ]], FMO2, FMO3, and FMO5 which were all functional.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO6 metabolized << benzydamine >> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, [[ FMO2 ]], FMO3, and FMO5 which were all functional.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO6 metabolized << benzydamine >> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, [[ FMO3 ]], and FMO5 which were all functional.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cynomolgus FMO6 metabolized << benzydamine >> only slightly, but minimal expression of FMO6 in all tissue precludes the importance of FMO6 in drug metabolism, unlike cynomolgus FMO1, FMO2, FMO3, and [[ FMO5 ]] which were all functional.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in << benzydamine >> N-oxygenation might be partly accounted for by the variable [[ FMO3 ]] expression.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Rates of benzydamine N-oxygenation (catalyzed by FMO3) varied (approximately 20-fold) among the 28 cynomolgus livers and were significantly correlated with FMO3 protein expression, indicating that the inter-animal variations in benzydamine << N >>-oxygenation might be partly accounted for by the variable [[ FMO3 ]] expression.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Metabolism of << triethylenetetramine >> and 1,12-diamino-3,6,9-triazadodecane by the [[ spermidine/spermine-N(1)-acetyltransferase ]] and thialysine acetyltransferase.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Metabolism of triethylenetetramine and << 1,12-diamino-3,6,9-triazadodecane >> by the [[ spermidine/spermine-N(1)-acetyltransferase ]] and thialysine acetyltransferase.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Metabolism of << triethylenetetramine >> and 1,12-diamino-3,6,9-triazadodecane by the spermidine/spermine-N(1)-acetyltransferase and [[ thialysine acetyltransferase ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Metabolism of triethylenetetramine and << 1,12-diamino-3,6,9-triazadodecane >> by the spermidine/spermine-N(1)-acetyltransferase and [[ thialysine acetyltransferase ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that << TETA >> is metabolized in vitro by polyamine catabolic enzyme [[ spermidine/spermine-N(1)-acetyltransferase ]] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that TETA is metabolized in vitro by << polyamine >> catabolic enzyme [[ spermidine/spermine-N(1)-acetyltransferase ]] (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that TETA is metabolized in vitro by << polyamine >> catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ([[ SSAT1 ]]) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that << TETA >> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase ([[ SSAT1 ]]) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that << TETA >> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by [[ thialysine acetyltransferase ]] (SSAT2) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We recently showed that << TETA >> is metabolized in vitro by polyamine catabolic enzyme spermidine/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase ([[ SSAT2 ]]) to its monoacetylated derivative (MAT).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The acetylation of << TETA >> is increased in [[ SSAT1 ]]-overexpressing mice compared with wild-type mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, SSAT1-deficient mice metabolize << TETA >> at the same rate as the wild-type mice, indicating the existence of another [[ N-acetylase ]] respons 2ible for its metabolism in mice.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Here, we show that siRNA-mediated knockdown of << SSAT2 >> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of [[ TETA ]] to MAT.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, << 1,12-diamino-3,6,9-triazadodecane >>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of [[ human recombinant SSAT2 ]] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(<< SpmTrien >>), a charge-deficient spermine analog, was an extremely poor substrate of [[ human recombinant SSAT2 ]] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient << spermine >> analog, was an extremely poor substrate of [[ human recombinant SSAT2 ]] and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, << 1,12-diamino-3,6,9-triazadodecane >>(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [[ SSAT1 ]] in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(<< SpmTrien >>), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [[ SSAT1 ]] in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient << spermine >> analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by [[ SSAT1 ]] in HEPG2 cells and in wild-type primary hepatocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Thus, despite the similar structures of TETA and SpmTrien, << SSAT2 >> is the main acetylator of [[ TETA ]], whereas SpmTrien is primarily acetylated by SSAT1.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas << SpmTrien >> is primarily acetylated by [[ SSAT1 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Ketamine >> is primarily metabolized to norketamine by hepatic [[ cytochrome P450 (CYP) 2B6 ]] and CYP3A4-mediated N-demethylation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Ketamine >> is primarily metabolized to norketamine by hepatic cytochrome P450 (CYP) 2B6 and [[ CYP3A4 ]]-mediated N-demethylation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results indicate a major role of << CYP2B6 >> in [[ ketamine ]] N-demethylation in vitro and a significant impact of the CYP2B6*6 allele on enzyme-ketamine binding and catalytic activity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << CYP2B6*6 >> Allele Significantly Alters the N-demethylation of [[ Ketamine ]] Enantiomers In Vitro.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << CYP2B6*6 >> allele is associated with reduced enzyme expression and activity that may lead to interindividual variability in [[ ketamine ]] metabolism.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We examined the N-demethylation of individual << ketamine >> enantiomers using human liver microsomes (HLMs) genotyped for the [[ CYP2B6*6 ]] allele, insect cell expressed recombinant CYP2B6 and CYP3A4 enzymes and COS-1 cell expressed recombinant CYP2B6.1 and CYP2B6.6 protein variant.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The intrinsic clearance for both << ketamine >> enantiomers by the high affinity enzyme in HLMs with [[ CYP2B6*1 ]]/*1 genotype were at least 2-fold and 6-fold higher, respectively, than those for CYP2B6*1/*6 genotype and CYP2B6*6/*6 genotype.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the << CYP2B6*6 >> allele on enzyme-[[ ketamine ]] binding and catalytic activity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< PLZ >> is also a substrate for [[ MAO ]], and studies suggest that a metabolite formed by the action of this enzyme on PLZ may be responsible for the increase in GABA observed.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "ORN levels (measured by an HPLC procedure) were dose- and time-dependently increased in PLZ-treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with TCP completely abolished the PLZ-induced increase in brain ORN, suggesting, as with GABA, that a metabolite of << PLZ >> formed by the action of [[ MAO ]] is responsible for the elevation of brain ORN observed.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "High << cholesterol >> turnover catalyzed by [[ cholesterol 24-hydroxylase ]] is essential for neural functions, especially learning.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< 24(S)-hydroxycholesterol >> is actively eliminated from neuronal cells by [[ ABCA1 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing << human ABCA1 >> or ABCG1; we clearly observed [[ 24-OHC ]] efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or << ABCG1 >>; we clearly observed [[ 24-OHC ]] efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << ABCA1 >> actively eliminates [[ 24-OHC ]] in the presence of HDL as a lipid acceptor and protects neuronal cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << Cl(-) >> secretory response is mediated via a non-[[ CFTR ]] pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Introduction: << 5-Lipoxygenase >> (5-LO) is a crucial enzyme of the [[ arachidonic acid ]] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Introduction: 5-Lipoxygenase (<< 5-LO >>) is a crucial enzyme of the [[ arachidonic acid ]] (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) with the help of FLAP, the 5-LO-activating protein.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This aminophospholipid \"<< flippase >>\" selectively transports [[ PS ]] to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, << N-methyl-phosphatidylserine >>, which is transported by the plasma membrane [[ flippase ]] at a rate equivalent to PS, is incapable of activating Atp8a1 activity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of << hamster LDH-X >> with respect to the substrate [[ alpha-ketobutyrate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The drug had a potent cytotoxic effect on RIN cells expressing << GLUT2 >>, but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood [[ glucose ]] levels of treated animals.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Consistent with these data, only << GLUT2 >>-expressing RIN or AtT-20ins cells transported [[ STZ ]] efficiently.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We conclude that expression of << GLUT2 >> is required for efficient killing of neuroendocrine cells by [[ STZ ]], and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by << STZ >>, and this effect is related to specific recognition of the drug as a transported substrate by [[ GLUT2 ]] but not GLUT1.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, << triamcinolone acetonide >>, flunisolide, budesonide, and fluticasone propionate, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, << flunisolide >>, budesonide, and fluticasone propionate, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, << budesonide >>, and fluticasone propionate, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and << fluticasone propionate >>, by the [[ CYP3A ]] family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< CYP3A5 >>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize [[ triamcinolone acetonide ]], budesonide, and fluticasone propionate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< CYP3A5 >>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, [[ budesonide ]], and fluticasone propionate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< CYP3A5 >>, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and [[ fluticasone propionate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In contrast, << flunisolide >> was only metabolized via [[ CYP3A4 ]], with no significant turnover by CYP3A5 or CYP3A7.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: << Bile acid-coenzyme A:amino acid N-acyltransferase >> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary [[ bile acids ]] to taurine and glycine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<< BAAT >>) is the sole enzyme responsible for conjugation of primary and secondary [[ bile acids ]] to taurine and glycine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The absence or presence of a cytosolic pool of << BAAT >> has important implications for the intracellular transport of unconjugated/deconjugated [[ bile salts ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting << inositol monophosphatase >>, the final enzyme of the [[ IP3 ]] metabolic cascade.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "It has been known for decades that lithium chloride (LiCl) leads to << D-myo-inositol 1-phosphate >> accumulation on GPCR activation by inhibiting [[ inositol monophosphatase ]], the final enzyme of the IP3 metabolic cascade.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of << Cd(2+) >> and Mn(2+), the expression of [[ ZIP8 ]] (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of << Cd(2+) >> and Mn(2+), the expression of ZIP8 ([[ Zrt-, Irt-related protein 8 ]]), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of << Cd(2+) >> and Mn(2+), the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [[ Slc39a8 ]], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of Cd(2+) and << Mn(2+) >>, the expression of [[ ZIP8 ]] (Zrt-, Irt-related protein 8), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of Cd(2+) and << Mn(2+) >>, the expression of ZIP8 ([[ Zrt-, Irt-related protein 8 ]]), encoded by Slc39a8, showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the possible transporters involved in the uptake of Cd(2+) and << Mn(2+) >>, the expression of ZIP8 (Zrt-, Irt-related protein 8), encoded by [[ Slc39a8 ]], showed a marked suppression in both RBL-Cdr and RBL-Mnr cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << ZIP8 >> plays a pivotal role in the transport and toxicity of [[ Cd(2+) ]] and Mn(2+) in RBL-2H3 cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that << ZIP8 >> plays a pivotal role in the transport and toxicity of Cd(2+) and [[ Mn(2+) ]] in RBL-2H3 cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << mitochondrial respiratory chain complex IV >> (cytochrome c oxidase) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular [[ oxygen ]], yielding water.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The mitochondrial respiratory chain complex IV (<< cytochrome c oxidase >>) is a multi-subunit enzyme that transfers electrons from cytochrome c to molecular [[ oxygen ]], yielding water.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of note, reciprocal expression of Asmt and << Bhmt >> is an important clue that altered [[ S-adenosylhomocysteine ]] metabolism underlies brain injury in WD, which is directly correlated to the decreased expression of S-adenosylhomocysteine hydrolase in hepatic tissue in LEC rats.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of note, reciprocal expression of Asmt and Bhmt is an important clue that altered << S-adenosylhomocysteine >> metabolism underlies brain injury in WD, which is directly correlated to the decreased expression of [[ S-adenosylhomocysteine hydrolase ]] in hepatic tissue in LEC rats.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The precise fashion in which these proteins interact and move << cholesterol >> from the OMM to [[ P450scc ]], and the means by which cholesterol is loaded into the OMM, remain unclear.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the << cholesterol >> side-chain cleavage enzyme, [[ P450scc ]], and its two electron-transfer partners, ferredoxin reductase and ferredoxin.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Upon differentiation, osteoclasts express << vesicular glutamate transporter 1 >> (VGLUT1), which is essential for vesicular storage and subsequent exocytosis of [[ glutamate ]] in neurons.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Upon differentiation, osteoclasts express vesicular glutamate transporter 1 (<< VGLUT1 >>), which is essential for vesicular storage and subsequent exocytosis of [[ glutamate ]] in neurons.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< VGLUT1 >> is localized in transcytotic vesicles and accumulates [[ L-glutamate ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reuptake of extracellular << noradrenaline >> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the [[ noradrenaline transporter ]] (NAT, uptake 1).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reuptake of extracellular << noradrenaline >> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ([[ NAT ]], uptake 1).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reuptake of extracellular noradrenaline (<< NA >>) into superior cervical ganglion (SCG) neurones is mediated by means of the [[ noradrenaline transporter ]] (NAT, uptake 1).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Reuptake of extracellular noradrenaline (<< NA >>) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter ([[ NAT ]], uptake 1).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by << MPP+ >>, guanidine, choline and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Our observations indicate an << OCT >>-mediated transmembrane transport of [[ [3H]-MPP+ ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, << guanidine >>, choline and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, << choline >> and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and << amantadine >> as potential substrates for [[ OCT ]]-related transmembrane transporters.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by << MPP+ >>, guanidine, choline and amantadine as potential substrates for OCT-related [[ transmembrane transporters ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, << guanidine >>, choline and amantadine as potential substrates for OCT-related [[ transmembrane transporters ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, << choline >> and amantadine as potential substrates for OCT-related [[ transmembrane transporters ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and << amantadine >> as potential substrates for OCT-related [[ transmembrane transporters ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of << MPP+ >>, indicating the [[ NAT ]] and not an OCT as their primary site of action.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of << [3H]-MPP+ >> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for [[ OCT ]]-related transmembrane transporters.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The outflow of << [3H]-MPP+ >> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related [[ transmembrane transporters ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Amongst the three OCTs expressed in the SCG, << OCT3 >> best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [[ [3H]-MPP+ ]] release.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Amongst the three << OCTs >> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [[ [3H]-MPP+ ]] release.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The hydrolysis of fluorescein << diphosphate >> by [[ PTP epsilon ]] and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The hydrolysis of fluorescein << diphosphate >> by PTP epsilon and [[ PTPmeg1 ]] was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In humans, << methionine synthase >> deficiency results in the accumulation of [[ methyltetrahydrofolate ]] at the expense of folate derivatives required for purine and thymidylate biosynthesis.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "An angiotensin II AT1 receptor antagonist, telmisartan augments << glucose >> uptake and [[ GLUT4 ]] protein expression in 3T3-L1 adipocytes.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of note, we demonstrated for the first time that telmisartan augmented << GLUT4 >> protein expression and [[ 2-deoxy glucose ]] uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Involvement of << P450 >> mediated metabolism in the absorption of [[ darunavir ]] could not be demonstrated in this rat model.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To evaluate to what extent the regional differences in expression of << P-gp >> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of [[ darunavir ]] across different small intestinal segments (duodenum, proximal jejunum and ileum).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "To evaluate to what extent the regional differences in expression of P-gp and << P450 enzymes >> affect the absorption of a dual substrate, we investigated the transport of [[ darunavir ]] across different small intestinal segments (duodenum, proximal jejunum and ileum).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The involvement of << P-gp >> in the absorption of [[ darunavir ]] was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on << P-gp >> as the main mechanism for the increased transport of [[ darunavir ]] across the small intestine.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of << estradiol >> in breast cancer by blocking sulfatase and [[ 17beta-hydroxysteroid-dehydrogenase type 1 ]] activities.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of << estradiol >> in breast cancer by blocking [[ sulfatase ]] and 17beta-hydroxysteroid-dehydrogenase type 1 activities.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: << 4-methoxy-2-naphthylamide >> of L-alanine for [[ aminopeptidase N ]], 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of << L-alanine >> for [[ aminopeptidase N ]], 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, << 4-methoxy-2-naphthylamide >> of L-leucine for [[ leucine aminopeptidase ]], 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of << L-leucine >> for [[ leucine aminopeptidase ]], 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, << 4-methoxy-2-naphthylamide >> of L-glutamic acid for [[ aminopeptidase A ]] and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of << L-glutamic acid >> for [[ aminopeptidase A ]] and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and << 4-methoxy-2-naphthylamide >> of L-arginine for [[ aminopeptidase B ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of << L-arginine >> for [[ aminopeptidase B ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, << CYP2D >> isoforms were the most efficient in catalyzing the [[ O ]]-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The catalytic competence of << cytochrome P450 >> in the synthesis of serotonin from [[ 5-methoxytryptamine ]] in the brain: an in vitro study.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, << CYP2D >> isoforms were the most efficient in catalyzing the O-demethylation of [[ 5-methoxytryptamine ]] to serotonin, but they were less effective than the human isoform CYP2D6.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the << O >>-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the [[ human isoform CYP2D6 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of << 5-methoxytryptamine >> to serotonin, but they were less effective than the [[ human isoform CYP2D6 ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Human liver microsomes of the wild-type << CYP2D6 >> metabolized [[ 5-methoxytryptamine ]] to serotonin more effectively than did the defective CYP2D6*4*4 ones.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Human liver microsomes of the wild-type CYP2D6 metabolized << 5-methoxytryptamine >> to serotonin more effectively than did the defective [[ CYP2D6 ]]*4*4 ones.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The obtained results indicate that << rat brain CYP2D >> isoforms catalyze the formation of serotonin from [[ 5-methoxytryptamine ]], and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Contributions of << rat Ctr1 >> to the uptake and toxicity of [[ copper ]] and platinum anticancer drugs in dorsal root ganglion neurons.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Contributions of << rat Ctr1 >> to the uptake and toxicity of copper and [[ platinum ]] anticancer drugs in dorsal root ganglion neurons.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of << rCtr1 >> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of [[ copper ]], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/<< rCtr1 >> cells) increased the uptake and cytotoxicity of [[ copper ]], oxaliplatin, cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of << rCtr1 >> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, [[ oxaliplatin ]], cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/<< rCtr1 >> cells) increased the uptake and cytotoxicity of copper, [[ oxaliplatin ]], cisplatin and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of << rCtr1 >> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, [[ cisplatin ]] and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/<< rCtr1 >> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, [[ cisplatin ]] and carboplatin, in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of << rCtr1 >> in HEK293 cells (HEK/rCtr1 cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and [[ carboplatin ]], in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Heterologous expression of rCtr1 in HEK293 cells (HEK/<< rCtr1 >> cells) increased the uptake and cytotoxicity of copper, oxaliplatin, cisplatin and [[ carboplatin ]], in comparison to isogenic vector-transfected control cells.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cultured rat DRG neurons endogenously expressed << rCtr1 >> protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up [[ copper ]], but were resistant to copper toxicity.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The uptake of << copper >> by both cultured rat DRG neurons and HEK/[[ rCtr1 ]] cells was saturable and inhibited by cold temperature, silver and zinc, consistent with it being mediated by rCtr1.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, << rCtr1 >> can transport [[ copper ]] and platinum drugs, and sensitizes cells to their cytotoxicities.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, << rCtr1 >> can transport copper and [[ platinum ]] drugs, and sensitizes cells to their cytotoxicities.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "DRG neurons display substantial capacity for accumulating << copper >> via a transport process mediated by [[ rCtr1 ]], but appear able to resist copper toxicity and use alternative mechanisms to take up oxaliplatin.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "DRG neurons display substantial capacity for accumulating copper via a transport process mediated by << rCtr1 >>, but appear able to resist copper toxicity and use alternative mechanisms to take up [[ oxaliplatin ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Proline dehydrogenase >> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of [[ proline ]] to glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (<< PRODH >>) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of [[ proline ]] to glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (PRODH) and << Delta(1)-pyrroline-5-carboxylate dehydrogenase >> (P5CDH) catalyze the two-step oxidation of [[ proline ]] to glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<< P5CDH >>) catalyze the two-step oxidation of [[ proline ]] to glutamate.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Finally, we demonstrate that << T. thermophilus PRODH >> reacts with [[ O(2) ]] producing superoxide.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of << PDE5 >> that breaks down [[ cGMP ]], the key pathway for the production of erectile function in humans.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Omega class GSTs >> have dehydroascorbate reductase and thioltransferase activities and also catalyze the reduction of [[ monomethylarsonate ]], an intermediate in the pathway of arsenic biotransformation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Doxorubicin >> is mainly excreted into the bile via [[ P-glycoprotein ]] (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Doxorubicin >> is mainly excreted into the bile via P-glycoprotein ([[ P-gp ]]) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Doxorubicin >> is mainly excreted into the bile via P-glycoprotein (P-gp) and [[ multidrug resistance-associated protein 2 ]] (Mrp2) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Doxorubicin >> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 ([[ Mrp2 ]]) in hepatobiliary route and metabolized via cytochrome P450 (CYP) 3A subfamily.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Doxorubicin >> is mainly excreted into the bile via P-glycoprotein (P-gp) and multidrug resistance-associated protein 2 (Mrp2) in hepatobiliary route and metabolized via [[ cytochrome P450 (CYP) 3A ]] subfamily.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The slower CL was due to the reduction of hepatic biliary excretion (67.0% decrease) and hepatic << CYP3A >> subfamily-mediated metabolism (21.9% decrease) of [[ doxorubicin ]].", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The protein exhibited modest H(2)O(2)-dependent << peroxidase >> activities with [[ guaiacol ]], potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The protein exhibited modest H(2)O(2)-dependent << peroxidase >> activities with guaiacol, [[ potassium iodide ]], and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The protein exhibited modest H(2)O(2)-dependent << peroxidase >> activities with guaiacol, potassium iodide, and [[ 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid ]] (ABTS).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The protein exhibited modest H(2)O(2)-dependent << peroxidase >> activities with guaiacol, potassium iodide, and 2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid ([[ ABTS ]]).", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Among the [Fe-S] cluster biosynthetic proteins are included a pyridoxal phosphate-dependent enzyme (<< NifS >>) that is involved in the activation of sulphur from [[ l-cysteine ]], and a molecular scaffold protein (NifU) upon which [Fe-S] cluster precursors are formed.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Choline dehydrogenase >> (CHDH) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in [[ choline ]] oxidation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Choline dehydrogenase (<< CHDH >>) and betaine-homocysteine methyltransferase (BHMT) are 2 enzymes involved in [[ choline ]] oxidation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Choline dehydrogenase (CHDH) and << betaine-homocysteine methyltransferase >> (BHMT) are 2 enzymes involved in [[ choline ]] oxidation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Choline dehydrogenase (CHDH) and betaine-homocysteine methyltransferase (<< BHMT >>) are 2 enzymes involved in [[ choline ]] oxidation.", "metadata": [], "label": "SUBSTRATE", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Involvement of << COX-1 >> and up-regulated prostaglandin E synthases in phosphatidylserine liposome-induced [[ prostaglandin E2 ]] production by microglia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Involvement of COX-1 and up-regulated << prostaglandin E synthases >> in phosphatidylserine liposome-induced [[ prostaglandin E2 ]] production by microglia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These observations strongly suggest that the up-regulation of terminal << PGESs >> that are preferentially coupled with COX-1, especially mPGES-2, plays the pivotal role in PS liposome-induced [[ PGE2 ]] production by microglia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with << COX-1 >>, especially mPGES-2, plays the pivotal role in PS liposome-induced [[ PGE2 ]] production by microglia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These observations strongly suggest that the up-regulation of terminal PGESs that are preferentially coupled with COX-1, especially << mPGES-2 >>, plays the pivotal role in PS liposome-induced [[ PGE2 ]] production by microglia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of << 17beta-hydroxysteroid dehydrogenase-7 >> (HSD17beta7; involved in [[ estradiol ]] production) and decreased expression of HSD17beta5 (involved in testosterone production).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (<< HSD17beta7 >>; involved in [[ estradiol ]] production) and decreased expression of HSD17beta5 (involved in testosterone production).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of << HSD17beta5 >> (involved in [[ testosterone ]] production).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of key genes important in << methionine >> metabolism, such as [[ methionine adenosyltransferase-1a ]], betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of key genes important in << methionine >> metabolism, such as methionine adenosyltransferase-1a, [[ betaine-homocysteine methyltransferase ]] and thioether S-methyltransferase, were suppressed.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The expression of key genes important in << methionine >> metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and [[ thioether S-methyltransferase ]], were suppressed.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to [[ pyruvate ]], ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, [[ ammonia ]], and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an [[ alpha-chloroenethiolate ]] (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an alpha-chloroenethiolate (with [[ DCVC ]]) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an [[ alpha-difluoroalkylthiolate ]] (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with [[ TFEC ]]) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cycloxygenase-2 >> (COX-2)-derived [[ prostaglandin E2 ]] (PGE2) has been shown to be important in esophageal tumorigenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cycloxygenase-2 (<< COX-2 >>)-derived [[ prostaglandin E2 ]] (PGE2) has been shown to be important in esophageal tumorigenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Cycloxygenase-2 >> (COX-2)-derived prostaglandin E2 ([[ PGE2 ]]) has been shown to be important in esophageal tumorigenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cycloxygenase-2 (<< COX-2 >>)-derived prostaglandin E2 ([[ PGE2 ]]) has been shown to be important in esophageal tumorigenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We have shown that << COX-2 >> mediates acid-induced [[ PGE2 ]] production.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "We conclude that << mPGES1 >> mediates acid-induced increase in [[ PGE2 ]] production and cell proliferation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Licofelone almost abolished << 5-LOX >> activity by inhibiting [[ leukotriene B4 ]] generation in rabbit neutrophils and prevented platelet thromboxane B2 production from whole blood.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Licofelone almost abolished << 5-LOX >> activity by inhibiting leukotriene B4 generation in rabbit neutrophils and prevented platelet [[ thromboxane B2 ]] production from whole blood.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Blocking << retinyl ester >> formation by a targeted knock down of [[ Lratb ]] results in significantly increased retinoic acid levels, which lead to severe embryonic patterning defects.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to retinal dehydrogenase 2 (<< raldh2 >>), the key enzyme for [[ retinoic acid ]] synthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "During embryogenesis, lratb is expressed in mostly non-overlapping domains opposite to << retinal dehydrogenase 2 >> (raldh2), the key enzyme for [[ retinoic acid ]] synthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In four (10Â %) patients the peak << ACTH >>-stimulated [[ cortisol ]] values were lower than 18Â Î¼g/dL.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< ACTH >>-stimulated peak [[ cortisol ]], delta cortisol, and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< ACTH >>-stimulated peak cortisol, [[ delta cortisol ]], and delta DHEA-S levels are decreased during hyperthyroidism, probably due to increased turnover.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< ACTH >>-stimulated peak cortisol, delta cortisol, and [[ delta DHEA ]]-S levels are decreased during hyperthyroidism, probably due to increased turnover.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and << xanthine oxidase >> was identified as the likely source of [[ TES ]]-stimulated superoxide production.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "As predicted, TES enhanced the production of both peroxynitrite precursors (i.e., superoxide and nitic oxide), and << xanthine oxidase >> was identified as the likely source of TES-stimulated [[ superoxide ]] production.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by << peroxynitrite >> formed from [[ xanthine oxidase ]]-generated superoxide and NO.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from << xanthine oxidase >>-generated [[ superoxide ]] and NO.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These findings, derived from a variety of analytical and functional approaches, provide evidence for a novel nongenomic signaling mechanism for androgen action in the microvasculature: TES-stimulated vasodilation mediated primarily by peroxynitrite formed from << xanthine oxidase >>-generated superoxide and [[ NO ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Statins are inhibitors of the enzyme << 3-hydroxy-3-methylglutaryl coenzyme A reductase >>, the rate-limiting step in [[ cholesterol ]] biosynthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "CONCLUSIONS: Total vitamin B6 is abnormally high in autism, consistent with previous reports of an impaired << pyridoxal kinase >> for the conversion of pyridoxine and pyridoxal to [[ PLP ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as << cyclooxygenase-2 >> (COX-2)-derived [[ prostaglandin E2 ]] (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<< COX-2 >>)-derived [[ prostaglandin E2 ]] (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as << cyclooxygenase-2 >> (COX-2)-derived prostaglandin E2 ([[ PGE2 ]]) inhibitory activity of murine macrophage RAW 264.7 cell line.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<< COX-2 >>)-derived prostaglandin E2 ([[ PGE2 ]]) inhibitory activity of murine macrophage RAW 264.7 cell line.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Diacylglycerol kinase >> (DGK) catalyzes the conversion of diacylglycerol to [[ phosphatidic acid ]], making it an attractive candidate for a signal transduction component.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Diacylglycerol kinase (<< DGK >>) catalyzes the conversion of diacylglycerol to [[ phosphatidic acid ]], making it an attractive candidate for a signal transduction component.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The specific activity of only << ornithine aminotransferase >> (OAT), the rate-limiting enzyme in the conversion of ornithine to [[ proline ]], increased in 2 weeks of hypertrophy.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The specific activity of only ornithine aminotransferase (<< OAT >>), the rate-limiting enzyme in the conversion of ornithine to [[ proline ]], increased in 2 weeks of hypertrophy.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< DHFS >> is present exclusively in the mitochondria, making this compartment the sole site of synthesis of [[ dihydrofolate ]] in the plant cell.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Aldo-keto reductases >> (AKRs) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [[ oxygen ]] species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aldo-keto reductases (<< AKRs >>) metabolize a wide range of substrates, including polycyclic aromatic hydrocarbons (PAHs), generating metabolites (o-quinones) and reactive [[ oxygen ]] species (ROS), which are capable of initiating and promoting carcinogenesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Cytochrome b5 has shown to be an essential component in << P450 3A4 >> catalyzed [[ 5-hydroxyelzasonan ]] formation and provides insights on the disconnect between human liver microsomes data and that of rCYP.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The altered activities of key enzymes such as << glucose-6-phosphatase >> and fructose-1,6-bisphosphatase of [[ carbohydrate ]] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The altered activities of key enzymes such as glucose-6-phosphatase and << fructose-1,6-bisphosphatase >> of [[ carbohydrate ]] metabolism significantly (p<0.05) increased whereas hexokinase, pyruvate kinase, glucose-6-phosphate dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Blockade of << LTC4 >> synthesis caused by additive inhibition of [[ gIV-PLA2 ]] phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Ribonucleotide reductase (<< RR >>) is responsible for the de novo conversion of the ribonucleoside diphosphates to [[ deoxyribonucleoside diphosphates ]], which are essential for DNA synthesis and repair.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Ribonucleotide reductase >> (RR) is responsible for the de novo conversion of the ribonucleoside diphosphates to [[ deoxyribonucleoside diphosphates ]], which are essential for DNA synthesis and repair.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Adenine phosphoribosyltransferase >> plays a role in purine salvage by catalyzing the direct conversion of adenine to [[ adenosine monophosphate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of << NO >> and the expression of [[ inducible nitric-oxide synthase ]] (iNOS) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of << NO >> and the expression of inducible nitric-oxide synthase ([[ iNOS ]]) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemfibrozil, a lipid-lowering drug, inhibits the induction of << nitric-oxide >> [[ nitric-oxide synthase ]] in human astrocytes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of << inducible nitric-oxide synthase >> [[ nitric-oxide ]] synthase (iNOS) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Gemfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible << nitric-oxide >> synthase ([[ iNOS ]]) in human U373MG astroglial cells and primary astrocytes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of << PGHS-2 >> causes this enzyme to form [[ 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ]] (15-HETE) instead of PGH2.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Aspirin irreversibly inhibits PGHS-1, preventing this isozyme from forming PGH2 or any other oxygenated product; in contrast, aspirin treatment of << PGHS-2 >> causes this enzyme to form 15-hydroxy-5c,8c,11c,13t-eicosatetraenoic acid ([[ 15-HETE ]]) instead of PGH2.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in glucosinolates, which upon << myrosinase >> hydrolysis release the corresponding [[ isothiocyanates ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Mouse brain serine racemase >> catalyzes specific elimination of L-serine to [[ pyruvate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< COX-1 >> inhibition was measured as percentage inhibition of serum [[ TXB2 ]] generation in clotting whole blood, and as closure time with use of the platelet function analyser PFA-100.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Hydrogen sulphide >> (H(2)S) is synthesized from L-cysteine via the action of [[ cystathionine-gamma-lyase ]] (CSE) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (<< H(2)S >>) is synthesized from L-cysteine via the action of [[ cystathionine-gamma-lyase ]] (CSE) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Hydrogen sulphide >> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ([[ CSE ]]) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (<< H(2)S >>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase ([[ CSE ]]) and cystathionine-beta-synthase (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Hydrogen sulphide >> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and [[ cystathionine-beta-synthase ]] (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Hydrogen sulphide >> (H(2)S) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ([[ CBS ]]).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (<< H(2)S >>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and [[ cystathionine-beta-synthase ]] (CBS).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Hydrogen sulphide (<< H(2)S >>) is synthesized from L-cysteine via the action of cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase ([[ CBS ]]).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this study, we investigated the presence of H(2)S and the expression of << H(2)S >> synthesizing enzymes, [[ CSE ]] and CBS, in isolated mouse pancreatic acini.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In this study, we investigated the presence of H(2)S and the expression of << H(2)S >> synthesizing enzymes, CSE and [[ CBS ]], in isolated mouse pancreatic acini.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In addition, cells pre-treated with DL-propargylglycine (PAG, 3 mM), a CSE inhibitor, reduced the formation of H(2)S in caerulein treated cells, suggesting that << CSE >> may be the main enzyme involved in [[ H(2)S ]] formation in mouse acinar cells.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that the pro-inflammatory effect of << H(2)S >> may be mediated by SP-[[ NK-1R ]] related pathway in mouse pancreatic acinar cells.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These results suggest that the pro-inflammatory effect of << H(2)S >> may be mediated by [[ SP ]]-NK-1R related pathway in mouse pancreatic acinar cells.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "METHODS: << Cyclooxygenase >> activity and selectivity was determined in vitro by measuring [[ prostaglandin E(2) ]] (PGE(2)) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "METHODS: << Cyclooxygenase >> activity and selectivity was determined in vitro by measuring prostaglandin E(2) ([[ PGE(2) ]]) production following incubation of varying concentrations of NSAID with human recombinant COX-1 or COX-2 and arachidonic acid.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Thymidylate synthase >> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of [[ 2-deoxythymidine-5-monophosphate ]], a precursor for DNA synthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Thymidylate synthase (<< TS >>) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of [[ 2-deoxythymidine-5-monophosphate ]], a precursor for DNA synthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The results suggest that individuals with high Vmax << beta 2-ADH >> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with [[ acetaldehyde ]] accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial << ALDH2 >>, accounting for approximately 45% of the Chinese population, may end up with [[ acetaldehyde ]] accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The << COX >> pathway generates inflammatory [[ prostaglandins ]], while the 5-LOX pathway generates inflammatory leukotrienes.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The COX pathway generates inflammatory prostaglandins, while the << 5-LOX >> pathway generates inflammatory [[ leukotrienes ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "6-DHSG was metabolised by GSH to form a GSH conjugate (<< GS-6-DHSG >>) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of [[ glutathione-S-transferase ]] (GST).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "6-DHSG was metabolised by GSH to form a GSH conjugate (<< GS-6-DHSG >>) in RAW 264.7 cells, via a potential mechanism involving the catalytic activity of glutathione-S-transferase ([[ GST ]]).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In cell culture experiments, it was found that triclosan inhibited << IL-1 beta >> induced [[ prostaglandin E2 ]] production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of << putrescine >>, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of putrescine, << spermidine >>, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of putrescine, spermidine, and << spermine >> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of [[ ornithine decarboxylase ]] (ODC) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of << putrescine >>, spermidine, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([[ ODC ]]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of putrescine, << spermidine >>, and spermine by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([[ ODC ]]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Depletion of putrescine, spermidine, and << spermine >> by DL-alpha-difluoromethylornithine (DFMO), a specific inhibitor of ornithine decarboxylase ([[ ODC ]]) that is the first rate-limiting enzyme for polyamine biosynthesis, decreased the apoptotic index.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of [[ spermidine ]] and spermine with a significant accumulation of putrescine and induction of ODC.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Inhibition of << S-adenosylmethionine decarboxylase >> by a specific inhibitor [diethylglyoxal bis-(guanylhydrazone); DEGBG] led to depletion of spermidine and [[ spermine ]] with a significant accumulation of putrescine and induction of ODC.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Valproic acid selectively inhibits conversion of arachidonic acid to << arachidonoyl-CoA >> by [[ brain microsomal long-chain fatty acyl-CoA synthetases ]]: relevance to bipolar disorder.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of << prostaglandin E2 >> (PGE2; a product of both [[ COX-1 ]] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of << prostaglandin E2 >> (PGE2; a product of both COX-1 and [[ COX-2 ]]) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<< PGE2 >>; a product of both [[ COX-1 ]] and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<< PGE2 >>; a product of both COX-1 and [[ COX-2 ]]) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The time course of << PGE2 >> production was consistent with early release due to [[ COX-1 ]] activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The time course of << PGE2 >> production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with [[ COX-2 ]] expression.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Celecoxib selectively suppressed << PGE2 >> but not TxB2 at time points consistent with [[ COX-2 ]] activity, while producing analgesia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of << COX-2 >> mediated [[ PGE2 ]] is temporally related to NSAID analgesia.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Dual function inhibitors targeting << phospholipase A(2) >> (PLA(2)) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [[ arachidonic acid ]] (AA) metabolic network and be used as new anti-inflammatory drugs.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Dual function inhibitors targeting phospholipase A(2) (<< PLA(2) >>) and leukotriene A(4) hydrolase (LTA(4)H) may balance the [[ arachidonic acid ]] (AA) metabolic network and be used as new anti-inflammatory drugs.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and << leukotriene A(4) hydrolase >> (LTA(4)H) may balance the [[ arachidonic acid ]] (AA) metabolic network and be used as new anti-inflammatory drugs.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Dual function inhibitors targeting phospholipase A(2) (PLA(2)) and leukotriene A(4) hydrolase (<< LTA(4)H >>) may balance the [[ arachidonic acid ]] (AA) metabolic network and be used as new anti-inflammatory drugs.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "In conclusion, only specific apical NHE3 inhibition increased DBS, whereas prostaglandin synthesis, Na+-HCO3- cotransporter activation, or intracellular << HCO3 >>- formation by [[ carbonic anhydrase ]] was not involved.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phosphatidylserine >> (PtdSer) is made in mammalian cells by two [[ PtdSer synthases ]], PSS1 and PSS2.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phosphatidylserine >> (PtdSer) is made in mammalian cells by two PtdSer synthases, [[ PSS1 ]] and PSS2.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Phosphatidylserine >> (PtdSer) is made in mammalian cells by two PtdSer synthases, PSS1 and [[ PSS2 ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, a normal level of expression of << PSS1 >> and/or PSS2 is not required for generating the pool of [[ PtdSer ]] externalized during apoptosis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, a normal level of expression of PSS1 and/or << PSS2 >> is not required for generating the pool of [[ PtdSer ]] externalized during apoptosis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because << 24(S)-hydroxycholesterol >> (24-OHC), produced by [[ 24-hydroxylase ]], induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because 24(S)-hydroxycholesterol (<< 24-OHC >>), produced by [[ 24-hydroxylase ]], induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Asparagine >> secretion by MSCs was directly related to their [[ ASNS ]] expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because of their low << asparagine synthetase >> (ASNS) expression and [[ asparagine ]] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Because of their low asparagine synthetase (<< ASNS >>) expression and [[ asparagine ]] biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: << Bile acid-coenzyme A:amino acid N-acyltransferase >> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [[ taurine ]] and glycine.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<< BAAT >>) is the sole enzyme responsible for conjugation of primary and secondary bile acids to [[ taurine ]] and glycine.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: << Bile acid-coenzyme A:amino acid N-acyltransferase >> (BAAT) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and [[ glycine ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "UNLABELLED: Bile acid-coenzyme A:amino acid N-acyltransferase (<< BAAT >>) is the sole enzyme responsible for conjugation of primary and secondary bile acids to taurine and [[ glycine ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by << D-myo-inositol 1,4,5-trisphosphate >> (IP3), a [[ PLC-beta ]] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<< IP3 >>), a [[ PLC-beta ]] hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a << PLC-beta >> hydrolysis product, or by measuring the production of [[ inositol phosphate ]] using cumbersome radioactive assays.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The bacterial enzyme maltodextrin phosphorylase (<< MalP >>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [[ glucose-1-phosphate ]] (Glc1P).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The bacterial enzyme << maltodextrin phosphorylase >> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as [[ glucose-1-phosphate ]] (Glc1P).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The bacterial enzyme << maltodextrin phosphorylase >> (MalP) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ([[ Glc1P ]]).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The bacterial enzyme maltodextrin phosphorylase (<< MalP >>) catalyses the phosphorolysis of an alpha-1,4-glycosidic bond in maltodextrins, removing the non-reducing glucosyl residues of linear oligosaccharides as glucose-1-phosphate ([[ Glc1P ]]).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< GPxs >> reduce hydroperoxides to the corresponding [[ alcohols ]] by means of glutathione (GSH).", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The catalytic competence of << cytochrome P450 >> in the synthesis of [[ serotonin ]] from 5-methoxytryptamine in the brain: an in vitro study.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, << CYP2D >> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to [[ serotonin ]], but they were less effective than the human isoform CYP2D6.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to << serotonin >>, but they were less effective than the [[ human isoform CYP2D6 ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Human liver microsomes of the wild-type << CYP2D6 >> metabolized 5-methoxytryptamine to [[ serotonin ]] more effectively than did the defective CYP2D6*4*4 ones.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to << serotonin >> more effectively than did the defective [[ CYP2D6 ]]*4*4 ones.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The obtained results indicate that << rat brain CYP2D >> isoforms catalyze the formation of [[ serotonin ]] from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of << CYP2D >> may affect [[ serotonin ]] metabolism in the brain.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Proline dehydrogenase >> (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [[ glutamate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (<< PRODH >>) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to [[ glutamate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (PRODH) and << Delta(1)-pyrroline-5-carboxylate dehydrogenase >> (P5CDH) catalyze the two-step oxidation of proline to [[ glutamate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (<< P5CDH >>) catalyze the two-step oxidation of proline to [[ glutamate ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Finally, we demonstrate that << T. thermophilus PRODH >> reacts with O(2) producing [[ superoxide ]].", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "This is significant because << superoxide >> production underlies the role of [[ human PRODH ]] in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Acetyl-coenzyme A carboxylase >> (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [[ fatty acid ]] biosynthesis and oxidation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetyl-coenzyme A carboxylase (<< ACC >>) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in [[ fatty acid ]] biosynthesis and oxidation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, << ACC1 >> and ACC2, which play critical roles in [[ fatty acid ]] biosynthesis and oxidation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and << ACC2 >>, which play critical roles in [[ fatty acid ]] biosynthesis and oxidation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The cytosolic << ACC1 >> is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in [[ fatty acid ]] biosynthesis.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The mitochondrial << ACC2 >> is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of [[ fatty acid ]] oxidation.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the production of << TXB2 >> during whole blood clotting was assessed as an index of the [[ cyclooxygenase ]] activity of platelet PGHS-1 ex vivo.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Moreover, the production of << TXB2 >> during whole blood clotting was assessed as an index of the cyclooxygenase activity of platelet [[ PGHS-1 ]] ex vivo.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet << PGHS-1 >>, caused a cumulative inhibition of urinary [[ 11-dehydro-TXB2 ]] and whole blood TXB2 production that recovered with a timecourse consistent with platelet turnover.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "The daily administration of low-dose aspirin (40 mg), a selective inhibitor of platelet << PGHS-1 >>, caused a cumulative inhibition of urinary 11-dehydro-TXB2 and whole blood [[ TXB2 ]] production that recovered with a timecourse consistent with platelet turnover.", "metadata": [], "label": "PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "<< Carbonic anhydrase >> (CA) is a zinc enzyme that catalyses the reversible hydration reaction of [[ CO2 ]] and plays a major role in the acid-base balance.", "metadata": [], "label": "SUBSTRATE_PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Carbonic anhydrase (<< CA >>) is a zinc enzyme that catalyses the reversible hydration reaction of [[ CO2 ]] and plays a major role in the acid-base balance.", "metadata": [], "label": "SUBSTRATE_PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Of note, reciprocal expression of << Asmt >> and Bhmt is an important clue that altered [[ S-adenosylhomocysteine ]] metabolism underlies brain injury in WD, which is directly correlated to the decreased expression of S-adenosylhomocysteine hydrolase in hepatic tissue in LEC rats.", "metadata": [], "label": "SUBSTRATE_PRODUCT-OF", "cid": "2", "custom_label": "INTERACTOR"}
{"text": "Several site-specific alterations in the << C >>-terminus of full-length [[ FGFR1IIIc ]], an isoform that otherwise absolutely rejects FGF-7, resulted in gain of FGF-7 binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Addition of a specific number of FGFR sequences to the << C >>-terminus of [[ Ig module II ]] resulted in a gain in affinity for FGF-7.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Ig module I and the << C >>-terminus of [[ Ig module III ]] are dispensable for high-affinity binding of FGF-1, FGF-2, and FGF-7.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The cellular << prion protein PrP(C) >> consists of two domains--a flexible [[ N ]]-terminal domain, which participates in copper and zinc regulation, and a largely helical C-terminal domain that converts to Î² sheet in the course of prion disease.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The cellular << prion protein PrP(C) >> consists of two domains--a flexible N-terminal domain, which participates in copper and zinc regulation, and a largely helical [[ C ]]-terminal domain that converts to Î² sheet in the course of prion disease.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Here, we identify a ZnÂ²âº-driven << N >>-terminal to C-terminal tertiary interaction in [[ PrP(C) ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Here, we identify a ZnÂ²âº-driven N-terminal to << C >>-terminal tertiary interaction in [[ PrP(C) ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This mutation is the first described in exon 9 and impairs the last 27 << amino acids >> of the [[ hormone-binding domain ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and << PTP1B >> phosphorylation at [[ serine ]] (Ser) 50, Ser 398 and tyrosine 152.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and << PTP1B >> phosphorylation at serine ([[ Ser ]]) 50, Ser 398 and tyrosine 152.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and << PTP1B >> phosphorylation at serine (Ser) 50, [[ Ser ]] 398 and tyrosine 152.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unsaturated FFAs increased DAGs, TAGs and PTP1B expression significantly, but cells remained insulin sensitive as assessed by robust AKt and << PTP1B >> phosphorylation at serine (Ser) 50, Ser 398 and [[ tyrosine ]] 152.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Saturated palmitic and stearic acids increased ceramides, up-regulated PTP1B, and had AKt and << PTP1B >> phosphorylation at [[ Ser ]] 50 impaired.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Only FFAs that increased ceramides caused impairment of AKt and << PTP1B >> phosphorylation at [[ Ser ]] 50.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "A clear relationship between << PTP1B >> phosphorylation levels at [[ Ser ]] 50 and its negative effect on insulin signaling is shown.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The pyridoxal 5'-phosphate binding << lysine >> in [[ mouse ODC ]] was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The pyridoxal 5'-phosphate binding lysine in << mouse ODC >> was identified as [[ lysine ]] 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[3H]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This lysine is contained in the sequence << PFYAVKC >>, which is found in all known [[ ODCs ]] from eukaryotes.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This << lysine >> is contained in the sequence PFYAVKC, which is found in all known [[ ODCs ]] from eukaryotes.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using a similar procedure to analyze << ODC >> labeled by reaction with [5-14C]DFMO, it was found that [[ lysine ]] 69 and cysteine 360 formed covalent adducts with the inhibitor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using a similar procedure to analyze << ODC >> labeled by reaction with [5-14C]DFMO, it was found that lysine 69 and [[ cysteine ]] 360 formed covalent adducts with the inhibitor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This << lysine >> is contained in the sequence [[ PFYAVKC ]], which is found in all known ODCs from eukaryotes.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Cysteine >> 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -[[ WGPTCDGL(I)D ]]-, which is present in all known eukaryote ODCs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Cysteine >> 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known [[ eukaryote ODCs ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -<< WGPTCDGL(I)D >>-, which is present in all known [[ eukaryote ODCs ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the << Arg-Gly-Asp >> (RGD) sequence of [[ fibrinogen ]] to obtain designed multiple ligands with potential antithrombotic activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, insulin treatment of Î±XBPKD cells reduced << tyrosine >> phosphorylation of [[ IRS-1 ]] (pY(896)), and phosphorylation of Akt, while enhancing serine phosphorylation (pS(307)) of IRS-1.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, insulin treatment of Î±XBPKD cells reduced tyrosine phosphorylation of IRS-1 (pY(896)), and phosphorylation of Akt, while enhancing << serine >> phosphorylation (pS(307)) of [[ IRS-1 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of [[ lysine ]] residues in proteins.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate << beta-lyases >> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with [[ epsilon-amino ]] groups of lysine residues in proteins.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, Nox4 activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (<< Cys >>226, Cys270) located in the extracellular E-loop of [[ Nox4 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, Nox4 activity is also stimulated by reducing agents that possibly act by reducing the disulfide bridge (Cys226, << Cys >>270) located in the extracellular E-loop of [[ Nox4 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Both << porcine TLR7 >> and TLR8 proteins were expressed in cell lines and were [[ N ]]-glycosylated.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Both porcine TLR7 and << TLR8 >> proteins were expressed in cell lines and were [[ N ]]-glycosylated.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% << amino acid >> identity with the known [[ rat 5-HT1A ]], rat 5-HT1B, rat 5-HT1D, and human 5-HT1E receptors, respectively.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% << amino acid >> identity with the known rat 5-HT1A, [[ rat 5-HT1B ]], rat 5-HT1D, and human 5-HT1E receptors, respectively.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% << amino acid >> identity with the known rat 5-HT1A, rat 5-HT1B, [[ rat 5-HT1D ]], and human 5-HT1E receptors, respectively.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% << amino acid >> identity with the known rat 5-HT1A, rat 5-HT1B, rat 5-HT1D, and [[ human 5-HT1E ]] receptors, respectively.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Degenerate oligonucleotides corresponding to conserved << amino acids >> from transmembrane domains III, V, and VI of known receptors [[[ 5-HT1A ]], 5-HT1C, and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Degenerate oligonucleotides corresponding to conserved << amino acids >> from transmembrane domains III, V, and VI of known receptors [5-HT1A, [[ 5-HT1C ]], and 5-HT2; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Degenerate oligonucleotides corresponding to conserved << amino acids >> from transmembrane domains III, V, and VI of known receptors [5-HT1A, 5-HT1C, and [[ 5-HT2 ]]; 5-HT is serotonin (5-hydroxytryptamine)] were used as primers for the sequential reactions.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We report herein the location of the binding site for the inhaled anesthetic halothane at the << amino acid >> residue level of resolution in the ligand binding cavity in a prototypical [[ G protein-coupled receptor ]], bovine rhodopsin.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We report herein the location of the binding site for the inhaled anesthetic halothane at the << amino acid >> residue level of resolution in the ligand binding cavity in a prototypical G protein-coupled receptor, [[ bovine rhodopsin ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Radiosequence analysis of [(14)C]halothane-labeled << rhodopsin >> revealed that halothane contacts an [[ amino acid ]] residue (Trp265) lining the ligand binding cavity in the transmembrane core of the receptor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic << amino acid >> residues, an event necessary for the maturation of a variety of important biologically active proteins, such as [[ insulin ]] and nerve growth factor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "A major part of this processing requires endoproteolytic cleavage at specific pairs of basic << amino acid >> residues, an event necessary for the maturation of a variety of important biologically active proteins, such as insulin and [[ nerve growth factor ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with << Human Serum Albumin >> (HSA: PDB 1E78), showing binding pattern with [[ amino acid ]] residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with Human Serum Albumin (<< HSA >>: PDB 1E78), showing binding pattern with [[ amino acid ]] residues Arg218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with << Human Serum Albumin >> (HSA: PDB 1E78), showing binding pattern with amino acid residues [[ Arg ]]218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with Human Serum Albumin (<< HSA >>: PDB 1E78), showing binding pattern with amino acid residues [[ Arg ]]218, Arg222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with << Human Serum Albumin >> (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, [[ Arg ]]222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with Human Serum Albumin (<< HSA >>: PDB 1E78), showing binding pattern with amino acid residues Arg218, [[ Arg ]]222 and Lys444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with << Human Serum Albumin >> (HSA: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and [[ Lys ]]444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Molecular docking studies were performed with Human Serum Albumin (<< HSA >>: PDB 1E78), showing binding pattern with amino acid residues Arg218, Arg222 and [[ Lys ]]444, identifies the ligand-HSA interaction for the transportation affinity of the ligand at the specific site of the target.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however << phospho-GSK-3-Î² >> ([[ Ser ]]9) was not altered in (PhTe)(2) injected rat.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and Ser840) within the membrane proximal region of the << GluK5 >> [[ C ]]-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using site-directed mutagenesis, we identified three << serines >> (Ser833, Ser836, and Ser840) within the membrane proximal region of the [[ GluK5 ]] C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using site-directed mutagenesis, we identified three serines (<< Ser >>833, Ser836, and Ser840) within the membrane proximal region of the [[ GluK5 ]] C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using site-directed mutagenesis, we identified three serines (Ser833, << Ser >>836, and Ser840) within the membrane proximal region of the [[ GluK5 ]] C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Using site-directed mutagenesis, we identified three serines (Ser833, Ser836, and << Ser >>840) within the membrane proximal region of the [[ GluK5 ]] C-terminal domain that, in combination, are required for mGlu1-mediated potentiation of KARs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "To determine whether these responses were common to other amphetamines of abuse, effects of methylenedioxymethamphetamine (MDMA) on the plasmalemmal DA transporter (DAT) and << vesicular monoamine transporter-2 >> [[ monoamine ]] transporter-2 (VMAT-2) were assessed.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Studies have indicated that the three-dimensional structure and the domains of << HuBChE >> ([[ acyl ]] pocket, lip of the active center gorge, and the anionic substrate-binding domain) that are critical for the binding of substrate are also essential for the selectivity and binding of inhibitors including OPs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Amino acid >> residues at the N- and C-termini are essential for the folding of active [[ human butyrylcholinesterase ]] polypeptide.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Glutaraldehyde >> crosslinked [[ albumin ]] nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to << methionine >> residues of [[ albumin ]] and is released in a reductive environment.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Albumin >> nanoparticles were surface-coated with bifunctional [[ polyethylene glycol ]] 3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Albumin >> nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 ([[ PEG ]]) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The << nucleotide >> sequence of [[ HmTx ]] contains 649 bp, and the mature protein is predicted to have 131 amino acid residues-104 of which make up the large subunit, and 27 of which make up the small subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The nucleotide sequence of << HmTx >> contains 649 bp, and the mature protein is predicted to have 131 [[ amino acid ]] residues-104 of which make up the large subunit, and 27 of which make up the small subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 ([[ Lys ]]24-His34), h2 (Cys59-Asp71), and h3 (Ala80-Phe89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 (Lys24-[[ His ]]34), h2 (Cys59-Asp71), and h3 (Ala80-Phe89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 ([[ Cys ]]59-Asp71), and h3 (Ala80-Phe89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-[[ Asp ]]71), and h3 (Ala80-Phe89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71), and h3 ([[ Ala ]]80-Phe89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 3D-structure of << HmTx >> consists of three conserved alpha-helices: h1 (Lys24-His34), h2 (Cys59-Asp71), and h3 (Ala80-[[ Phe ]]89).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The functional protein contains 1160 << amino acids >> with a large central [[ mucin domain ]], three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the C-terminal.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The functional protein contains 1160 << amino acids >> with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative [[ hyaluronan-binding motif ]], and a potential transmembrane domain near the C-terminal.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The functional protein contains 1160 amino acids with a large central << mucin domain >>, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative hyaluronan-binding motif, and a potential transmembrane domain near the [[ C ]]-terminal.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The functional protein contains 1160 amino acids with a large central mucin domain, three consensus sites for glycosaminoglycan attachment, two epidermal growth factor-like repeats, a putative << hyaluronan-binding motif >>, and a potential transmembrane domain near the [[ C ]]-terminal.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Removal of << N >>- and O-linked oligosaccharides reduces the M(r) to approximately 160,000, suggesting that approximately 60% of the mass of [[ SPACRCAN ]] is carbohydrate.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Removal of N- and << O >>-linked oligosaccharides reduces the M(r) to approximately 160,000, suggesting that approximately 60% of the mass of [[ SPACRCAN ]] is carbohydrate.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << arginase >>, two [[ cysteines ]] at the C terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << arginase >>, two cysteines at the [[ C ]] terminus of the protein are crucial for its epiarginase function but not for its catalytic activity and trimeric structure.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, [[ Asp ]]-182, Asn-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, Asp-182, [[ Asn ]]-184, Asn-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, Asp-182, Asn-184, [[ Asn ]]-185, Cys-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, [[ Cys ]]-289, and Glu-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In << OTCase >>, mutations of putative ornithine binding residues, Asp-182, Asn-184, Asn-185, Cys-289, and [[ Glu ]]-256 greatly reduced the affinity for ornithine and impaired the interaction with arginase.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The four lysine residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and << Lys >>-268, also play an important role in mediating the sensitivity of [[ OTCase ]] to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The four lysine residues located in the SMG loop, Lys-260, Lys-263, << Lys >>-265, and Lys-268, also play an important role in mediating the sensitivity of [[ OTCase ]] to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The four lysine residues located in the SMG loop, Lys-260, << Lys >>-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of [[ OTCase ]] to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The four lysine residues located in the SMG loop, << Lys >>-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of [[ OTCase ]] to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The four << lysine >> residues located in the SMG loop, Lys-260, Lys-263, Lys-265, and Lys-268, also play an important role in mediating the sensitivity of [[ OTCase ]] to ornithine and to arginase and appear to be involved in transducing and enhancing the signal given by ornithine for the closure of the catalytic domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform << hCA II >>, although it is devoid of the [[ His ]]64 proton shuttle.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This 40 kDa << PEG >>-conjugated [[ IFNalpha(2a) ]] ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a << lysine >> side-chain of [[ IFNalpha(2a) ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The two active sites of dimeric << 5-aminolevulinate synthase >> (ALAS), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential [[ amino acids ]] from each subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The two active sites of dimeric 5-aminolevulinate synthase (<< ALAS >>), a pyridoxal 5'-phosphate (PLP)-dependent enzyme, are located on the subunit interface with contribution of essential [[ amino acids ]] from each subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unlike << transferrin receptor >>, the protease domain of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [[ arginine ]] patch.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unlike transferrin receptor, the << protease domain >> of PSMA contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [[ arginine ]] patch.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Unlike transferrin receptor, the protease domain of << PSMA >> contains a binuclear zinc site, catalytic residues, and a proposed substrate-binding [[ arginine ]] patch.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [<< Sar >>(1),Gln(2),Ile(8)] [[ AngII ]], a specific analog that binds to the D281A mutant with better affinity than AngII.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [<< Sar >>(1),Gln(2),Ile(8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [[ AngII ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [Sar(1),<< Gln >>(2),Ile(8)] [[ AngII ]], a specific analog that binds to the D281A mutant with better affinity than AngII.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [Sar(1),<< Gln >>(2),Ile(8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [[ AngII ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [Sar(1),Gln(2),<< Ile >>(8)] [[ AngII ]], a specific analog that binds to the D281A mutant with better affinity than AngII.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "However, a lid conformation was induced by [Sar(1),Gln(2),<< Ile >>(8)] AngII, a specific analog that binds to the D281A mutant with better affinity than [[ AngII ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Binding of the agonist angiotensin II (AngII) and inverse agonist losartan in wild-type << AT1R >> changed the accessibility of reporter [[ cysteines ]], and the pattern was consistent with ligand-specific \"lid\" conformations of ECL2.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "These variants are expected to encode either a full length (<< OATP2B1-FL >>) or shortened protein lacking 22 [[ N ]]-terminus amino acids (OATP2B-Short).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "These variants are expected to encode either a full length (OATP2B1-FL) or shortened protein lacking 22 << N >>-terminus amino acids ([[ OATP2B-Short ]]).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "These variants are expected to encode either a full length (<< OATP2B1-FL >>) or shortened protein lacking 22 N-terminus [[ amino acids ]] (OATP2B-Short).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Little is known regarding the transport activity and regulation of << OATP2B1 >> variants with [[ N ]]-terminus truncation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Mutation analysis of KYNU encoding << kynureninase >> of the index case revealed homozygosity for a c.593 A > G substitution leading to a [[ threonine ]]-to-alanine (T198A) shift.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Mutation analysis of KYNU encoding << kynureninase >> of the index case revealed homozygosity for a c.593 A > G substitution leading to a threonine-to-[[ alanine ]] (T198A) shift.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Identification of << amino acids >> in the [[ factor XI apple 3 domain ]] required for activation of factor IX.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "To identify key amino acids involved in factor IX activation, recombinant << factor XIa >> proteins containing [[ alanine ]] substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the << N >> terminus and for Ser(258)-Ser(264) at the C terminus of the [[ A3 domain ]] markedly decreased factor XI coagulant activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Substitutions for Ile(183)-Val(191) and Ser(195)-Ile(197) at the N terminus and for Ser(258)-Ser(264) at the << C >> terminus of the [[ A3 domain ]] markedly decreased factor XI coagulant activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "To identify key << amino acids >> involved in [[ factor IX ]] activation, recombinant factor XIa proteins containing alanine substitutions for wild-type sequence were expressed in 293 fibroblasts and tested in a plasma clotting assay.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Amino acids >> between Ile(183) and Val(191) are necessary for proper [[ factor IX ]] activation, but additional sequence between Ser(195) and Ile(197) or between Phe(260) and Ser(265) is required for complete restoration of activation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Identification of << amino acids >> in the factor XI apple 3 domain required for activation of [[ factor IX ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Though microtubule mediated actin remodeling through PKCÎ¶, reorganization of microtubule depended on << tyrosine >> phosphorylation of [[ insulin receptor ]], the mechanism is different from insulin-induced actin remodeling, which relied on the activity of PI3-kinase and PKCÎ¶.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We found that, both in a cell-free system and in cells, NO/SNO donors such as S-nitrosocysteine and S-nitrosoglutathione readily induced the << S >>-nitrosylation of [[ Prx1 ]], causing structural and functional alterations.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic << cysteines >> (Cys-52 and Cys-173) and disrupted the oligomeric structure of [[ Prx1 ]], leading to loss of peroxidase activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (<< Cys >>-52 and Cys-173) and disrupted the oligomeric structure of [[ Prx1 ]], leading to loss of peroxidase activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and << Cys >>-173) and disrupted the oligomeric structure of [[ Prx1 ]], leading to loss of peroxidase activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic << cysteines >> (Cys-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of [[ peroxidase ]] activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (<< Cys >>-52 and Cys-173) and disrupted the oligomeric structure of Prx1, leading to loss of [[ peroxidase ]] activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In particular, nitrosylation promoted disulfide formation involving the pair of catalytic cysteines (Cys-52 and << Cys >>-173) and disrupted the oligomeric structure of Prx1, leading to loss of [[ peroxidase ]] activity.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In addition, a partial nucleotide and << amino acid >> sequence of the [[ rabbit alpha(2A)-adrenoceptor ]] (a region known to substantially influence the pharmacological characteristics of the alpha(2)-adrenoceptor) revealed marked differences between the rabbit and the human alpha(2A)-adrenoceptor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In this study, we investigated the expression and function of p53R2 and hRRM2 after UV treatment in human prostate cancer PC3 cells, which possess mutant << p53 >> with a truncated [[ COOH ]]-terminal, and in human oropharyngeal cancer KB cells, which possess wild-type p53.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four << amino acids >>, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, << Leu >>/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/<< Phe >>(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), << Leu >>/Phe(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/<< Phe >>(7.43), Ala/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), << Ala >>/Pro(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/<< Pro >>(7.46), and Pro/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and << Pro >>/Cys(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Point-mutation studies indicate that four amino acids, Leu/Phe(7.38), Leu/Phe(7.43), Ala/Pro(7.46), and Pro/<< Cys >>(7.47) in [[ TMH7 ]] are critical for ligand selectivity as well as receptor conformation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "[Trp(7)]GnRH-I and [Trp(8)]GnRH-I but not [His(5)]GnRH-I exhibit a higher potency in activating wild-type gmGnRHR-2 than native GnRH-I, indicating that << amino acids >> at positions 7 and 8 of [[ GnRHs ]] are more important than position 5 for differential recognition by type I and type II GnRHRs.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (<< Pro >>(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in [[ EL3 ]] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-<< Pro >>(7.32)-Ser(7.33) motif to Ser-Glu-Pro in [[ EL3 ]] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-<< Ser >>(7.33) motif to Ser-Glu-Pro in [[ EL3 ]] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to << Ser-Glu-Pro >> in [[ EL3 ]] and Leu(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of rat GnRHR) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and << Leu >>(7.38), Leu(7.43), Ala(7.46), and Pro(7.47) to those of [[ rat GnRHR ]]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), << Leu >>(7.43), Ala(7.46), and Pro(7.47) to those of [[ rat GnRHR ]]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), << Ala >>(7.46), and Pro(7.47) to those of [[ rat GnRHR ]]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, a combinatory mutation (Pro(7.31)-Pro(7.32)-Ser(7.33) motif to Ser-Glu-Pro in EL3 and Leu(7.38), Leu(7.43), Ala(7.46), and << Pro >>(7.47) to those of [[ rat GnRHR ]]) in gmGnRH-2 exhibited an approximately 500-fold increased sensitivity to GnRH-I, indicating that these residues are critical for discriminating GnRH-II from GnRH-I.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cresyl saligenin phosphate makes multiple adducts on free histidine, but does not form an adduct on << histidine >> 438 of [[ human butyrylcholinesterase ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "CBDP irreversibly inhibits << butyrylcholinesterase >> (BChE) in human plasma by forming adducts on the active site [[ serine ]] (Ser-198).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "CBDP irreversibly inhibits butyrylcholinesterase (<< BChE >>) in human plasma by forming adducts on the active site [[ serine ]] (Ser-198).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "CBDP irreversibly inhibits << butyrylcholinesterase >> (BChE) in human plasma by forming adducts on the active site serine ([[ Ser ]]-198).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "CBDP irreversibly inhibits butyrylcholinesterase (<< BChE >>) in human plasma by forming adducts on the active site serine ([[ Ser ]]-198).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Mass spectral analysis of CBDP-inhibited << BChE >> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on [[ lysine ]] 499, a residue far from the active site, but not on His-438.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Mass spectral analysis of CBDP-inhibited << BChE >> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on [[ His ]]-438.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We have expressed and characterized recombinant, << N >>-terminally His-tagged [[ human adenine phosphoribosyltransferase ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Incubation of purified << Pin1 >> with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues [[ His ]]-157 and Cys-113.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Incubation of purified << Pin1 >> with HNE followed by MALDI-TOF/TOF mass spectrometry resulted in detection of Michael adducts at the active site residues His-157 and [[ Cys ]]-113.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Furthermore, orbitrap MS data support the adduction of << Cys >>-113 in the [[ Pin1 ]] active site upon HNE treatment of MDA-MB-231 cells.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "NMR spectroscopy was also used to examine the hSOD1 mutants C57A, C146A, and C57A/C146A, which are unable to form the structurally conserved disulfide bond in SOD1, in order to investigate the role of these << cysteines >> during [[ hSOD1 ]] copper acquisition.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "D-Serine was previously identified in mammalian brain and was shown to be a co-agonist at the '<< glycine >>' site of the [[ N-methyl-D-aspartate (NMDA)-type receptors ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In addition to the << N >>-terminal and [[ Src homology 2 domains ]] that mediate these interactions, SOCS proteins contain a C-terminal SOCS box.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In addition to the N-terminal and Src homology 2 domains that mediate these interactions, SOCS proteins contain a << C >>-terminal [[ SOCS box ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "RESULTS: GW572016 inhibited constitutive and/or ligand-induced << EGFR >> or HER2 [[ tyrosine ]] phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "RESULTS: GW572016 inhibited constitutive and/or ligand-induced EGFR or << HER2 >> [[ tyrosine ]] phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [<< Nle >>(4), D-Phe(7)][[ Î±-melanocyte-stimulating hormone ]] (NDP-Î±-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-Î± levels; these effects of NDP-Î±-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), << D-Phe >>(7)][[ Î±-melanocyte-stimulating hormone ]] (NDP-Î±-MSH) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-Î± levels; these effects of NDP-Î±-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [<< Nle >>(4), D-Phe(7)]Î±-melanocyte-stimulating hormone (NDP-[[ Î±-MSH ]]) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-Î± levels; these effects of NDP-Î±-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Intravenous treatment, during coronary artery occlusion, with the melanocortin analogs [Nle(4), << D-Phe >>(7)]Î±-melanocyte-stimulating hormone (NDP-[[ Î±-MSH ]]) and adrenocorticotropic hormone 1-24 [ACTH-(1-24)], induced a left ventricle up-regulation of pJAK2, pERK1/2 and pTyr-STAT3 (JAK-dependent), and a reduction in pJNK and TNF-Î± levels; these effects of NDP-Î±-MSH and ACTH-(1-24) were associated with over-expression of the pro-survival proteins HO-1 and Bcl-XL, and marked decrease of the myocardial infarct size.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Despite a low << amino acid >> identity between [[ TWIK-1 ]] and TREK-1 (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Despite a low << amino acid >> identity between TWIK-1 and [[ TREK-1 ]] (approximately 28%), both channel proteins share the same overall structural arrangement consisting of two pore-forming domains and four transmembrane segments (TMS).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the << choline-binding site >> ([[ Trp ]]-84) and the acyl-binding pocket (Phe-288, Phe-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the << acyl-binding pocket >> ([[ Phe ]]-288, Phe-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of TcAChE, interacting with both the choline-binding site (Trp-84) and the << acyl-binding pocket >> (Phe-288, [[ Phe ]]-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of << TcAChE >>, interacting with both the choline-binding site ([[ Trp ]]-84) and the acyl-binding pocket (Phe-288, Phe-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of << TcAChE >>, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket ([[ Phe ]]-288, Phe-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The inhibitor binds at the base of the active site gorge of << TcAChE >>, interacting with both the choline-binding site (Trp-84) and the acyl-binding pocket (Phe-288, [[ Phe ]]-290).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We apply DFTB in a QM/MM framework to perform vibrational analysis of buried << aspartic acids >> in [[ bacteriorhodopsin ]] and channelrhodopsin-2.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We apply DFTB in a QM/MM framework to perform vibrational analysis of buried << aspartic acids >> in bacteriorhodopsin and [[ channelrhodopsin-2 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Of 18 mutations where << hNET >> [[ amino acid ]] residues were exchanged with those of the human dopamine transporter, MrIA had increased potency for inhibition of [3H]norepinephrine uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Comparisons of the structures of the cyanobacterial toxin:phosphatase complexes explain the biochemical mechanism by which microcystins but not nodularins permanently modify their << protein phosphatase >> targets by covalent addition to an active site [[ cysteine ]] residue.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Amino acid >> sequences of cynomolgus [[ FMO1-5 ]], respectively, shared high sequence identities (94-98%) and were closely clustered in a phylogenetic tree, with human FMO1-5.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Functional divergence of a unique << C >>-terminal domain of [[ leucyl-tRNA synthetase ]] to accommodate its splicing and aminoacylation roles.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Functional divergence of a unique C-terminal domain of << leucyl >> [[ leucyl-tRNA synthetase ]] to accommodate its splicing and aminoacylation roles.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Leucyl >> [[ Leucyl-tRNA synthetase ]] (LeuRS) performs dual essential roles in group I intron RNA splicing as well as protein synthesis within the yeast mitochondria.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Herein, we determined that a fiveamino acid << C >>-terminal deletion of [[ LeuRS ]], which does not complement a null strain, can form a ternary complex with the bI4 intron and its maturase splicing partner.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The x-ray co-crystal structure of LeuRS showed that a << C >>-terminal extension of about 60 amino acids forms a discrete domain, which is unique among the [[ LeuRSs ]] and interacts with the corner of the L-shaped tRNALeu.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The x-ray co-crystal structure of LeuRS showed that a C-terminal extension of about 60 << amino acids >> forms a discrete domain, which is unique among the [[ LeuRSs ]] and interacts with the corner of the L-shaped tRNALeu.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, deletion of the entire << yeast mitochondrial LeuRS >> [[ C ]]-terminal domain enhanced its aminoacylation and amino acid editing activities.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, deletion of the entire << yeast mitochondrial LeuRS >> C-terminal domain enhanced its aminoacylation and [[ amino acid ]] editing activities.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In striking contrast, deletion of the corresponding << C >>-terminal domain of [[ Escherichia coli LeuRS ]] abolished aminoacylation of tRNALeu and also amino acid editing of mischarged tRNA molecules.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In striking contrast, deletion of the corresponding C-terminal domain of << Escherichia coli LeuRS >> abolished aminoacylation of tRNALeu and also [[ amino acid ]] editing of mischarged tRNA molecules.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "We propose that the secondary role of << yeast mitochondrial LeuRS >> in RNA splicing has impacted the functional evolution of this critical [[ C ]]-terminal domain.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a << phenylalanine >> from the conserved [[ FxxA interaction motif ]] found in BRCA2.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The initial fragment hits were thoroughly validated biophysically by isothermal titration calorimetry (ITC) and NMR techniques and observed by X-ray crystallography to bind in a shallow surface pocket that is occupied in the native complex by the side chain of a << phenylalanine >> from the conserved FxxA interaction motif found in [[ BRCA2 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of << Histone 3 >> at [[ Ser ]]10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of << Cdk1 >> at [[ Tyr ]]15, expression of cyclin B1, and decreased expression of Cdc25c.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Mutation of a single << amino acid >> residue in the potential [[ BiP binding site ]] increased the secretion efficiency of factor VIII by threefold.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The myosin-18AÎ± isoform, additionally, has an << N >>-terminal [[ PDZ domain ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "For MICA3, a surface loop containing the sequence PEVKEK and two adjacent exposed helixes were identified in the PLP binding domain as well as a region of the << C >> terminus of [[ GAD65 ]] that has previously been identified as critical for MICA3 binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing << amino acids >>, and the surface of the [[ GAD65 PLP-binding domain ]] surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these amino acids.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Peptide sequences selected using MICA4 were rich in basic or hydroxyl-containing amino acids, and the surface of the << GAD65 PLP-binding domain >> surrounding Lys358, which is known to be critical for MICA4 binding, was likewise rich in these [[ amino acids ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala-->Ser or << Gly >> mutants of [[ Rdl ]] subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with Ala--><< Ser >> or Gly mutants of [[ Rdl ]] subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Drosophila GABA-gated chloride channel: modified [3H]EBOB binding site associated with << Ala >>-->Ser or Gly mutants of [[ Rdl ]] subunit.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302--><< Ser >> replacement in the [[ Rdl GABA receptor ]] subunit and in D. simulans to an homologous Ala-->Ser or Gly replacement.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the << Rdl GABA receptor >> subunit and in D. simulans to an homologous [[ Ala ]]-->Ser or Gly replacement.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the << Rdl GABA receptor >> subunit and in D. simulans to an homologous Ala-->[[ Ser ]] or Gly replacement.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Cyclodiene resistance in D. melanogaster has been attributed to a mutation resulting in an Ala302-->Ser replacement in the << Rdl GABA receptor >> subunit and in D. simulans to an homologous Ala-->Ser or [[ Gly ]] replacement.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In contrast, the Ala--><< Gly >> replacement has less impact in protecting the [[ chloride channel ]] from the action of insecticidal blockers.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "In contrast, the << Ala >>-->Gly replacement has less impact in protecting the [[ chloride channel ]] from the action of insecticidal blockers.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins >> (IGFBP-rPs) are newly described [[ cysteine ]]-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Insulin-like growth factor (IGF)-binding protein (IGFBP)-related proteins (<< IGFBP-rPs >>) are newly described [[ cysteine ]]-rich proteins that share significant aminoterminal structural similarity with the conventional IGFBPs and are involved in a diversity of biological functions, including growth regulation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Recombinant P2X3/CASK expression in HEK cells increased << serine >> phosphorylation of [[ P2X3 ]] receptors, typically associated with receptor upregulation.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The << N >>-terminal portion of [[ TSG-6 ]] shows sequence homology to members of the cartilage link protein family of hyaluronan binding proteins.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The << C >>-terminal half of [[ TSG-6 ]] contains a so-called CUB domain, characteristic for developmentally regulated proteins.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The protein that binds TSG-6 was purified from human serum and identified as inter-alpha-inhibitor (<< I alpha I >>) by [[ N ]]-terminal microsequencing.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The protein that binds TSG-6 was purified from human serum and identified as << inter-alpha-inhibitor >> (I alpha I) by [[ N ]]-terminal microsequencing.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Terbinafine resistance was transmitted with the mutated alleles in gene replacement experiments, proving that single << amino acid >> substitutions in the [[ Erg1 ]] protein were sufficient to confer the resistance phenotype.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The << amino acid >> changes caused by the point mutations were clustered in two regions of the [[ Erg1 ]] protein.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Interestingly, all exchanges identified involved << amino acids >> which are conserved in the [[ squalene epoxidases ]] of yeasts and mammals.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Moreover, we show that << USP22 >> is acetylated on multiple [[ lysine ]] residues and that alteration of a single lysine (K129) within the ZnF-UBP domain is sufficient to alter interaction of the DUBm with the core SAGA complex.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Moreover, we show that USP22 is acetylated on multiple lysine residues and that alteration of a single << lysine >> (K129) within the [[ ZnF-UBP domain ]] is sufficient to alter interaction of the DUBm with the core SAGA complex.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "<< PTP >> inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a [[ cysteine ]] residue are required for full inhibition.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Here, we report that a specific 29-<< amino acid >> peptide derived from the intracellular domain fragment of [[ p75(NTR) ]] interacts with and potentiates binding of NGF to TrkA-expressing cells, leading to increased neurite outgrowth in sympathetic neurons as a result of enhanced Erk1/2 and Akt signaling.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "An endogenous intracellular domain fragment of << p75(NTR) >> (p75(ICD)) containing these 29 [[ amino acids ]] is produced by regulated proteolysis of the full-length receptor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "An endogenous intracellular domain fragment of p75(NTR) (<< p75(ICD) >>) containing these 29 [[ amino acids ]] is produced by regulated proteolysis of the full-length receptor.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Experimentation using isoforms of alefacept engineered to have << amino acid >> substitutions in the [[ IgG1 C(H)2 domain ]] that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Experimentation using isoforms of << alefacept >> engineered to have [[ amino acid ]] substitutions in the IgG1 C(H)2 domain that impact Fc gamma R binding indicate that alefacept mediates cognate interactions between cells expressing human CD2 and CD16 to activate cells, e.g., increase extracellular signal-regulated kinase phosphorylation, up-regulate cell surface expression of the activation marker CD25, and induce release of granzyme B.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The binding of U46619 to the << PGIS >> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at [[ C-11 ]], H2C, and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The binding of U46619 to the << PGIS >> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, [[ H2C ]], and H20 of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The binding of U46619 to the << PGIS >> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and [[ H20 ]] of U46619 were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The binding of U46619 to the << PGIS >> protein was demonstrated by 1D NMR titration, and the significant perturbation of the chemical shifts of protons at C-11, H2C, and H20 of [[ U46619 ]] were observed upon U46619 binding to the engineered PGIS in a concentration-dependent manner.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons << H20 >> and H2, H18 and H2, and H18 and H4 are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons H20 and << H2 >>, H18 and H2, and H18 and H4 are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons H20 and H2, << H18 >> and H2, and H18 and H4 are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons H20 and H2, H18 and << H2 >>, and H18 and H4 are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons H20 and H2, H18 and H2, and H18 and << H4 >> are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The distances between the protons H20 and H2, H18 and H2, and << H18 >> and H4 are shorter following their binding to the [[ PGIS ]] in solution-down to within 5 A.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "By synthesizing and testing a series of << alanine >> point-mutated [[ cyclic peptides ]], we identified which amino acid was important for the inhibition of the phospholamban function.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The structures of active and inactive << alanine >>-mutated [[ cyclic peptides ]], and of phospholamban (1-36), were determined by NMR.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "By synthesizing and testing a series of alanine point-mutated << cyclic peptides >>, we identified which [[ amino acid ]] was important for the inhibition of the phospholamban function.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which << amino acid >> was important for the inhibition of the [[ phospholamban ]] function.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The CSN/IRF5 interaction occurred on the carboxyl and << amino >> termini of [[ IRF5 ]]; a single internal deletion from amino acids 455 to 466 (Î455-466) was found to significantly reduce IRF5 protein stability.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The CSN/IRF5 interaction occurred on the << carboxyl >> and amino termini of [[ IRF5 ]]; a single internal deletion from amino acids 455 to 466 (Î455-466) was found to significantly reduce IRF5 protein stability.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion from << amino acids >> 455 to 466 (Î455-466) was found to significantly reduce [[ IRF5 ]] protein stability.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The 2.0-A resolution structure of << Thermus thermophilus PRODH >> reveals a distorted (betaalpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the [[ carboxyl ]]-terminal ends of the strands of the barrel.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Antibodies to either the << C >>- or N- terminus of [[ VMAT-1 ]] detected two proteins (73 and 55 kD) in transfected COS-1 cells.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "Antibodies to either the C- or << N >>- terminus of [[ VMAT-1 ]] detected two proteins (73 and 55 kD) in transfected COS-1 cells.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The << C >>-terminal antibodies detected both proteins in extracts of mouse medulla/pons, cortex, hypothalamus, and cerebellum but only the 73 kD protein and higher molecular weight immunoreactive proteins in mouse adrenal and rat PC12 cells, which are positive controls for [[ rodent VMAT-1 ]].", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact << bovine pancreatic ribonuclease A >> (RNase A) and its [[ proline ]]-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact << bovine pancreatic ribonuclease A >> (RNase A) and its proline-42-to-[[ alanine ]] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<< RNase A >>) and its [[ proline ]]-42-to-alanine mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The refolding kinetics of guanidine-denatured disulfide-intact bovine pancreatic ribonuclease A (<< RNase A >>) and its proline-42-to-[[ alanine ]] mutant (Pro42Ala) have been studied by monitoring tyrosine burial and 2'-cytidine monophosphate (2'CMP) inhibitor binding.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The replacement of the conserved << cysteine >> residues in e2 of [[ CB2 ]] by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}
{"text": "The replacement of the conserved cysteine residues in e2 of << CB2 >> by [[ serine ]] also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm.", "metadata": [], "label": "PART-OF", "cid": "1", "custom_label": "PART-OF"}